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ABSTRACT 241 
 Cardiac arrhythmias can follow disruption of the normal cellular electrophysiological processes 242 
underlying excitable activity and their tissue propagation as coherent wavefronts from the primary sino-243 
atrial node pacemaker, through the atria, conducting structures and ventricular myocardium. These 244 
physiological events are driven by interacting, voltage-dependent, processes of activation, inactivation and 245 
recovery in the ion channels present in cardiomyocyte membranes. Generation and conduction of these 246 
events are further modulated by intracellular Ca2+ homeostasis, and metabolic and structural change. This 247 
review describes experimental studies on murine models for known clinical arrhythmic conditions in which 248 
these mechanisms were modified by genetic, physiological or pharmacological manipulation. These 249 
exemplars yielded molecular, physiological and structural phenotypes often directly translatable to their 250 
corresponding clinical conditions, which could be investigated at the molecular, cellular, tissue, organ and 251 
whole animal levels. Arrhythmogenesis could be explored during normal pacing activity, regular 252 
stimulation, following imposed extra-stimuli or during progressively incremented steady pacing frequencies. 253 
Arrhythmic substrate was identified with temporal and spatial functional heterogeneities predisposing to re-254 
entrant excitation phenomena. These could arise from abnormalities in cardiac pacing function, tissue 255 
electrical connectivity, and cellular excitation and recovery. Triggering events during or following recovery 256 
from action potential excitation could thereby lead to sustained arrhythmia. These surface membrane 257 
processes were modified by alterations in cellular Ca2+ homeostasis and energetics, as well as cellular and 258 
tissue structural change. Study of murine systems thus offers major insights into both our understanding of 259 
normal cardiac activity and its propagation, and their relationship to mechanisms generating clinical 260 
arrhythmias.  261 
I. INTRODUCTION  262 
(A) Scope of review 263 
 Cardiac arrhythmias result from disruption of the orderly physiological sequence of electrical 264 
excitation processes that initiates co-ordinated and effective cardiac contraction. Of the wide clinical variety 265 
of arrhythmic variants, ventricular arrhythmias, particularly ventricular fibrillation (VF), often preceded by 266 
ventricular tachycardia (VT), potentially leads to sudden cardiac death (SCD), defined as unexpected death 267 
from cardiac causes occurring <1 hour after onset of symptoms (971, 1152). This major worldwide source of 268 
morbidity and mortality causes >300,000 and ~70,000 deaths/year in the United States (USA) (535) and 269 
United Kingdom (UK) (215) respectively. Cardiac causes likely account for 56.4% of non-traumatic, sudden 270 
death in autopsies of patients aged 5 to 35 years. Amongst these, arrhythmic causes likely account for ~30% 271 
of cases. Although most of the latter cases result from ischaemic heart disease (87), autopsy fails to reveal a 272 
cause in ~4% of SCD cases and 14% of all resuscitation attempts performed on patients aged <40 years 273 
(206, 738–740, 1149). Furthermore, such deaths often occur in the absence of structural abnormalities. This 274 
suggests the possibility of underlying channelopathy (116, 1122). Of deaths in infants <1y, 60–80% are 275 
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autopsy-negative. They are accordingly defined as sudden infant death syndrome (SIDS) (47). 10–20% of 276 
these cases may result from channelopathy (575). Finally, arrhythmogenesis as a possible adverse effect of 277 
pharmacotherapeutic agents constitutes an important clinical problem with significant implications for 278 
pharmaceutical drug discovery (564). 279 
 Atrial arrhythmias are similarly becoming increasingly clinically and demographically important. 280 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, with an overall prevalence of 281 
around 1% to 2% of the general population (30, 683, 1093). AF is often associated with advancing age. It 282 
affects 4.7% and 9% of individuals of age >65 y and between 80-89 years respectively (285, 1212). It 283 
predisposes to further, major, cardiac and cerebrovascular morbidity and mortality (1093). Thus it increases 284 
risks of stroke fivefold (1268).  285 
 Sinus node disorder (SND) causes sinus bradycardia, sinus pause/arrest, chronotropic incompetence 286 
and sino-atrial node (SAN) exit block (271). Its incidence increases exponentially with age to one in ~600 287 
cardiac patients aged >65 years. It is responsible for ~50% of the million permanent pacemaker implants per 288 
year worldwide often in otherwise healthy individuals (272, 731).  289 
 Cardiac arrhythmogenesis poses significant clinical challenges in terms of both risk stratification and 290 
management (986). The latter are limited by our current inadequate understanding of the physiological 291 
mechanisms underlying initiation, maintenance or propagation of cardiac arrhythmias, whether in the atria, 292 
ventricles or the conducting tissues within or between them. Much valuable data has derived from human 293 
studies. However, much of this is inevitably observational. Physiological animal models of arrhythmic 294 
disease, whether involving pharmacological interventions or targeted genetic changes, permit more 295 
analytical studies of mechanisms and their consequences. Of these systems, transgenic mouse models are a 296 
relatively recent addition to other animal, rabbit and canine, systems. They offer a means of genetic and 297 
physiological manipulation that can be effectively directed at particular molecular targets strategic to cardiac 298 
electrophysiological function.  299 
This review describes studies using some of these approaches, relating arrhythmic phenomena to 300 
cardiac electrophysiological properties. The latter in turn bear upon the generation of atrial or ventricular 301 
action potentials (APs), any abnormal, triggered activity accompanying such events, and associated 302 
metabolic and structural changes. The analysis is made in the light of the features of different exemplars 303 
modifying the activity of specific ion channels, cellular properties or tissue or chamber structure. This 304 
involves first summarising the roles of the major ion channels that underly cardiac electrophysiological 305 
excitation, and the consequent excitation-contraction coupling processes involving the release and re-uptake 306 
of sarcoplasmic reticular (SR) store Ca2+. Alterations in these processes are next related to the properties of 307 
genetic murine exemplars of ion channel dysfunction. These include models for altered gap junction 308 
function compromising the spread of excitation, losses and gains of function in the Na+ , K+ and Ca2+ 309 
channels, and their subunits and associated proteins, affecting cell excitability, and ryanodine receptor 310 
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(RyR2) modifications affecting cellular Ca2+ homeostasis. Finally, further upstream, metabolic, energetic 311 
and structural changes are considered in relation to human arrhythmic conditions.  312 
 (B) Normal physiology of cardiac excitation 313 
(1) Ion current contributions to cardiac action potentials 314 
 Effective cardiac function depends upon repetitive cycles of AP excitation followed by recovery and 315 
the propagation of these events through the myocardial or conducting tissue as coherent electrical waves. 316 
This conduction takes place successively through the SAN, atria, atrioventricular bundles, purkinje 317 
conducting tissue and ventricular endocardial and epicardial myocardium. Repetitive atrial and ventricular 318 
excitation cycles normally depend upon SAN automaticity driven by pacemaker cells (See Section III(A)). 319 
The typical human ventricular AP waveform begins with a rapid (~400 V s−1) initial, phase 0, 320 
depolarisation. This is driven by a rapidly increasing voltage-gated Na+ current (INa) (~400 μA μF−1). This 321 
drives the myocardial membrane potential from its normal negative (~-90 mV) resting potential to a positive 322 
(+40 to +60 mV) voltage close to the Na+ Nernst potential (Figure 1A, and Table 1). This is followed by a, 323 
phase 1, initial rapid repolarisation from this positive value that results from both inactivation of INa and the 324 
activation of fast and slow transient outward (Ito), K+,  Ito,f and Ito,s, currents (Figure 1B, C) (Reviews: (71, 325 
827, 863, 1020, 1255)). 326 
 This partial recovery is then followed by a phase 2, plateau, phase brought about by the activation of 327 
Ca2+ current (ICaL) through voltage-gated L-type Ca2+ channels often termed dihydropyridine receptors 328 
(DHPRs), reflecting their pharmacological sensitivities (107, 131, 556, 1319).  329 
 The action potential is then terminated by a Phase 3 repolarisation. This returns the membrane to its 330 
resting potential. This is driven by outward currents mediated by a species-dependent variety of K+ 331 
channels. In human ventricles, these include the delayed rectifier IKr (1169) and IKs (1097), inwardly 332 
rectifying IK1 (693), and 2-pore domain K+ leak currents (IK2p) (1020).  333 
 This culminates in full repolarisation to electrical diastole (phase 4), in which the inward rectifying 334 
current IK1 plays a major part in maintaining a fully polarised (~-90 mV) resting potential.  With 335 
repolarisation, Nav1.5 channels recover their capacity for re-excitation. This recovery takes place over both 336 
absolute and relative relative (effective) refractory periods, ERPs. Following this, Nav1.5 channels become 337 
capable of beginning the next excitation cycle.   338 
 Atrial APs begin from more depolarised resting potentials. The latter mainly reflects their smaller 339 
IK1. They show triangular waveforms with a more prominent phase 1 recovery reflecting a larger Ito. Atrial 340 
myocytes also specifically express ultra-rapid delayed rectifier K+, IKur (1256), acetylcholine-activated, K+, 341 
IKACh, and Ca2+-activated K+ currents, IKCa (1020, 1257). They show a less prominent phase 2 plateau phases 342 
than observed in ventricular APs. This is the consequence of smaller IKr, IKs and IK1 currents but a more 343 
prolonged phase 3 repolarisation (822).  344 
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 Finally, adenosine triphosphate (ATP)-sensitive K+ current, IKATP occurs throughout the heart but 345 
generally accounts for relatively little current due to its inhibition by intracellular ATP (320, 324). However, 346 
IKATP may be activated under conditions of energetic stress (324, 419, 486, 1024). 347 
 (2) Excitation-contraction coupling 348 
 Excitation-contraction coupling in ventricular myocytes is initiated by the surface membrane 349 
depolarization described above and the transmission of this electrical change into the transverse tubules. 350 
This results in an opening of voltage-gated L-type Ca2+ channels within the membranes of the transverse 351 
tubules, which then mediate the inward Ca2+ currents, ICaL, responsible for the phase 2 plateau phase of the 352 
AP. The accompanying influx of extracellular Ca2+ produces a local elevation of cytosolic Ca2+ 353 
concentration, [Ca2+]i, in regions of the sarcolemmal–SR junctions (107). This triggers an opening of cardiac 354 
SR RyR2 Ca2+ channels by a process of Ca2+-induced Ca2+ release (CICR) (298). The resulting release of 355 
intracellularly stored SR Ca2+ produces the elevation of cytosolic Ca2+ concentration, [Ca2+]i, that drives the 356 
Ca2+-troponin binding which triggers mechanical activation. The cytosolic Ca2+-mediated regulation of 357 
cardiac, RyR2-Ca2+ release channel activity is facilitated by SR luminal Ca2+ (395, 622, 1069, 1285) and 358 
cytosolic ATP. It is inhibited by cytosolic Mg2+ (see Section VII(A)) (1313). RyR2 is also sensitive to thiol-359 
oxidation and reactive oxygen species (ROS) which may disrupt its interdomain stability (See Section 360 
VIII(A)) (785). The CICR process in cardiac muscle contrasts with the control of RyR1 opening by the more 361 
rapid direct allosteric control by voltage-dependent configurational changes in the DHPR in skeletal muscle. 362 
It explains the contrasting dependence and relative independence of these respective excitation contraction 363 
coupling processes upon extracellular [Ca2+] (458, 462). It also contrasts with RyR2 function in inexcitable 364 
osteoclasts in which the RyR2 assumes a surface rather than an endoplasmic membrane site (460, 1314–365 
1316).  366 
 The smaller atrial myocytes possess less prominent transverse tubular networks, particularly in 367 
hearts of small mammals such as the mouse. Their SR membranes are differentiated into: (1) corbular 368 
regions that form junctional elements close to the cell periphery. These regions are flanked by clusters of 369 
surface membrane L-type Ca2+ channels and SR membrane RyR2-Ca2+ release channels. (2) Noncorbular 370 
SR in the cell interior also contains membrane regions that express RyR2 but do not show this proximity to 371 
the cell surface. Depolarisation of the cell surface membrane triggers entry of extracellular Ca2+ through the 372 
activation of ICaL, resulting in a local increase in [Ca2+]i. This induces RyR2-mediated Ca2+-induced Ca2+ 373 
release at corbular SR. The resulting local elevation of [Ca2+]i then initiates Ca2+-induced Ca2+ release and 374 
its propagation through in adjacent, deeper regions of noncorbular SR. This results in an inward, centripetal, 375 
propagated Ca2+-induced Ca2+ release wave by noncorbular cytoplasmic SR within the cell interior (128, 376 
419, 521, 710, 1335, 1338). 377 
 (3) Recovery from excitation 378 
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Contractile relaxation follows reduction in the elevated [Ca2+]i back to baseline levels. This permits 379 
Ca2+-troponin dissociation. Cytosolic [Ca2+] is reduced by Ca2+ transport activity by SR Ca2+-ATPase 380 
(SERCA2), sarcolemmal Na+/Ca2+ exchange through the Na+/Ca2+ exchanger (NCX), the slow systems 381 
represented by sarcolemmal Ca2+-ATPase (PMCA) and mitochondrial Ca2+ uniport. The relative 382 
contributions of these different Ca2+ transport mechanisms to the restoration of resting levels of [Ca2+]i 383 
varies with species (110). In rabbit ventricular myocytes, SERCA2a activity eliminates 70%, NCX removes 384 
28%, and the slow systems ~1% of  released Ca2+ with similar levels for ferret, dog, cat, guinea-pig and 385 
human ventricle (450). Corresponding contributions in rat and mouse ventricle are 92%, 7% and 1% 386 
respectively (78, 140, 653).  387 
Of these processes, the NCX exerts potentially important effects on membrane potential through its 388 
electrogenic effects. These can contribute to arrhythmic tendency. Each cycle of NCX activity translocates 389 
1Ca2+ from the intracellular to the extracellular space in return for a transfer of 3Na+ in the opposite 390 
direction. This results in a net current, INCX, whose reversal potential depends upon both the Na+ and Ca2+ 391 
Nernst potentials, ENa and ECa, giving ENCX = 3ENa-2ECa. ENCX therefore falls within the range of voltages 392 
traversed by normal physiological activity. Consequently, whether INCX takes an inward, depolarising or 393 
outward, hyperpolarising direction varies with the changes in both [Ca2+]i and membrane potential that take 394 
place through the cardiac cycle. Thus, INCX takes an inward direction and exerts a depolarising effect on 395 
membrane potential under conditions when [Ca2+]i is elevated and thereby drives Ca2+ efflux. Conversely, 396 
INCX takes an outward direction exerting a hyperpolarising effect on membrane potential when [Ca2+]i is 397 
relatively low thereby driving Ca2+ influx. The pattern of INCX activity also varies with species-related 398 
differences in AP waveform. The long plateau phase in rabbit ventricular APs results in a sustained INCX-399 
mediated Ca2+ influx through the AP plateau phase (165). Following repolarisation, a large outward 400 
electrochemical gradient then drives Ca2+ efflux. In contrast, the short AP in rat ventricles results in a rapid 401 
initial INCX-mediated Ca2+ influx but this is followed by a more marked Ca2+ efflux. This results in a more 402 
rapid removal of the added Ca2+ load arising from electrical excitation and a lower subsequent diastolic 403 
NCX activity (1042). Either of these effects potentially modify the action potential duration (APD) (Figure 404 
1A, B) (265, 1025). 405 
 Of the overall energetic cost of contractile and excitable cardiac activity, ~60-70% of this cellular 406 
ATP is consumed by cardiac muscle contraction. The remainder maintains Ca2+ homeostasis and the 407 
transmembrane ion gradients.  408 
(C) Propagation of excitation 409 
(1) Electrical current flow between cardiac cells  410 
 The subsequent propagation of cellular-level events through conducting, atrial or ventricular tissue 411 
first involves a local spread of electrotonic excitation currents. These are driven typically in the more rapidly 412 
conducting cardiac tissues by INa (137, 496, 1043). Cable theory classically describes this current flow along 413 
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a constant intracellular, axial resistance ra from one depolarised myocyte to its quiescent neighbour (492, 414 
577). In cardiac tissue, ra reflects the electrical resistances formed respectively by the cytosol and 415 
intercellular gap junctions connecting successive adjacent cells. An axial current, ia, having traversed the 416 
resistance ra, then discharges the membrane capacitance, cm, of neighbouring quiescent cells. Where this 417 
resulting depolarisation exceeds the activation threshold of its voltage-sensitive Na+ channels this results in a 418 
regenerative production of further transmembrane depolarising currents in that cell. This continues the AP 419 
propagation process. Thus, in cardiac cells, resistance to conduction through intercellular gap junction 420 
channels, the membrane capacitance and the magnitude of INa are critical to AP propagation (958). 421 
(2) Determinants of conduction velocity 422 
 The velocity θ of AP conduction along a simple one-dimensional uniform cylindrical fibre of excitable 423 
tissue can be approximated by a nonlinear cable equation (550, 902). This has been applied to biological 424 
membrane with circuit elements that each incorporate a capacitance of unit fibre length, cm, (typically 425 
expressed in units of μF cm-1) in parallel with a linear membrane resistance of unit fibre length rm (kΩ cm). 426 
The membrane additionally contains further, nonlinear, time and voltage-dependent, membrane 427 
conductances representing the properties of its contained individual ion channels. These together generate 428 
the time (t) dependent total membrane ionic current ii (A cm-1) in unit fibre length, x (cm). Successive circuit 429 
elements are connected by terms arising from cytoplasmic resistances and the gap junction resistances 430 
between cells (See Section IV) (262, 1181). Any one of these factors could be modified by changes 431 
including tissue fibrosis or inflammatory processes (see Sections V(E), V(F) and IX(A)).  432 
 The membrane potential, V, at any given membrane site then depends on the charging of its unit 433 
length by currents traversing the membrane, ii, as well as the axial current flow, ia, coming from 434 
neighbouring regions along the length, x, of the membrane area in question through the equation:  435 
   (Eqn. 1) 436 
This equation reduces at constant conduction velocity, θ = dx/dt to: 437 
  (Eqn. 2) 438 
This simplified interpretation identifies ra, cm and ii as key determinants of θ, although interdependences 439 
between some of the terms involved preclude analytic solution (471). Explicit prediction instead requires 440 
numerical solution of a stiff equation involving iterative estimates of θ (492). This is particularly given 441 
potential further contributions from other membrane components including transverse tubular membrane 442 
resistances and capacitances, tubular luminal geometry and its resistance, and nonlinear capacitances (9, 443 
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457, 1047). A full cable analysis of AP propagation would also be required to incorporate the three-444 
dimensional nature of cardiac geometry.  445 
 Nevertheless, a number of useful, simple relationships between θ and its determinants arise from 446 
computational studies of one-dimensional electric current flow in skeletal muscle fibres whose APs 447 
upstrokes are similarly dominated by fast INa (330, 567, 880). These confirm the importance of iNa during the 448 
AP upstroke, and that the maximum Na+ current,  449 
iNa(max) α log(PNa(max)) (R2 = 0.9965).    (Eqn. 3) 450 
PNa(max) is the maximum permeability produced by the fast Na+ channels. It is accordingly dependent on Na+ 451 
channel density. Of the key determinants of θ, ra does not influence the AP waveform. It thus does not 452 
influence either its rate of upstroke voltage change, as given by the first derivative (dV/dt), or its second 453 
derivative (d2V/dt2), though the cable equation [2] predicts that θ2 α 1/ra. In contrast, increased cm does alter 454 
AP waveform. It reduces both dV/dt and d2V/dt2 as well as reducing θ, giving the simple approximations:  455 
θ2 α 1/cm,       (Eqn. 4) 456 
(dV/dt)max α log(cm),     (Eqn. 5) 457 
 and: (d2V/dt2)max α 1/cm,    (Eqn. 6)  458 
The subscript max designates the maximum value of the parameter in question. Finally, it is difficult to 459 
obtain analytic relationships between iNa(max) and θ. Nevertheless, it is possible to demonstrate the 460 
straightforward empirical relationship:  461 
θ α iNa(max),       (Eqn. 7) 462 
 and the following effects of iNa(max) upon AP waveform:  463 
(dV/dt)max α      (Eqn. 8) 464 
 and: (d2V/dt2)max α iNa(max)3.     (Eqn. 9) 465 
This cable analysis, confined to a simple cylindrical, geometrically one-dimensional, structure, can be 466 
generalised to a continuous electrically-coupled myocyte network. This provides cable equations extended 467 
from one to three dimensions analysing the conduction velocity resulting from a matching of current and 468 
load (577, 599). Such an approach has been used to characterise the passive cable properties of cardiac 469 
muscle including its relationships between dV/dt and macroscopic (>1 mm) propagation and altered cell to 470 
cell coupling (576, 1246). 471 
(3) Repolarisation gradients and action potential wavelength 472 
 Finally, normal atrial and ventricular myocardium shows a highly ordered sequence of AP 473 
repolarisation and return of the membrane to resting conditions. In the ventricular myocardium, this 474 
typically proceeds transmurally from epicardium to endocardium and from base to apex. These features 475 
reflect regional differences in K+ channel density and kinetics. This results in the normal spatial 476 
repolarisation gradients that may normally protect the orderly electrical and mechanical activation sequence. 477 
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This thereby ensures correctly timed and coordinated mechanical activation and relaxation of the chamber 478 
concerned. In contrast to the ventricles, the thinner walled atria do not show a marked transmural 479 
differentiation into epicardial and endocardial tissues. The geometrical distribution of excitable events then 480 
occur only within the plane of the atrial wall.  481 
 Together, the velocity θ of AP propagation and the recovery parameters of APD or the effective 482 
refractory period (ERP) define the AP wavelength (λ = θ. APD or θ.ERP). The APD reflects the period 483 
during which the membrane deviates from its normal resting value. It may closely correlate with the ERP in 484 
normally functioning canine and human hearts (243, 329, 624). The latter provides an indication of the time 485 
during which there is reduced likelihood of ectopic or re-entrant action potential activation in the membrane 486 
behind the propagating excitation wavefront. However, ERPs can be selectively affected by factors that need 487 
not similarly affect APD. These include alterations in the maximum amplitude and activation or inactivation 488 
kinetics of INa and IK, the amplitudes and durations of applied stimuli and myocyte injury and ischaemia 489 
(975). Subsequent sections will consider VERP-ERP differences and their significance in pro-arrhythmic 490 
situations including Brugada syndrome (Section V(C)(5) (50, 734) and hypokalaemia (Section V(E))(978).  491 
 However, measurement of ERP, typically from the shortest S1S2 interval following the last (S1) 492 
pacing stimulus at which a subsequent extrasystolic S2 stimulus elicits an AP, itself poses pose problems 493 
under particular experimental circumstances. Thus: (1) Some protocols are not amenable to such direct 494 
determinations of ERPs, yet (2) ERPs themselves vary with pacing protocol. (3) The observed ERPs 495 
critically depend upon the relationship between stimulus and recording sites. A detectable AP requires its 496 
successful propagation through the entire tissue pathway from stimulating to recording electrode. The 497 
resulting ERP consequently actually reflects recovery from refractoriness over the entire line of tissue 498 
between stimulus and recording sites. (4) This condition poses further problems for determinations of spatial 499 
ERP heterogeneities between recording sites. The difficulties are compounded if stimulus and recording 500 
sites have differing ERPs. (5) ERP determinations are further affected by conduction velocities in the paths 501 
intervening between stimulus and recording sites. This demonstrated in comparisons of ERP measurements 502 
(a) at the stimulus site itself, ERPs, and (b) the ERPr, given by the time interval separating AP upstrokes, at 503 
the recording site. ERPr then did not equal ERPs when the conduction velocity of the AP produced by the S1 504 
stimulus differed from the conduction velocity of the AP produced by the S2 stimulus. These discrepancies 505 
were accentuated at high pacing rates close to refractoriness, and with increasing distance between 506 
stimulation and recording sites (734). (6) Whereas absolute refractory period may be regarded as an 507 
invariant value, ERP depends upon the value of the effective stimulus intensity at the site of membrane 508 
excitation. Thus, an adaptive S1S2 protocol demonstrated differing ERPs corresponding to differing 509 
magnitudes of S2 extrastimulus. Representations involving ERP, rather than APD, are thus strongly 510 
dependent upon applied stimulus voltage (281).  511 
 The wavelength parameter nevertheless provides a useful description of the spatial extent of 512 
excitation by the travelling wave.  Larger values of λ would result in a reduction of the likelihood that areas 513 
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of depolarisation and repolarisation meet on encountering tissue heterogeneity. The resulting safety factor 514 
would then ensure that the traveling wave completely passes over the heterogeneity without disruption 515 
(1251). Conversely a decreased value of λ would increase the likelihood of a wave breakup into into 516 
multiple wavelets, formation of scroll-waves (244, 866, 1317), and a positive feedback formation of further 517 
wavebreaks giving wavelets along chaotic conduction pathways corresponding to VF (1084). For example, 518 
where alterations in heart rates decrease APD, ERP or θ they could thereby alter AP wavelength λ and 519 
thereby potentially exert arrhythmic effects (595, 753).  520 
 Figure 2 illustrates such situations for a sequence of murine AP waveforms (753). The relevant 521 
parameters can be quantified, in terms of their basic cycle lengths (BCL), APDs at 90% repolarisation 522 
(APD90), latencies and corresponding diastolic interval, DIs, at 90% repolarisation (DI90) separating the 523 
current and preceding action potentials.Together these yield active and resting wavelengths λ’ and λ0’ 524 
(Figure 2A). The latter sum together to give a basic cycle distance, BCD’ (Figure 2B). When an AP with 525 
long λ’ passes over a heterogeneity that can potentially cause conduction block, the back of the propagating 526 
wave blocks retrograde propagation. This leaves only an orthograde excitation wave (Figure 2C). In contrast 527 
when λ’ is short, the back of the wave passes the heterogeneity before retrograde excitation has passed 528 
through the unidirectional block. This initiates a new propagating retrograde wave which potentially sets up 529 
a sustained re-entrant circuit (Figure 2D). 530 
II. ARRHYTHMOGENESIS: DISRUPTION OF ORDERED EXCITATION AND 531 
CONDUCTION 532 
(A) Electrophysiological conditions initiating and perpetuating arrhythmia 533 
(1) Triggering events at the cellular level 534 
 Arrhythmias result from an inappropriate generation, or a breakdown in the orderly sequencing, of 535 
cardiac electrical activity. They often follow triggering events, and then take place in tissue with intrinsic 536 
instabilities resulting in arrhythmic substrate (284, 529, 931, 1111). Events reflecting such phenomena could 537 
occur at the single-cell level, during propagation of excitation at the tissue level, or at the level of entire 538 
cardiac chambers (560, 981).  539 
 At the cellular level, triggered activity results from extrasystolic membrane depolarisation that could 540 
potentially generate premature APs, and therefore, triggered beats, following an otherwise normal AP, if the 541 
voltage changes that they produce are sufficiently large. Of these, early after-depolarisations (EADs) 542 
intercept the repolarisation timecourse of a prolonged AP. They thereby permit time for L-type Ca2+ channel 543 
recovery from inactivation in a still depolarised membrane. The re-activated inward ICaL then produces a 544 
further depolarisation. This initiates a positive feedback process resulting in the afterdepolarisation 545 
potentially triggering AP firing (498). In contrast, delayed after-depolarisations (DADs) follow full AP 546 
repolarisation. They can result from an enhanced SR Ca2+ release. This in turn increases activation of 547 
electrogenic NCX or Ca2+ activated Cl- transient inward (Iti) currents. DADs are associated with conditions 548 
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of Ca2+ overload as occurs in digitalis toxicity and catecholaminergic polymorphic ventricular tachycardia 549 
(CPVT) (509). In the atria, triggering can also arise from the pulmonary or the superior caval veins and may 550 
thereby trigger episodes of AF (190) (See Section VIA and VIIA). 551 
 Rarer causes of arrhythmias initiated by abnormal AP triggering at the cellular level include the 552 
enhanced automaticity resulting from accelerations in depolarisation of pacemaker tissue. This might follow 553 
increased sympathetic activity, hypokalaemia or pharmacological intervention. In addition, parasystole 554 
could result from a parallel activation of two or more pacemaker regions (32).  555 
(2) Spatial electrophysiological heterogeneities at the tissue level 556 
At the tissue level, failure of the AP wave to completely extinguish after normal activation, leading to re-557 
excitation of regions that had hitherto recovered excitability can result in a re-entrant excitation. This can 558 
occur in the presence of spatial electrophysiological heterogeneities that result in (a) an obstacle around 559 
which the AP can circulate provided (b) this occurs with slowed conduction velocities that would permit 560 
each region to recover excitability before the wave returns, in the presence of (c) a unidirectional conduction 561 
block. The latter might occur with spatial gradients in the latency separating stimulation and depolarisation 562 
or the time between depolarisation and the end of the ERP (see Section V(C)) (740). Either would prevent 563 
the wave from self-extinguishing (778).   564 
 Figure 3 reconstructs the generation of arrhythmic substrate through such a combination of 565 
conditions. It illustrates the consequences of introduction of a slow conducting myocardial pathway passing 566 
through non-conducting myocardium (path 1; dark gray). This is bordered by a second pathway of normal 567 
myocardium (path 2; white). A normal AP (blue arrow) would propagate along path 2 following excitation 568 
(Figure 3A(i)). The myocardium then becomes refractory. As indicated above (Section I(C)(2)), the resulting 569 
normal action potential travelling along path 2 possesses an excitation wavelength λ (yellow region). 570 
Consequently the impulse conducting along path 1 cannot re-enter the circuit as it would collide with 571 
refractory tissue in path 2 (Figure 3A(ii)). Similarly, when an abnormal impulse from an ectopic focus is 572 
triggered immediately following the normal AP it cannot enter path 1 as this remains refractory (Figure 573 
3B(i)). It therefore splits at the end of path 2 to conduct retrogradely along path 1 and orthogradely along 574 
path 2 (Figure 3B(ii)). In contrast, a self-perpetuating re-entrant excitation can result when (i) an action 575 
potential conducting retrogradely along path 1 enters the beginning of path 2 (Figure 3C(i)) under conditions 576 
of (ii) reduced conduction velocity (θ) and/or reduced effective refractory period (ERP). The latter result 577 
together in a reduction in excitation wavelength (λ = θ × ERP), to values smaller than the dimensions of the 578 
available circuits (Figure 3C(ii)). This results in persistent re-entrant excitation (567). 579 
 Data from both canine right ventricular (RV) wedge preparations (801, 802) and the Scn5a+/ΔKPQ 580 
mouse model (see section VI(B)) further implicate re-entry arising from repolarisation abnormalities as 581 
exemplified by their epicardial dispersions of repolarisation in triggering ventricular arrhythmia. The 582 
simplest example of this might arise from substrate for re-entrant excitation arising from relative changes in 583 
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two key parameters describing the recovery from excitation. Thus, windows of re-excitation have been 584 
suggested in situations where critical intervals result from positive time differences between full action 585 
potential repolarisation and the refractory period. These parameters are often quantified by APD90 and 586 
VERP respectively. This could take place within, or between adjoining areas of myocardium, and are 587 
exemplified in Section V(E)(4) (978). 588 
 At the level of individual cardiac chambers, disruption of the normal sequence of repolarisation 589 
following the depolarisation wave accentuates arrhythmic tendency (1012). Mammalian ventricular 590 
myocardium normally shows a consistent and regular sequence of repolarisation. This proceeds from 591 
epicardium to endocardium resulting in a transmural repolarisation gradient that optimises the normal 592 
sequence and co-ordination of electro-mechanical activation and relaxation (see Section VI(A)(4)). These 593 
spatial differences are mainly determined by regional differences in repolarising K+ channel densities. 594 
Disturbances in these gradients may permit regions of depolarisation to re-entrantly re-excite already 595 
recovered areas (see Section VI(A)(2)).  596 
 Transmural gradients may be particularly important in producing repolarisation differences across 597 
relatively short distances. They have been implicated in a number of both canine models subject to 598 
pharmacological manipulation and murine models genetically modified to reproduce the Brugada (BrS) (see 599 
Section V) and long QT syndromes (LQTS) (See Section VI). In addition, a number of animal models show 600 
ventricular, base-to-apex, heterogeneities in AP characteristics (see Section VI). In human clinical situations, 601 
increases in this dispersion have been associated with arrhythmogenesis in cardiomyopathies, and have been 602 
related to increased incidences of T wave alternans and VT (181). Finally, left-right interventricular 603 
differences in APD have been implicated in arrhythmogenesis in BrS. BrS patients show characteristic right 604 
precordial electrocardiographic ST elevation, right bundle branch block and changes specific to RV 605 
epicardial AP waveforms (605) (See Section V(D)). 606 
(3) Temporal electrophysiological heterogeneities at the tissue level 607 
 Temporal electrophysiological heterogeneities may appear as beat-to-beat variations in AP 608 
amplitude or duration. These instabilities have been clinically associated with the appearance of alternans in 609 
electrical properties between beats. T-wave alternans reflecting alternating time courses in successive 610 
ventricular APs classically precedes breakdown of regular electrophysiological activity and an onset of 611 
major arrhythmias. Both T-wave alternans and dispersion of the QT interval thus constitute risk stratification 612 
markers in both patients susceptible to sustained ventricular arrhythmias (46, 823, 966) and experimental 613 
situations (872). At the cellular level, several hypotheses have suggested possible, potentially coexistent, 614 
mechanisms. Voltage-driven alternans can arise from instabilities in membrane voltage resulting from steep 615 
APD restitution properties (413, 838). These can reflect the properties of depolarising, INa, or repolarizing 616 
currents including Ito (701), Kir3.x in the case of atrial alternans (126), and currents giving rise to EADs 617 
(1005). Membrane voltage is also influenced by the Ca2+-sensitive ICaL, INCX, IKs and Ca2+ activated SK 618 
channels (1004, 1050, 1309, 1333). Nonlinearities can occur in intracellular Ca2+ cycling itself (894, 920, 619 
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1218). The latter can become unstable with SR Ca2+ overload, RyR2 sensitisation, or at high pacing rates. 620 
These can result in steep SR Ca2+ release vs SR Ca load relationships giving Ca2+ restitution properties 621 
predisposing to [Ca2+]i-driven alternans (204, 1050). At the tissue level, the resulting alternans may be 622 
spatially concordant in which the alternations in adjacent regions of a tissue are in phase, or discordant, 623 
when these are out of phase. 624 
 APD alternans may be an important mechanism for the generation of arrhythmic substrate. Spatially 625 
concordant alternans is not itself arrhythmogenic. However, it may represent a stage that precedes the 626 
development of discordant alternans. Discordant alternans in adjacent tissue areas produces APD gradients 627 
across their intervening regions which are separated by a nodal line region not showing alternans (872, 628 
1236). Discordant alternans greatly amplifies the dispersion of refractoriness, generates regions of 629 
conduction block, and predisposes to figure-of-8 re-entry phenomena. Triggered activity within the area 630 
with the short APD that propagates directly to the nodal line then likely collides with the electrical activity 631 
in the area with the long APD whilst this is still depolarised and refractory. It will then become extinguished. 632 
However, where its propagation is less direct over a longer distance, it would reach the nodal line at a later 633 
time when the area with the long APD has recovered (Figure 3 of (1250)). It would then induce re-excitation 634 
and a re-entrant circuit leading to VT, wavebreak and evolution into VF (928, 1236). 635 
(4) Heterogeneities arising from restitution phenomena 636 
 APD restitution phenomena were first reported in classic cardiac electrophysiological papers 637 
describing alternations in excitation duration, later measurable by intracellular recording as APDs, with 638 
increasing heart rate (436, 778). The subsequent classical analysis described below arose form observations 639 
that APDs recorded from canine papillary muscle decreased with increasing steady-state pacing rate. The 640 
latter findings had led to the development of a restitution theory seeking to integrate such observations 641 
(838). This theory has been recently successfully applied to murine hearts (979, 982) (See Sections V(C)(6) 642 
and VI(A)(5)).  643 
 The restitution analysis seeks to graphically predict the occurrence and magnitude of alternans with 644 
alterations in heart rate (Figure 4A). It does so through the expected oscillatory properties of a negative 645 
feedback system. The output of such a system, O is considered to be the result of an amplification, G, of an 646 
input I. The latter is itself controlled by an independent variable, X: 647 
     (Eqn. 10) 648 
The output, O in turn influences the input, to an extent which depends upon a fraction of the output (F) and 649 
the independent variable (X):  650 
     (Eqn. 11) 651 
The solution of these simultaneous equations [10] and [11] corresponds to the points of their graphical 652 
intersection. These thereby yield the set points giving the input I and output O at any value of X. The 653 
original analysis adopted as input variable the diastolic interval (DI) over which the membrane is restored to 654 
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the resting potential. Over this period, the membrane is recovering following the AP. The output variable is 655 
the APD. This is itself dependent upon the preceding DI. Thus, for any given, nth, beat:  656 
    (Eqn. 12) 657 
The independent variable controlling DI is the BCL. The DI in the subsequent, (n+1)th beat, DIn+1, depends 658 
upon both the BCL and the APD in the previous, nth beat, APDn:  659 
  (Eqn. 13) 660 
An A curve was obtained by plotting the output variable of APD against the input variable of DI. A family 661 
of D lines each taking the form:  662 
    (Eqn. 14) 663 
with a consistent negative unity gradient but variable ordinate intercepts set by the BCL was then plotted 664 
between the same axes. The intersection between the D line and the A curve would give the solution for for 665 
the steady-state APD and DI.  666 
 A perturbation in heart rate would result in an immediate transition between two separate D-lines 667 
representing the respective BCLs. A horizontal line from the steady-state point on the A curve to the new D 668 
line would then give the magnitude of the first subsequent DI. A vertical line drawn from there to the 669 
corresponding A-curve would give the corresponding subsequent APD. Graphical representations for the 670 
different cases are shown numbered [1] to [4] in Figure 4A. Each case would yield different predictions for 671 
the outcomes generated by continuation of this process. These would depend upon the gradient of the A-672 
curve at its intersection with the D line, and its variation with DI in this region.  673 
 Where this intersection occurs in a region of the A curve where its slope is zero (Figure 4A, point 1), 674 
a final steady-state APD is immediately reached without oscillations. Where the slope at the intersection 675 
falls between zero and unity (Figure 4A, point 2), the successive projection lines converge towards and 676 
ultimately attain the set point. Each corner on the A-curve then represents an individual oscillation, 677 
producing a transient alternans. With an intersection at a critical DI, DIcrit, where the the A curve assumes a 678 
unity slope, the projection lines form a square. The oscillation then does not converge (Figure 4A, point 3). 679 
This results in a sustained alternans whose magnitude is determined by the size of the square. Finally, where 680 
the intersection takes place in a region on the A curve where its slope is greater than unity, the progressive 681 
projections take a centrifugal trajectory. They thus veer away from the left-hand limit of the A-curve 682 
producing conduction block (Figure 4A, point 4). This state, particularly when heterogeneous across the 683 
myocardium may cause re-entry (754). 684 
 These different conditions can then be related to the remaining parameters describing cellular 685 
excitability in a fuller generic analysis of the restitution function. Figure 4B illustrates this development 686 
using the relationship relating APD90 to DI90 through different BCLs. In addition to the conventional 687 
measures of critical diastolic interval (DIcrit) and maximum gradient (mmax) this maps the maximum APD, 688 
APDmax, at low heart rates, DI90 at the effective refractory period (DIERP), and the horizontal axis intercept of 689 
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the restitution function, (DIlimit) corresponding to absolute refractoriness. These additional limits permit 690 
definition of different stability conditions within the plane of the restitution function. Thus stability would 691 
correspond to the condition when the gradient of the restitution function, m ≤ 1 as outlined above (unshaded 692 
areas). Instability would be expected under conditions when DIcrit > DI90> DIERP (filled areas). This would 693 
manifest in occurrence of either nonsustained (Figure 4C) or sustained arrhythmia (Figure 4D). These are 694 
exemplified in the recordings from murine Scn5a+/- RV epicardia at two respective BCL values (134 ms 695 
and 124 ms respectively). Relative loss of capture would be expected in the interval DIERP > DI90> DIlim, 696 
(dotted areas) and complete loss of capture when pacing takes place at a BCL shorter than the absolute 697 
refractory period when DI90<DIlim (hatched areas) (752). 698 
 The first restitution (A-) curves were deduced from transmembrane APs in isolated frog (Rana 699 
catesbiana) ventricles. These were paced at successively higher rates until refractoriness was reached. These 700 
gave a wide range of DIs. APD then varied minimally at low pacing rates. However, with increases in rate, 701 
the A-curve gradients became progressively but reproducibly steeper. Recordings obtained immediately 702 
following rate changes were variable. They showed a hysteresis respectively above and below the steady-703 
state line for accelerating and decelerating rates.  704 
 Parameters other than APD, such as voltage, may also show alternans and could be similarly 705 
graphically analysed. However, although often occurring together, the existence or extent of voltage 706 
amplitude alternans did not parallel the magnitude of duration alternans. Furthermore, wide interspecies 707 
variations exists in the time course and the final steady states of adaptations to change in BCL. Imposed 708 
increases in heart rate most frequently result in initial reductions in APD with reduced DI, then increasing to 709 
nevertheless still reduced steady state APD values, in human, guinea pig, mouse and frog ventricular APs. 710 
However, APD initially lengthens then rapidly decreases to shorter values expected at shorter DI in rabbit, 711 
dog and cat ventricles. This likely reflects incomplete Ito decay in rabbit and transient L-type Ca2+ current 712 
facilitation in dog and cat. Finally, APD actually lengthens and remains prolonged with decreased DI in rat 713 
heart. Ca2+ homeostasis has been implicated in restitution changes invoking actions of [Ca2+]i upon the 714 
activity of numerous other channels and carriers within the cell (166). Ionic mechanisms for APD 715 
accommodation to rate changes remain unclear. They almost certainly involve inactivation processes in 716 
depolarising INa and ICa currents or enhancement of repolarising K+ currents, with both processes 717 
accumulating with successive APs. However there are numerous differing reports on their relative 718 
importance. This has hampered attempts at in silico modelling of APD restitution. Recent clinical reports 719 
similarly suggest complexities in the use of such plots in predicting human arrhythmia (818). 720 
 Conduction velocity restitution plots of θ against DI similarly reflect the changes in θ with DI in 721 
consecutive AP waves. Conduction velocity alternans results in a compression and rarefaction of APs as 722 
they travel through the tissue. Slowed θ also reduces the distance between nodes. This results in a higher 723 
number of nodes thus predisposing to re-entry. θ restitution thus depends primarily upon Na+ channel and 724 
intercellular coupling properties whereas APD restitution is also affected by Ca2+ (212, 530), and K+ channel 725 
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properties and is thus engaged at lower pacing rates (928). In silico modelling studies suggested that θ 726 
alternans initiated at higher pacing rates may be responsible for the breakdown of concordant to discordant 727 
alternans (1236). However, θ restitution, as represented by plots of θ against DI are not amenable to the 728 
systems analysis of the kind illustrated in Figure 4 and equations [10]-[14]. Thus the variable θ does not 729 
directly feed into that of DI. Furthermore, θ restitution is primarily concerned with the wavefront whereas 730 
APD restitution describes both the wavefront and the recovery from excitation that follows (753). 731 
Nevertheless, a recent analysis has unified restitution analysis involving APD and θ respectively into a 732 
single λ restitution analysis. This may offer a more general approach relating restitution conditions to 733 
arrhythmic tendency (see Section V(C)(6)) (753). 734 
(B) Experimental models in studies of arrhythmic phenomena 735 
(1) Animal models for arrhythmic disease 736 
 Genetic exemplars useful for clarification of physiological and arrhythmic effects of particular 737 
molecular modifications are available from a range of species. Rabbit ventricular cardiac APs share similar 738 
ionic currents and positive plateau phases whose durations resemble the corresponding features in human 739 
hearts. Of rabbit ion channel variants: (1) Transgenic rabbits with LQTS respectively contain pore mutations 740 
in KCNQ1 and KCNH2. They showed LQTS1 and LQTS2 phenotypes corresponding to their absence of IKs 741 
and IKr respectively (152). LQTS2 rabbits showed high incidences of spontaneous SCD (>50 % at 1 year) 742 
due to polymorphic VT. Optical mapping studies revealed increased spatial dispersions of repolarisation in 743 
LQTS2 rabbits. In both, elimination of one repolarising current (e.g. IKr) was associated with 744 
downregulation of the other (e.g. IKs). This contrasts with the upregulation found in mouse LQTS models 745 
(383, 384). (2) Rabbits with chronic atrioventricular block showed biventricular hypertrophy, QT interval 746 
prolongation following IKs and IKr downregulation, spontaneous torsades de pointes and shortened lifespan 747 
(1147). (3) hypercholesterolaemic rabbits showed an electrophysiological and neural cardiac remodelling 748 
including cardiac hypertrophy, QT prolongation and a vulnerability to VF (682). Of hypertrophic variants, 749 
there are (4) Hypertrophic cardiomyopathic (HCM) rabbit models affecting the β-myosin heavy chain 750 
through the β-myosin heavy chain (MyHC)-R400Q mutation (725) and a cardiac-restricted expression of the 751 
mutant β-MyHC-Q403 known to cause clinical HCM (950). These exhibited cardiac hypertrophy, myocyte 752 
disarray, interstitial fibrosis, and SCD. However they often did not exhibit electrophysiological properties 753 
normally accompanying proarrhythmia (see Section IX(B)).   754 
 The earliest described spontaneous mutation causing nonhuman HCM involved a feline G to C variant 755 
in cardiac myosin binding protein C (MYBPC3) producing a alanine to proline (A31P) substitution (771). 756 
This was followed by similar reports with a feline C820T mutation (770). Both variants resulted in a 757 
computationally predicted alteration in protein conformation. 758 
 Canine hearts show ion current and AP waveforms characteristic resembling those in human 759 
myocardium. (1) Dog hearts with chronic atrioventricular block showed complex structural hypertrophic 760 
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and electrophysiological remodeling. The latter was associated with IKs and IKr downregulation (1205), NCX 761 
upregulation (Sipido et al. 2000) and predispositions to torsades de pointes and SCD (375, 858, 1068, 1206, 762 
1207). (2) Boxer dogs provide a spontaneous model of arrhythmogenic right ventricular cardiomyopathy 763 
(ARVC) and SCD. Their clinical and pathological features closely resembled the human condition. These 764 
included VT arising from an enlarged RV showing myocyte loss with fatty or fibrofatty replacement, 765 
myocarditis, and apoptosis, in some cases accompanying altered RyR2 expression (81, 769). (3) Finally, 766 
dogs affected with X-linked Duchenne's muscular dystrophy also showed calcified myocardia and 767 
surrounding dense connective tissue associated with ventricular arrhythmias (791). 768 
(2) Transgenic mouse models as disease systems 769 
 In addition to spontaneous mutations producing phenotypes recapitulating human disease, genetic 770 
modifications can be produced from insertion into the animals’ genome a mutated human gene (transgene), 771 
or introduction of a mutation at a particular locus by gene targeting (160). Amongst mammalian models, the 772 
mouse remains the most amenable to such genetic modifications. The resulting animals often reproduced the 773 
corresponding congenital human arrhythmic disorders, particularly when they involved established 774 
monogenic mutations (200, 246, 563, 831, 995). Many of these latter genetic variants are clinically rare. 775 
Nevertheless they may model better defined pathological mechanisms than variants representing more 776 
common and often more complex conditions. They thus potentially yield important and widely applicable 777 
pathophysiological insights. Use of genetic exemplars additionally avoids the need to replicate clinical 778 
phenotypes through the use of potentially nonspecific pharmacological manipulations (319, 594, 774, 1054, 779 
1055).  780 
 Conventional gene targeting involves homologous recombination of an engineered exogenous DNA 781 
fragment containing a targeting vector and selection marker conferring resistance to a cytotoxic drug with 782 
the genome of an embryonic stem (ES) cell. The modified ES cell is then screened for presence of the 783 
fragment using the cytotoxic agent. It is then injected into a blastocyst that develops into a chimeric animal 784 
where the desired gene is present in the gametes. Targeted ES cells injected into wild-type (WT) mouse 785 
blastocysts can then contribute to the germ line of chimeric mice. These can then be used to generate 786 
progeny containing the targeted gene. Selective breeding then creates heterozygous, then possibly 787 
homozygous, offspring. Knock-in models contain alterations in the genetic code resulting in a modified 788 
mRNA producing a protein with loss or gain of, or modified, function. In knock-out models, no mRNA is 789 
produced from the altered gene (246).  790 
 Alternative methods expediting genome modification generate DNA double-strand breaks by directly 791 
injecting DNA or mRNA coding for site-specific nucleases into the one-cell embryo (660). The latter utilise 792 
zinc-finger nucleases (ZFNs) (163, 350, 1160), transcription activator–like effector nucleases (TALENs) 793 
(1101) or the RNA-guided clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-794 
associated (Cas) nuclease system (648, 1290). The double stranded breaks occur at a specified genomic 795 
locus. They are then repaired by error-prone nonhomologous end joining to resulting mutant alleles (163, 796 
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350, 1101, 1216). The Cre-lox system has proven a useful technique to restricting expression of a mutated 797 
gene to the heart. It is particularly applicable where the mutation is embryonically lethal when involving the 798 
entire organism. It also makes it possible to achieve temporal control over gene expression (414, 601, 813). 799 
It ensures that recombination events only occur only in specific cell types expressing the site-specific DNA 800 
cyclization recombinase (CRE).  801 
(3) Murine hearts as models for human arrhythmic disease 802 
 Murine hearts are similar in overall anatomy to human hearts. However, there was initial uncertainty 803 
as to whether their considerably smaller tissue volumes could sustain the polymorphic arrhythmias shown by 804 
larger hearts (343, 526). In the latter event, they would not accommodate the multiple drifting rotors then 805 
thought necessary to produce the scroll waves required to generate polymorphic arrhythmia (1264). 806 
However later reports from rabbit heart demonstrated that a single drifting rotor generated scroll waves 807 
leading to such polymorphic arrhythmia could thus exist in relatively small volumes of tissue (371). 808 
Polymorphic arrhythmia was subsequently observed in mouse ventricles (172, 301, 505, 736, 752–754, 809 
1162). Some of these also demonstrated transitions from a monomorphic to the polymorphic character 810 
pattern (982) as observed in larger hearts (1259).  811 
 In common with findings in human hearts, murine ventricular APs show rapid depolarisation phases 812 
driven by inward INa (384). Furthermore, human and murine hearts have similar transmural AP conduction 813 
velocities (428, 668). It is generally thought that the effective refractory period ends before the completion 814 
of the repolarisation process ((301, 582, 977, 980, 995) but see (59)). These features expedited their use in 815 
studying physiological effects of SCN5a mutations that can underlie BrS and LQTS3, and of effects of class 816 
I, Na+ channel blocking drugs (See Section V, and Table 5).  817 
 However, AP waveforms in mouse ventricles show recovery phases distinct in character from those 818 
found in the ventricles of larger animals and humans. The latter show clearcut plateau phases. These are 819 
attributable to activation, followed by inactivation, of ICaL in combination with voltage-dependent changes in 820 
the specific K+ currents. The K+ current contributions are dominated by rapid, IKr, and slow, IKs delayed 821 
rectifier currents. Of these, IKr rapidly activates with phase 0 AP depolarisation. However, its inactivation, 822 
that rapidly follows, makes the channel nonconducting during phases 0–2 of the AP. The initial phase 3 823 
repolarisation then releases the inactivation and reopens the channel. Its subsequent, slow, deactivation then 824 
permits a sustained phase 3 and early phase 4 IKr. In contrast, IKs activates slowly with depolarisation to a 825 
relatively positive >-20 mV potential, and barely inactivates. It gradually increases over phase 2 to become a 826 
major phase 3 K+ conductance (696, 697, 1169, 1170).  827 
 In contrast, AP repolarisation in mouse ventricles results in shorter, triangulated, APDs (~30–80 ms) 828 
when compared to those of humans (~150–400 ms respectively) (Figure 1D) (236). K+ currents are similarly 829 
central to this AP repolarisation though there are smaller ICaL contributions. However, repolarisation is 830 
driven mainly by fast, Kv4.3 and Kv4.2-mediated, Ito,f, as well as the more slowly inactivating Kv1.4-831 
mediated Ito,s, components of the rapidly activating and inactivating transient outward current Ito (Figure 1B, 832 
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D). Both Ito,f and Ito,s become activated at potentials >-30 mV (829). They show distinct time constants for 833 
inactivation and recovery from inactivation. For Ito,f, these fell in the range 20-100 ms for both processes. In 834 
the case of Ito,s these processes took took hundreds of ms and seconds respectively (833). Murine hearts also 835 
showed rapidly activating but slowly inactivating 4-aminopyridine-sensitive and insensitive, Kv1.5 836 
(KCNA5)-mediated IK,slow1 and Kv2.1 (KCNB1)-mediated IK,slow2, as well as a steady-state Iss (829, 1284).  837 
 Recent evidence suggests murine hearts do express both IKr and IKs but their roles are unclear (53, 64, 838 
276). IKATP and IK1 continue to be important in repolarisation and electrical diastole (324, 828, 830). Mouse 839 
ventricles also show additional repolarising rapidly activating and sustained delayed rectifier K+ current, Iss, 840 
and slow K+, IKslow, currents (669). Murine hearts additionally exhibit inward rectification properties 841 
attributed to IK1. These strongly reduce K+ conductance at voltages >-20 mV in phases 0-2, permit outward 842 
currents with repolarisation to <-40 mV late in phase 3, and stabilise the phase 4 diastolic resting potential 843 
(357, 1020).   844 
 Atrial myocytes additionally show an ultra-rapid, IKur, in phase 1. There is also the IKACh.which is 845 
activated through its interaction with the βγ part of acetylcholine muscarinic receptor associated Gi proteins 846 
particularly in the SAN but also in the atria and ventricles (1020). Studies exploring effects of 847 
parasympathetic challenge in Girk4-/- mice implicate IKACh in AF (589). Finally, IKATP is normally a small 848 
current. However, its activation by reduced intracellular ATP levels associated with energetic stress exerts 849 
triangulating effects on AP waveform (320, 486).  850 
 Finally, recent evidence suggests that induced pluripotent stem cells derived from carriers of clinical 851 
conditions might replicate some of the expected cellular properties. This may have potential utility in the 852 
development of novel treatment strategies in the LQTS2 (488), LQTS3 (718), CPVT (307, 525) and some 853 
overlap syndromes (248), given the appropriate correlations between basic molecular physiology and our 854 
understanding of arrhythmia in structurally intact hearts. 855 
 (C) Experimental studies on murine systems  856 
(1) Studies at the organism or tissue levels  857 
 Arrhythmogenesis itself ultimately takes place at the whole heart level and likely depends upon 858 
electrophysiological properties through populations of coupled cells in addition to events within single cells. 859 
These may include myocardial properties, such as re-entry mechanisms and gradients of excitation or 860 
recovery from excitation operating at the tissue and whole chamber level. Culture methods that might 861 
reproduce such cell populations show initial promise (158). Studies in mouse systems bred on 862 
electrophysiologically stable, typically 129/sv or C57BL/6, genetic backgrounds, permit examination of 863 
such phenomena whether related to mechanisms of SND, and both atrial and ventricular arrhythmia. These 864 
could carry well-defined genetic modifications strategically selected to reflect genotypes associated with 865 
specific disease conditions. Such modifications could also be used to expedite experimental clarification of 866 
the role of alterations in the function of particular ion channels in arrhythmic mechanisms. Use of WT hearts 867 
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also permit investigations of acute, reversible, often pharmacological, manipulations, replicating clinical 868 
situations and potentially modifying arrhythmogenicity. Investigations of either case typically begin by 869 
verifying reproducible arrhythmic phenotypes. This would relate the experimental system to the 870 
corresponding clinical condition, providing a translational background for studies proceeding to clarify their 871 
underlying mechanisms. The latter investigations are directed at successive, interacting, organism, organ, 872 
tissue, in addition to the cellular and molecular levels.  873 
 Of these, in vivo electrocardiographic (ECG) studies in ambulatory or anaesthetised intact animals 874 
(e.g. (184, 1040)) can demonstrate spontaneous rhythm disruptions, electrocardiographic abnormalities (742, 875 
1340), or chronic changes in electrophysiological properties. The latter have been demonstrated in particular 876 
genetic conditions with age (e.g. Section V(E)) (503). They have also been instrumental in the analysis of 877 
the effects of genetic connexin modifications on ventricular conduction and excitation reflected in their PR, 878 
QRS and QT intervals (378, 803, 1132). They could be extended to localisations of atrioventricular 879 
conduction abnormalities to supra-Hisian and particularly, infra-Hisian, conduction tissues, in common with 880 
human clinical findings in a murine myotonic dystrophic model (976). These studies additionally established 881 
strategic conditions of temperature, anaesthesia and selection of electrocardiographic parameters as 882 
important in such determinations (111).  Recent studies have successfully correlated QT intervals with 883 
simultaneously measured APDs in Langendorff-perfused murine hearts. This further makes ECG recording 884 
a useful quantitative tool (236, 782, 1219, 1341).  885 
 Ex-vivo isolated Langendorff-perfused preparations permit closer investigations for triggering 886 
arrhythmic events occurring spontaneously during intrinsic activity. In addition, arrhythmic substrate may be 887 
detected through an appearance of spontaneous arrhythmia during spontaneous activity, regular epicardial or 888 
septal pacing. Arrhythmia could also be provoked by programmed electrical stimulation (PES). This 889 
typically involves imposition of extrasystolic (S2) beats following successively decrementing S1S2 time 890 
intervals following trains of regular S1 pacing beats (240, 392, 561, 1095). Alternatively, dynamic pacing 891 
protocols could apply sequences of successively incremented steady state pacing rates (e.g. (735, 752–754, 892 
979, 982)). Some atrial studies also include burst pacing protocols involving delivery of successive high 893 
frequency stimulus trains (245, 402, 659).  894 
 Different recording techniques can then explore for underlying pathophysiological and 895 
pharmacological processes through closer studies of AP initiation, propagation, repolarisation and 896 
refractoriness (392, 978). Of these, intracellular recordings using sharp glass microelectrodes provide 897 
definitive indications of absolute resting and AP waveforms including their durations and their maximum 898 
rates of rise (e.g. Section VII(D)) (dV/dt)max (569, 1340). 899 
 Extracellular recording methods offer stable and prolonged in situ estimates of such parameters, 900 
and can be applied to specific cardiac regions in intact preparations. Unipolar recordings made against 901 
remotely positioned reference electrodes represent tissue electrical activity in the form of single large 902 
negative intrinsic deflections reflecting arrival of the excitation process immediately beneath the electrode 903 
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contact with tissue. These are superimposed upon the extrinsic deflections produced by far-field effects. The 904 
latter cause positive deflections as the excitation wave travels from remote regions of tissue towards, and 905 
negative deflections as the wave subsequently moves away, from the recording electrode. The result is an 906 
overall, biphasic, wave (646, 1271). The steep negative intrinsic deflection in the unipolar electrogram 907 
coincides with the transmembrane AP upstroke. This makes it possible to determine wave velocity from the 908 
time at which it assumes maximum negative slope (275).  909 
 Bipolar extracellular recordings comparing voltages at two recording electrodes positioned close to 910 
the conducting path for tissue excitation similarly yield biphasic waveforms. The latter reflect a summation 911 
of two unipolar recordings. The two terminals are affected to almost the same degree by the extrinsic 912 
potentials and far field effects. The latter are therefore minimised by taking the difference between 913 
recordings from the positive and negative poles of the amplifier (493). Comparison between biphasic waves 914 
obtained under conditions of bipolar recording with biphasic waves obtained under conditions of unipolar 915 
recording correlate the fast part of the intrinsic deflection in the unipolar recording with the top of the 916 
differential spike obtained from the bipolar recording. Thus, in bipolar, in contrast to unipolar, electrograms, 917 
the intrinsic deflection coincides with the top of the spike. 918 
 Bipolar electrogram (BEG) recordings thus yield electrogram latencies and durations (EGDs). They 919 
have been used in conjunction with PES procedures. The resulting extracellular waveforms have been 920 
analysed by programmed electrogram fractionation analysis (PEFA). This involved plotting conduction 921 
latencies in the recorded BEG deflection components at progressively shortened S1S2 intervals in clinical 922 
studies. This analysis had first successfully assessed clinical arrhythmogenic risk in HCM and cardiac 923 
channelopathy (461, 1009, 1011, 1012). It thus associated arrhythmogenic re-entrant substrates with 924 
increased EGD. The latter reflects the distribution or spread (‘fractionation') of ventricular myocardial 925 
conduction velocities at reduced S1S2 intervals. This approach proved applicable to murine systems (see 926 
Sections V(D)(2), V(G)(4) and VI(B)(3)) (64, 416, 1095, 1096).  927 
 Monophasic AP (MAP) recordings additionally reproduce many features of AP waveforms without 928 
requiring cell impalement, particularly the AP repolarisation phases, and their quantification as APDs and 929 
ERPs (559, 560, 562, 563, 1129). They also are potentially translatable from studies in mouse to human 930 
hearts (796). These in turn yield APD90/ERP ratios. Increases in such ratios are associated with increased 931 
arrhythmogenicity (978).  932 
 MAPs were initially recorded by suction electrodes as injury potentials (443, 512). Subsequent 933 
contact MAP recordings measured the voltage drop between a positive contact electrode firmly pressed 934 
against, and an adjacent, closely placed (~5 mm), negative electrode in light contact with, the myocardial 935 
surface. The volume conductor hypothesis suggested that the pressure exerted by the positive electrode 936 
depolarises the underlying cells to ~-20 to -30 mV by opening membrane stretch-sensitive ion channels. 937 
This locally inactivates their contained voltage-gated Na+ channels. This makes the local membrane 938 
unexcitable and assuming a fixed reference potential, but leaves the adjacent cells capable of AP generation. 939 
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During electrical diastole, the inactivated region acts as a current source as it is relatively depolarised 940 
compared to the surrounding myocardium. The resulting current flow between source and sink regions 941 
originates from a large number of cells, given the ~1-2 mm tip diameter of the positive electrode. It is 942 
determined by the potential gradient and the number of cells contributing to the source-sink interface, and 943 
reverses during electrical systole. Alterations in the number of cells generating the MAP voltage by altering 944 
the contact pressure, studying the atria rather than the ventricles, or differently sized hearts, alter the 945 
amplitude of the MAP recording.  946 
 Comparisons with intracellular recordings confirm that MAP recordings faithfully represent the AP 947 
timecourse, particularly its repolarisation phase, which largely comprises low frequency electrical signals, 948 
where they show smooth upstrokes over <5 ms rise times to overall amplitudes >10 mV uncontaminated by 949 
intrinsic or QRS deflections and fall to smooth stable diastolic baselines (217, 328, 582). The latter 950 
condition can be affected by motion artefacts resulting from cardiac contraction but such artefacts may be 951 
minimised by spring mounting of the electrode. MAP recordings reproduce alterations in, but not absolute 952 
values of, resting and plateau voltage. They yield significantly smaller (~7 V s-1) values of (dV/dt)max than 953 
intracellular recording (200-300 V s-1). This likely reflects the lower seal resistances made between tissue 954 
and MAP compared to those made by intracellular electrodes. In addition MAP recordings reflect thae 955 
activity of large numbers of potentially sequentially activated, rather than single cells.  956 
 Electrical contact or optical mapping methods provide patterns and timings of wavefront 957 
propagation of either electrical excitation or spectrofluometrically measured Ca2+ release (292, 296, 427, 958 
632, 736, 803, 1109). Unipolar, multi-electrode array (MEA) recording from the left or right atrial or 959 
ventricular epicardial surfaces can follow AP propagation from either stimulated or spontaneously beating 960 
hearts. They thereby yield isochronal maps displaying activation times (AT) to the point of maximal 961 
negative slope (dV/dt)max of each recorded electrogram. Recovery times (RT) can be measured as the 962 
(dV/dt)max for a negative T wave or the (dV/dt)min of a positive T wave. They thereby provide activation 963 
recovery intervals (ARI) separating their respective AT and RT. ARI proved comparable to APD values 964 
obtained from MAP electrode measurements. It is then also possible to determine activation and 965 
repolarisation time differences (ATD and RTD) between the first and last ATs and RTs and the ARI 966 
differences (ARID) between the shortest and longest ARI (see Section V(C)(7)) (736).  967 
 MEA recording also permits determination of conduction velocity parameters. It can provide both 968 
effective conduction velocities representing AP conduction through recording points in the array as a whole, 969 
or from local vector analyses giving both the magnitude and direction of AP conduction (see Sections 970 
V(B)(2) and VII(C)(6)) (996, 1336). Fluorescence imaging permits a spatiotemporal characterization not 971 
only of voltage, but also changes in calcium cycling in tissue labelled with voltage-sensitive (e.g. di-4-972 
ANEPPS, RH237) or Ca2+ indicators (such as Rhod-2-AM). This involves appropriate excitation of the 973 
signals, and separating and collecting emissions of the appropriate wavelengths. These give results that 974 
clarify the pattern of the activation and calcium release, and presence of diastolic calcium leak (59, 1218). 975 
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(2) Studies in single cells and at the molecular level 976 
 Single cell studies in intact or perforated whole-cell patch-clamped myocardial cells enzymically 977 
isolated from Langendorff-perfused hearts have studied Ca2+ (1128) and K+ current activation (561) and 978 
activation, inactivation and recovery from inactivation of Na+ channels under both acute, including 979 
hypokalaemic, conditions and in genetically modified, including Scn5a+/- and Scn5a+/∆KPQ, myocytes 980 
(see Section V(C)(2)) (416, 741, 867). In addition, a recent, loose patch-clamp, technique (22, 23, 1304) has 981 
been introduced to examine differences in current-voltage relationships of peak INa in intact Scn5a+/-, RyR2-982 
P2328S and WT atria. These have included studies of the effects of high extracellular Ca2+, caffeine, or 983 
cyclopiazonic acid (CPA). All these agents are expected to acutely increase [Ca2+]i (see Section VII(C)(6)) 984 
(568). This technique shows significant future promise for studies of biophysical events in intact hearts 985 
(935). Transfection methods whether involving α- or β-subunits in expression systems such as those offered 986 
by Chinese hamster ovary (CHO) or human embryonic kidney (HEK) cells have been used to study and both 987 
activation and recovery properties for subsequent modelling (696, 697, 887, 1170) as well as reconstruct 988 
channel behaviour in response to simulated APs (273, 406, 1060). 989 
 Isolated atrial and ventricular fluophore-loaded myocardial cells were also used to examine Ca2+ 990 
signalling properties by themselves or following acute pharmacological interventions. These have studied 991 
measures of SR Ca2+ release or re-uptake, or cellular Ca2+ entry or expulsion, and their effects upon 992 
arrhythmic properties. These were first explored in WT murine hearts (see Section VII(B)) (62, 63, 352, 993 
446, 1335, 1338) prior to their introduction to genetically modified systems (see Section VII(C)) (e.g. (364, 994 
387, 1334). 995 
 At the molecular level, assessments of longer-term factors contributing to arrhythmia have involved 996 
examination of gene expression characteristics, by quantitative reverse transcriptase polymerase chain 997 
reaction (qPCR) and western blotting, of a wide range of ion channels and regulatory genes. These have 998 
included genes for Na+ channel subunits, Ca2+ channel subunits and Ca2+-handling proteins, K+ channel 999 
subunits, hyperpolarisation-activated cyclic nucleotide-gated (HCN) channels, gap junction proteins, 000 
transcription factors and other selected genes, including transforming growth factor-β1 (TGF-β1) and 001 
vimentin gene expression (see Sections VI(F) and IX(A)) (245, 392, 408).  002 
 (3) Studies of contributions from morphological change 003 
 Finally, explorations can be made of morphological changes extending from gross organ and tissue 004 
architecture, through hypertrophic and fibrotic tissue changes, to electronmicroscopic analysis, associated 005 
with particular arrhythmic conditions. These studies have assessed contributions of age and/or genotype to 006 
the observed arrhythmic changes. This has included studies of gross tissue architecture, as well as 007 
quantitative digital microscopy studies of the results of picrosirius red staining and vimentin fibroblast 008 
immunostaining, in different cardiac chambers of the right and left sides of the heart (see Sections V(E), 009 
V(F) and IX) (408, 501, 502, 968, 1180). 010 
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 (4) Computational modelling studies  011 
 Quantitative computational reconstructions have explored the consequences of the individual changes 012 
in properties obtained by the studies above for properties at the systems level. These could optimally link 013 
findings in murine hearts (133) to properties of human hearts under circumstances of both normal (154, 369, 014 
489, 1153) and abnormal function (551, 552, 1154, 1155). Recent modelling approaches now potentially 015 
permit further incorporation of electroneutral solute and osmotic fluxes, and interacting alterations in the 016 
resulting ion compositions and cell volumes (331, 332). At higher levels of organization they extend to 017 
whole chamber reconstructions of the spread and recovery of the electrophysiological change (1140), with 018 
significant promise of clinical translatability (936). 019 
 Studies analysing experimental findings in murine hearts have initially examined situations involving 020 
relatively simple geometry as exemplified by the spread of excitation from the SAN into and through the 021 
atria. These provided models that implicated INa in AP propagation through the SAN and from SAN to atria, 022 
its effects upon heart rate, and their reconstruction of features of clinical SND. This clarified possible roles 023 
for Na+ channels in both normal SAN function and SND following targeted disruption of the murine cardiac 024 
sodium channel gene (See Section V(F)(3)) (408, 456, 632, 634, 1276). They extended to investigations of 025 
the effects of fibrotic, resulting in morphological, change (see Section IX(A)(3)) (245). Computational 026 
reconstructions have also been used to guide interpretation of ion channel changes (e.g. (1276)). They have 027 
also provided theoretical predictions of the effects of particular ion channel variants for which experimental 028 
murine models are not available as in some short QT syndrome (SQTS) variants (see section VI(H)) (e.g. 029 
(6–8)). Computational studies thus represent an approach that will become increasingly valuable as 030 
physiological, anatomical and molecular data become progressively available.  031 
(5) Murine exemplars for the study of cardiac arrhythmias 032 
 The remainder of this article reviews experimental and theoretical studies of electrophysiological 033 
mechanisms underlying cardiac arrhythmias. They make systematic examinations of specific murine 034 
exemplars variously representing ventricular, atrial and sino-atrial arrhythmic clinical disease. In each case, 035 
these could be used to assess the relevance of the biophysical and physiological principles underlying stable 036 
and unstable atrial or ventricular excitation as outlined above. Such instabilities could disrupt the normally 037 
orderly sequence of cardiac electrophysiological activation and recovery and its propagation.  038 
 Of these, primary electrophysiological disorders could arise from reversible pharmacological 039 
manipulations or loss or gain of function genetic modifications that involve proteins directly concerned with 040 
cardiac excitable activity or its modulation. They thereby influence electrophysiological stability even in the 041 
presence of normal cardiac anatomy. Such changes can occur against a background of changes in heart rate. 042 
Section III discusses exemplars bearing on sino-atrial pacing disorders. The resulting propagated 043 
electrophysiological activity can then be characterised in terms of a wavelength (λ) of excitation as well as 044 
events falling within the resting wavelength following recovery from activity (λ0) that follows (Section IC 045 
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and IIA). By defining the spatial extent of excitation terms, λ would clarify the tendency for wave 046 
breakdown leading to arrhythmic substrate. A first term determining λ is the conduction velocity θ. This in 047 
turn is first dependent (section IC(1) and IC(2) above) upon the intracellular resistance ra, which determines 048 
passive spread of local circuit currents through Cx molecules between successive myocytes. Murine hearts 049 
with expected alterations in these are explored in Section IV. Local circuit current activation resulting in AP 050 
propagation relevant to cellular excitation in turn depends on INa (see section IB(1)). The consequences of 051 
compromised INa are accordingly examined using examples discussed in Section V. Section VI then 052 
discusses the consequences of abnormalities in the remaining, recovery, term determining λ, viz. the APD or 053 
ERP. Section VII and section VIII then explore inputs to excitable properties from intracellular events. 054 
These often bear upon Ca2+ homeostasis and cardiac energetics. These may alter both excitation as well as 055 
triggering events following AP repolarisation. Finally, development of anatomical abnormalities could 056 
potentially result in arrhythmic substrate through alterations in the relationship between the spatial indicators 057 
of electrophysiological activity, particularly λ, and the effective length of the conducting excitation paths. 058 
These are considered in Section IX. 059 
III. MODELS FOR SINO-ATRIAL PACING DISORDER 060 
(A)  Murine models for sino-atrial pacing function 061 
 Successive cycles of cardiac activity are normally driven by sino-atrial node (SAN) automaticity, 062 
effectively constituting an oscillator generated by a combination of time-dependent outward, and constant or 063 
voltage-dependent inward currents activated during AP repolarisation (723). The high background SAN 064 
pacing rate in murine compared to human hearts, and the wide variation of heart rates through different 065 
species may suggest similarly varying roles of the different ion mechanisms that have been implicated in this 066 
function. Similarly, isolation of murine SAN cells is challenging owing to the small size of murine 067 
pacemaker regions (136, 137, 197, 210, 440, 632, 637, 722). Nevertheless, mouse strains carrying specific 068 
genetic modifications in particular ion channels have offered useful models for pacemaker dysfunction 069 
(Table 2) (700).  070 
(B) Role of the rapid K+ current, IKr 071 
 In rabbit SAN, IKr and IKs are activated during the AP upstroke and then deactivate relatively slowly 072 
during the end of the repolarisation and diastolic depolarisation phases. IKr likely controls AP repolarisation 073 
and sets the maximum diastolic potential. Nanomolar E-4031 concentrations partially blocking IKr thus 074 
positively shift the maximum diastolic potential, decrease the (dV/dt)max and amplitude, and prolong the 075 
repolarisation duration of the AP (855, 1189). The resulting reduction in recruitment of other depolarising, 076 
diastolic currents (210) then slows pacing rate. Complete IKr block by micromolar E-4031 terminates 077 
automaticity and leaves a depolarised (-30 to -40 mV) resting potential (855). Mouse pacemaker cells 078 
showed similar effects of E-4031-mediated IKr block (210). Erg1b-/- hearts lack fast IKr and demonstrate 079 
bradycardic episodes (See Section VI(F)(2); (626)). 080 
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(C) Role of the hyperpolarisation-activated cyclic nucleotide-gated (HCN) current, If 081 
 The initial phase of the diastolic depolarisation that follows likely includes ‘membrane clock’ 082 
contributions from inward, depolarising, cAMP-sensitive If carried by hyperpolarisation-activated cyclic 083 
nucleotide-gated (HCN) channels (122). If is activated within diastolic depolarisation voltage ranges 084 
(−40~−60 mV) (72, 73, 153). Diastolic depolarisation may include additional contributions from time-085 
independent background current including ICl (114) or TRPM4-mediated Ib (252) and decay of outward IKr 086 
(400). Nevertheless studies of the If blockers Cs+ (256), UL-FS 49 (1127), ZD-7228 (733) and ivabradine on 087 
pacemaker activity demonstrated a definite role for If in controlling diastolic depolarisation rates not only in 088 
rabbits (1126) but also mice (280, 643).  089 
(D) Murine models with altered HCN4 channels 090 
 Genetic alterations involving If, mediated by HCN channels, are associated with both mild and 091 
severe clinical arrhythmic conditions (72). Of the four HCN isoforms, HCN4 is likely to be the major 092 
contributor to HCN-mediated pacemaker currents in adult SAN of most species, including mouse and 093 
human. Hearts with homozygous Hcn4 deletions showed marked bradycardia and decreases (75-90%) in If, 094 
and a residual current, possibly carried by Hcn1 and Hcn2, before lethality at embryonic day (ED) 9.5~11.5 095 
(1094). This is consistent with HCN4 function becoming important only after this embryonic stage. In 096 
common with both global and cardiac-specific constitutive Hcn4-/- mice, Hcn4-R669Q/R669Q mice with 097 
altered cyclic nucleotide binding that would result in an inability to respond to adrenergic stimulation (410) 098 
were similarly bradycardic before dying at ED 11–ED 12 (179, 906). Similarly, constitutive deletion of the 099 
transcription factor implicated in SAN, Shox2, permitted normal development until an onset of severe 100 
bradycardia and decreased Hcn4 expression at ~ED 10.5 and lethality between ED 11.5~12.5. Similar 101 
findings occurred with Hcn4-KO mice (297). 102 
 However, hearts from adult mice with inducible Hcn4 knockouts, whether globally with a 103 
tamoxifen-inducible Cre construct (426) or specific to Hcn4-expressing cells (435) showed limited changes 104 
in cardiac pacemaker generation and modulation. Hearts showed normal mean basal heart rates, albeit 105 
interrupted by ~8-16 sinus pauses/min with duration ~320 ms. Yet patch-clamped SAN cells showed 106 
reduced (60-80%) If that nevertheless retained normal activation-voltage curves. AP activity was absent in a 107 
significant proportion of cells. However, where such activity was present, spontaneous firing rates were 108 
normal. Sympathetic challenge by isoproterenol or treadmill activity in ambulant mice produced alterations 109 
in heart rates similar to those found in control mice albeit with increased frequencies of post-exercise sinus 110 
pauses (426). However, muscarinic stimulation produced more marked bradycardic effects in Hcn4-KO than 111 
WT (426, 435).  112 
 Tamoxiphen-inducible models have been produced by crossing floxed Hcn4 mice (74) with mice 113 
carrying the Cre-recombinase controlled by the cardiac-specific α-myosin heavy chain (αMHC) promoter 114 
(1075), sparing neuronal Hcn4 channel expression. These showed a similar ~70% reduction in If. But this 115 
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now accompanied progressive, up to 50%, reductions in heart rates without sinus pauses, with reduced rate 116 
responses to isoproterenol challenge during telemetric recording. There was also an unexpected prolonged 117 
PQ interval and atrioventricular block, eventually proving lethal. Mouse models in which it was possible to 118 
induce an elimination of Hcn4-expressing cardiomyocytes and their substitution with collagen fibres were 119 
similarly bradycardic with a similarly reduced tachycardic response to isoproterenol adminstration on 120 
ambulant ECG recording (424). However, the elimination of HCN4-expressing cells additionally resulted in 121 
sino-atrial pauses, and atrioventricular node conduction changes increasing PR interval and producing 122 
complete heart block and supraventricular tachycardia or VT. 123 
 The hHCN4–573X mutation has also been correlated with clinical SAN dysfunction. It produces a 124 
dominant negative abolition of cAMP-mediated HCN4 modulation (20, 1028). Ambulant transgenic mice 125 
with an α-MHC promoter and a Tet-Off system-controlled cardiac-specific over-expression of Hcn4–573X 126 
(20) showed ~20% reductions in resting heart rates but no changes in PQ and QTc intervals. They retained 127 
albeit reduced tachycardic effects of exercise. Their If showed slower activation kinetics and a negative, -20 128 
mV, shift in voltage dependence. Their isolated SAN cells were either quiescent or, in a small fraction of 129 
cells, showed sub-threshold membrane potential oscillations followed by regular firing at reduced rates. 130 
Isoproterenol challenge restored regular pacemaker activity but to lower rates than when applied to WT 131 
(425). 132 
(E) Murine models with modifications in the remaining HCN1-3 channels 133 
 The occurrences of HCN1 and HCN2 are species dependent and their levels of expression are lower 134 
than that shown by HCN4; There are nevertheless reports of Hcn1 signal in the SAN (425). Recent 135 
immunohistochemical studies demonstrated Hcn1 in WT mouse SAN (310). However, a generalised 136 
knockout Hcn1-/- mouse developed normally (837). Nevertheless, Hcn1-/- mice were bradycardic with low 137 
cardiac output, sinus dysrhythmia, and recurrent sinus pauses on telemetric in vivo ECG and 138 
echocardiographic study. Single Hcn1-/- spindle and elongated SAN cells showed significantly reduced If 139 
amplitudes. If activation kinetics was slowed, consequently resembling that of cloned HCN4 channels. 140 
Isolated Hcn1-/- SAN cells accordingly showed reduced pacing frequencies (310). These findings suggest a 141 
role for Hcn1 in stabilizing SAN pacemaker function. Hcn1 was also expressed in mouse cardiac conducting 142 
tissue (425, 726). Hcn1 has also been demonstrated in rabbit SAN (804). Together with Hcn4 it could there 143 
contribute to If (25). Finally, Hcn1 has been implicated in rhythmic and resting neuronal activity in mouse 144 
brain (122).  145 
 Hcn2 occurs mainly in adult mouse ventricles. It is hardly detectable in atria and SAN. Nevertheless, 146 
global and cardiac-specific constitutive Hcn2-deficient mouse models showed sinus dysrhythmic features. 147 
Their resting heart rates were normal but resting ambulatory ECGs showed increased RR variability (699). 148 
Isoproterenol and exercise challenge accomplished similar maximum rates as those in control mice and 149 
reduced the sinus dysrhythmia. Their isolated SAN cells showed slowed activation kinetics and ~30% 150 
reductions in If and a -5 mV hyperpolarisation in maximum diastolic potential.  151 
32 
 
 Hcn3 subunits have long been regarded as little relevant to cardiac activity. Hcn3 was not observed 152 
in SAN (145, 178, 311, 425). There have been no reports of Hcn3 mRNA or protein expression in rodent 153 
SAN cells (311, 425). There are varying in situ hybridisation, real time PCR or protein expression reports in 154 
mouse and rat hearts (425). Global and constitutive Hcn3-/- knockout mice were born with normal 155 
Mendelian ratios. Ambulant ECG recording showed normal sinus rhythm. However, under bradycardic 156 
conditions T-wave amplitudes and duration, and QT intervals all increased. Epicardial cells showed 157 
shortened APDs and ∼30% reduced If. These findings suggest a role as a ventricular background current that 158 
opposes ventricular AP repolarisation (311). 159 
(F) Role of Ca2+ currents ICa 160 
 Late diastolic depolarisation may further involve contributions from depolarising, ICaL and T-type 161 
Ca2+ channel current, ICaT (998). It is compromised in mice homozygously lacking either L-type, Cav1.3 162 
(Cacna1d), or T-type, Cav3.1 (Cacna1g), channels (768). Both genetic and pharmacological data implicated 163 
ICa,L, with its more negative threshold in SA than ventricular myocytes, in both diastolic depolarisation and 164 
the AP upstroke through the actions of Cav1.3 and Cav1.2 (Cacna1c) respectively (720, 721). In vivo ECG 165 
studies in anaesthetised mice demonstrated that dihydropyridine Ca2+ channel blockers induced bradycardia 166 
(620). Studies in genetically modified murine platforms suggested a role for Cav1.3 in automaticity and 167 
Cav1.2 in excitation contraction coupling.  168 
 Cav1.3 channels activated at the more negative potentials (~−50 mV) within the range corresponding 169 
to diastolic depolarisation (720). Both intact Cav1.3-/- mice and Cav1.3-/- atria were bradycardic, the former 170 
even following autonomic block (901). This altered function was reflected in corresponding properties of 171 
isolated SAN (1344) and pacemaker cells, the latter showing erratic pacemaker function (720) The Cav1.3 172 
inactivation produced a 70% reduction in ICa,L in pacemaker cells with the persisting ICa,L then likely arising 173 
from Cav1.2. Thus ICa in Cav1.3-/- pacemaker cells showed a greater dihydropyridine sensitivity (720) and 174 
faster inactivation kinetics (1344) than in WT. Maximal pacing rates in Cav1.3-/- hearts following 175 
isoproterenol challenge were slightly lower than those shown by WT hearts (751). This could reflect the 176 
effect of β-adrenergic activation negatively shifting thresholds for Cav1.3-mediated ICa,L, activation to ~−55 177 
mV (720). In contrast, in Cav1.2-DHP−/− mice with dihydropyridine insensitive Cav1.2, dihydropyridines 178 
continued to exert in vivo bradycardic effects implicating Cav1.3 in this effect (1066). 179 
 The ICa,T inhibitors Ni2+ and tetrametrine slowed SAN cell pacemaker activity (399, 1008). Yet there 180 
is relatively little ICa,T activity through diastolic membrane voltages. Mouse SAN expresses both Cav3.1 and 181 
Cav3.2 mRNA. However, although their SAN ionic currents and automaticity have not been studied, 182 
Cav3.2-/- mice had normal ECG characteristics (186). In contrast, Cav3.1−/− SAN and AVN cells entirely 183 
lacked ICa,T with no evidence for a residual ICa,T that would be expected from the remaining Cav3.2. In 184 
contrast, only Cav3.1- and not Cav3.2-mediated ICa,T occurred in postnatal rat atria (315, 834). These 185 
findings suggest that Cav3.2 is expressed in developing heart whereas Cav3.1 expression dominates the 186 
phenotype in adult heart. Spontaneous activity in isolated SAN pacemaker cells was slowed by ∼30%. 187 
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Cav3.1-/- mice showed slowed atrioventricular conduction and a moderate bradycardia persistent even 188 
following pharmacological autonomic block reflecting the slowing of intrinsic SAN automaticity (724).  189 
 Finally, murine models for N-type (Cav2.2: Cacna1b) and R-type (Cav2.3: Cacna1e) channels have 190 
been investigated for changes in autonomic rather than intrinsic pacing mechanisms (479, 698, 1247). 191 
(G) Role of Na+ currents, INa 192 
 The upstroke components of pacemaker cell APs are primarily driven by Ca2+. Nevertheless, the 193 
SAN expresses both TTX-sensitive neuronal Nav1.1, likely important in pacemaking (75, 77, 635, 714) and 194 
TTX-resistant Nav1.5 that may mediate intranodal conduction (632, 635). In neonatal rabbit SAN, TTX (3 195 
μM) slowed pacemaker activity by 63% through slowing late phase diastolic depolarisation, decreasing AP 196 
thresholds and reducing overshoot. INa contributed a window current that declined with age (75). INa was 197 
activated by ramp depolarisations to extents that varied with ramp slopes. This suggested an inward current 198 
contribution resulting from incomplete inactivation of the INa that was initiated during the AP upstroke 199 
during diastolic depolarisation (76). Nav1.1 becomes downregulated in the adult consistent with roles in 200 
increasing basal heart rate primarily in neonates (75, 76). However, adult mouse pacemaker cells expressed 201 
both TTX-sensitive and -resistant INa. Nav1.1 may assume a pacemaker role in adult mice (197, 635, 722). 202 
INa inhibition by lidocaine reduced heart rate (620), and low, 50–100 nM, TTX concentrations reduced 203 
pacing rates in Langendorff-perfused mouse hearts (714). The roles for the effects of Nav1.5 204 
haploinsufficiency in intranodal and sino-atrial conduction is discussed in further detail in section V(F)(2).  205 
(H) Contributions of Ca2+ homeostatic processes 206 
 Further contributions to SAN pacing may arise from RyR2-mediated Ca2+ release in conjunction 207 
with the electrogenic effects of a resulting increase in INCX and the decay of delayed rectifier currents. 208 
Whereas ryanodine mediated block of Ca2+ release reduced the rate of late diastolic depolarisation, Cs+-209 
mediated block of If reduced initial diastolic depolarisation (652, 972). Distinct cytosolic, early, delayed and 210 
late Ca2+ transients have been observed in SAN cells. These have been attributed to events reflecting action 211 
potential activation, nuclear Ca2+ change and subsarcolemmal local Ca2+-induced Ca2+ release respectively 212 
(523). Of these, the last has been implicated in a distinct intracellular “Ca2+ clock” driven by spontaneous 213 
SR Ca2+ release that could contribute to the pacemaker process (161, 459, 616, 719, 722, 946, 1121). 214 
Increases in RyR2-mediated Ca2+ spark activity that would drive this pacing mechanism might occur when a 215 
critical SR Ca2+ level is regained during diastole (193), or arise from particular kinetic properties of SR Ca2+ 216 
uptake or release proteins (132, 615, 1121, 1199).  217 
 The properties of SAN cells are consistent with such a mechanism. SAN cells both contain the 218 
requisite SR Ca2+ stores and express RyR2 and RyR3 (748). They also have high basal cAMP levels. This 219 
could facilitate a protein kinase A (PKA)-dependent phosphorylation of RyR2 that would enhance RyR2-220 
mediated SR Ca2+ release. The consequent, appropriately timed elevations of local [Ca2+]i would then 221 
enhance INCX whose electrogenic effects would then contribute to the observed depolarising potentials 222 
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(1198). Increases in [Ca2+]i could also activate physiologically important enzymes such as 223 
calcium/calmodulin-dependent protein kinase II (CaMKII) (132, 616). This scheme would be consistent 224 
with observations in which the rapid Ca2+ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic 225 
acid (BAPTA) slowed and ultimately abolished AP firing in guinea pig isolated SAN myocytes (161). Such 226 
suggestions are potentially testable through the use of genetic paradigms for RyR2 or SERCA outlined in 227 
section VII(D) and (E). 228 
(I) Roles of other charge carriers 229 
 Of the remaining charge carriers, both murine genetic exemplars and pharmacological probes are 230 
lacking for the sustained current Ist (136, 783). Its function in SAN automaticity has been studied by 231 
modeling studies (783, 1327). Further contributions to pacing may arise from Na+, K+-ATPase (INaK), INCX 232 
and its modification by intracellular Ca2+ handling (132, 136). Preliminary reports additionally implicated 233 
transient receptor potential cation channel, subfamily C, member 3, (TrpC3), the endoplasmic reticular Ca2+ 234 
sensor stromal interacting molecule (STIM) and the surface membrane channel, Ca2+ release-activated Ca2+ 235 
channel protein 1 (Orai1), involved in store-operated Ca2+ entry (SOCE) in inexcitable cells in this complex 236 
regulatory mechanism (524, 670). Finally, studies in Girk4-/- mice deficient in Kir3.4, implicate IKACh in 237 
regulation of pacemaker activity and heart rate following sympathetic stimulation (767). 238 
IV. TISSUE CONNECTIVITY AND ARRHYTHMIC DISORDER  239 
(A) Gap junction proteins and tissue electrical connectivity 240 
 Following initiation at the SAN, a wave of regenerative electrophysiological activity is conducted 241 
through successive cardiac structures initiating their activation (Section I(C)(3)). A first determinant of the 242 
conduction (θ) term in the expression for the wavelength, λ, of this conducted AP arises from the 243 
longitudinal resistance, ra. The latter depends on gap-junction-mediated passage of the local circuit current 244 
between cells which spreads the excitation. Each gap junction comprises two apposed and connected 245 
connexon hemichannels. The latter are protein hexamers of one of a variety of genetically distinct connexon 246 
protein isoforms. The six connexin (Cx) subunits surround an aqueous, conducting, pore electrically 247 
coupling successive cells (283, 495, 578, 606, 1192).  248 
 Of the major murine cardiac Cx isoforms (Table 3), Cx40 occurs at intercalated disks in atrial 249 
myocytes, atrioventricular-node and ventricular conduction system (247). Cx43 occurs in both atrial and 250 
ventricular myocytes and distal conduction system (495, 942, 1179). Cx45 mainly occurs in SAN, 251 
atrioventricular node and conducting bundles (1179). Altered gap junction expression slows conduction 252 
enhancing arrhythmogenecity. It can occur by itself or can accompany alterations in other AP conduction 253 
determinants such as fibrotic change or other remodelling accompanied by excitability change (496, 803, 254 
948, 1038, 1091). Thus, Cx43 distribution and expression both alter with most human ventricular 255 
remodelling following cardiac overload. This was first demonstrated with the fibre disarray in infarct border 256 
zones (888). Early compensated hypertrophic remodelling following aortic stenosis was accompanied by 257 
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increased Cx43 expression (587). HCM is accompanied by either Cx43 downregulation (888) or 258 
lateralization (1036). Dilated cardiomyopathies (DCMs) also correlate with reduced and lateralised Cx43 259 
expression. 260 
 (B) Connexin (Cx)-deficient murine hearts  261 
(1) Sinus node function 262 
 Mice deficient in Cx43 (286, 389, 803), Cx40 (57, 1109, 1172, 1191), Cx30.2 (1026), combined Cx40 263 
(596) and Cx45 or Cx30.2 (1026) showed normal sinus node function. However, Cx40-/- hearts 264 
demonstrated shifts in leading pacemaker activity from SAN to secondary sites including the sulcus 265 
terminalis, RA free wall, and right superior vena cava. Cx40−/− mice also showed prolonged ECG P-wave 266 
durations (57), PQ intervals, and QRS durations (1191). This could possibly reflect local conduction blocks 267 
prolonging intra-atrial activation path length and therefore conduction time. However, their resting 268 
membrane potentials, (dV/dt)max, AP amplitude, or APD were normal compared to WT Cx40+/+ (57).  269 
(2) Atrial arrhythmia 270 
 Both animal and human AF occur with altered atrial Cx40 expression and distribution (820). Cx40-/- 271 
atria showed reduced RA epicardial conduction velocities (57), with prolonged ECG P-wave durations in 272 
some (57, 396, 1191) but not all reports (1109, 1172). They also showed increased incidences of 273 
supraventricular arrhythmias (176, 396, 573, 1191). In contrast, Cx43-haploinsufficient or conditional Cx43 274 
knockouts showed normal P wave durations (286, 1132) and conduction velocities (1132). Increased 275 
proportions of Cx40 decreased, whilst increased proportions of Cx43 increased conduction velocity in 276 
cultured atrial myocyte strands from Cx40 or Cx43 deficient mice (85). 277 
(3) Atrioventricular conduction 278 
 Mouse atrioventricular conduction systems contain Cx40, Cx30.2, and Cx45 (496, 592, 948, 1026), as 279 
well as the murine-specific Cx30.2 (590). Cx40 knockout prolonged PQ intervals (57, 1026, 1065, 1172, 280 
1191). This was attributable to prolonged his-ventricle interval (1026) with or without increased atrial-his 281 
intervals (1172). They also showed QRS widening and fractionation (57, 596, 1026) during anterograde but 282 
not apical ventricular pacing (1191) despite normal ventricular conduction velocities. These findings are 283 
consistent with delayed bundle branch conduction (1109, 1191). This delayed conduction was directly 284 
observable in both right (947, 1109) and left bundle branches (947). 285 
 In contrast, Cx45 haploinsufficiency did not affect ECG measures of atrioventricular conduction. PQ 286 
and QRS duration then were similar to control. However, it accentuated the effects of Cx40 insufficiency on 287 
PQ and QRS duration (596). Finally, Cx30.2 knockout surprisingly was associated with reduced PQ 288 
durations. This suggested increased atrioventricular conduction velocities attributable to decreased atrial-His 289 
as opposed to His-ventricle intervals (590, 592). In contrast, combined Cx40 and Cx30.2 deficiency resulted 290 
in normal atrial-His and His-ventricular intervals consistent with opposing actions in respectively increasing 291 
or decreasing conduction velocity (1026). Loss or redistribution of Cx40 accompanies other murine models 292 
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of AF including overexpression of Ras Homolog Gene Family Member A of RHOA, angiotensin converting 293 
enzyme, tumour necrosis factor (TNF) and cAMP response element modulator (CREM) (539, 572, 990, 294 
1013). 295 
(4) Ventricular arrhythmia 296 
 Complete knockout of the main ventricular connexin, Cx43-/- causes perinatally lethal pulmonary 297 
outflow tract malformation (937). Cx43+/- mice, 50% Cx43-haploinsufficient, were viable but showed 298 
increased ventricular activation delays reflecting reduced conduction velocities in some (296, 1132) but not 299 
all studies (803, 948). Cultured strands of perinatally obtained Cx43+/- and Cx43-/- myocytes accordingly 300 
showed 0% and 96% reductions in conduction velocities respectively (84). Several conditional Cre/LoxP 301 
Cx43 knockout mouse models provided expression systems with >50% Cx43 reduction (237, 389). Even 302 
very low Cx43 levels then permitted conduction velocities that were ~50% of normal. Nevertheless, a >80% 303 
reduction in Cx43 did slow ventricular conduction, particularly in the transverse as opposed to longitudinal 304 
myocardial fibre direction. These effects were greater in the RV than the left ventricle (LV) (389, 948). They 305 
accompanied arrhythmias initiating in the RV (389, 948) and lethal ventricular tachyarrhythmias during 306 
telemetric recording (286, 389).  307 
 Computational predictions correspondingly demonstrated nonlinear dependences of conduction 308 
velocity upon junctional conductance. Gap junction uncoupling enhanced both safety factor (957) and 309 
(dV/dt)max (1083). Consequently, large gap junction conductance reductions were required to slow 310 
conduction (520, 1043). 311 
V. ELECTROPHYSIOLOGICAL EXCITATION AND ARRHYTHMIC DISORDER  312 
(A)  The Na+ channel, Nav1.5 (Scn5a), α-subunit 313 
 Cardiac Na+ channel function is essential for myocardial excitation. In addition to voltage dependent 314 
activation properties, it demonstrates transitions into and from fast and slow inactivated states, resulting in 315 
entry into and recovery from refractoriness to re-excitation (171, 970, 1184, 1200). These properties in turn 316 
are altered by Nav1.5 modification through a wide range of agents.  317 
 The main, Nav1.5, Na+ channel, α-subunit 260 kD protein, encoded by SCN5A, comprises four 318 
homologous domains (I-IV). These are assembled around a central ion-selective pore. Each domain contains 319 
six transmembrane segments (S1-S6). Of these, S5 and S6 and their connecting loop regions form the pore 320 
module. The charged amphipathic S4 segments move towards the membrane extracellular face on 321 
depolarisation. This gating transition initiates conformational changes opening the pore (878). 322 
Conformational changes in domains I-III show relatively rapid kinetics and result in ion channel opening 323 
(177). In contrast, the slower changes in domain IV permit an inactivation component connecting S6 of 324 
domain III to S1 of domain IV. This occludes the pore to cause channel inactivation (171). The α, Nav1.5, 325 
subunit thus provides the primary and often sufficient requirement for functional, voltage-gated, channel 326 
opening, ion selectivity, and channel activation and inactivation (11).  327 
37 
 
 SCN5A itself shows evidence of alternative promoter usage and splicing resulting in multiple 328 
transcripts of Nav1.5 protein resulting in differing functional properties. Nav1.5 may additionally undergo 329 
post-translational glycosylation and phosphorylation by protein kinases A and C, and modification by 330 
tyrosine kinases and phosphatases. Nav1.5 may also be a regulatory target for intracellular Ca2+, calmodulin 331 
(CaM) and CaM-dependent protein kinase II (CaMKII) (Rook et al., 2012), as well as ROS and the cell 332 
NAD+/NADH ratio (see Section VIII(A) and VIII(C)). INa is also modifiable by either indirect, PKA-333 
dependent, and direct, PKA-independent mechanisms. The PKA-independent response may involve 334 
stimulation through G protein subunit-α (Gsα) - caveolin-3 binding resulting in access to caveolar-associated 335 
Na+ channels (963).  336 
 In ventricular myocytes, Na+ channels may exist in three subpopulations. These have distinct 337 
properties, localizations and associated molecules (889). Nav1.5 channels at intercalated disks were 338 
associated with β2 and β4-subunits, ankyrin-G, synapse-associated protein 97 (SAP97) and junctional 339 
proteins (889, 1006). Genetic variants reducing ankyrin-G/Nav1.5 affected intercalated disk but not 340 
sarcolemmal Nav1.5 channels. They reduced INa, and produced human or mouse BrS (716, 787). Nav1.5 341 
demonstrated by recordings at the lateral and tubular membranes were associated with the α1-syntrophin 342 
PDZ (post synaptic density protein/Drosophila disc large tumor suppressor/zonula occludens-1 protein) 343 
domain of syntrophin/dystrophin through the C-terminal, S-I-V motif of Nav1.5 β1 and β3-subunits (1063). 344 
Mutations deleting the C-terminal motif of α1-syntrophin affected lateral membrane but not intercalated disk 345 
Nav1.5. However, they also reduced INa (1063). There have been recent suggestions of differing kinetic 346 
properties of INa arising from Nav1.5 at the two latter sites. There is also a tetrodotoxin (TTX)-sensitive, Na+ 347 
channel subpopulation unlikely to reflect Nav1.5. However, this likely makes only minimal INa contributions 348 
(662). 349 
 Genetic alterations involving Nav1.5 and its associated molecules are correspondingly associated with 350 
a wide variety of cardiac arrhythmic disorders. These include BrS (Section V(B) (32, 95, 189), progressive 351 
cardiac conduction disease (Section V(B)(3)) (PCCD; Lev-Lenegre syndrome) (737, 1021), congenital 352 
LQTS3 (Section VI(B)) (1224), SND (Section V(F)) (100), and SIDS (575, 862) (Editorials: (456, 633, 353 
985)). The comparative studies of these using murine models implicated abnormalities in some or all the 354 
fundamental electrophysiological processes of conduction, depolarisation and repolarisation in arrhythmic 355 
substrate. Single SCN5A mutations can also accompany combinations of as opposed to single clinical 356 
symptoms. These could include BrS with cardiac conduction disorder (609, 1027, 1073) SND and/or atrial 357 
standstill (1073) and LQTS3 (see section VI(B)(7)) (115, 412). 358 
(B) The Brugada Syndrome (BrS) 359 
(1) Occurrence and inheritance 360 
 BrS is characterised by increased risks of arrhythmogenic SCD occurring particularly in middle aged 361 
(~40-45 y) males (147, 289, 912). Although relatively recently identified, BrS is implicated in 4–12% of 362 
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unexpected sudden deaths. It accounts for up to 20% of deaths in patients with structurally normal hearts 363 
worldwide. This suggests a population incidence of such SCD of around 0.05% (31). There is a greater male 364 
prevalence. There are also significant worldwide variations in incidence. Thus, BrS may be the commonest 365 
cause of sudden death in anatomically normal hearts below age 50 y in South Asia (749).  366 
 BrS is inherited as an autosomal dominant trait with incomplete penetrance and so genetic testing may 367 
aid diagnosis. However, the known causative mutations are demonstrable only in ~30% of cases. The 368 
commonest mutation concerns SCN5A encoding Nav1.5, in 15% – 30% of BrS cases. There are links to 369 
almost 300 different mutations in the gene (537). Mutations in other genes are also associated with BrS. In 370 
addition to Na+ channel α-(SCN5A and SCN10A (453)) and β-subunits (SCN1B, SCN2B and SCN3B) 371 
(Section V(G)(2)-(4)), these include glycerol-3-phosphate dehydrogenase 1-like (GPD1-L)(see Section 372 
VIII(C)). Other genes involved encode proteins associated with the Na+ channel. These include GTP-373 
binding nuclear protein guanine nucleotide release factor (RANGRF), sarcolemma associated protein 374 
(SLMAP), and plakophilin 2 (PKP2). There are also K+ (ABCC9, KCNE3, KCNJ8, HCN4, KCND3 and 375 
KCNE5) and Ca2+ channel associations (CACNA1C, CACNB2B, CACNA2D1 and TRPM4) (1003). Recently, 376 
murine knockouts of the naturally occurring protein inhibitor of Kv4.3 which underlies Ito, SEMA3A, have 377 
been identified with an arrhythmic BrS-like phenotype (130). Table 4 summarises murine models used in 378 
studies of BrS phenotypes. 379 
(2) The clinical BrS electrophysiological phenotype 380 
 BrS is characterised electrocardiographically by right precordial ST elevation, negative T waves, RV 381 
delay, and one of three types of repolarisation pattern. The diagnostic type 1 pattern shows a coved ST 382 
segment elevation >2 mm followed by a negative T wave. Type 2 refers to a saddleback appearance 383 
producing a >2 mm ST segment elevation followed by a biphasic or positive T wave. Type 3 is characterised 384 
by a saddleback or coved ST elevation of <1 mm. There is also variability in clinical severity. In some cases 385 
the classical electrocardiographic type I characteristics can be elicited by administration of the INa blockers, 386 
flecainide, ajmaline, or procainamide or appear under particular clinical or pharmacological circumstances 387 
including pyrexia (554).  388 
 BrS symptoms mainly appear during adulthood. The mean age for sudden death around 40 years but 389 
there is a wide range of ~2 days to 84 y (33). Both the syncopal episodes and SCD are often preceded by fast 390 
polymorphic VT or VF. These often originate from the RV outflow tract (RVOT) (800). They are commoner 391 
in males than females. This has been suggested to partly reflect sex-related differences in IK and ICaL (987, 392 
1057). Males consequently show a more marked epicardial Ito-mediated notch often related to testosterone 393 
levels (318). In contrast, females have longer QT intervals and therefore APDs that may protect against BrS-394 
associated arrhythmia (847) (but see Section V(E)). 395 
 Detailed mechanisms by which BrS leads to ventricular arrhythmia remain under discussion. 396 
Experimental studies in canine pharmacological ventricular preparations (1288) and some small clinical 397 
studies implicated a primary repolarisation disorder (1051). The deep phase 1 notch, particularly in the RV 398 
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epicardial AP, makes it susceptible to effects of reduced INa. This produces a steep RV transmural voltage 399 
gradient. This potentially causes epicardial reactivation by neighboring regions of myocardium with longer 400 
APs. The outcome would be a functional, phase 2, re-entry. Alternatively, reduced INa might slow AP 401 
conduction, and appears to do so particularly in the RVOT, in a depolarisation disorder hypothesis (619, 402 
811). This could implicate the RVOT in both the electrocardiographic abnormalities and the delayed 403 
epicardial conduction associated with potentially fatal ventricular arrhythmia in BrS (442, 766, 907). The 404 
RVOT might then act as a site for initiation of arrhythmias. The resulting regional differences in epicardial 405 
conduction velocity between the RVOT and RV might then then trigger epicardial re-entrant excitation 406 
waves (766). This is discussed in detail in Section V(D)(1). 407 
(3) Anatomical abnormalities associated with BrS 408 
 Cardiac structure in BrS patients was initially thought to be normal. Several studies then reported 409 
progressive myocardial structural abnormalities (117, 940). Some patients showed a fatty replacement and 410 
fibrosis in the RVOT, despite normal LV anatomy (220). Nav1.5 changes, exemplified by SCN5A-D1275N, 411 
were also associated with ventricular dysfunction and structural changes including DCM (346, 758). The 412 
latter is consistent with known Nav1.5 interactions with cytoskeletal components (see Section V(A)).  413 
 Nav1.5 abnormalities have also been associated with a heterogeneous group of inherited progressive 414 
conduction diseases (PCCD) often of unknown cause (367). The Lev-Lenegre variant manifests as 415 
progressive His-Purkinje conduction slowing with left (LBBB) or right bundle branch block (RBBB) and 416 
QRS complex widening. This can advance to complete atrioventricular block. PCCD is sometimes 417 
associated with syncope or SCD. Postmortem studies revealed diffuse fibrotic degeneration through the 418 
fibrous skeleton of the heart (644) or localised conduction tissue fibrosis (640). The earliest association of 419 
PCCD with Nav1.5 was observed in a family whose members showed progressive RBBB, LBBB, left 420 
anterior or posterior hemiblock, and long PR intervals (1021). Subsequent studies revealed a wide range of 421 
associated SCN5A mutations, as well as mutations in a range of other genes. These were implicated in loss 422 
of channel function that could result from abnormalities in channel trafficking into the membrane or gating, 423 
activation and/or inactivation behavior once the protein is inserted into the membrane, some of whose 424 
effects additionally were modified by Cx gene polymorphisms (737).  425 
(C) Experimental models for Scn5a insufficiency 426 
(1) Genetic models for Scn5a haplo-insufficiency 427 
 BrS has been modelled in canine RV wedge preparations. However, these experiments entailed use of 428 
potentially nonspecific pharmacological manipulations to replicate the phenotypes under examination. 429 
Furthermore, they did not permit localisation of arrhythmias between intact cardiac chambers or regions, 430 
including in particular the RVOT. Experimental systems directly replicating genetic modifications in BrS 431 
include the murine heterozygotic Nav1.5 haplo-insufficient Scn5a+/- mouse. The Scn5a+/- heterozygotes 432 
were generated by replacing exon 2 of the Scn5a gene with a splice acceptor (SA)-Gfp-PGK-neomycin 433 
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cassette (867). Homozygous Scn5a-/- embryos died at midgestation. Scn5a+/- heterozygotes survived but 434 
demonstrated compromised atrial and atrio-ventricular conduction even at age 8-10 weeks. Myocytes from 435 
8-10 week mice showed a ~50% INa reduction compared to WT. Both the Scn5a+/- and the Scn5a-1798insD 436 
variants (see Section VI(B)(7)) (1091) also proved useful as physiological models for both atrial and 437 
ventricular arrhythmic properties in human BrS (408, 632, 1095).  438 
 Loss of Nav1.5 function following Scn5a mutations resulted in a range of murine phenotypes that 439 
directly recapitulated clinical findings. These included SND, atrial arrhythmia and progressive conduction 440 
disorders in addition to the ventricular phenotypes. Thus Scn5a+/- hearts replicated the ventricular, atrial 441 
and sino-atrial arrhythmogenicity, and age-dependent fibrotic, properties observed in clinical BrS (408, 503, 442 
632, 867, 968, 1095). Programmed electrical stimulation techniques demonstrated that Scn5a+/- hearts 443 
showed increased susceptibility to ventricular arrhythmias (867). These were accompanied by accentuations 444 
of the increases in EGD normally observed with progressively shortening S1S2 intervals (1095). The latter 445 
feature had been previously clinically associated with re-entrant substrates (461, 1011, 1012). These 446 
investigations also recapitulated clinical observations of increased and decreased arrhythmic incidences 447 
following challenge by the normally anti-arrhythmic agents flecainide and quinidine respectively. These 448 
were correspondingly accompanied by accentuations or reductions in the EGD alterations (743, 1095). 449 
Studies on atrial arrhythmic susceptibility then suggested that 50% of Scn5a+/- but 0% of WT hearts had 450 
spontaneous atrial arrhythmia. This was eliminated by both flecainide and quinidine (240) (see Section 451 
V(F)(1)). Their accompanying alterations in electrophysiological (740) and pharmacological (742) 452 
properties thus throw light on mechanisms for arrhythmia particularly in relationship to altered AP 453 
conduction. 454 
(2) Biophysical features of the murine Scn5a+/- system 455 
 Combined biophysical and molecular biological analyses separately examining the LV and RV of 456 
Scn5a+/- ventricles confirmed their selective loss of Nav1.5 function. They established a basis for clarifying 457 
the arrhythmic mechanisms that follow (Figure 5) (741). Thus, Scn5a+/- ventricles showed reduced Nav1.5 458 
mRNA and protein expression. These changes were more marked in the RV than the LV. These findings 459 
concurred with results from patch-clamp analyses of INa. These revealed reduced maximum INa (Figure 5A, 460 
B). Scn5a+/- myocytes also showed correspondingly decreased AP upstroke velocities ((dV/dt)max) and 461 
maximum INa densities than WT, changes again more noticeable in the RV compared to the LV (Figure 5C). 462 
There were concordant alterations in the density of the late Na+ currents (INaL). Despite normal steady-state 463 
dependences of activation upon test voltage (Figure 5D), INa showed a negative shift in the voltage 464 
dependence of its inactivation function (Figure 5E). These findings are consistent with depolarisation 465 
abnormalities that would be expected to slow action potential conduction.  466 
 In contrast, both Scn5a+/- and WT RVs showed similarly higher Kv4.2, Kv4.3 and KChIP2 467 
expression levels than the LV. Both Scn5a+/- and WT ventricles accordingly showed greater RV than LV 468 
transient outward current (Ito) densities (741).  469 
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 These findings correlate with studies at the organ level in Scn5a+/- hearts as described below. These 470 
further clarified the clinical evidence for BrS being primarily a RV condition. They additionally 471 
distinguished contributions to this property from alterations in ion channel expression and consequent 472 
electrophysiological abnormalities. These could result in abnormal depolarisation (1091) or repolarisation 473 
(39), fibrotic change, or reduced Cx expression (See Section V(E)) (501–503, 1180). 474 
(3) Electrocardiographic features of Scn5a+/- hearts 475 
 Intact anaesthetised Scn5a+/- mice showed ECG features also compatible with conduction 476 
abnormalities that could be directly attributed to reduced Na+ channel function. The initial studies observed a 477 
second degree atrioventricular block and increased PR intervals (742). The changes were directly 478 
translatable to clinical observations in BrS patients with identifiable SCN5A mutations (717, 1052, 1148). 479 
Flecainide increased these PR intervals and the QRS durations particularly in the Scn5a+/- mice. This also 480 
paralleled the clinical effects of flecainide in normal and BrS patients (899, 1052). Scn5a+/- mice also 481 
showed accentuated QT dispersions, suggesting an increased repolarisation heterogeneity. These were 482 
further increased by flecainide but not quinidine. This recapitulated their respective clinical pro-arrhythmic 483 
and anti-arrhythmic effects, and their accompanying on temporal QT dispersion, in clinical BrS (477, 899). 484 
The prolongations in PR and QRS intervals increased with age (968), particularly in male in contrast to 485 
female Scn5a+/- mice (501–503, 1180). 486 
 (4) Action potential waveforms in Scn5a+/- ventricles 487 
 Endocardial and epicardial MAP recordings in isolated Langendorff-perfused Scn5a+/- hearts 488 
demonstrated similar RV and LV endocardial APDs that nevertheless exceeded their corresponding 489 
epicardial APDs. APDs were shorter in the Scn5a+/- compared to WT particularly in the RV. This resulted 490 
in greater RV than LV transmural repolarisation gradients as quantified through ∆APD90 values, differences 491 
particularly marked in Scn5a+/- hearts. Flecainide and quinidine exerted similar patterns of pharmacological 492 
effects in Scn5a+/- and WT hearts. In both cases, flecainide shortened whereas quinidine lengthened the 493 
APDs. It did so for all four, endocardial and epicardial, and right and left, ventricular regions but particularly 494 
so for the RV epicardium. These changes accentuated the reduced RV transmural gradients that occurred 495 
even before pharmacological challenge. They thereby resulted in strongly positive RV but not LV 496 
transmural gradients in the flecainide-treated Scn5a+/- hearts which has been suggested as being potentially 497 
arrhythmogenic (see Section VI(A)(2)). In contrast, quinidine lengthened the APDs in all ventricular regions 498 
in the Scn5a+/− hearts, particularly in RV epicardium. This decreased the RV transmural gradients which 499 
were now similar to the gradients observed in untreated WT ventricles (743). 500 
 (5) Conduction and refractoriness in Scn5a+/- ventricles 501 
 Increased RV transmural repolarisation gradients in Nav1.5-deficient ventricles combined with 502 
localised AP shortening could potentially reduce the AP dome. This would potentially increase the 503 
likelihoods of the early epicardial phase II re-excitation previously implicated in arrhythmia in BrS (1288). 504 
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However, such early re-entry mechanisms would require corresponding reductions in epicardial refractory 505 
periods, if the re-excitation were to take place. Normal canine (243, 329) and human (624) hearts indeed 506 
showed a concordance between changes in APDs and changes in ventricular effective refractory periods 507 
(VERPs). However, VERPs can be selectively affected by factors that spare APD. Thus, contrasting changes 508 
in VERPs in BrS were reported in clinical (50) and cell expression studies (118). Contrasting APD and 509 
VERP changes occur under other arrhythmogenic circumstances including hypokalaemia (977, 978, 980).  510 
 In murine Scn5a+/- ventricles, increased arrhythmogenicity accompanied shortened APDs and 511 
increased RV repolarisation gradients. The corresponding VERPs were increased rather than decreased, 512 
particularly in the presence of arrhythmogenic Scn5a+/- phenotypes (734). Both WT and Scn5a+/- hearts 513 
also showed regional VERP heterogeneities, consistent with both clinical reports (703) and known Ito 514 
differences (1124). Computational analysis confirmed that these findings were consistent with the reduced 515 
numbers of Na+ channels available for re-excitation in Scn5a+/- hearts (930, 1090). Refractory period would 516 
depend upon recovery of a critical number of then re-activatable Na+ channels. This level would be achieved 517 
at a greater interval following repolarisation when total channel numbers were reduced. Furthermore, 518 
notwithstanding their contrasting pro-arrhythmic and anti-arrhythmic effects, flecainide and quinidine both 519 
increased VERP. This is in agreement with their known effects in canine, rabbit and human hearts (148). 520 
Quinidine exerted the greater effects, likely reflecting its K+ channel blocking actions in contrast to the 521 
predominant Na+ channel blocking effect of flecainide (1231). However, increased VERPs along the 522 
patterns found in Scn5a+/- ventricles are inconsistent with an arrhythmia initiated by early local phase 2 re-523 
excitation (1288).  524 
 Nevertheless, the findings remained compatible with roles for VERPs, particularly their spatial 525 
variations, and the consequences of these for conduction of excitation, in re-entrant substrate. The Scn5a+/- 526 
hearts, particularly their RVs, in addition to the greater VERPs, showed a greater conduction slowing 527 
following S2 stimuli than did WT, as expected from their reduced INa. This effect was accentuated by 528 
flecainide, and, though less so, by quinidine challenge, concordant with clinical findings (907). Thus, 529 
whereas flecainide produced a more marked conduction slowing, quinidine exerted greater effects in 530 
increasing VERP. Either could potentially produce conditions of a slowed conduction or even conduction 531 
block through such partially refractory tissue with heterogeneously increased VERPs sufficient to result in 532 
arrhythmic substrate. These results paralleled other findings in LQTS (59), SQTS (775) and ischaemic 533 
experimental models (487), and modelling studies (1141). LQTS (1175) and arrhythmic post-infarct patients 534 
(781) similarly show increased refractory period dispersions and greater heterogeneities in tissue excitability 535 
and refractoriness (1231).  536 
 (6) Steady state analyses of action potential stability in Scn5a+/- ventricles 537 
 These differences in AP properties between Scn5a+/- and WT translated into differing ventricular 538 
electrical instabilities during protocols applying progressively incremented steady state pacing rates.  This 539 
could be observed with decreasing BCLs ranging between 130 and 30 ms (see Section II(A)(4)) (754). Such 540 
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protocols ended with either an onset of refractoriness and a 2:1 block, or VT or VF. Scn5a+/- ventricles 541 
showed more frequent arrhythmic endpoints leading to VT, particularly in the RV (Matthews et al. 2010; 542 
2011). Flecainide increased the frequency of such arrhythmic events. These events then took place earlier in 543 
the pacing protocol and therefore at longer BCLs. In contrast, quinidine diminished the frequencies of such 544 
events.  545 
 Scn5a+/- and WT ventricles also demonstrated differing onsets of alternans in MAP magnitude and 546 
duration at RV and LV, epicardial and endocardial sites before and following flecainide and quinidine 547 
challenge in the course of the pacing procedures. Scn5a+/- ventricles accordingly demonstrated longer BCLs 548 
and DIs corresponding to the onset of either transient (tr) or sustained (ss) APD (DI*) and AP amplitude 549 
(DI’) alternans. Following flecainide challenge the RV epicardium showed the greatest evidence for 550 
potential instability. It then showed an onset of alternans at longer BCLs and larger amplitudes than the 551 
corresponding endocardium. This would generate transmural heterogeneities and potential discordant 552 
alternans. These findings thus provided an empirical basis for implicating the RV in the observed clinical  553 
arrhythmogenesis (752, 754).  554 
 Quantitative analysis of the corresponding restitution properties (see Section II(A)(4)) similarly 555 
selectively implicated the RV epicardium in the Scn5a+/- pro-arrhythmic phenotype. Refractory properties, 556 
reflected in the DIERP associated with onset of either 2:1 block or arrhythmia were indistinguishable between 557 
corresponding recording sites in WT and Scn5a+/- before pharmacological manipulations. However DIERP 558 
was increased in both RV epicardial and RV endocardial in flecainide or quinidine-treated Scn5a+/- hearts. 559 
Onsets of instability, reflected in DI values corresponding to unity slope, DIcrit, in APD vs. DI plots, were 560 
similar in WT and Scn5a+/-, at each recording site. However, Scn5a+/- RV ventricles showed steeper 561 
restitution functions than the corresponding WT. Flecainide then specifically destabilised Scn5a+/- RV, 562 
selectively increasing DIcrit (752, 754). This corroborated the alternans findings implicating RV epicardium 563 
in Scn5a+/- arrhythmia. This is consistent with suggestions that APD restitution is a predictor for arrhythmic 564 
tendency (274, 817).  565 
 In the above analyses, the relationship between alternans magnitude and restitution curve slope was a 566 
continuous second order one. This would contrast with the direct linear function containing an abrupt 567 
instability threshold predicted by voltage feedback mechanisms produced by AP repolarisation and 568 
refractoriness properties (838). This prompted more complete analyses of electrophysiological instabilities 569 
which additionally explored for contributions from abnormalities in conduction velocities θ. Previous 570 
studies had implicated changes in the broadness of restitution functions representing effects on θ of similarly 571 
decreasing BCLs and consequently of DIs, as indicators of observed arrhythmia and alternans (929). These 572 
studies did not yield such findings. Nevertheless they demonstrated that maximum achievable magnitudes of 573 
θ and DI corresponding to conduction failure correlated well with arrhythmic tendency, particularly in the 574 
Scn5a+/- RV epicardium. The latter was the case both before or following flecainide challenge. They also 575 
demonstrated θ alternans. Although less frequent than APD alternans, it abruptly appeared at pacing rates 576 
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close to producing refractoriness. Finally, flecainide increased θ alternans specifically in Scn5a+/− RV 577 
epicardium (752). 578 
 (7) Wavelength restitution analysis in Scn5a+/- hearts 579 
 The restitution analysis could then be further extended to consider indices of excitation that reflected 580 
both θ, and recovery as represented by APD. This utilized the excitation wavelength, λ= APD × θ (see 581 
Section I(C)(3)). Such wavelengths, λ, then fell nonlinearly with falling DI in agreement with previous 582 
reports (695). However, the variables in the plots of λ against DI were differently dimensioned in distance 583 
and time respectively. They were consequently not amenable to feedback instability analysis. Nevertheless, 584 
a systems restitution analysis was made possible by expressing DI in terms of a resting, as opposed to 585 
excitation wavelength, λ0 = DI × θ. Comparisons of λ against λ0 gave rise to identically dimensioned plots of 586 
active and resting wavelengths. In these, the BCL variable was similarly transformed into a basic cycle 587 
distance, BCD = BCL × θ. It was then possible to analyse electrophysiological stability in terms of the 588 
wavelength parameters λ and λ0 thus incorporating the effects of BCL upon APD, latency and DI. The 589 
resulting, more general, instability analysis then demonstrated differing, epicardial and endocardial, 590 
maximum λ in untreated hearts at low heart rates. Quinidine decreased these in WT endocardium and 591 
abolished endocardial–epicardial differences in Scn5a+/− hearts. These findings were consistent with 592 
quinidine exerting pro-arrhythmic effects in WT but anti-arrhythmic effects in Scn5a+/− hearts (753).  593 
 Increased heart rates then resulted in an onset of λ-alternans, failed wave propagation and re-entrant 594 
foci corresponding to a positive feedback condition at unity gradients in the λ - λ0, plots. This critical 595 
condition further corresponded to similar critical values of resting (λ0crit) and total, basic cycle distance, 596 
BCD, wavelengths through both genotypes and all recording sites and all conditions of flecainide or 597 
quinidine challenge. This analysis thus yielded a common critical instability point which would thereby 598 
correspond to achievement of both necessary and sufficient conditions for initiating arrhythmia. Common 599 
instability points also implicate particular intrinsic cellular mechanisms underlying excitation and resting 600 
wavelengths. These could arise from interactions between channel opening and voltage change (1236), or 601 
other signalling that may modulate channel properties potentially through altered Ca2+ (204, 1137) and ATP 602 
homeostasis. 603 
 Pacing rates at which instability occurred were indistinguishable between untreated Scn5a+/- and WT 604 
hearts. However, they were decreased by both flecainide and quinidine specifically in Scn5a+/− RV 605 
epicardium, and by quinidine challenge in WT RV endocardium. Finally, over the studied pacing rates, 606 
alternans magnitude agreed more closely with the gradient of the λ than the APD restitution function. Thus, 607 
analysis of λ rather than its component variables of an isolated θ or APD provides an analysis closer to 608 
mechanisms underlying alternans thereby better predicting arrhythmia (753).  609 
 These findings are consistent with simple schemes directly relating changes in wavelength parameters 610 
to the occurrence or otherwise of wavebreak re-entry leading to arrhythmia when the propagating AP 611 
encounters heterogeneities. With a long wavelength, as the AP passes over the heterogeneity, the back of the 612 
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propagating wave blocks and extinguishes any retrograde excitation whilst orthograde excitation continues. 613 
With a short wavelength, the back of the AP wave may traversed the heterogeneity before retrograde 614 
excitation passes through the unidirectional block. This generates a new propagating retrograde, potentially 615 
re-entrant excitation wave (see Section I(C)(3)).  616 
 (8) Direct visualization of re-entrant circuit formation in Scn5a+/- ventricles 617 
 The two main BrS arrhythmogenic mechanisms involving slowed conduction and repolarisation 618 
heterogeneity proposed in the experiments above could be both directly visualised and integrated by contact 619 
multielectrode (0.5 mm) array (MEA) mapping techniques applied to the RV and LV epicardial surfaces 620 
(736). Use of spontaneously beating hearts before and following flecainide or quinidine challenge provided 621 
more realistic indications of in vivo epicardial electrophysiological patterns following physiological 622 
activation, than possible with imposed pacing. Each electrode array site recorded biphasic electrograms 623 
comprising negative followed by positive deflections. Spontaneously beating WT hearts showed neither 624 
ventricular ectopic (VE) nor VT phenomena before, and only low frequencies of these following, 625 
pharmacological challenge. The low incidences of ventricular ectopic events and VT in Scn5a+/- markedly 626 
increased with flecainide but not quinidine challenge.  627 
 Electrophysiological features derived from MEA recording could be integrated with those obtained 628 
from MAP studies. Activation (AT) and recovery times (RTs) corresponded to points of maximal negative 629 
slope (dV/dt)min of the initial and second negative deflections respectively. Activation recovery intervals 630 
(ARIs), obtained from the AT-RT interval, correlated linearly with MAP measures of APD. Their 631 
dispersions were expressed as the AT, RT and ARI differences, ATD, RTD and ARID, between values of 632 
the first and last values in each set of electrograms of the arrays. Isochronal maps of these measures were 633 
then used to clarify the interactions between depolarisation and repolarisation abnormalities and the 634 
appearance and evolution of arrhythmic substrate through re-entrant circuits.  635 
 The mapping studies directly demonstrated slowed conduction with dispersion of activation and lines 636 
of block in Scn5a+/- ventricles. LV and RV MEA recordings of excitation in both WT and Scn5a+/- hearts 637 
usually showed single planar wavefronts arriving at the epicardium with the intraepicardial vector directed 638 
from apex to base. However, WT ventricles showed similar LV and RV ATDs. Both increased in Scn5a+/- 639 
ventricles which additionally showed longer RV than LV ATDs. Flecainide, but not quinidine increased the 640 
ATDs in the RVs of WT and LVs and particularly RVs of Scn5a+/- ventricles.  641 
 The mapping studies also directly demonstrated evidence for shorter, and increased dispersion of 642 
recovery in Scn5a+/- ventricles. Scn5a+/- ventricles thus showed shorter but more heterogeneous ARIs. 643 
ARIs and ARIDs indicating recovery timecourses were similar in LVs and RVs of WT. However, ARIs 644 
were shorter and ARIDs increased in RVs of Scn5a+/- hearts. Flecainide decreased the ARIs whilst 645 
increasing the ARIDs. In contrast, quinidine increased ARIs and spared ARIDs in both RVs and LVs of both 646 
WT and Scn5a+/- hearts. Flecainide thus resulted in greater RV ARIDs in Scn5a+/- than WT hearts.  647 
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 WT ventricles showed ARI maps closely similar in pattern to the corresponding activation maps. The 648 
longest and shortest ARIs respectively occurred in regions of earliest and latest regions of activation. In 649 
contrast, Scn5a+/- ventricles showed disorganised ARI maps without clear gradients. There was also greater 650 
RT heterogeneity with RTs spread over wider time courses in Scn5a+/- ventricles. Finally, WT hearts 651 
showed similar RTDs in the LV and RV that were spared by flecainide. In contrast, Scn5a+/- hearts showed 652 
increased RTDs in the LV and RV, with the RTDs additionally greater in the RV than LV. Flecainide 653 
increased these RTDs in the Scn5a+/- but not WT. Quinidine decreased them in both Scn5a+/- and WT.  654 
 These features promoted an initiation of VT, originating in the RV and arising from lines of 655 
conduction block leading to induction of reentrant circuits. Figure 6 illustrates the generation of a premature 656 
ventricular beat following arrival of activation at the RV epicardium. Results are shown for a flecainide-657 
treated, spontaneously beating, Scn5a+/- heart leading to initiation of polymorphic VT. Such ventricular 658 
ectopics often occurred with increased RTDs in their preceding sinus beats. Figure 6A-F summarises the 659 
sequence of events, mapped onto the ECG (Figure 6G, letters A-F). The last sinus beat shows close 660 
isochronal contours reflecting delayed arrival of epicardial activation (Figure 6A). Its corresponding 661 
repolarisation map shows increased repolarisation heterogeneities in all cases where premature beats led to 662 
the re-entrant VT circuits that followed (Figure 6A”). A superimposed, premature ventricular activation 663 
produces a line of block. Impulse propagation flows around this (Figure 6B). A subsequent ventricular 664 
ectopic event initiates a circuit running anticlockwise (Figure 6C). This persists into the following beat, 665 
initiating VT (Figure 6D). VTs most frequently followed premature ventricular beats that were specifically 666 
synchronised with the T wave (Figure 6J). The continually changing line of block produces a nonstationary 667 
vortex accounting for the polymorphic nature of the VT (Figure 6E and F). The VT then propagates as a 668 
wavefront across the LV from its initiation site in the RV (Figure 6I) (736). 669 
(D) Initiation sites for ventricular arrhythmia in Scn5a+/- hearts 670 
(1) The right ventricular outflow tract (RVOT) as a site for arrhythmia initiation in 671 
clinical BrS 672 
 In addition to outlining the basis for formation of arrhythmic substrate in BrS models, the previous 673 
section included evidence for preferential initiation of arrhythmia in the RV as opposed to the LV. Further 674 
evidence more specifically implicated the RVOT in this initiation of clinical arrhythmia in BrS. It also 675 
indicated that the murine Scn5a+/- system models both the human arrhythmia and its possible underlying 676 
mechanisms. The localization of the background depolarisation and repolarisation changes in RVOT as 677 
opposed to the remaining RV, and the LV, in BrS may reflect their differing embryological origins (1312). 678 
The RVOT originates from cells that also contribute to the slow conducting atrioventricular region (797). 679 
This may relate to suggestions for an existence of slow conducting tissue in the RVOT dependent upon L-680 
type Ca2+ channel rather than Nav1.5 activation (766), or of a further reduced Nav1.5 expression in the 681 
RVOT particularly with flecainide challenge (1183). 682 
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 The RVOT has been implicated in both the clinical ECG abnormalities (see Section V(B)) and a 683 
delayed epicardial conduction potentially associated with initiation of ventricular arrhythmia in clinical BrS 684 
(102, 218, 538, 766, 801, 907, 1148). These in turn were attributed to RVOT structural abnormalities such as 685 
fibrotic or fatty endocardial infiltration in BrS. Non-invasive clinical studies such as echocardiographic 686 
investigations for wall motion abnormalities (1148), body surface mapping (287, 491, 1148), signal-687 
averaged ECGs (433) or tissue Doppler echocardiography indeed posed evidence for RVOT conduction 688 
delays (1148).  689 
 Some invasive RVOT endocardial studies demonstrated increased activation delays (531), electrogram 690 
prolongations, narrower activation recovery interval (ARI) and steeper restitution curves (619). A more 691 
restricted number of epicardial investigations demonstrated activation delays (811) and shortened RVOT 692 
ARIs on catheter recording in the great cardiac vein during ST elevation, as well as epicardial, but not 693 
endocardial spike-and-dome AP waveforms in BrS hearts during open chest surgery (605). Finally, 694 
explanted human BrS hearts showed VF associated with RVOT subendocardial rather than subepicardial re-695 
entry and RV activation slowing. In contrast, there was an absence of transmural repolarisation gradients  696 
(218, 442). They also showed a reduced basal RV subepicardial local activation associated with the ST 697 
segment elevation (441). Both these studies also reported fibrosis and fatty infiltration in the RV. This could 698 
accentuate the current-to-load mismatch between the abnormal RVOT and more normal myocardial tissue 699 
already established by altered INa. This could explain the reduced conduction velocities and ECG patterns 700 
(441).  701 
 (2) Murine Scn5a+/- hearts model the RVOT as an initiation site for arrhythmia in BrS 702 
 Comparisons of isolated Langendorff-perfused murine Scn5a+/- and WT ventricles provided a 703 
physiological basis for a possible RVOT involvement in the VT associated with BrS. These comparisons 704 
systematically compared arrhythmogenic tendency and the related electrophysiological parameters of 705 
VERPs, response latencies, electrogram durations (EGDs), APDs, the presence or absence of concordant or 706 
discordant alternans, and restitution curves. This involved making bipolar electrogram and MAP recordings 707 
at multiple RV and LV epicardial locations before and following flecainide and quinidine challenge (735). 708 
The bipolar electrogram measurements implicated the RVOT as an arrhythmogenic focus in Scn5a+/− 709 
hearts. Thus imposition of extrasystolic stimuli at progressively shorter intervals following regular pacing 710 
spikes elicited earlier occurrences of VT in the RVOT than the base of the LV in the Scn5a+/- but not the 711 
WT heart, which further showed only one VT episode. The same protocol demonstrated a greater degree of 712 
electrogram fractionation, previously used to assess the existence of arrhythmogenic reentrant pathways, in 713 
Scn5a+/- than WT ventricles. This was particularly so at the RVOT compared to the remaining recording 714 
sites.  715 
 The basis of these findings emerged from the MAP assessments of VERPs and conduction velocities. 716 
Both Scn5a+/- and WT showed marked apical-basal VERP gradients, However, these gradients were greater 717 
in Scn5a+/- than WT ventricles, specifically in the RV. Scn5a+/- ventricles also showed greater response 718 
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latencies reflecting slowed conduction velocities than in WT. Both these differences were accentuated by 719 
flecainide challenge. Furthermore, the RVOTs showed shorter APDs and VERPs and steeper gradients of 720 
these values than elsewhere in both WT and Scn5a+/- hearts.  721 
 RVOTs of WT and Scn5a+/- hearts showed similar onsets of concordant alternans in incremental 722 
pacing protocols whether before or following pharmacological intervention. However, RVOTs of Scn5a+/- 723 
hearts showed more frequent transitions from concordant to discordant alternans. This in turn led to 724 
arrhythmogenesis, during pacing protocols involving progressively increased frequencies of stimulation. 725 
This tendency was exacerbated by flecainide and relieved by quinidine. In parallel with this, RVOTs of 726 
Scn5a+/- hearts showed the greatest heterogeneities in response latencies, and the largest APD and VERP 727 
gradients. The discordant alternans were always observed prior to any observed transitions into VT. 728 
Scn5a+/− RVOTs also showed steeper restitution curves. In these curves, the diastolic interval at which the 729 
gradient reached unity strongly correlated with the diastolic interval corresponding to the onset of discordant 730 
alternans (735). 731 
(3) Arrhythmic tendency, fibrotic change and Nav1.5 expression in the RVOT of 732 
murine Scn5a+/- hearts  733 
 Further experiments correlated these arrhythmic features of the RVOT with key determinants for both 734 
arrhythmic tendency and conduction velocity. They demonstrated reduced Nav1.5 protein expression in both 735 
the RV and RVOT of Scn5a+/- compared to WT hearts. They also observed increased levels of fibrosis in 736 
the RVOT than the RV in both WT and Scn5a+/- (1336). Corresponding electrophysiological studies then 737 
first confirmed that stimulation at the RVOT as opposed to the remaining RV elicited increased arrhythmic 738 
incidences in Scn5a+/- but not WT hearts. Yet, Scn5a+/- showed greater VERPs than WT in both the RVOT 739 
and remaining RV. Furthermore VERPs in the RVOT were greater in Scn5a+/- than WT, but were similar in 740 
the remaining RV in both Scn5a+/- and WT. These findings were subsequently paralleled in clinical reports 741 
(810). Both are at variance with a phase II re-entry induced arrhythmia, particularly if this were to take place 742 
in the RVOT of Scn5a+/- hearts (702, 1182) (see also Section V(C)(5)).  743 
 In contrast, positive findings emerged from correlations of the arrhythmic properties with MEA 744 
assessments of AP conduction. First, overall AP conduction velocities were determined from simple 745 
regressions to planar fits to the local activation times of each MEA recording site. This correlated a reduced 746 
velocity with both the Scn5a+/- as opposed to the WT genotype, and in recordings from the RVOT as 747 
opposed to recordings from the RV. Second, the magnitudes of conduction velocities were averaged over the 748 
MEA recording sites by a local vector analysis. These magnitudes were reduced in the Scn5a+/- compared 749 
to WT, without variation between, RV or RVOT, recording sites. Third, dispersions in the conduction 750 
direction were assessed from the same vector analysis. The resulting dispersions were greater in the RVOT 751 
than in the RV, but there was then no influence of or interaction with, Scn5a+/- vs WT, genotype. Finally, 752 
these results were correlated with biochemical and histological results. Nav1.5 expression was 753 
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correspondingly reduced in both RVOT and the remaining RV of Scn5a+/- as opposed to WT hearts. But 754 
interstitial fibrosis was greater in the RVOT than the remaining RV in both Scn5a+/- and WT hearts (1336). 755 
 (E) The Scn5a+/- genotype, age-dependent fibrotic change and arrhythmogenesis  756 
(1) Age dependence of the BrS arrhythmic phenotype.  
 BrS thus includes additional phenotypic features not directly explicable solely in terms of Nav1.5-757 
related biophysical changes. As indicated above (section V(B)(2)) its clinical manisfestations are often 758 
postponed until adulthood giving an average age of SCD of 40 years (33). There is also a greater male 759 
prevalence (749). Nav1.5 haploinsufficiency is also associated with the fibrotic changes in the related 760 
condition of PCCD (Lev-Lenegre disease), which can also exist in an overlap syndromes with BrS (919) 761 
(see Section V(B)(3)). Experimental studies in Scn5a+/- murine hearts recapitulated co-existent Nav1.5 762 
deficiencies with fibrotic changes dependent upon age and sex that would accentuate conduction and 763 
therefore arrhythmic disorders (500). 764 
(2) Sex and age-dependent fibrotic phenotypes in Scn5a+/- hearts 
 Aged murine Scn5a+/- hearts demonstrated prolonged electrocardiographic P wave, PR and QRS 765 
durations, and evidence of spontaneous arrhythmic tendency (Figure 7A) (392). This accompanied a 766 
significant degree of ventricular fibrosis, decreased Cx43 expression, increases in the hypertrophic cardiac 767 
markers β-MHC and skeletal α-actin, and reductions in atrial levels of the atrial-specific gap junction 768 
protein, Cx40 (642, 968). They showed elevated microarray and real-time PCR assays of Atf3 and Egr1 769 
transcription factor (1180).  770 
 With epicardial MEA mapping (Figure 7C, D), even young (3-4 month) Scn5a+/- showed slowed RV 771 
conduction compared to the corresponding WT results, in an absence of demonstrable fibrosis or altered 772 
Cx43 expression. These findings were therefore primarily attributable to the direct biophysical consequences 773 
of a Nav1.5 haploinsufficiency (736). However, old WT mice showed slowed RV conduction associated 774 
with interstitial fibrosis. Old Scn5a+/- ventricles showed slowed conduction in both the RV and LV, severe 775 
reactive fibrosis and downregulated Cx43 expression (1180). The Scn5a+/- mice then could additionally be 776 
stratified into subgroups with severe (QRS >18 ms) and mild (QRS ≤ 18 ms) ventricular conduction defects. 777 
This stratification correlated with the extent of fibrotic change and arrhythmic severity. These findings 778 
paralleled heterogeneities also observed in human SCN5A-mutated patients (Figure 7E, F). Ageing 779 
conserved and accentuated this stratification, together with its related reductions in Scn5a mRNA expression 780 
and INa. QRS durations with even the mild Scn5a+/- phenotype then exceeded that of WT (642).   781 
 Systematic, quantitative studies then analysed the effects of, and interactions between, genotype, age 782 
(3 vs >12 months) and sex upon both conduction and fibrotic change in murine Scn5a+/- hearts. 783 
Electrocardiographic PR intervals were longer in young female compared to young male WT and Scn5a+/- 784 
anaesthetised mice. However, these intervals increased with age with a development of evidence for RV 785 
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conduction block on chest lead recording in male but not female Scn5a+/- hearts (Figure 7B) (502). In 786 
contrast, old female Scn5a+/- and WT hearts showed similar PR intervals (503).  787 
 In isolated Langendorff-perfused WT hearts, MEA mapping of activation times demonstrated 788 
sequential propagations of RV epicardial activation from a localised region. This suggested orderly 789 
propagation of such excitation either through the plane of the epicardium or from endocardium to 790 
epicardium. In contrast, Scn5a+/- hearts showed a more fragmented activation pattern (Figure 7C, D (501)). 791 
This often included multiple random firing points consistent with greater likelihoods of re-entrant pro-792 
arrhythmic events between neighboring epicardial sites where these showed strongly different activation 793 
times (501).  794 
 Quantification of these activation times in terms of average and maximum activation delays indicated 795 
interacting effects upon these of all three factors of genotype, age, and sex, with the greatest effects 796 
consequently observed in old male Scn5a+/- hearts. It was possible first to quantify temporal variations in 797 
activation time at any given recording site. These depended upon genotype and not upon age and sex. They 798 
specifically gave larger variations in activation times in old male Scn5a+/- than the corresponding old WT 799 
hearts. Second, it was possible to assess spatial dispersions of activation times amongst recording sites 800 
within any given cardiac cycle. These were influenced by interacting effects of all the three variates of 801 
genotype, age, and sex. Old male Scn5a+/- hearts then gave greater dispersions than either old male WT or 802 
the remaining Scn5a+/- groups (501).  803 
 Analysis of frequency distributions in these activation times attributed these differences to alterations 804 
in an initially bimodal activation time distribution reflecting distinct early and late activation phases (Figure 805 
7G). Old male Scn5a+/- showed a reduced early and a correspondingly increased late component relative to 806 
distributions shown by young male Scn5a+/-, old female Scn5a+/-, and old male WT. The corresponding 807 
morphometrically determined patterns of fibrosis then closely matched these electrophysiological findings 808 
among the experimental groups when these were sorted by genotype, age, and sex (502).  809 
(3) Regulatory consequences of Nav1.5 deficiency. 810 
 Studies in murine Scn5a+/- hearts also suggested that the BrS condition itself accentuates 811 
anatomical, fibrotic, change. The latter could potentially contribute to its typically adult (~40 y) rather than 812 
juvenile presentation and primarily male prevalence (749). Na+ channels might thus exert regulatory 813 
functions distinct from their mediation of electrophysiological excitability (3, 408). As indicated previously, 814 
Na+ channels occur clustered with other proteins. Alterations in their properties or expression could 815 
therefore impact on expression or properties of other molecules. This could potentially include agents 816 
affecting fibroblast development. Nav1.5 haploinsufficiency correlated with upregulation of the stress 817 
inducible gene, Atf3, and the early growth response gene Egr1 (642, 968, 1180). In atrial preparations 818 
Nav1.5 deficiency was associated with increased TGF-β1 and vimentin transcript expression. These could 819 
potentially increase collagen and fibroblast abundance resulting in interstitial fibrosis (408). Such effects 820 
could accentuate the biophysical consequences of Nav1.5 downregulation particularly in Scn5a+/- RV (741). 821 
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 (4) Possible combined effects of Nav1.5 haploinsufficiency and fibrotic change in 822 
ventricular arrhythmogenesis 823 
 Nav1.5 haploinsufficiency in the murine Scn5a+/- system thus appears to result in both biophysical 824 
and structural change, particularly in the RV. This is consistent with its overlapping pro-arrhythmic clinical 825 
manifestations in the form of BrS and PCCD. This would account for the clinical evidence. Table 5 826 
summarises the resemblances between human BrS and the murine Scn5a+/- model The experimental 827 
findings suggest that it is the overlap of these changes that together resulted in accentuated arrhythmic 828 
substrate sufficient to produce spontaneous arrhythmic events particularly in aged male Scn5a+/-hearts. 829 
 In such a scheme, the Nav1.5 deficiency would produce a background electrophysiological ion 830 
channel abnormality compromising conduction of excitation. This itself produces arrhythmic substrate if 831 
unmasked by flecainide or ajmaline challenge. This underlying phenotype could then interact with a co-832 
existing tissue disruption arising from fibrotic change with age. This would be the effect of Na+ channels 833 
exerting regulatory or metabolic functions in addition to those of electrophysiological excitability 834 
particularly in male Scn5a+/- resulting in preferential expression of slowly at the expense of rapidly 835 
conducting pathways. Fibrotic change would compromise ephaptic, gap-junction-mediated, myocyte-836 
myocyte coupling, It could thereby compromise AP conduction between cells particularly with the 837 
accompanying Nav1.5 downregulation (741). It would also distort tissue geometry dispersing conduction 838 
through alternative conducting branches prolonging conduction pathlengths (see also Section IX(A)(3)). 839 
 Arrhythmic tendency would then be the consequence of a combination of Nav1.5 haploinsufﬁciency 840 
and an evolving structural change in Nav1.5 associated arrhythmic disease including both progressive 841 
cardiac conduction defect and BrS. The background Nav1.5 haploinsufficiency would produce arrhythmic 842 
substrate typically unmasked by ﬂecainide or ajmaline challenge that accentuates an underlying conduction 843 
defect (500). Cardiac ﬁbrotic changes with age, accentuated in males, could then accentuate the arrhythmic 844 
substrate to an extent sufﬁcient to lead to arrhythmic events (Figure 8). Such suggestions based on studies in 845 
murine hearts have proven translatable into clinical findings (810). 846 
 A recently developed SCN5A-E558X porcine model provided a large animal system with features that 847 
were comparable with the arrhythmic phenomena in murine hearts (868). The porcine model showed heart 848 
rates, cardiac size, AP shape and autonomic innervations as well as cardiac depolarisation and repolarisation 849 
kinetics similar to that of humans. Langendorff-perfused porcine SCN5A-E558X heart reproduced many 850 
clinical loss-of-Nav1.5 function phenotypes. They thus confirmed many features modelled by murine 851 
Scn5a+/- hearts. They thus shared increased incidences of pacing-induced or spontaneous VF, diminished 852 
Nav1.5 protein expression and INa. However, the porcine hearts did not show the macroscopic and 853 
microscopic structural changes shown by murine Scn5a+/- hearts (See Section V(B)(3)). Such a system 854 
could nevertheless complement the mouse models. Nevertheless, their ease in genome manipulation, and 855 
shorter reproductive cycles (~20 vs. 111 days gestation) will favour murine models particularly in disease 856 
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occurring in later adulthood given longer porcine (between 15-17 years) compared to murine (~48 weeks) 857 
life expectancies.  858 
(F) Nav1.5 haploinsufficiency and abnormal sino-atrial and atrial 859 
electrophysiology 860 
(1) Physiological changes accompanying atrial and sinus node disorder 861 
 Loss of Na+ channel function is also associated with SND and atrial tachyarrhythmia. SAN pacemaker 862 
function in both humans and other mammals normally declines with age, decreasing intrinsic heart rates and 863 
increasing SAN conduction times (272, 731). Sinus node dysfunction (SND) causes sinus bradycardia, 864 
pause or arrest, atrial chronotropic incompetence, and SAN exit block. Its incidence increases exponentially 865 
with age, accounting for ~50% of the million permanent pacemaker implants per year worldwide (272, 731). 866 
It may involve a range of ion channel changes (see Section III(A)). Ageing guinea-pig SANs showed 867 
reduced Cav1.2 expression reflected in a greater sensitivity of their electrical activity to L-type Ca2+ channel 868 
block. They also showed decreased Cx43 expression in the vicinity of the SAN (517). This could increase 869 
SAN conduction time and incidences of SAN exit block (518). Ageing rat SANs showed decreased Kv1.5 870 
expression that might explain increased SAN APDs (Alings et al., 1993; Tellez et al., 2006). They also 871 
showed altered RyR2 expression. This could also compromise SAN pacemaking through actions on its Ca2+ 872 
clock mechanism of pacemaking (1115, 1298) 873 
(2) Sinus node disorder in murine Scn5a+/- hearts 874 
 Familial SND is also associated with ~13 human Nav1.5 mutants (634, 637). These were variously 875 
associated with apparently normal (e.g., SCN5A-L212P, P1298L, DelF1617 and R1632H), reduced (e.g. 876 
E161K, T220I, and D1275N) or undetectable (e.g.,T187I, R878C, G1408R, and the truncated variants 877 
W1421X, K1578fs/52, and R1623X; (379, 1339)) peak INa in expressed heterologous systems.  878 
 Physiological evidence implicated both neuronal Nav1.1 and cardiac Nav1.5 channels in normal SAN 879 
function, suggesting that Nav1.1 was involved in pacing activity, and Nav1.5 was primarily involved in AP 880 
conduction through the SAN and from the SAN to surrounding atrial myocytes. It also suggested that these 881 
separate but related functions predominated in the smaller central pacing cells and larger conducting 882 
peripheral SAN cells respectively. Nevertheless Nav1.5-mediated INa can modify heart rate by modifying 883 
impulse propagation within the SAN and from the SAN to the atrium (632).  884 
 Voltage-clamp studies of INa, and SAN tissue staining with anti-Nav antibodies distinguished TTX-885 
sensitive INa associated with Nav1.1 and TTX-resistant, INa, associated with Nav1.5 expression (632, 635). In 886 
intact WT mouse hearts, selective Nav1.1 block by low (50 nM) TTX concentrations reduced pacemaker 887 
rates in isolated SAN and isolated SAN pacemaker cells (635, 714). The TTX-sensitive INa could be 888 
demonstrated by action potential clamp experiments to normally occur late in diastolic depolarisation and 889 
during the AP upstroke (635). Block of both Nav1.1 and the relatively TTX-resistant Nav1.5 by mM TTX 890 
concentrations additionally slowed or even blocked AP conduction through the SAN periphery from its 891 
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leading pacemaker site, and to surrounding atrium (635). Additionally, although Scn5a+/− mice retained 892 
normal circadian variations in telemetrically determined heart rates, they replicated the reduced overall mean 893 
rates and SA block observed in clinical SND (52).  894 
 Langendorff-perfused Scn5a+/- hearts showed sinus bradycardia, slowed SA conduction and sino-895 
atrial exit block. Isolated Scn5a+/- SAN and atrial preparations showed slowed SA conduction and frequent 896 
SA conduction block in mapping experiments (Figure 9A) (632). These findings correlated with results from 897 
patch-clamped Scn5a+/- SAN cells which showed normal steady-state Nav1.5 activation and inactivation 898 
characteristics but reduced maximum INa compared to WT. These whole animal, tissue and cellular findings 899 
could then be unified by modelling of the resulting roles for Nav1.5 in AP propagation through the SAN and 900 
from SAN to atria. These replicated the changes in pacing rate, and demonstrated that these changes were 901 
brought about by effects of loss of Nav1.5 function upon the electrical coupling between peripheral SAN 902 
and atrial cells (632). 903 
 Aging and associated fibrotic processes interacted with Nav1.5 haploinsufficiency in modifying SAN 904 
electrophysiological properties. This finding paralleled the associations between Scn5a+/- and ventricular 905 
fibrotic changes outlined above (see Section V(E)(4)). Nav1.5 disruption increased P-wave duration, RR, 906 
PR, and QRS intervals, and SAN recovery times. It interacted with ageing in decreasing heart rate variability 907 
with the greatest effects in old Scn5a+/- mice. Aging and Nav1.5 insufficiency exerted both individual and 908 
interacting effects in increasing cycle lengths and SA conduction times in ex vivo, isolated, SAN 909 
preparations (Figure 9B, C) (408), as well as in Langendorff-perfused hearts (391).  910 
 Both the Scn5a+/- phenotype and aging correspondingly resulted in downregulated Nav1.5 expression 911 
to the following sequence of extents: old Scn5a+/- > old WT > young Scn5a+/- > young WT. They 912 
interacted in increasing collagen and fibroblast levels and the corresponding expression of the fibrotic 913 
modulator transforming growth factor-β1 (TGF-β1) and the fibroblast marker vimentin. The greatest effects 914 
were observed in aged Scn5a+/- (Figure 9D(a),(b)). Nav1.5 expression levels consequently negatively 915 
correlated with TGF-β1 and vimentin levels (Figure 9E). Increased TGF-β  production by both cardiac 916 
myocytes and cardiac fibroblasts could be replicated by acute application of either Nav1.5-E3 antibody or 917 
Na+ channel blocker (Figure 9F). This was consistent with previous reports that pharmacological block of 918 
electrical activity in Na+ channels upregulated TGF-β activity in rat primary myotubes (1159). Such activity 919 
could form a cell signaling pathway leading to fibrotic change and atrial electrophysiological pathology in 920 
other clinical circumstances (454). Nav1.5 haploinsufficiency in combination with ageing was also 921 
accompanied by altered expression in a wide range of ion channels and regulatory genes in the SAN 922 
associated with aging. Ageing itself accentuated the reduction in Nav1.5 expression found in Scn5a+/-. 923 
There were accompanying reductions in the tbox transcription factor Tbx3. This is known to regulate the 924 
SAN pacemaker gene expression program and decreased expression of a wide range of SAN ion channels. 925 
(2) Atrial arrhythmia in murine Scn5a+/- hearts 926 
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 Finally, BrS (10–30%) is associated with increased tendency to AF. This often clinically precedes its 927 
ventricular manifestations in patients with a severe type I phenotype (26, 607). Langendorff-perfused 928 
Scn5a+/− hearts similarly showed an increased atrial arrhythmogenicity (240). This was greatest in young 929 
Scn5a+/- atria. Scn5a+/- atria particularly from aged hearts showed slower AP conduction whether 930 
measured by MEA mapping or PR intervals (391, 503). Young Scn5a+/− hearts showed the most prolonged 931 
monophasic APDs (240).  However, the aged Scn5a+/− atria showed increased AERPs and therefore 932 
showed the smallest APD90/AERP. Atria from young Scn5a+/- hearts also showed the greatest prolongations 933 
in electrogram duration following extrasystolic stimulation. Slowed conduction and increased APD90/AERP 934 
ratio thus correlate with the increased AF tendency particularly shown by young Scn5a+/− hearts (390). 935 
(G) Arrhythmic changes with abnormalities in Na+ channel β-subunits 936 
(1) Features of Navβ subunits 937 
 SCN5A forms macromolecular or signalling complexes with a number of further proteins (3, 852). 938 
These could directly or indirectly modify INa, Nav1.5 localisation, or both (759). Of these, Navβ-subunits are 939 
prominent integral, single-spanning, membrane glycoprotein components of Nav signalling complexes 940 
(844). Their extracellular N-terminal region contains a V-type immunoglobulin domain with a short ‘neck’ 941 
connected to a single α-helical transmembrane domain and intracellular C- terminal region (170, 484, 759, 942 
1111). Navβ1 and Navβ3 have the more closely related primary sequences. They non-covalently bind to the 943 
α-subunit possibly at similar C-terminal sites close to domain IV. This contrasts with the disulfide bonding 944 
suggested for Navβ2 and Navβ4 (239). Atomic resolution X-ray crystallographic studies of human Navβ3 945 
and Navβ4 suggest that Navβ3 and therefore possibly Navβ1 could trimerise. If so, Nav α-subunits could 946 
correspondingly co-assemble into oligomeric complexes stabilised by Navβ3 (or Navβ1) subunits. This 947 
assembly could then potentially have effects upon electrophysiological properties through possible 948 
interactions between component Nav1.5s (765, 814). 949 
 Navβ subunits do not themselves mediate ion permeation. They rather perform multiple functions in 950 
cell adhesion, recruitment of scaffolding or anchoring proteins including ankyrins (485, 759). They may also 951 
be involved in trafficking Na+ channels to the cell membrane, thereby increasing peak INa, and negatively 952 
shifting steady-state activation and inactivation consistent with biophysical effects of providing screening 953 
charge (138, 231, 403). Navβ subunit mutations are associated with inherited conditions including epilepsy, 954 
neuropathies, cardiac conduction diseases and some cancers (815). 955 
 Navβ1 and Navβ3 subunits occur in transverse tubulular and surface membranes whereas  Navβ2 and 956 
Navβ4 subunits occur at cell membranes in the regions of the intercalated disks (713). Navβ2 and Navβ3 are 957 
discussed here in terms of the arrhythmic effects of Na+ channel loss of function. Loss of Navβ1 function 958 
has been associated with experimental LQTS, despite clinical BrS-like phenotypes, and is discussed in 959 
Section VI(B)(7). Navβ4 subunits produce negative shifts in activation (353, 1310). Their loss of function is 960 
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associated with arrhythmogenesis accompanied by increased late INa (10). They are discussed in Section 961 
VI(B)(8) also in connection with LQTS. 962 
(2) Scn2b-encoded Navβ2 subunit variants 963 
 Scn2b-encoded Navβ2 subunits occur in intercalated disks particularly in the epicardium of human 964 
atria and ventricles (336, 713) in association with SCN5A (261). SCN2B-R28Q and SCN2B-R28W patients 965 
often show lone AF (1234). SCN2B-R28W patients additionally show prolonged PR intervals and right 966 
precordial ST elevation. Oocyte Navβ2 co-expression with neuronal Nav1.1 α subunits increased INa, but left 967 
INa kinetics unchanged (484). It exerted negative shifts in voltage-dependences of both activation and 968 
inactivation. These alterations were additive to the Navβ1 effects, to extents dependent upon glycosylation 969 
(514). Navβ2 reduction or absence decreased INa. In CHO expression systems, SCN2B-R28G reduced INa 970 
density and shifted activation; SCN2B-R28W positively shifted inactivation. In both cases, INaL was not 971 
affected  (1234).  Scnb2-/- mice showed seizures accompanied by reduced neuronal Na+ channel density 972 
(185). However the possible cardiac phenotypes have not been examined.  973 
(3) Scn3b-encoded Navβ3 subunit variants 974 
 SCN3B-encoded Navβ3 subunits occur in both ventricles (452) and atria of human hearts (852). Navβ3 975 
subunits may function in both trafficking of SCN5A to the surface membrane and modifying its 976 
electrophysiological properties (482). Their presence increases, and absence reduces, INa. There are variable 977 
effects on INa voltage dependence and kinetics. Heterologous oocyte Navβ3 co-expression with SCN5A 978 
increased INa threefold, accelerated recovery from refractoriness, and positively shifted steady state voltage-979 
dependent inactivation whilst sparing activation properties (304). Human SCN3B-L10P is implicated in the 980 
BrS7 variant (452), SCN3B-R6K, L10P and M161T in familial AF (852), and SCN3B-V54G in idiopathic 981 
VF (1165). Studies in TSA201, CHO-5 or HEK-293 expression systems related these conditions to reduced 982 
INa and reduced cell surface SCN5A expression. In the last case, these features were partly rescued by co-983 
expression with Navβ1 (452, 1165). SCN3B-V36M and SCN3B-A130V are associated with SIDS and AF 984 
respectively. Studies using HEK-293 expression systems related these to decreased INa with either increased 985 
late relative to peak INa (SCN3B-V36M) or without decreased SCN5A surface expression (SCN3B-A130V) 986 
(1110, 1221).  987 
 Scn3b-encoded Navβ3 subunits also normally occur in mouse ventricles (403, 452) and atria (402, 988 
852) and sheep ventricular and Purkinje but not atrial tissue, where they are similarly associated with 989 
SCN5A (304). Homozygous Scn3b-/- hearts showed the expected absence of Scn3b mRNA but showed 990 
elevated Scn1b mRNA, and increased RV Scn5a mRNA. Isolated, Langendorff-perfused Scn3b-/- hearts 991 
showed increased incidences of monomorphic or polymorphic VT on programmed electrical stimulation. 992 
Their accompanying electrophysiological abnormalities showed both parallels with and contrasts from those 993 
of Scn5a+/- hearts (403). They showed a consistently reduced Na+ channel function compatible with BrS-994 
like phenotypes (Figure 10). Whole-cell patch-clamped Scn3b-/- myocytes showed reduced maximum peak 995 
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INa (~-60 pA/pF vs. –90 pA/pF in WT) (Figure 10A). This suggested reduced membrane expression or 996 
proportions of functional Na+ channels. Inactivation curves were shifted in the negative direction relative to 997 
those in WT (Figure 10B). However, the timecourses of recovery from inactivation were not changed 998 
(Figure 10C).  999 
 Bipolar electrogram recordings obtained during programmed electrical stimulation yielded 000 
defelections whose latencies mapped onto demonstrated conduction curves suggesting lengthened 001 
electrogram durations compared to WT, particularly at the shortest S1S2 intervals. This suggested reduced 002 
AP conduction velocities (Figure 10D). Scn3b-/- ventricles also showed shorter VERPs than WT. MAP 003 
recordings demonstrated reduced endocardial and epicardial APDs. However, the resulting endocardial-004 
epicardial differences, ΔAPD90s, were indistinguishable from those of WT (Figure 10E). Finally, both 005 
flecainide and quinidine selectively reduced arrhythmic incidence in Scn3b-/- relative to WT hearts without 006 
affecting ΔAPD90, likely through increasing VERP (404). 007 
 Sino-atrial and conduction properties in Scn3b−/− complemented these findings. They also suggested 008 
a compromised Na+ channel-mediated excitability and conduction. Scn3b mRNA and protein was expressed 009 
in the atria of WT but not Scn3b-/- hearts. ECGs from Scn3b-/- mice showed slower heart rates, and 010 
prolonged P waves and PR intervals (Figure 10F). Spontaneously active Langendorff-perfused Scn3b-/- 011 
hearts showed abnormal atrial electrophysiological properties and partial or complete atrioventricular block. 012 
Scn3b-/- hearts also showed atrial tachycardia and fibrillation on atrial burst pacing and longer sinus node 013 
recovery times than WT hearts (Figure 10Ga, b,c) (402). 014 
 (H) Nav1.5 and scaffolding proteins 015 
 Nav1.5 is also associated with scaffolding proteins: In addition, two PDZ domain-scaffolding 016 
proteins, SAP97 and α1-syntrophin) mediate reciprocal interactions upon cardiomyocyte membrane 017 
expression levels of Nav1.5 and Kir2.1; the latter underlies the inward rectifying IK1 (1262). Recent 018 
evidence from effects of inheritable mutations suggest similar additional interactions involving plakophilin-019 
2, ankyrin-G, dystrophin, syntrophin and caveolin-3 (1262).  020 
 Of these, (1) Caveolin-3 (Cav-3) promotes formation of cave-like membrane structures (65) and 021 
organization and concentration of particular molecules interacting with caveolin. Its precise association with 022 
Nav1.5 is uncertain (861). It may produce an adrenergic INa upregulation mediated by G proteins (1301). 023 
Cav-3 mutations are associated with HCM (415) (see also Section VI(C)(3)). (2) Mutations in the cytosolic 024 
scaffolding protein α-1-syntrophin (SNTA1) (12) increase INaL. They are associated with LQTS12 (1158) 025 
and SIDS (194).  These are considered in detail in section VI(C)(1). 026 
 (3) The scaffolding protein Ankyrin-G may connect ion channels, including Nav1.5, to the spectrin-027 
actin cytoskeleton (99). Ankyrin polypeptides are known to be critical to ion channel and transporter 028 
targeting in both excitable and nonexcitable cells. Ankyrin-G interaction with Nav1.5 is disrupted by the 029 
SCN5A-E1053K mutation resulting in BrS (787). Studies on cardiac-selective ankyrin-G-/- mice suggested 030 
that ankyrin G is a functionally important intercalated disc receptor for both Nav1.5 and βIV spectrin. The 031 
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C-terminal domain of βIV spectrin in turn associates with the Nav1.5 regulator CaMKIIδ. Ankyrin-G-cKO 032 
mice were bradycardic, showed cardiac conduction abnormalities, QRS prolongation, and ventricular 033 
arrhythmias following challenge by Na+ channel antagonists. Their myocytes showed reduced INa and 034 
decreased AP amplitudes and (dV/dt)max. Nav1.5 expression was decreased particularly at intercalated discs. 035 
This accompanied a reduced βIV spectrin recruitment to intercalated disc membranes. In common with 036 
mouse qv4J hearts carrying βIV spectrin lacking its C-terminal domain, they showed defective CaMKIIδ 037 
targeting and defective CaMKIIδ regulation of INaL There was additionally a reorganization of the resident 038 
desmosome protein plakophilin-2. The latter is critical to intercalated disc integration with the intermediate 039 
filament-based cytoskeleton and lethal arrhythmias in response to β-adrenergic stimulation (716). However, 040 
such reduced ankyrin-G expression did not affect peripheral sarcolemmal Nav1.5. 041 
 (4) The desmosomal proteins plakophilin 2 (PKP2) and desmoglein-2 (DSG2) are localised to 042 
intercalated discs associated with Nav1.5 (1007). Mutations in both are associated with human ARVC (see 043 
Sections IX(D)(2), IX(D)(5)) (251). However, VF and SCD often occur prior to the onset of morphological 044 
change. Experimental studies attributed this to cross-talk between desmosomes and the Na+ channel 045 
complex. Murine Pkp2+/- hearts showed ultrastructural but not histological or anatomical abnormalities, with 046 
sporadic or absent desmosomes, and unevennesses in intercellular spaces. INa was reduced in maximum 047 
amplitude in both Pkp2+/- and with a number of heterozygous missense mutations (173). Voltage 048 
dependences of activation were unchanged but there were negative shifts in steady-state inactivation and 049 
slowed recoveries from inactivation. Flecainide affected electrocardiographic parameters in anaesthetised 050 
animals, and ventricular conduction in Langendorff-perfused hearts. It reduced myocyte INa to greater 051 
extents in Pkp+/- than WT. It triggered ventricular arrhythmias and death in anaesthetised Pkp2+/- but not 052 
WT animals (174). Hearts from Dsg2-N271S mice similarly showed reduced INa and conduction velocities 053 
(952). 054 
 (5) In common with α-1-syntrophin, the membrane-associated guanylate kinase (MAGUK) protein 055 
synapse associated protein-97 (SAP97) includes PDZ domains. SAP97-M861T has recently been associated 056 
with BrS (1262). However, myocytes from a murine model with a cardiomyocyte-specific Sap97 deletion 057 
showed reduced IK1, Ito, and IKur but unaltered INa yet slightly increased NaV1.5 protein expression, 058 
indicating a requirement for further experiment (355). 059 
(I) Idiopathic ventricular fibrillation 060 
 A small proportion (~5%) of sudden adult death cases had classically occurred in an absence of 061 
identifiable hereditary causes. However, recent reports indicate that a significant proportion of these share 062 
the J-point or ST-segment elevations with BrS (784). Some of these cases may be associated with abnormal 063 
Ca2+ (CACNA1C, CACNB2, and CACNA2D1) or KATP channel (KCNJ8) genes (156). Some of the remaining 064 
cases of idiopathic VF may involve the DPP6 gene which regulates Ito (932). No murine genetic models yet 065 
exist for these conditions. 066 
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VI. RECOVERY FROM EXCITATION AND ARRHYTHMIC DISORDER  067 
(A) Action potential repolarisation and QT prolongation 068 
 (1) Arrhythmogenic clinical long QT syndromes (LQTS) 069 
 In addition to altered AP activation and conduction (Sections IV and V), arrhythmic substrate can also 070 
arise from alterations in AP repolarisation and refractoriness. The latter can arise from alterations in Na+ 071 
channel recovery from fast or slow inactivation and development of late Na+ currents, INaL. It could also 072 
result from  changes in the magnitude or timecourse of Ca2+ and K+ currents that normally are activated 073 
following the initial Na+ channel activation that triggers the AP. AP repolarisation and recovery from 074 
refractoriness can thus be prolonged by persistent or increased inward depolarising, plateau INa or ICaL, or 075 
compromised repolarising, IK, currents. The resulting delayed myocardial repolarisation clinically results in 076 
LQTS (563, 692). The characteristic prolonged ECG QT intervals accompany an increased predisposition to 077 
atypical ventricular, torsades de pointes, arrhythmias and SCD (549). The incidences of these phenomena 078 
appear to correlate with the extent of this QT prolongation (918). Some LQTS variants are also associated 079 
with early onset AF (515). 080 
 Acquired forms of LQTS can follow a number of clinical conditions as well as a wide range of 081 
medications (37, 313, 334). The latter often produce LQTS through reducing IKr (953). Hereditary LQTS 082 
were first described as the autosomal recessive Jervell and Lange Nielsen (JLN) syndrome accompanied by 083 
congenital sensorineural deafness (506) and the more common autosomal dominant Romano-Ward (RW) 084 
syndrome (549, 961, 1232).  However, only ~50% of LQTS patients have known mutations with 25-30% of 085 
patients remaining genotype-negative (1197). The remainder may be associated with genetic conditions 086 
causing abnormal ion channel function often with incomplete penetrance and phenotypic overlaps (144, 224, 087 
358, 1031, 1253). LQTS has been associated with genetic modifications in Na+ channel α-subunits (Nav1.5 088 
encoded by SCN5A, giving LQTS3), their associated Navβ4 subunits (Navβ4 encoded by SCN4B: LQTS10), 089 
various K+ channel α-subunits mediating IKs (Kv7.1 encoded by KCNQ1: LQTS1), IKr (Kv11.1, encoded by 090 
KCNH2: LQTS2), IK1 (amongst others, Kir2.1, encoded by KCNJ2: LQTS7 or Anderson-Tawil syndrome) 091 
and IKAch (Kir3.4, encoded by KCNJ5: LQTS13), the K+ channel β-subunits MinK and MiRP (encoded by 092 
KCNE1 and KCNE2: LQTS5 and LQTS6), and Ca2+ channel α-subunits (Cav1.2 encoded by CACNA1C: 093 
LQTS8 or the Timothy Syndrome (TS)). LQTS is also associated with abnormalities in the cyoskeletal 094 
proteins. The latter include caveolin-3 (encoded by CAV3: LQTS9), A-kinase anchor protein 9 (encoded by 095 
AKAP9: LQTS11) and α-1-syntrophin (encoded by STNA1: LQTS12). All these variants can present as a 096 
Romano-Ward Syndrome. Some LQTS1 and LQTS5 can also present with Jervell and Lange-Nielsen 097 
syndrome. The clinical prevalence of inherited LQTS is around 0.01% of the population. The commonest, 098 
LQTS1, LQTS2 and LQTS3, account for 45%, 45% and 5% respectively of inherited and genotype-099 
confirmed LQTS cases (1030). 100 
 (2) Electrophysiological phenomena associated with LQTS arrhythmia 101 
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 Clinical and experimental evidence associates LQTS-mediated arrhythmogenesis, exemplified in 102 
murine models of the kind listed in Table 6, with two potentially pro-arrhythmic electrophysiological 103 
abnormalities (827). First, the normally smooth timecourse of AP repolarisation can be interrupted. Where 104 
this follows phase 2 plateaus, EADs result. EADs were experimentally observed following exposure to 105 
drugs implicated in acquired LQTS, or catecholaminergic or hypoxic challenge, and in genetically modified 106 
murine hearts modelling human LQTS, particularly under bradycardic conditions (1128). EADs have been 107 
clinically observed in both bradycardic hypokalaemic conditions (1058, 1059) and in congenital LQTS 108 
patients (Shimizu et al 1991a). EADs have been attributed to a prior conditioning by plateau currents under 109 
conditions of AP prolongation combined with L-type Ca2+ channel recovery from inactivation within the 110 
voltage-window range of such recovery. The resulting L-type Ca2+ channel reactivation then produces 111 
depolarising current. If it involves sufficient numbers of cardiomyocytes, this produces ectopic beats. The 112 
latter can trigger polymorphic VT when they occur within a pro-arrhythmic myocardial substrate (498, 499). 113 
Other suggestions for mechanisms producing EADs invoked increased INaL (416) or INCX (1204).  114 
 In contrast, where the membrane potential is unstable following full AP repolarisation, DADs result. 115 
DADs accompany conditions of disrupted Ca2+ homeostasis. The latter in turn can follow challenge with 116 
pharmacological agents including cardiac glycosides or catecholamines, or genetic conditions such as CPVT 117 
(see Section VII(C)). DADs have been attributed to transient inward currents (Iti) resulting from increased 118 
inward INCX or Ca2+-activated Cl- current (I(Ca)Cl) following excessive SR Ca2+ release. In common with 119 
EADs, DADs potentially result in triggered beats initiating arrhythmia where the displacements in 120 
membrane potential they produce reach the threshold for re-excitation (498, 499). 121 
 Second, enhanced dispersion of repolarisation can potentially generate arrhythmogenic re-entrant 122 
circuits (19, 38). Normal cardiac repolarisation takes spatial directions running from epi- to endocardium 123 
and apex to base. These reflect longer endo- than epicardial and basal than apical APDs (687, 1228, 1287). 124 
The latter are the consequence of differing myocardial repolarisation rates reflecting varying local densities 125 
of ion channels mediating repolarising K+ currents. The epi-/endocardial transmural gradients themselves 126 
contribute to a coordinated process of initiation of, followed by recovery from electrophysiological 127 
excitation (558, 563, 981).  128 
 As indicated in Section II(B)(3), mouse ventricles show shorter, triangulated, APs (~30–80 ms), as 129 
opposed to the prolonged AP waveforms that contain distinct plateau phases in larger mammals including 130 
humans (~150–400 ms respectively) (Figure 1D) (236). AP recovery is thus dominated by the fast, Kv4.3 131 
and Kv4.2-mediated, Ito,f, and more slowly inactivating Kv1.4-mediated Ito,s, components of the transient 132 
outward current Ito  and includes smaller ICaL contributions (Figure 1B, D).  133 
 The dispersions of repolarisation in murine hearts correspondingly arise from spatial variations in Ito 134 
giving gradients of excitation and recovery that similarly enhance the overall cohesiveness of cardiac 135 
activation (826, 989, 1228). Of Ito components, Ito(fast), mediated by the pore-forming Kv4.3/Kv4.2 (267) and 136 
its regulatory β-subunit KChIP2 (604, 876), are expressed along the apical–basal, epicardial–endocardial 137 
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and interventricular axes of adult murine hearts (1108). In contrast, Ito(slow), mediated by Kv1.4, appears 138 
confined to the interventricular septum (151, 1284). Region-specific myocardial Kv4.2 and KChiP2 139 
distributions were assessed using both standard manual and laser capture microdissection giving 80-100 μm 140 
width myocardial slices particularly useful in analyses of small murine hearts. Quantitative RT-PCR 141 
measurements were assessed against control, uniform, transmural distributions of Kir2.1. There were no 142 
apex–base expression gradients but greater RV than LV, and greater epicardial than endocardial Kv4.2 143 
expression levels in both LV and RV (1124). The laser capture microdissection went on to demonstrate 144 
similar, though less marked, LV and RV, KChIP2 transmural gradients. These observations contrasted with 145 
an absent of spatial gradients in the other selected K+ channel genes. These Kv4.2 and KChIP2 expression 146 
differences could thus underly Ito gradients between RV and LV, and epicardium and endocardium, but not 147 
apex and base in adult mouse ventricles (151). These findings parallel the overall transmural current density 148 
gradients found in ventricles of larger mammals (875), although human and canine Ito differences may 149 
primarily reflect KChIP2 expression gradients (964, 965). In both events, alterations in such gradients have 150 
been associated with myocardial disease states (863).  151 
 Nevertheless, manipulations involving Ito accomplished alterations in membrane potential recovery, 152 
refractory periods, and their spatial variations as well as the occurrence of triggered activity that paralleled 153 
those shown by the more prolonged APs shown in larger animals. Murine hearts thus remain valuable 154 
models for understanding mechanisms of arrhythmogenesis more broadly, including arrhythmic phenomena 155 
associated with AP repolarisation. 156 
 Perfused, canine ventricular wedge preparations of larger mammalian hearts (36) have been reported 157 
to contain a further, midmyocardial cell (or M-cell) layer. This is located at varying locations within the 158 
thickness of the ventricular wall (35).  Such M-cells showed the greatest repolarisation times. This was 159 
attributed to a decreased IKs but increased INaL and the greatest APD sensitivity to bradycardia and IKr 160 
antagonists. This property results in an overall increase in transmural dispersion of repolarisation (TDR). 161 
Thus, the difference between longest and shortest APD would then be the difference between M cell and 162 
epicardial APDs (1056). This property had been implicated in arrhythmogenecity in BrS and both congenital 163 
(1053) and acquired LQTS (37, 772). However, the contribution of M cells to myocardial repolarisation and 164 
arrhythmogenesis in intact hearts remains under discussion (40, 216, 859). Furthermore, although observed 165 
in isolated cells and ventricular tissue preparations, the existence of M cells in intact porcine (955), canine 166 
(859) or human hearts is uncertain (1106).   167 
 Langendorff-perfused mouse hearts did show regional APD heterogeneities, as reflected in differences 168 
between epi- and endocardial APD90s in common with larger mammalian hearts.. The availability of murine 169 
models with specifiable genetic modifications made it possible to directly relate mutations seen in LQTS 170 
patients to physiological mechanisms of cardiac arrhythmias (560, 563). These issues are explored in 171 
specific examples in Sections VI(B)(4), VI(E)(4) and VI(F)(2) and (3). 172 
(B) Arrhythmic properties and Na+ channel recovery from excitation 173 
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(1) The late Na+ current INaL 174 
 Arrhythmogenic gain of Na+ channel function can result from SCN5A mutations that result in a 175 
slowing of INa inactivation and rates of its recovery from inactivation. This is thought to be the basis of 176 
clinical LQTS3 (98, 416, 843). It could also be acquired in association with epileptic conditions (125). In 177 
either case, the resulting increased APDs and QT intervals predispose the myocardium to EADs and 178 
arrhythmogenesis (235, 1223). Normally, a gradually increasing late Na+ current, INaL, accompanies the AP 179 
potential plateau. LQTS3 is associated with increases in this normally small INaL (806) whether in acute or 180 
chronic, or inherited or acquired, pathological settings. This type of INaL could result from alterations in the 181 
gating, trafficking or cytoskeletal anchoring of the Na+ channel. It results in both triggering events and 182 
arrhythmic substrate (88).  183 
 Increased INaL thus can prolong the APD and increases its variability. This enhances the genesis of, 184 
and arrhythmic triggering by, EADs (444, 499). In addition, it produces increases in temporal and the spatial 185 
dispersions of repolarisation. These in turn increase APD restitution curve gradients and the development of 186 
APD alternans, produce local conduction block, to result in re-entrant arrhythmic activity (381, 891). The 187 
increased inward INaL also decreases repolarisation reserve or causes diastolic depolarisation. Both enhance 188 
automaticity in partially depolarised cardiomyocytes. Finally, increased INaL causes increases in [Na+]i. This 189 
potentially induces reverse mode NCX (1062). This could elevate diastolic [Ca2+]i, and thereby promote 190 
spontaneous SR Ca2+ release, Ca2+ waves and DADs at more negative voltages and EADs at more positive 191 
voltages (162, 444, 988). The consequent elevations in [Ca2+]i potentially activate CaMKII and its protein 192 
phosphorylation effects. These could enhance spontaneous RyR2-mediated SR Ca2+ release (1203) and INaL 193 
(51, 467).  194 
 INaL itself can be activated by CaMKII. This action is localised to a Ser-571 phosphorylation site 195 
located in the Nav1.5 DI-DII linker. Studies in Scn5a knock-in murine models whose Nav1.5 carries a 196 
phosphomimetic Ser571 (S571E) mutation, or in which the phosphorylation site is ablated (S571A) 197 
suggested that Ser-571 specifically regulates INaL but not other channel properties linked to CaMKII. The 198 
resulting increased INaL altered repolarisation and intracellular Ca2+ homeostasis. These had pro-arrhythmic 199 
consequences (363). INaL is also modified by more direct interactions with CaMKII through Nav1.5-200 
associated proteins. CaMKII associates with a C-terminal motif in actin-associated βIV-spectrin protein 201 
involved in CaMKII-mediated phosphorylation of the subpopulation of voltage-gated Na+ channels residing 202 
in the cardiomyocyte intercalated discs (467, 716). This may modulate not only steady-state Na+ channel 203 
inactivation and recovery from inactivation, but also the magnitudes of INaL through separate Nav1.5 204 
modulation pathways (467, 1209). Modelling studies suggested positive feedback interactions in which 205 
CaMKII causes increases in often arrhythmogenic INaL in turn increasing [Na+]i and [Ca2+]i and resulting in 206 
further activation of CaMKII (105). CaMKII may also complex with SAP97. This may define its interaction 207 
with Kv4.3 α mediating Ito (295). 208 
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(2)  Long QT3 syndrome, LQTS3  209 
 The arrhythmic features of LQTS3 differ from those of BrS. This is exemplified in their responses to 210 
anti-arrhythmic agents (914). The class IA cardiotropic agent, quinidine is pro-arrhythmic and the class IC 211 
agent flecainide is anti-arrhythmic in LQTS3 (805, 954). This directly contrasts with the respective anti-212 
arrhythmic effects of quinidine and proarrhythmic effects of flecainide in BrS (150). LQTS3 also differs 213 
from other LQTS variants in that 39% of fatal arrhythmias occur during sleep or rest (954). In contrast, 214 
arrhythmia in LQTS1 and LQTS2 is associated with stress or arousal (1029). Furthermore, in LQTS3, β-215 
adrenoceptor agonists paradoxically exert anti-arrhythmic effects. LQTS3 patients derive less benefit from 216 
β-adrenoceptor antagonist therapy than do LQTS1 and LQTS2 patients (915). 217 
(3) Murine LQTS3 exemplars: Scn5a+/ΔKPQ hearts 218 
 In WT murine hearts, the sea-anemone, Anemonia sulcata, toxin and INaL agonist, ATX-II, produced 219 
effects resembling an acquired LQTS3. It slowed intrinsic heart rate, prolonged PR and QT intervals, 220 
increased MAP durations and increased sinus node recovery times. Its application resulted in an appearance 221 
of EADs, DADs and rapid, repetitive ventricular tachyarrhythmias and sino-atrial bradyarrhythmias. ATX-II 222 
slowed sinus node pacemaking. This resulted in in bradycardic arrhythmias in isolated sino-atrial 223 
preparations. The INaL antagonist ranolazine (10 μM) inhibited such effects (1275). This finding suggests 224 
potential translational, anti-arrhythmic, therapeutic application (385). 225 
 Two murine genetic, LQTS3, models were independently produced by targeted deletion of 226 
ΔKPQ1505-1507 residues in the Nav1.5 inactivation domain (416, 843). Scn5a+/ΔKPQ ventricular 227 
myocytes showed prolonged AP waveforms (Figure 11A) increased peak INa despite normal Nav1.5 228 
expression, increased INaL (Figure 11B, C) and EAD events (Figure 11D, E) (416). These features were 229 
replicated in patient-specific induced pluripotent stem cells harboring a SCN5A mutation for the condition 230 
(707). They were alleviated by the INaL antagonist ranolazine (333).  231 
 Isolated, Langendorff-perfused, Scn5a+/ΔKPQ, hearts showed increased arrhythmogenecity on 232 
programmed electrical stimulation imposing extrasystolic S2 stimuli at progressively decreased S1S2 233 
intervals following trains of pacing S1 stimuli (Figure 11F, G). These studies yielded conduction curves for 234 
which paced electrogram fractionation analysis demonstrated increased electrogram durations (EGDs) 235 
compared to WT (416, 1095, 1096). Similar findings were previously associated with clinical re-entrant 236 
substrate and arrhythmogenesis in both HCM (1009) and LQTS (1011) (Table 5). Abrupt rate accelerations 237 
transiently increased ventricular APDs with potentially arrhythmic effects (843). Pharmacological challenge 238 
altered arrhythmic tendencies in parallel with its clinical effects. Thus, in the murine Scn5a+/ΔKPQ hearts, 239 
flecainide exerted anti-arrhythmic and quinidine exerted pro-arrhythmic effects. This directly contrasted 240 
with the effects of these agents in Scn5a+/- hearts (1095, 1096). Arrhythmogenesis persisted with 241 
propranolol perfusion which further increased EGD, reflecting accentuated re-entrant substrate (416).  242 
(4) Spatial repolarisation heterogeneities and triggering events in Scn5a+/ΔKPQ hearts 243 
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 Monophasic AP waveform recordings in Langendorff perfused Scn5a+/ΔKPQ hearts related the 244 
arrhythmias at the whole-heart level to abnormal ventricular myocardial EADs that could potentially act as 245 
arrhythmic triggers. Thus, Scn5a+/ΔKPQ but not WT hearts showed EADs that were often followed by VT. 246 
They also showed spatial differences in electrophysiological recovery properties that could additionally 247 
potentially result in arrhythmic substrate. The latter took the form of abnormal transmural repolarisation 248 
gradients.  249 
 Thus, Scn5a+/ΔKPQ hearts showed increased epicardial APD90 (~60 ms vs ~47 ms in WT) despite 250 
normal endocardial APD90 (~52-54 ms in both Scn5a+/ΔKPQ and WT hearts). The increased epicardial 251 
APD possibly reflected regional differences in INaL in Scn5a+/Δ hearts. This could provide the necessary 252 
critical voltage ‘window’ that has been described for L-type Ca2+ channel reactivation (1128). In addition, 253 
the preferential prolongation of epicardial APD90 in Scn5a+/ΔKPQ resulted in abnormal transmural 254 
repolarisation gradients. This was quantified by the difference, ΔAPD90. Such ΔAPD90 changes showed a 255 
pattern that was the inverse of that in WT. Epicardial APD now exceeded endocardial APD. Endocardial 256 
repolarisation consequently preceded epicardial repolarization, the reverse of the transmural epicardial to 257 
endocardial repolarisation sequence normally found in WT (1128). Hearts from larger mammalian models 258 
made to pharmacologically replicate LQTS3 similarly showed altered EADs and transmural repolarisation 259 
gradients (1056).  260 
 It was possible separately to implicate EAD phenomena in the triggering of arrhythmia, and alterations 261 
in ΔAPD90 in the generation of re-entrant substrate by examining their respective sensitivities to 262 
pharmacological agents. First, nifedipine was useful as a specific dihydropyridine L-type Ca2+ channel 263 
antagonist (1190). It exerted anti-arrhythmic effects in several experimental animal models (28, 821). This 264 
contrasts with the actions of phenylalkylamine Ca2+ channel blocker verapamil used in previous 265 
pharmacological investigations (16, 773) which also affects INa and IKr (1330). Nifedipine at progressively 266 
increasing concentrations (10 nM - 1μM) correspondingly decreased the incidences of both EADs and 267 
arrhythmias evoked by programmed electrical stimulation in Scn5a+/ΔKPQ hearts in parallel (Figure 11J, 268 
K). However, it did so without altering either epicardial or endocardial APD90, the resulting ΔAPD90 (Figure 269 
11L), or VERP (Figure 11M) in either Scn5a+/ΔKPQ or WT. Thus, suppression of EADs alone sufficed to 270 
suppress arrhythmogenesis without alterations of underlying re-entrant substrate. Patch clamp studies in 271 
isolated ventricular myocytes confirmed that these effects of nifedipine were the result of alterations in ICaL 272 
but not INa (Figure 11 H, I) (1128). This makes it likely that alterations in SR-Ca2+ loading might also 273 
contribute to the arrhythmic phenotype (664). 274 
 Secondly, treatment with varying concentrations of the β-adrenoceptor antagonist, propranolol, made 275 
it possible empirically to separate distinct contributions of EADs, and arrhythmic substrate arising from 276 
repolarisation gradients, to arrhythmogenesis in Scn5a+/ΔKPQ hearts (1129). Thus, low propranolol 277 
concentrations (100 nM) suppressed both spontaneous and provoked arrhythmias. It also both suppressed 278 
EADs and reduced epicardial APD. The latter change accordingly corrected the repolarisation gradient 279 
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abnormalities in Scn5a+/ΔKPQ hearts. In contrast, high (1 mM) concentrations eliminated both EADs and 280 
spontaneous arrhythmias. However, it increased susceptibility to provoked arrhythmogenesis, whilst also 281 
prolonging epicardial yet reducing endocardial APDs (1129). This would exacerbate the abnormalities in 282 
repolarisation gradient shown by Scn5a+/ΔKPQ hearts. The latter findings concur with similar differential 283 
actions of propranolol upon ventricular epicardial and endocardial APs previously reported in canine 284 
ventricular wedge preparations (593). Together these findings provide a physiological basis for clinical 285 
reports that β-adrenoceptor block is relatively ineffective in suppressing arrhythmia in LQTS3. This is in 286 
contrast to their use to suppress arrhythmia in LQTS1 and LQTS2 (915). 287 
 Thirdly, agents specific for K+ channel as opposed to Ca2+ homeostatic function furnished a final 288 
separation of the contributions of EADs acting to trigger, and repolarisation gradients providing substrate for, 289 
persistent cardiac arrhthymia (445). Thus, the KATP channel opener nicorandil exerts antiarrhythmic effects in 290 
clinical LQTS. It reduces QT intervals and spatial repolarisation gradients (17, 324, 1056). It also suppreses 291 
APD alternans in idiopathic LQTS (335). Nicorandil at concentrations of ~20 mM have been reported to 292 
increase time-independent outward currents whilst sparing L-type Ca2+, delayed rectifier or transient 293 
outward currents (430). Such concentrations reduced the incidence of arrhythmia provoked by programmed 294 
electrical stimulation in Langendorff-perfused Scn5a+/ΔKPQ hearts during MAP recording. This was 295 
accompanied by a reduction of LV epicardial but not LV endocardial APD90s in both Scn5a+/ΔKPQ and 296 
WT. This resulted in a restoration of normal transmural repolarisation gradients in Scn5a+/ΔKPQ ventricles. 297 
Scn5a+/ΔKPQ hearts also showed greater epicardial critical intervals for re-excitation, reflected in APD90-298 
VERP differences, than WT hearts, but these were reduced by nicorandil (445).  299 
 Finally, alterations in electrophysiological properties of the purkinje cell conducting system (1163) in 300 
the Scn5a+/ΔKPQ variant were consistent with increased incidences of triggering effects. Isolated 301 
ventricular and purkinje cell myocytes could be distinguished using offspring from crosses of Scn5a+/ΔKPQ 302 
or WT, with contactin2-Egfp BAC. The latter murine variants express a fluorescent reporter gene within the 303 
purkinje fiber network. Whole-cell patch clamp studies have proven possible in murine cardiac purkinje 304 
cells (780). These demonstrated increased INaL in both Scn5a+/ΔKPQ (Egfp+) purkinje cells and 305 
Scn5a+/ΔKPQ (Egfp-) ventricular myocytes. Scn5a+/ΔKPQ purkinje cells showed the greater increases in 306 
INaL and APD, as well as frequent EADs not observed in the ventricular myocytes, features reversible by 307 
mexiletine. The latter events correlated with repetitive oscillations of microfluometrically measurable [Ca2+]i 308 
(490). 309 
 (5) Temporal heterogeneities and arrhythmic phenomena in Scn5a+/ΔKPQ hearts 310 
 Electrophysiological activity in Scn5a+/ΔKPQ hearts also showed greater temporal heterogeneities in 311 
the form of epicardial and endocardial APD90 alternans, particularly at increased pacing rates, than WT. The 312 
derivation of epicardial and endocardial restitution curves from such experiments made it possible to derive 313 
the values of DIcrit at which the slopes of such curves exceeded unity. The latter point is known to correlate 314 
with an onset of arrhythmic phenomena (see section II(A)(4)). In control WT hearts, both quinidine and 315 
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flecainide increased DIcrit. This would agree with the observed correspondingly increased incidences of 316 
arrhythmic activity. Both Scn5a+/ΔKPQ and Scn5a+/− hearts similarly showed greater DIcrit in parallel with 317 
their increased arrhythmic activity. Furthermore, quinidine (1 μM) and flecainide (1 μM) challenge then 318 
exerted contrasting effects on DIcrit. Thus, in Scn5a+/ΔKPQ hearts, quinidine increased and flecainide 319 
decreased the DIcrit values in parallel with their observed pro-arrhythymic and anti-arrhythmic effects. In 320 
contrast, in Scn5a+/− hearts, quinidine correspondingly decreased and flecainide increased DIcrit in parallel 321 
with decreased and increased arrhythmic activity respectively (983). Nicorandil reduced the epicardial and 322 
endocardial DIcrit values to levels indistinguishable from untreated WTs through an overall flattening of their 323 
restitution curves, It correspondingly reduced arrhythmogenicity in Scn5a+/ΔKPQ hearts (445). 324 
 (6) Atrial phenotypes in Scn5a+/ΔKPQ hearts 325 
 Murine Scn5a+/ΔKPQ hearts also showed age-dependent atrial arrhythmic phenotypes. Both young 326 
and aged Scn5a+/ΔKPQ hearts showed slowed sinus rates compared to corresponding WT. They thus 327 
showed an overlap in phenotype with Scn5a+/− hearts. Atrial arrhythmic tendencies in young Scn5a+/ΔKPQ 328 
were indistinguishable from or even reduced relative to young WT. However, they were increased in aged 329 
Scn5a+/ΔKPQ compared to WT (241, 392). These findings were explicable in terms of alterations in the 330 
properties of atrial AP initiation, propagation and recovery. MEA recordings thus demonstrated slowed 331 
intra-atrial conduction in Scn5a+/ΔKPQ (1276). Furthermore, atrial Scn5a+/ΔKPQ cardiomyocytes showed 332 
prolonged APD90 values and frequent EADs particularly with slow pacing (127, 241). Both these effects 333 
were rescued by ranolazine (<2 Hz) (639, 812). Atrial APDs and P wave durations were similarly prolonged 334 
in regularly paced Scn5a+/ΔKPQ relative to WT particularly with age (241, 392). AERPs were similar in 335 
young WT and Scn5a+/ΔKPQ but increased with ageing in WT but not Scn5a+/ΔKPQ. This left aged 336 
Scn5a+/ΔKPQ with the greatest APD90/AERP ratios and consequent arrhythmic substrate. These findings 337 
correlated with observations of  a greater Nav1.5 expression in young Scn5a+/ΔKPQ relative to young WT, 338 
but increases in Nav1.5 expression with age in WT but not Scn5a+/ΔKPQ (241, 392).  339 
 Murine Scn5a-F1759A atria also showed incomplete Nav1.5 inactivation, resulting in increased INaL, 340 
prolonged APD and spontaneous and prolonged AF episodes. It was possible to demonstrate atrial rotors and 341 
wave and wavelets in parallel with human AF. There was an accompanying fibrosis, atrial and ventricular 342 
enlargement, myofibril disarray, and mitochondrial injury. Both the atrial and ventricular arrhythmias were 343 
inhibited by acute inhibition of the NCX, likely through its effects on the increased Na+ entry (1214).  344 
(7) Multiple phenotypes associated with mutations involving Nav1.5: overlap 345 
syndromes 346 
 A final and important group of Nav1.5 variants appear to be associated with overlapping combinations 347 
of phenotypes. These were then associated with both loss of SCN5A function producing BrS and conduction 348 
disease (1111), and gain of function mutations producing increased INaL resulting in LQTS3 (115, 941, 349 
1215). First, a number of albeit uncommon monogenic SCN5A mutations (SCN5A-D1114N and SCN5A-350 
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delF1617) are clinically associated with a overlapping combination of LQTS3 and BrS (191, 914, 1085) or 351 
impaired cardiac conduction (1322). A SCN5A-delK1500 in the intracellular DIII-DIV linker close to the 352 
LQTS3-associated mutation SCN5A-delKPQ1505-1507 similarly results in a heterogeneous clinical LQTS, 353 
BrS and conduction disease (370). Finally, members of a family carrying SCN5A-1795insD variously 354 
showed ECG evidence for isolated or combined features of SND, conduction disease, BrS and LQTS3 355 
(115). Expression studies demonstrated reduced INa, and negatively shifted inactivation-voltage curves in an 356 
absence of INaL, in Xenopus oocytes (115). Alternatively, there was a contrasting, increased INaL resulting 357 
from disrupted fast inactivation, and increased slow inactivation that reduced maximum INa at high pacing 358 
frequencies in HEK-293 cells (1184). However, computational analysis suggested that both sets of 359 
characteristics were required to reproduce a combined LQTS and BrS, depending on heart rate (208).  360 
 Nevertheless, heterozygous Scn5a-1798insD/+ mice recapitulated the corresponding human SCN5A-361 
1795insD/+ phenotype (939). They showed both signs of SND, of prolonged PQ, QRS, and QTc intervals 362 
on ECG recording, and of slowed conduction, especially in the RV, on epicardial mapping in isolated hearts. 363 
Patch electrode recordings demonstrated prolonged AP repolarisation phases particularly at low, and 364 
reduced INa particularly at high pacing frequencies. Accompanying marked reductions in peak INa there was 365 
a prolonged time course of fast inactivation, and an increased INaL. (208, 1184).  366 
 Secondly, other expression system studies similarly correlated multiple biophysical defects in Nav1.5 367 
with overlapping clinical consequences. Scn5a+/delK1500 enhanced INa inactivation but induced an 368 
increased INaL (370). Scn5a+/delF1617 was associated with reduced peak INa, slowed recovery from 369 
inactivation. It showed an increased INaL only at positive membrane potentials, and reduced open times at 370 
negative potentials. Both variants were associated with an overlapping LQTS3/BrS phenotype with 371 
conduction disease. 372 
 A third group of SCN5A-V1777M and SCN5A-V1763M mutations are associated with LQTS3 in the 373 
presence of conduction disease. These displayed an increased INaL, yet showed no decrease in peak INa or 374 
other properties suggesting loss of Nav1.5 function (180). This may reflect further contributions besides 375 
biophysical INa properties, possibly involving structural changes (see Section V(E)) in producing the overlap 376 
syndromes. Nav1.5 changes, exemplified by SCN5A-D1275N, are also associated with SND and atrial 377 
arrhythmias (238, 614, 941). 378 
(C) Arrhythmic consequences of genetic modifications in Na+ channel associated proteins 379 
(1) Mutations in Scn1b subunits of the Na+ channel 380 
 The general features of Navβ-subunits as well as the Navβ2 and Navβ3 variants associated with BrS-381 
like phenotypes have been discussed above (see Section V(G)). Of the remaining variants, consequences of 382 
Navβ1 changes differed when studied in co-expression in vitro systems, murine hearts, and clinical studies. 383 
Thus:  384 
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  (a) Navβ1 co-expression with Nav1.5 in HEK293 cells and Xenopus oocytes resulted in overlapping 385 
increases in INa and decreases in INaL (842, 1166). It increased rates with which INa recovered from 386 
inactivation (304). Conversely, in CHO cells, co-expression with SCN1B-D153N and SCN1B-R85H 387 
decreased INa relative to findings with WT Navβ1 (1234). 388 
 (b) Scn1b-/- mice showed prolonged QT and RR intervals expected for LQTS as opposed to BrS 389 
phenotypes. Their acutely dissociated ventricular myocytes showed increases in both peak INa and INaL (~1.6 390 
fold) and in Nav1.5 expression (~1.3 fold ). Gating and kinetic properties were unchanged and AP 391 
repolarisation phases were prolonged (694). Nav1.5, Navβ, ankyrin B, ankyrin G, N-cadherin, and Cx43 392 
showed normal membrane localisation on immunostaining. In juvenile mice cardiac specific for Scn1b-/-, 393 
macropatch and scanning ion conductance microscopy methods demonstrated increases in TTX-sensitive INa 394 
specific to the midsection of isolated ventricular myocytes that could even precede full transverse tubule 395 
formation. Finally, ventricular myocytes from adult Scn1b-/- mice showed indications of increased 396 
transverse tubular expression of TTX-sensitive INa as well as the increased Scn5a mRNA.  397 
 (c) Clinical loss of Navβ1 function was associated with BrS rather than LQTS phenotypes, despite 398 
increased INaL observed in the experimental systems. Thus, a truncated SCN1B-p.Trp179X and a SCN1B-399 
1E87Q mutation was associated with clinical BrS and cardiac conduction disease (1235). Furthermore, 400 
SCN1B-R85H and D153N was associated with lone AF (1234) and SCN1B-R85H with the right precordial 401 
electrocardiographic ST elevation diagnostic of BrS.  402 
 The different, experimental and clinical, situations thus yielded important differences in results. Levels 403 
of INa expression were decreased in (a) yet increased in (b), whilst both (a) and (b) reported increased INaL. 404 
Such findings would be predictive of clinical overlap and LQTS phenotypes respectively. The available 405 
clinical evidence (c) agreed with predictions from (a) but differed from those arising from (b) in reporting a 406 
BrS rather than a LQTS phenotype. Findings in (c) also differed from those in both (a) and (b) whose 407 
observed increases in INaL would have predicted a LQTS clinical phenotype. Further investigations into these 408 
differences might then yield fundamental insights clarifying the relationship between expression systems, 409 
murine models and clinical effects. They would be of particular interest in view of a number of additional 410 
features associated with Scn1b-/-. Thus:  411 
 (a) Scn1b-encoded Navβ1 subunits were associated with not only Nav1.5 α-subunits but also with 412 
ankyrin-B (787) in cardiac and neuronal tissue (926, 927, 1234). They also occurred as alternative Navβ1 or 413 
Navβ1b splice variants (926).  414 
 (b) Scn1b-/- myoctes showed increased mRNA staining for neuronal Scn3a. This was consistent with 415 
increased TTX-sensitive Nav1.3 protein nevertheless excluded from expression around the intercalated disc. 416 
 (c) Scn1b-/- hearts showed evidence for altered cellular Ca2+ homeostasis. They showed triggered 417 
beats, delayed Ca2+ transients and frequent spontaneous Ca2+ release events accompanying the increased 418 
susceptibility to polymorphic ventricular arrhythmias. These abnormalities in Ca2+ homeostasis were 419 
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prevented by TTX at concentrations (100 nM) expected to block the TTX-sensitive, Nav1.3 mediated INa 420 
(663).  421 
 (d) Murine Scn1b-/-, but not Scn1b+/-, mice also showed neurophysiological changes. This took the 422 
form of an epileptic phenotype. They mimicked the severe myoclonic epilepsy of infancy normally 423 
associated with heterozygous SCN1A mutations in Dravet syndrome. Hippocampal slice recordings of CA3 424 
neurons exhibited higher peak voltages in APs of correspondingly increased amplitude compared to WT 425 
Scn1b+/+ whilst not showing the altered INa exhibited by the Nav1.1, Scn1a+/-, variant of Dravet syndrome 426 
(877).  427 
(2) Mutations in Scn4b subunits of the Na+ channel: LQTS10  428 
 LQTS10 was first associated with a genetic, SCN4B-L179F, variant (138, 761). Subsequently a 429 
SCN4B- S206L mutation was associated with SIDS (1110). Both conditions were associated with increased 430 
INaL and prolonged APDs when overexpressed in rat ventricular myocytes (1110). SCN4B-V162G and 431 
SCN4B-I166L were then associated with AF (656). Navβ4 subunits have largely been studied 432 
experimentally in connection with neuronal function, permtting resurgent INa generation leading to high-433 
frequency firing by nerve and muscle Nav isoforms (67, 159, 645). Navβ4 subunit co-expression with 434 
Nav1.2 and Nav1.4 in tsA201 cells negatively shifts their activation (1310). Navβ4 subunits also occur in 435 
mouse ventricle (713). The arrhythmic effects of Navβ4 mutations may thus result from resurgent INa (373) 436 
or increased INaL. It co-immunoprecipates with SCN5A in the HEK293 expression system. However, in the 437 
latter situation it  did not affect INa kinetics or density, or INaL (761).  438 
 (3) Caveolin-3 (Cav3) mutations: LQTS9 439 
 Caveolae are rounded, 50-100 nm diameter, surface membrane invaginations abundant in ventricular, 440 
atrial and nodal cells (65). Their structure depends upon interactions between their contained cholesterol and 441 
specific scaffolding proteins, exemplified by caveolins 1-3. The latter are encoded by CAV1, CAV2, and 442 
CAV3 respectively. Caveolin-3 is also associated with the transverse tubules during skeletal muscle 443 
development (870). Human caveolin-3 mutations are classically associated with skeletal muscle phenotypes. 444 
These take the form of limb girdle muscular dystrophy, rippling muscle disease, distal myopathy and 445 
hyperCKemia (elevated serum creatine kinase) (1273). Gene mutations involving caveolin-3 are also 446 
associated with LQTS9. 447 
 Cav-3, via its scaffolding domain, likely interacts with numerous signaling molecules. These include 448 
G-protein-coupled receptors (GPCRs), ion channels, and receptor tyrosine kinases.  CAV3 may be important 449 
for G-protein-mediated adrenergic cardiac INa upregulation (1301). Cav-3 inhibits neuronal nitric oxide 450 
synthase (nNOS) (1186) and SCN5A nitrosylation by such nNOS increases INaL (195, 1158). Expression of 451 
WT Cav-3 with SCN5A in HEK293 cells did not affect either peak INa or INaL (223, 1177). However, the 452 
clinical CAV3 mutations CAV3-F97C and CAV3-S141R, that first demonstrated a LQTS, resulted in an 453 
increased INaL in HEK293 cells (1177). So did the CAV3-V14L, CAV3-T78M and CAV3-L79R mutations 454 
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found in a SIDS cohort (223). The CAV3-F97C mutation was also associated with increased SCN5A 455 
nitrosylation and increased INaL and APD in HEK293 cells (223). Cav3 mutations have also been linked to 456 
HCM through an as yet unclear mechanism (415, 1272). 457 
 Murine knockout or knock-down studies implicated Cav3 in cardiomyocyte caveolus formation (337). 458 
These may integrate ion channel and exchangers, including pacemaker Hcn4, Cav1.2, Kv1.5, Kir6.2/Sur2a 459 
and Nav1.5 channels, and NCX, into specific signalling complexes (65, 1082, 1303). Two independent 460 
groups reported generation of caveolin-3-deficient mice by targeted exon 2 disruption involving the Cav3 461 
caveolin-scaffolding, transmembrane domains and the C-terminal region (337, 401). The mice also showed 462 
mild myopathic changes resembling those of limb-girdle muscular dystrophy-1C in patients with CAV3, 463 
exon 2 mutations (434, 779).  464 
 Cav3-/- mice showed an abnormal, diffuse, tubular dihydropyridine receptor DHPR1-α and RyR1 465 
localization. Their transverse tubular systems were disorganised. They exhibited dilated and longitudinally 466 
oriented transverse tubules (337). The mice developed a progressive cardiomyopathic phenotype. Thus 467 
magnetic resonance imaging and transthoracic echocardiographic studies demonstrated hypertrophy, dilation 468 
and reduced fractional shortening. Histological examination revealed cardiomyocyte hypertrophy, cellular 469 
infiltratation and interstitial fibrosis. Such changes were evident even at age four months. There was an 470 
accompanying increase in activity in the p42/44 mitogen-activated protein kinase (MAPK)/extracellular 471 
signal-regulated kinase (ERK1/2) cascade. The latter is normally inhibited by Cav3 (1272). Conversely, 472 
cardiac-specific Cav-3 overexpression resulted in lower resting heart rates at rest, prolonged PR interval but  473 
shortened QTc intervals, and alterations in ion channel expression in an absence of alterations in metabolic 474 
background activity (727, 728, 1017). 475 
(4) Arrhythmic consequences of genetic abnormalities in α-1-syntrophin (SNTA): 476 
LQTS12  477 
 The rod-shaped scaffolding protein α-1-syntrophin (SNTA) forms part of the dystrophin glycoprotein 478 
complex that is involved in linking proteins to the cytoskeleton. It is associated with multiple further 479 
proteins including other syntrophins and dystrophin (12). It may be associated through its PDZ domain to 480 
the three specific residues, Ser-Ile-Val, at the distal end of the C-terminus (1063) of those SCN5A channels 481 
that are located in the lateral membranes of cardiac myocytes (345, 889, 1158). SNTA mutations are 482 
associated with LQTS12 (Ueda et al., 2008) and SIDS (194). The LQTS12, SNTA-A390V, mutation 483 
selectively dissociates the plasma membrane calcium transporter and nNOS inhibitor PMCA4b from this 484 
complex (846). This increases SCN5A nitrosylation and thereby increases INaL (Ueda et al., 2008). In 485 
contrast, mice with genetically modified α1-syntrophin lacking the C-terminal motif (ΔSIV) showed altered 486 
targeting of Nav1.5 to the lateral membrane, normal Nav1.5 targeting to intercalated discs and reduced INaL 487 
(1063). 488 
(D)Arrhythmic properties and altered ICaL: Timothy Syndrome (TS) (LQTS8) 489 
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(1) Clinical features of Cav1.2 abnormality 490 
 Slowed Cav1.2 inactivation constitutes a further source of AP plateau prolongation that may promote 491 
lethal arrhythmias. Timothy Syndrome (LQTS8, TS) results from rare, autosomal dominant gain-of-function 492 
missense CACNA1C-G406R mutations involving the junction between DI/S6 and the I-II loop of the L-type 493 
Ca2+ channel (Cav1.2). It may occur with or without an accompanying CACNA1C-G402S mutation (1086). 494 
AP prolongation may be the result of abnormal stabilisation of the open state of Cav1.2 involving the 495 
scaffolding protein AKAP79 (AKAP150 in rodents). The enhanced Ca2+ influx may be further accentuated 496 
by increased channel activity resulting from physical interactions between neighboring channels through 497 
their C-tails (268). The condition is often accompanied by congenital heart disease, syndactyly, 498 
immunodeficiency, cognitive abnormalities, and autism.  499 
(2) Murine models for Timothy Syndrome (TS) 500 
 Two distinct TS mouse lines have been used respectively to illustrate its resulting neurological (56) 501 
and cardiac phenotypes (192). In the cardiospecific transgenic mouse LQTS8 model of TS, ~30% of the 502 
Cav1.2 channels were Cav1.2-TS. The LQTS8 hearts were hypertrophied relative to WT. Their ventricular 503 
myocyte ICaL showed a slowed inactivation. This likely accounts for the prolonged AP waveforms and 504 
longer QT intervals. It likely also accounts for the increased incidences of exercise-induced arrythmogenic 505 
events including premature ventricular depolarisations and torsades de pointes, in intact hearts. Cell-attached 506 
patch recordings attributed this to greater opening probabilities, open time durations, and coupled gating 507 
frequencies in the Cav1.2 (192). Cav1.2-TS channel expression also appeared to increase background 508 
sarcolemmal Ca2+ leak in resting ventricular myocytes, increasing diastolic intracellular [Ca2+] relative to 509 
WT. This was attributed to an increased SR Ca2+ load and Ca2+ spark activity. The latter also resulted in 510 
larger amplitudes of evoked Ca2+ transients and Ca2+ wave frequencies (277). Crossing LQTS8 with 511 
AKAP150-/- giving LQTS8/AKAP150-/- rescued all these phenotypes (192, 1150). 512 
 (E) Hypokalaemic murine models for acquired LQTS 513 
(1) Arrhythmic consequences of acquired LQTS 514 
 Inheritable LQTS-mediated arrhythmias account for only 1–2% of lethal clinical ventricular 515 
arrhythmias. The remaining, LQTS are associated with acquired rather than congenital risk factors. These 516 
include metabolic conditions, electrolyte abnormalities, particularly hypokalaemia, and bradycardic 517 
situations (37, 288, 953, 1037, 1171). A significant number of drugs not initially associated with cardiac 518 
effects also exert significant cardiotoxic profiles that include QT prolongation. In some cases these 519 
predispose to polymorphic VT and torsades de pointes (953). Even therapeutic levels of some cardiac drugs 520 
such as dofetilide and ibutilide can noticeably (~50 ms) increase QT interval and risk of torsades de pointes 521 
(513, 953). However, even agents slightly increasing QT interval (5-10 ms) can increase risk of torsades de 522 
pointes (288, 910). These effects often have been attributed to inhibition of K+ current, particularly IKr 523 
(1171). 524 
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(2) Murine hearts as models for clinical hypokalaemia 525 
 Experimental murine cardiac models permitted a modeling of acquired LQTS following reversible 526 
imposition of their causative conditions in physiological studies of often common, clinically important, 527 
situations (562). For example, both increased and decreased [K+]o clinically predispose to major arrhythmias 528 
(230). Decreased [K+]o increases risks of torsades de pointes (37). This may involve a delayed repolarisation 529 
prolonging the QT interval that predisposes to EADs in turn triggering premature beats (953). These 530 
appeared within a substrate resulting from heterogeneous transmural ion channel distributions altering 531 
transmural dispersions of repolarisation (TDR) and therefore refractoriness, particularly when accompanied 532 
by increased APD (494). Reduced [K+]o has been used to assess arrhythmic effects of pharmacological 533 
agents implicated in acquired LQTS or generation of arrhythmias (288, 772, 774). 534 
 Mouse hearts replicate the [K+]o-sensitivity shown by the major voltage-dependent repolarising K+ 535 
currents shown in hearts of larger mammals (561, 829, 1294). In particular, IK1 similarly contributes 536 
membrane current through the voltage sensitivity arising from its inward rectification properties. These 537 
reduce K+ conductance at membrane potentials >-20 mV during phases 0-2 of the action potential, but 538 
permit outward currents following repolarisation to <-40 mV late in phase 3, and stabilise the diastolic, 539 
phase 4, resting potential (357, 1020). In ventricles, these effects are augmented by currents arising from its 540 
tubular localisation (211, 322). Ventricular transverse tubules form a restricted extracellular space permitting 541 
K+ accumulation following depolarisation where this results in outward K+ current activation. The tubular 542 
K+ accumulation shifts the local tubular K+ Nernst potential, activating IK1, thereby modulating AP recovery. 543 
This activation was demonstrated in single adult mouse ventricular myocytes in the form of transient inward 544 
tail currents observed following termination of depolarizing voltage steps sufficient to elicit outward current 545 
by repolarisations to holding potentials close to the normal cell resting potential (211, 317).The latter effect 546 
was modified by both increased and decreased [K+]o (see Section VI(E)). Murine hearts thus therefore can 547 
usefully physiologically model the effects of clinical hypokalaemia (301, 559, 563, 979, 982, 983). 548 
(1) Triggering and arrhythmic substrate associated with hypokalaemia  549 
 Studies that examined the electrophysiological effects of decreasing [K+]o in murine cardiomyocytes 550 
(559–561, 978) confirmed previous reports in other systems of decreased Ito, IKr and IK1 despite increased 551 
driving forces on outward K+ currents (164, 317, 1001). Under normokalaemic (5.4 mM [K+]o) conditions, 552 
patch-clamped epicardial myocytes showed greater Ito than endocardial myocytes (561) (Figure 12A). This 553 
was in keeping with the higher epicardial than endocardial levels of their corresponding proteins (151, 967). 554 
The resulting transmural Ito differences were in turn predictive of the normally observed transmural APD 555 
differences. Hypokalaemic conditions decreased epicardial (Figure 12Aa,b) but not endocardial Ito (Figure 556 
12Ac,d). This would predict preferential epicardial over endocardial increases in APD, and diminished 557 
repolarisation gradients. In contrast, epicardial and endocardial myocytes under normokalaemic conditions 558 
showed similar IK1 obtained in response to hyperpolarising steps. These were reduced to similar extents by 559 
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hypokalaemia. This would be consistent with effects in increasing APD but not to the resulting transmural 560 
repolarisation gradients.  561 
 AP recordings in intact, Langendorff-perfused mouse hearts fulfilled these predictions from this 562 
cellular analysis of changes in Ito and IK1 (Figure 12B, C) (561). Under normokalaemic conditions, they thus 563 
showed longer ventricular endocardial than epicardial MAPs. This led to transmural APD gradients of ~14 564 
ms. This difference closely correlates with previous studies of in vivo murine MAP recordings (Figure 565 
12Ba). Reduced [K+]o prolonged both the epicardial and the endocardial MAPs. However, it did so to 566 
differing extents. This led to a reduction in the transmural APD gradients as quantified by ∆APD90 values 567 
(Figure 12Bb, Ca-c). In addition, the more bradycardic of intrinsically active hearts showed EADs even with 568 
reductions in [K+]o,from 5 to 4 mM. They also showed a 29% incidence of VT (Figure 12D). These findings 569 
directly parallel clinical findings in male hypertensive patients on diuretic therapy in which each 1 mM 570 
reduction in [K+]o increases ventricular arrhythmic risk by 28% (214). Further reduced, 3 mM, [K+]o 571 
additionally resulted in triggered beats followed by episodes of non-sustained VT (Figure 12Dc). This would 572 
implicate L-type Ca2+ channels as a possible depolarising charge carrier at low slow stimulation rates 573 
(1325).  574 
 Pharmacological manouevres using the L-type Ca2+ channel-blocker, nifedipine and CaMKII inhibitor 575 
KN-93 made it possible to separate the contributions made by EADs and transmural repolarisation gradients 576 
to the arrhythmic process. They suggested that the mechanisms responsible for triggering and those 577 
producing re-entrant substrate leading to persistent arrhythmia were separate (Figure 12E) (559). Thus, both 578 
nifedipine (100 nM) and KN-93 reduced EADs and spontaneous arrhythmias (Figure 12Ea). However, 579 
neither prevented arrhythmias provoked by programmed electrical stimulation (Figure 12Eb). Nor did they 580 
alter either epicardial or endocardial APD. They thus preserved the abnormal repolarisation gradients 581 
associated with the hypokalaemic conditions. In contrast, higher (1 μM) nifedipine concentrations abolished 582 
all arrhythmic phenomena, whether spontaneous or provoked. It now correspondingly shortened the 583 
epicardial APDs and restored the transmural repolarization gradients ΔAPD90 to control values. This 584 
implicated the alterations in ΔAPD90 in arrhythmic substrate (559). Together these findings were also 585 
compatible with a prolongation of the AP repolarisation thereby inducing EADs through Ca2+ channel 586 
reactivation. This in turn would trigger premature APs and triggered beats (Figure 13A, B) (301, 497). These 587 
findings concurred with findings in murine (KChIP2-/-) cardiomyocytes lacking KChIP2, which encodes 588 
three auxiliary subunits of Kv4.2 and Kv4.3. These cells similarly lacked Ito, showed increased APD, and 589 
were susceptible to induced, but not spontaneous ventricular arrhythmias (604). 590 
 Other pharmacological manipulations similarly culminating in altered APD and the appearance of 591 
EAD phenomena yielded concordant results. For example, NS1643 (30 μM) is known to reduce HERG 592 
inactivation (169). It reduces APD in isolated guineapig ventricular myocytes (407). The KATP channel 593 
activator nicorandil (20 μM) was reported as anti-arrhythmic in LQTS (1056). Both of these agents reduced 594 
the occurrences of both spontaneous, unprovoked VT, and VT folllowing premature stimulation in murine 595 
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hearts studied under hypokalaemic conditions. This was accompanied by reduced incidences of EADs and 596 
reductions in epicardial APD that thereby restored the normal transmural repolarisation gradients (562). 597 
 Evidence from murine systems thus attributed arrhythmic tendencies in both Scn5a+/ΔKPQ (Section 598 
VI(B)) and hypokalaemic hearts to alterations in AP repolarisation and refractoriness. This would be in 599 
direct contrast to the altered conduction velocity implicated in Scn5a+/- hearts (see Section V(B) and V(C)). 600 
Such a distinction was confirmed in investigations of arrhythmic or refractory endpoints in adaptive 601 
programmed electrical stimulation protocols that consisted of regular pacing (S1) stimulus trains that were 602 
followed by S2 extrastimuli. S1S2 intervals were progressively decreased, but S2 amplitudes were 603 
progressively increased in order to to maintain stimulus capture. Control normokalaemic WT, test 604 
hypokalaemic WT and Scn5a+/ΔKPQ hearts all showed similar relationships between conduction velocity 605 
and S1S2 coupling interval and between re-excitation thresholds and S1S2 coupling interval. Yet the onset 606 
of arrhythmia did not correspond to a given change in conduction velocity. When arrhythmias were induced 607 
by extrasystolic APs in the LQTS, hypokalaemic WT and Scn5a+/ΔKPQ, groups, these took place at higher 608 
AP conduction velocities and lower S2 stimulus amplitudes than in the normokalaemic WT controls. 609 
Furthermore, where there were arrhythmic as opposed to refractory outcomes, the APs initiating such 610 
arrhythmias showed lower conduction velocities than when there were refractory outcomes. These 611 
conduction velocities were higher and occurred at longer S1S2 coupling intervals and smaller stimulus 612 
amplitudes in the LQTS groups compared with controls (281).  613 
(2) Transmural heterogeneities and arrhythmic substrate in hypokalaemic hearts 614 
 Section II(A)(2) discussed situations in which substrate for re-entrant excitation arose from relative 615 
changes in parameters describing AP repolarisation and refractoriness. This suggested that windows of re-616 
excitation could result from an appearance of critical intervals produced by positive time differences 617 
between measures of action potential repolarisation such as APD90, and recovery from refractoriness as 618 
exemplified by VERP. Such differences could either take place within a given cardiac region or involve 619 
adjoining, electrotonically coupled regions of myocardium (978). These predictions were demonstrated in 620 
isolated hypokalaemic (~3 mM [K+]o) Langendorff perfused hearts (Figure 13C, D). These made it possible 621 
to test the effects of conditions under which alterations in transmural repolarisation gradients would give rise 622 
to re-entrant excitation in LQTS models (Figure 12C).  623 
 In this analysis, hypokalaemia increased the epicardial but not the endocardial APD90. It also 624 
decreased both the epicardial and endocardial VERPs. However, it left differences in endocardial and 625 
epicardial AP latencies unchanged. Lignocaine abolished the arrhythmogenecity associated with the 626 
hypokalaemia. It also abolished these alterations in recovery parameters. The differences in the endocardial 627 
and the epicardial intervals between stimulation and 90% repolarisation remained unchanged. These 628 
findings gave rise to quantititave predictors of arrhythmic behaviour involving AP latency, APD90 and 629 
VERP. Risks of local re-excitation in either the epicardium or endocardium could thus be obtained from 630 
critical intervals that were based on their respective (APD90–VERP) differences. Risks of transmural re-631 
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entrant epicardial excitation by endocardium, or endocardial excitation by the epicardium could be predicted 632 
by critical intervals given by (endocardial APD90 + Δlatency − epicardial VERP) and (epicardial APD90 + 633 
Δlatency − endocardial VERP), respectively. The Δlatency term corrected for delays between endocardial 634 
and epicardial excitation. These findings were corroborated by computer modelling of AP waveforms using 635 
established data on the effects of hypokalaemia on ionic conductivities in ventricular myocytes (978). 636 
 The relevance of incorporating a VERP term reflecting recovery from refractoriness was further 637 
justified by extending the analysis of arrhythmic tendency in hypokalaemic hearts through a range (80-180 638 
ms) of, as opposed to single, BCLs. These extended to bradycardic conditions. This gave a graphical 639 
analysis of local and transmural relationships plotting epicardial and endocardial APD90, appropriately 640 
corrected for conduction times, against VERP. Hearts studied under normokalaemic (5.2 mM [K+]) 641 
conditions then yielded straight line loci close to lines of equality. These lines thus subtended an angle ≈ 45 642 
degrees with the abscissa. Hypokalaemia shifted the APD90 values above these reference lines. These 643 
differences increased with BCL. The latter was correctly predictive of correspondingly increasing 644 
arrhythmic tendency. It also direct paralleled the corresponding increases in critical (APD90-VERP) and in 645 
the subtended angle. The anti-arrhythmic effects of lignocaine directly correlated with its effect in 646 
modifying this relationship. It decreased the subtended angle and (APD90-VERP) in hearts studied under 647 
both normokalaemic and hypokalaemic conditions (977). 648 
(3) Temporal heterogeneities and arrhythmic substrate in hypokalaemic hearts 649 
 Hypokalaemia also contributed a dynamic component to the arrhythmic substrate. This was apparent 650 
first, in the features of extrasysolic APs that were obtained in response to premature (S2) stimuli. The APs 651 
that followed subsequent (S3) stimuli then showed alterations in their transmural repolarisation gradients 652 
ΔAPD90 under hypokalaemic conditions. This effect was not observed under normokalaemic conditions 653 
(980). Furthermore, in parallel with its anti-arrhythmic effects both in murine preparations and in clinical 654 
situations (938), lignocaine abolished these ΔAPD90 changes. Secondly, hypokalaemia also contributed 655 
changes to alterations in restitution properties with progressively decreasing BCL. Isolated, Langendorff-656 
perfused hearts studied under hypokalaemic (3 mM) but not normokalaemic (5.2 mM [K+]) conditions 657 
showed APD alternans and arrhythmia with progressive increases in heart rates. This was associated with 658 
increased restitution curve slopes. Both such effects were prevented by lidocaine (10 μM). Hypokalaemia 659 
increased the values of both epicardial and endocardial maximum gradients and DIcrit corresponding to unity 660 
gradient identified with the onset of arrhythmia. In contrast, lidocaine decreased such gradients and DIcrit 661 
under hypokalaemic but not normokalaemic conditions (979, 982). 662 
 (F) Genetic modifications in voltage-dependent K+ channels and their associated subunits  663 
(1) Loss of function in transient outward currents, Ito 664 
 The pore-forming Kv4.3 α-subunit co-assembles with a range of modulatory β-subunits, particularly 665 
KChIP2, but also KCNE2 (MiRP1) and DPP6 (2, 294). Co-assembly of Kv4.3/KChIP2 channels with 666 
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MiRP1 slowed activation and inactivation in whole cell patch-clamped CHO cells (933). Murine Kcne2-/- 667 
ventricles showed prolonged APDs, accompanied by 25% reductions in Ito,f and 50% reductions in IK,slow1, 668 
implicating associations between Kcne2 and Kv1.5 for the first time. There was an accompanying 669 
coimmunoprecipitation of ventricular MiRP1 protein with native Kv1.5 and Kv4.2 but not Kv1.4 or Kv4.3 670 
(956). Kcne2 knockdown by RNA interference similarly prolonged APD and decreased Ito in both neonatal 671 
and adult mouse myocytes. In contrast, Kcne2 overexpression produced by adenoviral gene delivery 672 
shortened APD and increased Ito in neonatal but not adult myocytes (679).  673 
  The magnitude of Ito normally falls with the LV epicardial-endocardial gradient. This transmural 674 
gradient is likely important in normal ventricular repolarisation (151, 383, 604). Studies in Nfat-/- mice, 675 
deficient in nuclear factor of activated T cell, suggest that this may reflect control of Kv4 expression by 676 
calcineurin and NFATc3 (967). APD is consequently shorter in their LV epicardial than their LV 677 
endocardial myocytes (209, 604). Transgenic mice with altered Ito components can show APD and QT 678 
prolongation. This may correlate with arrhythmic tendency where these involve regional Ito,f  and Ito,s 679 
variations. The latter in turn may alter regional apex–base, endocardium–epicardium, or septum–ventricular 680 
free wall patterns of ventricular repolarisation (70, 151, 383, 691, 1284).  681 
 The consequences of reduced Ito for APD, apical-basal APD gradients, and arrhythmogenecity varied 682 
with the extent to which these reductions affected Ito,f, Ito,s or both. Thus, Kv4.2 (KCND2) dominant negative 683 
transgenic (Kv4.2-DN) mice lacking Ito,f, but not Kv1.4 (KCNA4)-/- mice lacking Ito,s, showed increased 684 
APD and prolonged QT. Neither showed spontaneous arrhythmias. However, double transgenic (Kv4.2-DN 685 
× Kv1.4-/-) mice lacking both Ito,f and Ito,s showed both AP and QT prolongation, and spontaneous 686 
ventricular tachyarrhythmias. With optical mapping using di-4-ANEPPS, Langendorff-perfused Kv4.2-DN, 687 
Kv1.4-/- and Kv4.2-DN × Kv1.4-/- hearts showed similar activation patterns and conduction velocities, but 688 
longer APD75 (~28, ~28 and ~34.3 ms) than WT (~20.3 ms). However, Kv4.2-DN hearts showed reduced 689 
apicobasal dispersions of refractoriness compared with WT. They did not show VT on premature 690 
stimulation. Voltage-clamped Kv4.2-DN myocytes showed 30% greater apical than base Ito,f. In contrast, 691 
both Kv1.4-/- and Kv4.2-DN × Kv1.4-/- hearts showed increased dispersions, and VT, on premature 692 
stimulation (558, 687). 693 
 (2) Loss of function in the rapid delayed rectifier K+ current, IKr: LQTS2 and LQTS6 694 
 The Kv11.1 (KCNH2)-mediated IKr is important both for completing phase 3 repolarisation and 695 
preventing arrhythmias induced by EADs in hearts of larger mammals (1070). Phase 0 depolarisation 696 
rapidly activates initially resting IKr channels into their open state. But this is rapidly succeeded by channel 697 
inactivation. However, repolarisation produces a rapid recovery from inactivation involving transitions 698 
through the open state preceding return to the resting state. The latter produces a tail current (696, 697, 1000, 699 
1070, 1170). Loss-of-function KCNH2 (formerly termed HERG, the human form of ERG) mutations affect 700 
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IKr (229), particularly in the S5/pore region (472, 1342). The consequent clinical LQTS2 results in low-701 
amplitude bifid T waves in the ECG (806) reflecting increased transmural dispersions of repolarisation, 702 
cardiac arrhythmic events following sudden arousal, and episodic sinus bradycardia (1002, 1307). 703 
 IKr is also the dominant repolarising current in fetal (~day 18) mouse hearts. IKr block by dofetilide 704 
then caused EADs and failurure of repolarisation. IKr block in fetal mice produced bradycardia and 705 
arrhythmia resulting in lethal circulatory failure (1219). Simlarly, complete knockout of all the ERG1 706 
isoforms is intrauterine lethal.  707 
 However, in adult mice, IKr may only play minor roles in ventricular repolarisation. Nevertheless, it 708 
likely retains a role in SAN pacemaker function (see Section III(A)). Thus, results in mice in which the B 709 
transcript was eliminated while preserving the A transcript suggested that in adult myocytes, Erg1B is 710 
necessary for IKr surface membrane expression and that its knockout predisposes to episodic sinus 711 
bradycardia (627). However, QT intervals were normal notwithstanding loss of the rapidly decaying 712 
component of IKr. Murine LQTS2 models carrying the G628S dominant negative mutation showed normal 713 
QT durations but minor abnormalities in QRS and T waveforms. There was a loss of IKr and increased APDs 714 
in isolated myocytes, but normal AP waveforms in ventricular strips (53). Merg1b-/- mice showed episodic 715 
abrupt sinus bradycardia. This finding parallels clinical observations in some LQTS2 families where this can 716 
trigger arrhythmias (1307). However, they also showed normal QT intervals despite an abolished IKr in 717 
isolated myocytes (626), whilst not excluding a persistence of repolarising K+ currents produced by other 718 
mERG isoforms (690). Nevertheless, epicardial optical mapping studies related an increased VT propensity 719 
in a Merg+/- mouse to prolonged apical and basal APDs and VERPs, despite conduction velocities similar to 720 
those found in WT (994). 721 
 Studies in murine models have also yielded important results bearing on roles of alternatively spliced 722 
isoforms. Human and mouse hearts express two, A and B, isoforms in the underlying ERG1. These have 723 
differing NH2 termini and show slow and rapid de-activation properties respectively (627). The A transcript 724 
is relatively abundant in both human and mouse hearts. The B transcript is abundant in mouse but not human 725 
hearts (627). Most reports bearing on LQTS2 appear to reflect properties of the A isoform. Studies in 726 
Xenopus oocyte expression systems suggest that functional IKr in mouse hearts requires heteromeric 727 
assembly of different, mERG1a, mERG1a’ and mERG1b isoforms. Currents from expressed mERG1a alone 728 
resembled those obtained following HERG expression. Currents from mERG1a’, lacking the first 59 N-729 
terminal amino acids, and mERG1b currents showed a tenfold more rapid deactivation. Co-expression of 730 
mERG1a and mERG1b gave currents closely resembling murine IKr (690). hERG 1b is also likely to be 731 
critical to normal repolarisation with its deficiency resulting in pro-arrhythmic effects in human 732 
cardiomyocytes. sh-RNA-induced knockdown of the 1b subunit halved its corresponding mRNA and protein 733 
levels as well as IKr, increasing AP duration and variability, with an appearance of EAD phenomena in 734 
cardiomyocytes from human induced pluripotent stem cells. These features were replicated by converting 735 
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hERG heteromers to hERG1a homomers by expressing a fragment representing the HERG1a-specific N-736 
terminal Per–Arnt–Sim domain absent in hERG1b (516). 737 
 IKr channels may require further co-assembly of auxiliary modulatory subunits with different channel 738 
isoforms to reproduce their in vivo function. Thus native IKr differs from currents recorded from hERG 739 
channels in heterologous expression systems in their gating, external K+ regulation, and drug sensitivity 740 
properties (207). Normal in vivo IKr function thus also depends upon association of KCNH2 with the 741 
accessory KCNE2 (minK-related, MiRP1) protein (1, 2, 294). This results in a current with +5 to +10 mV 742 
shifts in steady-state activation, enhanced rates of deactivation and reduced unit channel conductance from 743 
13 to 8 pS compared to electrophysiological findings associated with expression of KCNH2 alone (696, 744 
697). Loss of function KCNE2 mutations are associated with LQTS6 (1085). This has phenotypic 745 
consequences similar to those of LQTS2. Conversely, the gain of function KCNE2-R27C mutation has been 746 
associated with familial AF (1295). 747 
(3) Loss of function in the slowly activating delayed rectifier K+ current, IKs: LQTS1 748 
and LQTS5 749 
 The slow, IKs, current observed in hearts of larger mammals is mediated by the K+ channel protein 750 
KCNQ1. This protein is modulated by its association with the single transmembrane domain β-subunit 751 
KCNE1 (Mink) (69, 999). Adult mouse hearts do express Kcnq1 (276) but their Kcne1 expression declines 752 
with age (276, 308) from age ~1 week (253). Adult mouse myocytes consequently lack typical IKs (53, 253). 753 
In addition, alternative splicing of KCNQ1 results in an isoform 1 with a long N-terminal end (69) and an 754 
isoform 2 with a short amino-terminal end of only two amino-acids (253). Isoform 2 does not form 755 
functional channels but exerts strong dominant-negative effects on isoform 1. 756 
 KCNQ1 mutations are associated with clinical LQTS1. Cardiac incidents typically occur during 757 
exercise (1222). Kcnq1-/- mice recapitulated the morphological inner ear abnormalities, auditory defects, 758 
and the shaker/waltzer and cardiac phenotypes of Jervell and Lange-Nielsen Syndrome, with which clinical 759 
LQTS1 often presents. Intact Kcnq1-/- mice showed abnormal in vivo electrocardiographic P and T waves, 760 
prolonged QT intervals and episodic non-sustained arrhythmias. In contrast, isolated perfused murine 761 
Kcnq1-/- hearts showed normal QT intervals and APDs. In Kcnq1-/- but not WT hearts these were 762 
nevertheless prolonged by nicotinic or sympathomimetic stimulation. This implicates extrinsic cardiac 763 
innervation in reproducing the clinical phenotype (1138). Nevertheless, mice overexpressing human KCNQ1 764 
isoform 2, which exerts dominant negative effects on murine Kcnq1 isoform 1, showed marked QT 765 
prolongation. They also showed SND and atrio-ventricular block. The latter was associated with prolonged 766 
atrial-His but normal His-ventricular intervals in His bundle recordings. Their patch-clamped mutant 767 
cardiomyocytes showed increased APD. However, there was also evidence for additional 768 
electrophysiological remodeling. This took the form of reductions in Ito and Iss through downregulation of 769 
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Kv4.2 and Kv1.5 and upregulation of Kv4.3 (254). Thus complex physiological changes add to those 770 
directly arising from the genetic changes in vivo. 771 
 Loss of function mutations involving the β-subunit KCNE1 are associated with LQTS5 (1085, 1087). 772 
Its phenotype resembles that of LQTS1, with prolonged APs and increased arrhythmic risk (121, 999). 773 
Homozygous Kcne1-/- mice with a deletion in the entire KCNE1 coding sequence recapitulated both the 774 
sensorineural and the arrhythmic effects clinically associated with LQTS5 (64, 1195). They showed circular 775 
movements, repetitive falling, head nodding and bilateral deafness attributed to deficient transepithelial 776 
endolymphatic K+ transport (1195).  777 
 Kcne1-/- mice showed increased QT intervals at slow heart rates that paradoxically shortened at 778 
increased heart rates (276). Spontaneously beating Langendorff-perfused Kcne1-/- hearts showed frequent 779 
EADs, closely coupled triggered beats and spontaneous VT. Regular pacing demonstrated increased bipolar 780 
electrogram durations. Premature stimuli during programmed electrical stimulation frequently provoked 781 
monomorphic VT episodes (64, 447). Prolonged epicardial and endocardial APDs resulted in reduced 782 
critical intervals as given by APD90-VERP differences. They also resulted in reduced transmural 783 
repolarisation gradients, consistent with spatial re-entrant substrate (1130). These changes took place in an 784 
absence of epicardial apical-basal APD90s measured by optical mapping (994). Temporal re-entrant substrate 785 
appeared as increased APD90 alternans and steeper epicardial and endocardial APD90 restitution curves 786 
during dynamic pacing. Nifedipine suppressed the EADs, triggered beats and repolarisation alternans. It 787 
selectively shortened epicardial APD, restoring the transmural repolarisation gradient (1130).  788 
 Pharmacological manipulations directed at K+ channel rather than Ca2+ homeostatic function using 789 
nicorandil yielded concordant results (562). Nicorandil increases K+ conductance (478, 528), enhancing 790 
repolarisation reserve (478), and shortening APD90 in atrial (1289) and Purkinje fibres (478), and isolated 791 
guinea pig and rabbit ventricular myocytes (528). These effects were independent of external [Na+] (478). 792 
They occurred despite normal ICa (528), (dV/dt)max (478, 528) or maximum diastolic membrane potentials. 793 
Nicorandil (20 µM) rescued both the spontaneous and provoked arrhythmogenic phenomena. It also restored 794 
the AP parameters reflecting re-entrant substrate towards the normal values in untreated WT, further shifting 795 
them in WT hearts in similar directions (447). 796 
 (4) Loss of function in Islow 797 
 In addition to rapidly decaying outward Ito, mouse ventricular myocytes show gradually decaying 798 
contributions from a rapidly activating but slowly inactivating, 4-aminopyridine–sensitive Islow. This is likely 799 
at least partially carried by Kv1.5. There is also a constant current component (1348). Murine studies 800 
demonstrated potentially arrhythmic contributions arising from abolition of Islow. These employed a 801 
dominant negative transgenic mouse overexpressing a cardiac Kv1.1 N-terminal fragment controlled by the 802 
α-myosin heavy chain promoter (688). The truncated channel fragment coassembles with WT Kv1.x. This 803 
traps heteromeric channels in the endoplasmic reticulum. The latter accounts for the dominant negative 804 
reduction in Kv1.x currents in heterologous expression systems (321).  805 
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 The transgenic mice showed prolonged QT intervals, and spontaneous nonsustained VT on ambulatory 806 
telemetry. Programmed stimulation applied to the RV induced polymorphic VT in anaesthetised, open-chest 807 
preparations. The patch-clamped ventricular myocytes showed prolonged APDs attributable to reduced Islow. 808 
Studies using voltage-sensitive dyes and optical mapping techniques demonstrated the normal apical-basal 809 
activation in apically paced hearts. Mean AP conduction velocities (~0.5 m s-1) were also similar to those 810 
showed by WT. Transgenic hearts showed increased APD75 and APD90 (59). They showed altered restitution 811 
properties. Thus, APD did not show the normal decrease with decreased BCL. There was instead a flattened 812 
dependence on decreased BCL. These findings implicate Islow in the adaptation of APD to altered heart rate, 813 
particularly at short BCLs. These properties together culminated in marked re-entrant substrate. Premature 814 
apical stimuli triggered prolonged (≥30 min) re-entrant VT episodes in transgenic but not WT hearts. 815 
(5) Other K+ channel variants 816 
 Deficiencies in inward rectifying K+ current, IK1, resulting from loss-of-function KCNJ2 mutations 817 
encoding Kir2.1 are associated with Anderson-Tawil syndrome (LQTS7) (1143, 1144). In common with 818 
Jervell and Lange Nielsen syndrome there are accompanying extra-cardiac phenotypes. In LQTS7 these 819 
include periodic paralysis, dysmorphic facial features and syndactyly (1144). Kcjn2-/- mouse neonates 820 
lacking Kir2.1 did not demonstrate ectopic beats or re-entry arrhythmias but were bradycardic on ECG 821 
recording. Their ventricular myocytes lacked detectable IK1 whilst showing persistent sustained outward K+ 822 
currents and L- and T-type channel mediated Ba2+ currents. They showed broader APs and more frequent 823 
spontaneous APs. Kcjn12-/- mice lacking Kir2.2 showed 50% reductions in IK1 (1323). This contrasts with 824 
the association between the gain of IK1 function KCNJ2-V93I mutation and familial AF (1278).  825 
 Murine models with decreased ultrarapid delayed rectifier potassium current (IKur), mediated by 826 
Kv1.5, resulting from loss of Kcna5 function showed atrial AP prolongation, increased incidences of EADs, 827 
and AF (853). 828 
 (G) K+ channels and scaffolding proteins 829 
(1) Genetic abnormalities in Ankyrin B (Ank2): LQTS4 830 
 In common with Na+ channels, K+ channels are associated with scaffolding proteins (1071). Of these, 831 
ankyrin-B, ANK2, is critical in regulating cardiac membrane protein expression. ANK2 dysfunction can 832 
follow myocardial infarction (377, 469). Genetic ANK2 variants are clinically associated with LQTS4 but 833 
may correlate with arrhythmic susceptibility in general (1034). ANK2 loss-of-function results in complex 834 
phenotypic abnormalities including sinus node and conduction disorder, ventricular arrhythmia, and SCD 835 
(788–790, 1033). LQTS4 patients showed increased QT intervals and arrhythmias with additional features 836 
including sinus bradycardia and paroxysmal AF (1023). 837 
 Ankyrin-B+/− mice recapitulated the latter findings. Mice with heterozygotic, loss of function, 838 
ankyrin-B +/E1426G mutations showed reduced transverse tubular targeting and protein levels in Na+-K+-839 
ATPase, NCX and inositol-1,4,5-trisphosphate receptors. All the latter proteins are known to bind ankyrin-B 840 
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(789). Abnormalities in Na+-K+-ATPase and NCX expression would potentially increase intracellular Na+ 841 
overload and reduce Ca2+ extrusion. The consequent SR Ca2+ overloading might then account for the 842 
abnormal SR Ca2+ release events following adrenergic stimulation. The adult cardiomyocytes 843 
correspondingly showed potentially arrhythmic abnormal intracellular SR Ca2+ transients and EADs and 844 
DADs following adrenergic challenge (788). In vivo ECGs showed prolonged QT intervals and polymorphic 845 
VT episodes.  846 
 Subsequent studies of further mutational variants reported a wide range of clinical phenotypes. These 847 
included bradycardia, VF and AF, though not always QT interval prolongation (790). Ankyrin-B also 848 
associates with Kir6.2, in the complex that includes Na+-K+-ATPase (579). This is consistent with its 849 
possible regulation of IKATP gating which in turn may cardioprotect from ischaemia. Ankyrin B-/- hearts and 850 
cardiomyocytes showed deficient Kir6.2 membrane expression and decreased IKATP. (649). Ankyrin-B in 851 
turn is recruited to the cardiac dyad by the actin associated βII spectrin. The ankyrin-B-p.R990Q mutation 852 
disrupts this interaction causing a severe human arrhythmia phenotype. Correspondingly, βII spectrin-/- 853 
mice showed SND and ventricular arrhythmia associated with afterdepolarisation phenomena and abnormal 854 
Ca2+ waves (1072).  855 
 Disruption of ankyrin B may also clinically predispose to atrial arrhythmias. Ambulant ankyrin-B+/− 856 
mice developed spontaneous atrial arrhythmias. This was attributed to altered interactions with Cav1.2 857 
reducing ICaL and APD (225). They also show evidence of altered pacemaker function (361). 858 
(2) Genetic abnormalities in A-kinase anchoring protein-9 (AKAP-9): LQTS11 859 
 Scaffolding A-kinase anchoring protein subtypes (AKAPs) structurally and functionally link particular 860 
enzyme molecules and their end targets. The latter include ion channels, thereby affecting cardiac myocyte 861 
excitation and contraction (755). Genetic abnormalities in AKAP9, also known as Yotiao, are associated 862 
with LQTS11. AKAP9 complexes with KCNQ1, the type II regulatory subunit (RII) of PKA, and protein 863 
phosphatase 1 (PP1). It thereby conveys PKA to the vicinity of the channel where PKA phosphorylates 864 
serine residue S27 on the KCNQ1 amino terminus. AKAP9 possess two KCNQ1 binding sites located 865 
respectively close to its N- and C- termini. Thus, the AKAP9-G589D mutation near its LZ motif disrupted 866 
both AKAP9-KCNQ1 interaction and functional regulation of IKs by PKA-mediated phosphorylation. A 867 
clinically observed AKAP9-S1570L mutation in the latter region similarly reduced KCNQ1 binding and 868 
phosphorylation. It also diminished cAMP-mediated enhancement of IKs channel activity and prolonged 869 
APD on computational modelling particularly following isoproterenol stimulation (188). AKAP9 thus 870 
mediates sympathetic regulation of IKs channel regulation. Disruption of this produces pathological effects 871 
that may include LQTS (187, 746). 872 
(H) Short QT syndromes (SQTS) 873 
 SQTSs (388) are characterised by often familial occurrences of shortened electrocardiographic QT 874 
intervals (<∼320 ms) and peaked T-waves despite normal cardiac anatomy (874). They are clinically 875 
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associated with syncope, shortened AERPs and VERPs and increased atrial and ventricular 876 
arrhythmogenicity potentially causing SCD (359). The known genetic SQTS variants complement some of 877 
the genetic changes in LQTS. SQTS1-3 result from gain-of-function K+ channel mutations in KCNH2, 878 
KCNQ1 and KCNJ2 encoding α-subunits mediating IKr (149), IKs (93) and IK1 respectively (257). SQTS4–879 
SQTS6 result from loss-of-function CACNA1C, CACNB2b (34) and CACNA2D1 mutations (1116). These 880 
involve L-type Ca2+ channel α1C, β2b and α2δ-1- subunits respectively. Future studies on these will likely 881 
yield important insights on arrhythmogenic mechanisms complementing those derived from LQTS models. 882 
Available physiological analysis applying K+ channel openers in LV wedge preparations implicated 883 
increased transmural repolarisation dispersions and shortened VERP as arrhythmogenic substrate (873).  884 
 A murine SQTS model with increased Kir2.1 expression and therefore increased IK1 showed shortened 885 
QT intervals and APDs (841). This was accompanied by bradycardia, extrasystoles, atrioventricular block 886 
and atrial flutter (651) as well as ventricular arrhythmias (893). These included prolonged episodes of high 887 
frequency VT (841). Recent computational analysis replicated QT interval shortening in hERG-N588K 888 
SQTS1 and Kir2.1-D172N SQTS3 mutations, modelling experimental data from recombinant WT and 889 
hERG-N588K channels (7, 8, 257, 464, 911, 1326, 1328). These predicted increased tissue vulnerability to 890 
premature stimuli and an increased tendency to formation of re-entrant excitation waves (7). 891 
VII. ARRHYTHMIC CONSEQUENCES OF ALTERED CA2+ HOMEOSTASIS 892 
(A) Effects of cellular Ca2+ homeostasis on myocyte electrophysiology.  893 
(1) Modulation of the excitation-contraction coupling process 894 
 The process of contractile activation following membrane excitation brought about by the ion 895 
channel function discussed in previous sections begins with a voltage-triggered, L-type Ca2+ channel-896 
mediated, influx of extracellular Ca2+ (Figure 1A, C). This locally increases [Ca2+]i in the vicinity of each 897 
individual L-type Ca2+ channel and its nearby RyR2s. A Ca2+-induced Ca2+ release then initiates Ca2+ release 898 
sparks. The amplitudes of these are graded with that local Ca2+ current flow (193, 1092). A nonregenerative, 899 
spatial and temporal, graded, summation of such unit events makes up the resulting [Ca2+]i transient (480, 900 
1226). The consequent increase in [Ca2+]i turn drives the Ca2+ binding to troponin that initiates myofilament 901 
mechanical activity (see Section I(B)(2)).  902 
 The released Ca2+ is subsequently returned from the cytosol to the SR for resequestration by 903 
calsequestrin. This transport process is mediated by a phospholamban (PLN)-regulated SERCA2a. Ca2+ is 904 
also returned to the extracellular space by two major routes. The electrogenic NCX provides a low affinity 905 
and a high capacity transporter (129, 265). In contrast, the PMCA, for which translocation of 1 Ca2+ is 906 
coupled to hydrolysis of one ATP, acts as a high affinity (Km 100 ~ 200 nM) low capacity transporter 907 
effective even at the normally very low [Ca2+]i (143) (see Section I(B)(3)).  908 
 The molecules involved in the above sequence can undergo modifications in response to extrinsic 909 
physiological demands. Kinase-mediated protein phosphorylation exerts strategic regulatory effects on 910 
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myocyte excitation-contraction coupling, metabolism, intracellular Ca2+ homeostasis, mitochondrial 911 
function and protein transcription. This can be driven by upstream β-adrenergic signalling. This stimulates G 912 
proteins (Gs) that activate adenylate cyclise. The latter in turn increases cellular cAMP levels. cAMP 913 
dissociates the inhibitory regulatory (R) subunit (R subunit) from PKA. The resulting PKA activation 914 
phosphorylates multiple proteins involved in cardiac excitation, contraction and relaxation dynamics (see 915 
Section VII(B)(1)) (544). This may account for the multiple, inotropic, chronotropic and lusitropic effects of 916 
cAMP signalling (103) (Figure 14A).  917 
 Thus, PKA-mediated phosphorylation of the C-terminal tail region of the Cav1.2, L-type Ca2+ channel 918 
modifies both the ventricular AP plateau phase as well as SAN pacemaker potentials. That of RyR2 reduces 919 
the binding of a highly expressed regulatory cis-trans peptidyl prolyl isomerise, FK506 binding protein type 920 
12.6 (FKBP12.6), whose binding to RyR2  normally stabilises its closed state. This FKBP12.6-RyR2 921 
dissociation increases the Ca2+ sensitivity of RyR2-mediated release of SR Ca2+. Hyperphosphorylation 922 
inducing leaky channels may occur in pathological situations of sympathetic overactivity, as may occur in 923 
cardiac failure (see Section VII(C)(7)) (729, 730, 747, 1239, 1241). Phosphorylation of PLN removes its 924 
inhibition of SERCA2 in its re-uptake of previously released cytosolic Ca2+ (544).   925 
 The protein phosphatases PP1 and PP2A conversely mediate protein dephosphorylation. This often 926 
takes place at the same protein substrates and serine/threonine sites as catalysed by PKA (704). PP2A acts 927 
preferentially on L-type Ca2+ channels reversing the β-adrenergic effects of PKA (405). Its actions are up-928 
regulated with stimulation of inhibitory G proteins, Gi, through other signalling processes (547). In saponin-929 
permeabilised cardiomyocytes, both PP1 and PP2A increased frequencies of spontaneous Ca2+ sparks. This 930 
was followed by a disappearance of such events, reflecting the consequent SR Ca2+ store depletion. These 931 
effects were inhibited by the PP1 and PP2A phosphatase inhibitors okadaic acid and calyculin A (89, 1119). 932 
PP1 caused dephosphorylation of the SERCA2a inhibitor PLN with a consequent reduction in SERCA2a 933 
activity. PP2A also reduced Cx43 conductivity (see Section VII(G)) (14, 636). 934 
 An alternative or co-existent, PKA-independent, mechanism of cAMP-dependent catecholaminergic 935 
signalling may offer a further level of adrenergic control. This occurs downstream of β-adrenergic receptor-936 
dependent cAMP generation but upstream of Ca2+-induced Ca2+ release (See Section VII(B)(2)) (Figure 937 
14B). It involves signalling by cAMP-dependent, exchange proteins directly activated by cAMP (Epac) 938 
(541, 962). Of Epac isoforms, Epac1 contains a single cAMP-binding domain and appears to be ubiquitously 939 
expressed. Epac2 contains two cAMP-binding sites and occurs preferentially in brain, pituitary, and adrenal 940 
gland (134, 962). Cardiac Epac1 forms part of the macromolecular regulatory complex for RyR2 possibly 941 
through RyR2-Epac functional coupling along with the muscle-specific A-kinase anchoring protein 942 
(mAKAP) and PKA (437). Use of a novel fluorescent Epac analogue has differentially localised Epac1 and 943 
Epac2 to the nucleus and the Z lines respectively in cardiomyocytes, consistent with their having separate 944 
intranuclear and calcium homeostatic roles (885). 945 
(2) Direct and indirect physiological effects of modified Ca2+ homeostasis. 946 
83 
 
 Modifications in [Ca2+]i and Ca2+ homeostasis in turn affect strategic molecules that may further 947 
modify the Ca2+ homeostatic processes themselves, alter potentially electrogenic transmembrane ion fluxes 948 
or modify particular enzymic signalling sequences. These in turn potentially directly or indirectly modify 949 
membrane excitation and stability with potential arrhythmogenic consequences (556, 1210). These 950 
modifications can result from direct actions of Ca2+ itself. Alternatively, they could involve mechanisms 951 
directly or indirectly involving a wide possible range of intracellular targets. Besides PKA and protein 952 
kinase C (PKC), the latter include CaM and calcium/calmodulin kinase II (CaMKII) (166). Both CaM and 953 
calcium/calmodulin kinase II (CaMKII) may sense local [Ca2+] through Ca2+ binding to EF-hand motifs at 954 
the N- and C-terminals of calmodulin (CaM). The binding results in formation of a Ca2+/CaM complex. This 955 
then binds to the CamKII regulatory domain. The binding relieves the baseline action of the CaMKII 956 
autoinhibitory domain. Thr-287 autophosphorylation then preserves the resulting activated state even 957 
following return of [Ca2+] to its resting level, until a phosphatase-mediated dephosphorylation (29). 958 
 CaMKII is a multifunctional serine/threonine kinase that exists in cardiomyocytes as various splice 959 
variants of its δ isoform, CaMKIIδ (29). These variants have a wide range of downstream targets. 960 
Cytoplasmic CaMKIIδ2 (CaMKIIδC) is localised close to, and associates with, L-type Ca2+ channels and 961 
RyR2. Further CaMKII subpopulations occur in the intercalated disc and mitochondria (1103). These act 962 
upon PLN, Nav1.5, and multiple voltage-gated and ATP sensitive K+ and Cl- channels (468, 898). Kinase-963 
mediated protein phosphorylation thus exerts strategic regulatory effects in myocyte excitation-contraction 964 
coupling, metabolism, intracellular Ca2+ homeostasis, mitochondrial function and protein transcription (see 965 
Section VII(B)(5) and VII(F)). As detailed below, these actions perturb the balance between inward ICaL and 966 
outward IK currents determining cardiac AP plateau durations (24) and modify intracellular Ca2+ in turn 967 
modifying CaM and CaMKII activity (898).  968 
(3) Effects on Ca2+ release and its triggering 969 
 These direct and indirect regulatory mechanisms potentially alter both the triggering and the Ca2+ 970 
release process itself through effects on ICa, (see Section VII(B)(1)) and on the RyR2-Ca2+ release channel 971 
(Figure 14C) (see Section VII(B)(3)). Increased subsarcolemmal [Ca2+] exerts rapid negative feedback 972 
inhibitory effects on ICaL. These take place in addition to, and over much more rapid timecourses compared 973 
to, the slow voltage-mediated inactivation of ICaL following its initial activation by the AP upstroke (1067). 974 
The feedback effects likely entail Ca2+ binding to CaM itself prebound to the L-type Ca2+ channel C-975 
terminal (641). In contrast, Ca2+-free CaM reduces L-type Ca2+ channel inactivation (897). The resulting 976 
Ca2+/CaM then interacts with a closely located IQ domain. This in turn blocks the inner pore of the L-type 977 
Ca2+ channel (712). This mechanism potentially provides a mechanism by which Ca2+ either entering from 978 
the extracellular fluid or released from the SR exerts a normal negative feedback inactivating L-type Ca2+ 979 
channel activity. Such an action would normally prevent Ca2+ overload.  980 
 Increased [Ca2+]i may also potentiate ICaL. This may also involve a Ca2+ binding to CaM. This in turn 981 
activates CaMKII which then promotes phosphorylation of the C-terminal of the L-type Ca2+ channel α1-982 
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subunit (27, 1311). Moderate increases in [Ca2+]i following repetitive stimulation do produce such a 983 
calmodulin-mediated CaMKII activation (1311). Recovery from Ca2+-mediated ICaL inactivation then 984 
requires a fall in subsarcolemmal [Ca2+] typically brought about by the NCX, whose activity is also voltage-985 
dependent. These mechanisms together result in complex interactions between L-type Ca2+ channel and 986 
NCX activity, membrane potential and intracellular Ca2+ (341). 987 
 RyR2s also show Ca2+-dependent adaptation and inactivation properties dependent upon separate 988 
mechanisms sensing both local cytosolic and SR intraluminal [Ca2+]. These may involve luminal (L-) (KD = 989 
~60 µM), cytoplasmic (A-) (KD = ~0.9 µM) activation sites, and a cytoplasmic Ca2+ inactivation (I2-) site 990 
(KD = ~1.2 µM). Regulation by luminal and cytoplasmic [Ca2+] are closely related. L-site activation 991 
produces brief (1 ms) <10/s openings. These nevertheless give luminal Ca2+ access to the A-site whose 992 
occupancy by Ca2+ produces considerable longer openings. They also give access to the I2 site, which 993 
inactivates the RyR2 at high Ca2+ turnovers. In addition, luminal Mg2+ (at ~1 mM) is essential for the 994 
control of SR excitability in inhibiting cardiac muscle RyR2 but not skeletal muscle RyR1. It competes with 995 
Ca2+ for the L-site (Review: (622)). In consequence, alterations in cytosolic Ca2+ influence the triggering of 996 
RyR2-mediated Ca2+ release. SR luminal Ca2+ levels also influence the Ca2+ available for, and the extent of 997 
SR Ca2+ release, and the likelihood of spontaneous and propagated release phenomena. RyR2-Ca2+ release 998 
channels also show inactivation/adaptation phenomena dependent upon the level and the rate of Ca2+ 999 
increase (394). Finally, Ca2+-free CaM decreases RyR2 open channel probabilities by ~60%, effects 000 
reversible by Ca2+ itself (898) and CaMKII action results in RyR2 phosphorylation promoting release of SR-001 
Ca2+ (1243). 002 
 Finally, significant increases in [Ca2+]i (to >320–560 nM) could close gap junctions mediating 003 
intercellular coupling (389, 756, 839, 1074).  004 
 (4) Effects on cellular Ca2+ efflux processes 005 
 As indicated above, NCX extrudes much of the L-type Ca2+ channel-mediated Ca2+ entry. A smaller 006 
part is transported by plasma membrane Ca2+-ATPase. NCX activity is electrogenic: it transports 3Na+ in 007 
exchange for one Ca2+ (129, 265). The direction of its current flow depends on the Na+ and Ca2+ gradients, 008 
and the membrane potential, Em. Thus, INCX is inwards and depolarising when Ca2+ is extruded, and 009 
outwards and hyperpolarising with Ca2+ influx. Consequently, increased diastolic [Ca2+]i potentially 010 
activates transient inward currents (Iti) mediated by a forward mode NCX-mediated Na+ influx (101, 354). 011 
This could cause premature sarcolemmal depolarisation and a consequent triggered activity which causes 012 
systolic dysfunction and increases arrhythmic tendency (see Section VII(B)(4) and VII(C)(4)) (903). It is 013 
also possible that increased SR Ca2+ leak into the restricted space of the dyadic cleft could increase local 014 
NCX activity removing the resulting increased local Ca2+. This in turn would correspondingly increase local 015 
[Na+]i potentially reducing the driving force for Na+ entry through nearby Na+ channels, and the resulting INa 016 
(124, 666).  017 
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 Both heart failure and hypertrophic cardiomyopathies are associated with increased spontaneous SR 018 
Ca2+ leak (13, 226, 864). An increased SR Ca2+ would then activate inward depolarising NCX-mediated 019 
current. If sufficiently large, such transient inward currents (Iti) could initiate pro-arrhythmic spontaneous 020 
DAD phenomena (106). Human cardiac heart failure is also associated with a decreased INa (1164). The 021 
consequent reductions in CV could similarly increase susceptibility to AF (362). 022 
 Finally, PMCA activity is enhanced by Ca2+/calmodulin and calmodulin binding (143). 023 
 (5) Effects on Nav1.5 function and expression 024 
 Several studies suggest that altered cytosolic Ca2+ also more directly modifies either Nav1.5 function 025 
(15, 51, 1112) or expression (196, 282, 1114) (see Section VII(C)(6)). The functional effects may involve 026 
direct and/or indirect Ca2+ binding to Nav1.5 itself. Direct Ca2+ binding can take place at an EF hand motif 027 
close to the Nav1.5 carboxy-terminal. This shifted the voltage dependence of Na+ channel inactivation in a 028 
positive direction, potentially increasing Na+ channel activity (1265). Indirect Ca2+ binding involves an 029 
additional binding site, the ‘IQ’ domain, for Ca2+/CaM in the Nav1.5 C-terminal region, or multiple 030 
phosphorylatable sites, including serines 516 and 571, and threonine 594, in the DI-II linker region which is 031 
targeted by CaMKII (368, 799, 1211).  032 
 These two mechanisms both require prior Ca2+ binding to the EF hand motifs of Ca2+/CaM or 033 
CaMKII. They shift INa activation in a positive direction along the voltage axis (51). They also enhance slow 034 
INa inactivation (1112). Thus,. increased pipette [Ca2+] reduced INa density and (dV/dt)max in patch-clamped 035 
myocytes (168). Increased and decreased [Ca2+]i following increasing extracellular [Ca2+] and the 036 
acetomethoxy ester, BAPTA-AM, respectively increased and decreased INa densities in cultured neonatal rat 037 
myocytes whilst sparing unit Na+ channel conductance or gating (196). The Ca2+ channel antagonist, 038 
verapamil and the Ca2+ ionophore, calcimycin, respectively increased and decreased Nav1.5 mRNA and 039 
Nav1.5 protein expression in rat cardiomyocytes (282, 850, 1114). Such properties appeared specific to 040 
cardiac as opposed to skeletal muscle Na+ channels (260, 1308). However, recent rapid Ca2+ photorelease 041 
methods did not induce Ca2+ modulation in Nav1.5, but did so in Nav1.4 (96).  042 
 Further, more indirect, interactions, that may in particular influence INaL (see Section VI(B)(1)), may 043 
involve protein subunits associated with the Na+ channel. CaMKII associates with a C-terminal motif in 044 
actin-associated βIV-spectrin protein. The latter is strongly homologous to a binding domain within the L-045 
type Ca2+ channel β subunit that has been invoked in the increased open probability and mean open time 046 
following channel phosphorylation (105, 1103). The CaMKII/βIV-spectrin interaction also operated in 047 
CaMKII-mediated phosphorylation of those voltage-gated Na+ channels residing at the cardiomyocyte 048 
intercalated disc (467, 716). This may mediate the modulation of steady-state Na+ channel inactivation, 049 
recovery from inactivation, and the magnitudes of INaL components observed in heterologous cells and 050 
primary myocytes. These actions likely involve separate Nav1.5 modulation pathways (467, 1209). 051 
(6) Effects on repolarisation processes  052 
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 Alterations in both [Ca2+]i and its consequent phosphorylation levels thus modulate both ICaL and INa 053 
and therefore action potential propagation and plateau duration respectively. These alterations also affect 054 
membrane processes related to recovery from excitation. These may similarly have potential arrhythmic 055 
effects. Guinea-pig ventricular APs do not involve K+-mediated Ito: its function may be replaced by a Ca2+-056 
activated Cl- current in turn activated by SR Ca2+ release (1067). In addition, IKs is enhanced by increased 057 
[Ca2+]i (1136), α- or β-adrenergic stimulation, or PKC activation (1213). IKr is increased by PKA likely 058 
through increased [Ca2+]i and PKC activation, primarily through altering its inward rectification properties 059 
(418). Modelling studies suggested that changes in IKs modify APD restitution to a greater extent than 060 
changes in IKr, although the ratio between the two currents is likely important. Spatial variations in the 061 
magnitude of these currents across the myocardium may also influence their restitution properties. This 062 
would be particularly the case in areas with steeper AP repolarisation slopes including subendocardial M-063 
cell layer, with possible implications for altered Ca2+ homeostasis upon restitution properties (752, 753, 064 
1201). 065 
 Of membrane transporters, the Na+-K+-ATPase is maximally activated at physiologically occurring K+ 066 
concentrations. Instead, it is intracellular Na+ concentration, in turn dependent upon INa and NCX activity, 067 
that may limit its activation. However, Na+-K+-ATPase activity is also increased by its phosphorylation by 068 
PKC following adrenergic stimulation or increased Ca2+ (Gao et al., 1992). Na+-K+-ATPase activity is thus 069 
stimulated by β- and α-adrenergic receptor activation and increased [Ca2+]i (340). NCX in turn is 070 
energetically dependent upon transmembrane Na+ gradients and therefore Na+-K+-ATPase activity.  071 
(B) Acquired arrhythmic disorders associated with altered cellular Ca2+ homeostasis 072 
(1) Ventricular arrhythmic effects of β-adrenergic activation. 073 
 Abnormal cellular Ca2+ homeostasis is accordingly implicated in a wide range of arrhythmic 074 
pathologies. Cardiac failure and hypertrophy exemplify acquired conditions associated with arrhythmic 075 
phenomena (1244, 1299). Of these, cardiac failure is associated with chronically elevated adrenergic 076 
receptor mediated cellular signalling (1238, 1242). In common with the inherited condition of CPVT, it has 077 
been analysed in terms of schemes involving a PKA-mediated phosphorylation of RyR2 serine 2809 (or 078 
serine 2808, depending on species). This increases its open probability (Po) by dissociating FKBP12.6 from 079 
RyR2 (1238). However, there remains uncertainty in the exact phosphorylatable RyR2 sites and the 080 
individual protein kinases involved, whether involving CaMKII or protein kinase G (PKG), and the 081 
functional roles of such phosphorylation (109, 1279).  082 
 At all events, murine systems provide useful models for the acute arrhythmic effects of altered Ca2+ 083 
homeostasis. This extends their utility in studies of the arrhythmic effects of altered ion channel expression 084 
(Sections V and VI). For example, isolated murine hearts recapitulated the effects of β-adrenergic 085 
stimulation and L-type Ca2+ channel blockade both on ventricular arrhythmogenesis in intact Langendorff-086 
perfused hearts and Ca2+ homeostasis in isolated myocytes. Programmed stimulation thus demonstrated 087 
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arrhythmogenic tendencies predisposing to VT following both isoproterenol challenge and elevated 088 
extracellular [Ca2+]. Programmed electrophysiological fractionation analysis suggested that this took place 089 
with normal AP conduction, in contrast to the increased EGDs at shortened S1-S2 intervals in arrhythmic 090 
Kcne1-/- and Scn5a+/- hearts. The latter had then suggested re-entrant as opposed to triggered arrhythmia 091 
(64, 416, 867, 1095).  092 
 These comparisons were consistent with the existence of an arrhythmogenic tendency that could 093 
result from triggered activity. Accordingly, in isolated ventricular myocytes, both isoproterenol and elevated 094 
extracellular [Ca2+] increased the amplitudes of electrically evoked Ca2+ transients as reported in other 095 
cardiac systems (104). Pretreatment with the dihydropyridine or benzothiazepine L-type Ca2+ channel 096 
blockers nifedipine or diltiazem, both suppressed the VT and decreased, and prevented the isoproterenol-097 
induced increases in Ca2+ transient amplitudes (63). Murine hearts thus recapitulate the increased inward ICaL 098 
and consequently SR Ca2+ uptake, in turn producing spontaneous SR Ca2+ release and increased Iti with β-099 
adrenergic stimulation (905).  100 
(2) Ventricular arrhythmic effects of Epac activation 101 
 Murine systems also permitted an examination of the effects of Epac pathway activation on cardiac 102 
Ca2+ homeostasis, electrophysiological properties and arrhythmic tendency (see Section VII(A)(1)). Of Epac 103 
isoforms, Epac1 is localised and functionally involved in nuclear signalling. Epac2 is located at the 104 
transverse tubules and may regulate arrhythmogenic SR Ca2+ leak (885). Baseline basal [cAMP] and Epac 105 
activation levels appeared low in adult ventricular myocytes in the absence of β-adrenergic activation. 106 
Murine Epac1-/-, Epac2-/- and CaMKIIδ-/- hearts showed normal in vivo baseline cardiac structure, ratios 107 
of heart to body weight or early pressure overload–induced hypertrophy. They also showed normal 108 
physiological indices of ventricular ejection, heart rate and LV pressure indices. All these indices 109 
furthermore showed normal responses to dobutamine challenge. Western blot studies revealed normal 110 
SERCA and NCX expression levels. Isolated Epac1-/- and Epac2-/1 myocytes showed normal Ca2+ 111 
transient amplitudes and decline timecourses, SR Ca2+ content, NCX function and diastolic Ca2+ spark 112 
frequency when normalised to SR Ca2+ load (883). 113 
 RyR2 activation produced by Epac activation that is independent of PKA action was attempted using 114 
8-(4chlorophenylthio)-2’-O-methyladenosine 3’, 5’-cyclic monophosphate (8-CPT). Low (1 μM) as opposed 115 
to high (100 μM-1 mM) 8-CPT concentrations provide a specific >300-fold efficacy in activating Epac 116 
rather than PKA (437). In Langendorff-perfused mouse WT hearts, this produced arrhythmic effects often 117 
resulting in triggered activity and VT (446). 8-CPT also increased the frequencies of spontaneous cytosolic 118 
Ca2+ transients in neonatal rat cardiac myocytes (798), amplitudes of electrically evoked Ca2+ transients in 119 
mouse ventricular myocytes (849), and frequencies of Ca2+ sparks in isolated rat ventricular myocytes (884). 120 
There were also associated Ca2+ homeostatic abnormalities observable in isolated cardiomyocytes (446). 121 
There was thus a propensity to generate the spontaneous Ca2+ waves previously associated with cardiac 122 
arrhythmogenesis triggered by Iti resulting in DADs (Figure 15A,B) (101, 903). There were also increased 123 
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incidences of ectopic Ca2+ release in both paced and resting cells (Figure 15Ca,b). These were abolished by 124 
treatment with the CaMKII inhibitor KN-93 (Figure 15Cc). 125 
 At the level of intact Langendorff-perfused murine hearts, challenge by either 8-CPT or a combination 126 
of isoproterenol and the PKA inhibitor H-89 (808) increased the incidences of VT provoked by programmed 127 
electrical stimulation (Figure 15D). It also increased incidences of triggering events following AP activation 128 
(Figure 15E). In contrast, spatial electrophysiological ventricular heterogeneities whether in the form of 129 
epicardial or endocardial APD90, transmural or apico-basal gradients of repolarisation, or of VERP, 130 
remained unchanged (Figure 15F). Temporal AP properties in the form of maximum APD90 restitution 131 
gradients also remained normal (446). These findings provide clearcut contrasts with the altered, negative, 132 
ΔAPD90s and altered restitution properties thought to mediate arrhythmogenesis through the resulting re-133 
entrant substrate in the murine congenital LQTS and hypokalaemic models described above (Sections VI 134 
(B)-(D) and Section VI (E)) (561, 1128, 1130).  135 
 Both the cellular effects of Epac on Ca2+ homeostasis, and its arrhythmic effects in intact hearts were 136 
reduced by CaMKII inhibition using 1 μM KN-93. This was consistent with a dependence of Epac action on 137 
CaMKII activity (446). Finally, genetic ablation of Epac2, β1-AR, CaMKIIδ and RyR2-S2814 138 
phosphorylation all abolished Epac-dependent arrhythmogenic effects. These findings implicate Epac2 in 139 
β1-adrenergic arrhythmias through mechanisms involving CaMKIIδ and RyR2-S2814 phosphorylation 140 
(883).  141 
(3) Ventricular arrhythmic effects of direct RyR2-SR Ca2+ release channel activation 142 
 Interventions directly opening RyR2-Ca2+ release channels (1139) employed either caffeine or the 143 
immunosuppressant FK506 known to alter RyR2-FKBP12.6 binding (142, 527, 618, 1282, 1300). These 144 
also altered myocyte Ca2+ homeostasis and exerted arrhythmogenic effects in murine hearts (62). This 145 
agrees with previous reports in canine and rabbit hearts in vivo (481, 762). Programmed electrical 146 
stimulation confirmed that these proarrhythmic effects took place under conditions of normal conduction 147 
(62).  148 
 Caffeine either conserved or reduced the amplitudes of regularly evoked cytosolic [Ca2+] transients in 149 
isolated mouse myocytes consistent with a partial SR Ca2+ depletion (62). The latter would parallel the 150 
reduced myocyte SR Ca2+ in human heart failure (665). Both caffeine and FK506 increased the frequencies 151 
of spontaneous periodic peaks resulting from propagating Ca2+ waves (62) associated with SR Ca2+ loading 152 
by increased extracellular [Ca2+] (263, 1139, 1258). The latter effect is thought to result from increased Ca2+ 153 
spark frequency and to trigger arrhythmia (325) through activated NCX (760). These effects were abolished 154 
by the RyR inhibitor tetracaine.  155 
 However, diltiazem but not nifedipine prevented VT following programmed electrical stimulation in 156 
caffeine treated hearts (1300). It also abolished the effects of both caffeine and FK506 upon the frequency of 157 
spontaneous Ca2+ release events. These findings correlate well with findings that diltiazem but not 158 
nifedipine inhibited RyR2-mediated SR Ca2+ leak in canine SR vesicles after addition of FK506 (1300) in 159 
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addition to their L-type Ca2+ channel block (64). Such Ca2+ wave phenomena have also been observed in 160 
skeletal muscle under conditions of dihydropyridine receptor-RyR1 decoupling. These showed similar 161 
pharmacological sensitivities to caffeine, L-type Ca2+ channel block and tetracaine challenge (183). 162 
 Cyclopiazonic acid (CPA) inhibits the activity of SR Ca2+-ATPase (SERCA) (1035) by blocking its 163 
Ca2+ channel (794). It inhibits SERCA activity in myocardial vesicle preparations (1032) whilst sparing Ca2+ 164 
sensitivity in contractile myofilaments, Ca2+ currents and NCX activity (1107, 1302). It would therefore be 165 
expected to produce delayed reductions in SR Ca2+. CPA (100 and 150 nM) accordingly produced delayed 166 
rather than immediate reductions in Ca2+ transients in regularly stimulated fluo-3 loaded isolated myocytes. 167 
It correspondingly antagonised arrhythmic effects of isoproterenol, elevated extracellular [Ca2+] or caffeine. 168 
However, it did so only when the latter agents were added following rather than simultaneously with 169 
introduction of CPA. Both this introduction of arrhythmia and its rescue occurred without appearance of re-170 
entrant substrate, MAP waveforms or VERPs (351). 171 
(4) Ventricular arrhythmic effects of purinergic receptor activation 172 
 Murine models also modelled the arrhythmic effects of extracellular fluid alterations resulting from 173 
metabolic change in surrounding tissue. A number of these may produce arrhythmia through Ca2+-dependent 174 
mechanisms. For example, both in normal and ischaemic cardiac cells, sympathetic nerve terminals release 175 
ATP (934). Conversely, ventricular myocytes express both ionotropic P2X receptors and G-protein-coupled 176 
P2Y receptors (1176). Cardiac ischaemia is often accompanied by elevated interstitial [ATP] (165) and is 177 
often also associated with ectopic beats and VT. Extracellular ATP induced oscillatory contractions and 178 
ectopic APs (203) in isolated ventricular myocytes which additionally then showed after-depolarisations 179 
with isoprenaline challenge (1079). Similarly, Langendorff perfused murine hearts showed ectopic beats and 180 
VT (386) with challenge by extracellular ATP levels (~100-μM) close to those previously reported under 181 
pathological conditions. Such findings did not occur with adenosine and uridine-5'-triphosphate (UTP). 182 
(213).  183 
 These findings implicated P2 purinergic rather than adenosine-activated P1 or UTP-activated P2 184 
receptors. Thus, ATP correspondingly induced sustained increases in diastolic Ca2+ and triggered Ca2+ 185 
waves that possessed relatively early (10-20 s) rather than prolonged (~min) onsets. Single cell voltage-186 
clamp experiments demonstrated ATP-activated multiple cationic inward currents. These showed positive 187 
reversal potentials as expected of the Ca2+ (1 mM) rather the monovalent (Na+ and Cs+) ion concentrations 188 
in which the isolated ventricular myocytes were studied. All these arrhythmic, Ca2+ homeostatic and 189 
electrophysiological, effects were antagonised by the P2 receptor antagonists suramin and 190 
pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid (PPADS). These observations are consistent with a 191 
Ca2+ influx following P2X receptor opening. These currents could induce arrhythmogenic changes in resting 192 
membrane potentials. APs induced by repetitive (2 Hz) current clamp steps in the presence of ATP (100 193 
μM) were followed by oscillatory resting membrane potential changes, DADs and triggered ectopic APs  194 
and EADs, and themselves were frequently prolonged (386).  195 
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 In contrast, metabotropic P2Y receptors are mainly coupled to Gq-proteins. They then activate PKC 196 
through phospholipase C-dependent production of diacylglycerol (DAG) (157). PKC in turn can target L-197 
type Ca2+ channels, RyR2s, and voltage-gated Na+ and K+ channels. ADP (100 μM), associated with P2Y 198 
receptor activation, did not produce even delayed (>3 min) diastolic Ca2+ elevations. However, its 199 
application was followed by gradual declines in diastolic Ca2+ and [Ca2+]i transients. Its sustained 200 
application (>3–5 min) resulted in prolonged waveforms of Ca2+ transients induced by field stimulation. 201 
There was then an ultimate failure of subsequent stimulation to induce [Ca2+]i transients. These changes 202 
persisted even following ADP washout (386).  203 
(5) Ventricular arrhythmic effects of acidotic stress. 204 
 Murine hearts also recapitulated the acute arrhythmic effects tht followed the imposition and 205 
withdrawal of acidotic challenge. These effects showed features consistent with altered Ca2+ homeostasis 206 
involving CaMKII action (860). This may be important in ischaemia/reperfusion injury. Intracellular 207 
acidosis is then a component of the ischaemia. The reperfusion that follows produces rapid return of pH to 208 
its background value. Cell acidification is also an early accompaniment to acute myocardial ischaemia 209 
(1168). Such acidication produced both arrhythmogenic effects (860) and increased CaMKII activity (466, 210 
586).  211 
 MAPs recorded from Langendorff-perfused rat and mouse hearts subject to imposition followed by 212 
withdrawal of respiratory acidosis showed ectopic beats. Their frequency was reduced by the CaMKII 213 
kinase inhibitor KN-93, the SR uptake inhibitor thapsigargin and the RyR2 SR Ca2+ release blockers 214 
ryanodine and dantrolene (992). They were not observed in transgenic mice expressing a Ca2+/calmodulin-215 
dependent kinase II inhibitory peptide targetted to cardiac longitudinal SR (507). The acidosis increased 216 
phosphorylation of the Thr17 site of phospholamban (PT-PLN) increasing SR Ca2+ load. KN-93 inhibited the 217 
latter effect. The ectopic activity was triggered by DADs, particularly in epicardial myocytes. The latter was 218 
also prevented by KN-93.  219 
 Acidification also produced spontaneous SR Ca2+ release, spontaneous AP firing and triggered 220 
arrhythmias (264). It increased the amplitudes of caffeine-induced Ca2+ transients that were abolished by 221 
KN-93 (586). These were attributed to increased NCX activity in response to Ca2 + leak from an overloaded 222 
SR likely due to CaMKII-dependent increase in SR Ca2 + uptake (860). Thus, arrhythmias following acidosis 223 
result from a CaMKII activation that increases SR Ca2+ load occurring mainly through from increased PT-224 
PLN activity. 225 
 MAP recordings from Langendorff-perfused whole murine heart preparations could be performed in 226 
parallel with single whole-ventricular myocyte AP and Ca2+ fluorescence measurements under acidotic 227 
stress conditions. These made it possible to separate CAMKII-dependent and CAMKII-independent 228 
contributions to the arrhythmic changes following metabolic acidification (879). Lactate challenge induced 229 
spontaneous arrhythmogenesis in both intrinsically active and regularly paced Langendorff-perfused murine 230 
hearts. It also induced spontaneous Ca2+ waves in isolated intact Fluo-4-loaded myocytes. Both these effects 231 
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were reversibly abolished by KN-93. Acidification also produced spontaneous AP firing and membrane 232 
potential oscillations in isolated ventricular myocytes whose patch pipette solutions permitted [Ca2+]i to 233 
increase. Both KN-93 and use of EGTA-buffered pipette solutions holding cytosolic [Ca2+]i constant during 234 
the acidosis abolished the latter effects. Together these findings implicate CaMKII-dependent waves of SR 235 
Ca2+ release in spontaneous arrhythmic events during metabolic acidification.  236 
 However, programmed electrical stimulation similarly induced VT during metabolic acidification. 237 
This correlated with appearance of an arrhythmic substrate resulting from reduced LV transmural 238 
repolarisation gradients that resulted from prolongations of epicardial but not endocardial APD90. However, 239 
these latter parameters were KN-93-resistant both before and following acidification. Thus, agents inhibiting 240 
CaMKII action reduced AP triggering whilst sparing the associated arrhythmic substrate produced by cell 241 
acidification (879).  242 
 (6) Roles of Ca2+ in acute atrial arrhythmogenesis 243 
 Mechanisms initiating AF are incompletely understood. Nevertheless, significant contributions to 244 
these may arise from alterations in cellular Ca2+, particularly diastolic, signalling. These could involve 245 
release of Ca2+ from nevertheless finite SR Ca2+ stores, a process induced by an initial extracellular Ca2+ 246 
entry (1202). The resulting increase in NCX activity might then result in EAD or DAD phenomena initiating 247 
focal firing. Acute episodes of acquired atrial arrhythmias can follow cardiothoracic, particularly coronary 248 
artery bypass grafting surgery, typically at ~2 but rarely beyond 7–15 postoperative days. They are reduced 249 
by either β-adrenoceptor or Ca2+ channel antagonism (60). Sustained arrhythmia may require re-entrant 250 
substrate that might arise from altered balances between conduction velocity (θ) and refractory period (269, 251 
819, 822). Such substrate may develop following physiological and anatomical remodelling (184, 269, 270, 252 
451, 658, 923, 1194). 253 
 Murine WT Langendorff-perfused hearts recapitulated these roles of altered Ca2+ homeostasis in 254 
producing acute acquired atrial arrhythmias. They related these arrhythmias to an occurrence of diastolic 255 
Ca2+ events in isolated atrial myocytes. It was then possible to pharmacologically separate the contributions 256 
from altered SR Ca2+ storage or release, and extracellular Ca2+ entry, in this initiation (1338). These studies 257 
thus implicated an increased Ca2+-induced Ca2+ release from a nevertheless finite SR Ca2+ store ultimately 258 
dependent upon entry of extracellular Ca2+ in such arrhythmogenesis.  259 
 Thus, in isolated Langendorff-perfused hearts, caffeine exerted atrial pro-arrhythmic effects 260 
immediately following but not >5 min after application. Regularly-stimulated atrial myocytes then 261 
correspondingly showed diastolic Ca2+ waves and progressive reductions in their evoked Ca2+ transients and 262 
these diastolic events with prolonged exposure (1338). Both findings are directly explicable in terms of 263 
increased Ca2+ release through sensitised SR RyR2-Ca2+ release channels from a finite and therefore 264 
depletable intracellular Ca2+ store (1187). The arrhythmic phenomena associated with caffeine challenge 265 
could thus be abolished by pretreatment with either the SERCA inhibitor CPA or the ICaL blocker nifedipine 266 
(1338). At the cardiomyocyte level, CPA applied by itself, produced successive reductions in the amplitudes 267 
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of evoked Ca2+ transients. Use of nifedipine as a ICaL blocker implicated a dependence of extracellular Ca2+ 268 
entry on these effects (1048, 1142). Thus, nifedipine by itself promptly reduced the evoked Ca2+ transients. 269 
These again increased then declined in amplitude with caffeine challenge but in an absence of diastolic Ca2+ 270 
events (1338).  271 
 The dependence of acute atrial arrhythmogenesis upon extracellular Ca2+ entry was contrastingly 272 
accentuated by the Ca2+ channel opening agent FPL-64176. This is known to prolong depolarisation-induced 273 
L-type Ca2+ channel opening and slow repolarisation-induced L-type Ca2+ channel closure (306, 1347). FPL-274 
64176 challenge elicited diastolic Ca2+ events in isolated myocytes and atrial arrhythmogenesis intact 275 
perfused hearts. It did so without changing AERP. Both effects were inhibited by pretreatment with 276 
nifedipine, caffeine or CPA. Enhanced extracellular Ca2+ entry thus exerts acute atrial arrhythmogenic 277 
effects nevertheless dependent upon diastolic Ca2+ release (1335).  278 
(C) Genetic abnormalities in the RyR2-SR Ca2+-release channel: catecholaminergic 279 
polymorphic ventricular tachycardia (CPVT) 280 
(1) Clinical features of catecholaminergic polymorphic ventricular tachycardia (CPVT) 281 
 Genetic disorders have also provided useful systems to study how abnormal Ca2+ homeostasis may 282 
cause cardiac arrhythmogenesis (676, 917). One such exemplar of these is offered by the CPVT typically 283 
associated with RyR2 or calsequestrin (CASQ) mutations (786, 1241). An autosomal dominant CPVT is 284 
associated with cardiac RyR2 (916). A recessive variant is associated with homozygous cardiac calsequestrin 285 
(CASQ2) gene mutations (610). CPVT-like conditions are also associated with ankyrin B mutations (790). 286 
RyR2 mutations are also implicated in ARVC type 2 (82, 234, 621, 1135). 287 
 CPVT presents as an occurrence of acute VT on adrenergic stimulation that may degenerate into 288 
potentially fatal VF (175, 913). It typically presents earlier, at age ~7-9 years, than BrS (625). CPVT 289 
patients show relatively normal resting ECGs. However, exercise or catecholaminergic challenge elicits 290 
arrhythmic features that include bi-directional VT with 180 degree beat-to-beat alternations in the QRS axis. 291 
Clinical management involves β-blocker therapy but ~30% of patients require implantable cardioverter 292 
defibrillators (ICDs) (913). Left cardiac sympathetic denervation is considered for intractable arrhythmias 293 
(1261). CPVT has a poor prognosis, particularly in males with a RyR2 mutation. It likely contributes ~15% 294 
of SCD in structurally normal hearts (678, 1123). A third of CPVT patients have family histories of 295 
premature sudden death or stress-related syncope (625). Of these 50-70% show a genetic abnormality (58, 296 
913).  297 
(2) Human and murine RyR2 mutations in CPVT 298 
 Two groups of investigators made the initial identifications of RyR2 mutations in CPVT (613, 916). 299 
Five clinically affected carriers proved to have RyR2-S2246L, RyR2-R2427S, RyR2-N4104K and RyR2-300 
R4497C. Three unrelated Finnish families carried RyR2-P2328S, RyR2-Q4201R and RyR2-V4653F. The 301 
latter abnormalities were accompanied by a 30–33% mortality by age 35 years. RyR2-P2328S was 302 
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associated with normal resting ECGs including normal QTc intervals. 10 of 12 such patients showed 303 
exercise-induced VT. Two were asymptomatic but exhibited abnormalities on clinical testing.  304 
 A large proportion of the >70 RyR2 mutations reported subsequently in CPVT, a number of which 305 
have been replicated in murine models (Table 7), have similarly been base-pair substitutions involving 306 
highly conserved residues. The mutations mainly cluster in three, N-terminal (176–433), central (2246–307 
2504) and C-terminal regions (4104–4653) of the RyR2 gene (1240). ~20 have been studied in vitro (676). 308 
All three regions are represented in murine studies of ventricular properties associated with the RyR2-309 
R420W (851), RyR2-R176Q/+ (534), RyR2-R4496C/+ (172), RyR2-R2474S/+ (1157), and heterozygotic and 310 
homozygotic RyR2-P2328S exemplars respectively (364, 1340). All the murine variants showed normal 311 
structure and histology, despite known associations of RyR2-R176Q with human ARVC2. Finally, studies in 312 
HEK293 expression systems indicate that large deletions encompassing exon 3 in the NH2-terminal RyR2 313 
region remain compatible with continued RyR2 stability and function through insertion of a flexible loop 314 
into the β trefoil domain (119). Ca2+ release then terminates at a lower luminal Ca2+ (1113). 315 
 (3) Electrocardiographic features of murine models with genetically modified RyR2 316 
 Genetically modified RyR2 mouse models recapitulated electrophysiological phenomena associated 317 
with initiation of arrhythmogenesis in CPVT. In vitro studies associated gain-of-function RyR2, and loss-of-318 
function Casq2, mutations with increased SR Ca2+ leakage thereby increasing [Ca2+]i (509, 631). This would 319 
give a situation resembling clinical digitalis toxicity (625). In either case there would be an expected 320 
increase in NCX activity. This would increase Iti that in turn drives DADs. The latter have been suggested to  321 
potentially cause triggered activity where they produce membrane depolarisations attaining the INa re-322 
activation threshold (581, 673). This would particularly affect Purkinje fibres owing to their greater 323 
susceptibility than ventricular myocytes to Ca2+ overload due to their greater Na+ loads and longer APDs 324 
(1174). Clinical arrhythmic activity in both CPVT and digitalis toxicity is thus accompanied by bidirectional 325 
VT reflected in alternating 180° rotations of the electrocardiographic QRS axis between beats (625, 674). 326 
This can then be followed by degeneration into rapid polymorphic VT and VF.  327 
 Electrocardiographic properties of a significant number of these mice expressing variant RyR2 328 
recapitulated these clinical arrhythmic and ECG features. Polymorphic VT and/or bidirectional VT was 329 
observed in ambulant RyR2-R4996C/+ (172, 673) and RyR2-P176Q/+ mice (534) upon combined or 330 
individual epinephrine and caffeine administration, and in RyR2-R2474S/+ mice during treadmill testing 331 
(585, 629, 1157). Endocardial optical potentiometric mapping localised the arrhythmic foci in the RyR2-332 
R4496C/+ to triggered firing alternating between the left and left purkinje bundles. Thus, chemical ablation 333 
of the RV purkinje network converted the bidirectional VT to a monomorphic, wide-QRS, VT (175).  334 
 Episodes of bigeminy and BVT also occurred in anaesthetised heterozygotic RyR2-P2328S/+ 335 
(RyR2S/+) hearts following isoproterenol challenge. They further occurred in anaesthetised homozygotic, 336 
RyR2-P2328S/P2328S (RyR2S/S) hearts in association with multiple ventricular ectopic beats, both before 337 
and following isoproterenol challenge (1334). These findings potentially implicated an involvement of 338 
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purkinje system conduction in CPVT-associated arrhythmia (1016). Thus, before pharmacological 339 
challenge, there was only a single BVT episode amongst 12 RyR2S/S mice. Pharmacological, epinephrine and 340 
caffeine, challenge selectively increased the number of RyR2S/S, but not RyR2S/+ or WT mice showing 341 
arrhythmias in the form of bigeminy, bidirectional, monomorphic or polymorphic VT. In common with 342 
clinical findings, the bidirectional VT appeared as salvos of >4 beat-to-beat 180 degree QRS axis 343 
alternations and bigeminy. They formed repeated occurrences of a ventricular premature complex succeeded 344 
by a normal beat. Polymorphic VT or VF appeared as series of >3 ventricular ectopics with irregular QRS 345 
axes. Monomorphic VT was identified in runs of abnormally shaped ECG complexes nevertheless occurring 346 
with regular rates and rhythms (1340).  347 
(4) Altered Ca2+ homeostasis in murine models of altered RyR2 348 
 The murine models for altered RyR2 consistently showed evidence of abnormal Ca2+ homeostasis. 349 
Murine RyR2-R176Q/+ cardiomyocytes showed higher incidences of spontaneous, nontriggered Ca2+ 350 
oscillations compared to WT both before and following isoproterenol stimulation. Isoproterenol (100 nM) 351 
induced a range of Ca2+ transients. These included slowed decays, spontaneous diastolic transients and 352 
prolonged evoked transients (534). A comparison of Ca2+ transients from regularly stimulated WT, 353 
heterozygotic (RyR2S/+), and homozygotic (RyR2S/S), RyR2-P2328S myocytes similarly suggested altered 354 
Ca2+ release patterns and a resulting SR Ca2+ depletion (364). Thus, WT, RyR2S/+ and RyR2S/S myocytes 355 
showed indistinguishable peak amplitudes in their evoked Ca2+ transients. RyR2S/S myocytes showed 356 
subsidiary events, as well as irregular Ca2+ signalling patterns. Isoproterenol (100 nM) elicited ectopic peaks 357 
and subsidiary events in WT and RyR2S/S but not RyR2S/+. However, it reduced the amplitudes of evoked 358 
peaks in the RyR2S/+ myocytes. Isoproterenol-treated RyR2S/S myocytes additionally showed spontaneous 359 
Ca2+ propagating waves (Figure 16A). Such waves have been previously associated with arrhythmogenic 360 
properties under conditions where they were produced by caffeine (62). RyR2-R2474S/+ myocytes showed 361 
markedly greater Ca2+ spark frequencies with isoproterenol addition (584). They also showed SR Ca2+ 362 
thresholds for spontaneous Ca2+ transients, cAMP-induced Ca2+ sparks and waves following PKA-mediated 363 
RyR2 phosphorylation that were greatly reduced compared to WT (1157). 364 
 (5) Spontaneous and provoked arrhythmia related to electrophysiological properties  365 
 Electrophysiological studies in Langendorff-perfused RyR2S/+ and RyR2S/S hearts went on to 366 
distinguish between phenotypes reflecting tendencies to provoked, and both provoked and spontaneous 367 
arrhythmia. These employed conditions of either regular or programmed electrical stimulation. They were 368 
performed both before and following isoproterenol challenge (364) (Figure 16B-E). Unchallenged RyR2S/S 369 
though not RyR2S/+ hearts showed extrasystolic events. These were often followed by spontaneous sVT 370 
during intrinsic activity (Figure 16B, C). RyR2S/+  hearts correspondingly showed non-sustained VT with 371 
programmed electrical stimulation but not regular pacing. However, following isoproterenol treatment, 372 
RyR2S/+  hearts showed both non-sustained and sustained VT with both regular pacing and programmed 373 
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electrical stimulation. RyR2S/S hearts then showed higher incidences of non-sustained VT before and mainly 374 
sustained VT during both regular pacing and programmed electrical stimulation, particularly at higher 375 
pacing frequencies (Figure 16D, E). Correspondingly, isolated RyR2-R4496C/+ but not WT myocytes 376 
showed DAD and triggered activity. These increased in frequency with isoproterenol administration and 377 
were abolished by ryanodine (673). This increased Ca2+ release could extend to compromising SR Ca2+ 378 
stores sufficiently to compromise both atrial and ventricular contractility (314). 379 
 (6) Evidence for re-entrant substrate in RyR2-P2328S hearts 380 
 In addition to demonstrating such potential triggering events, Langendorff-perfused RyR2S/S hearts 381 
additionally demonstrated evidence for arrhythmic substrate (816, 1340). Regularly paced RyR2S/+ and 382 
RyR2S/S hearts showed ventricular AP recovery characteristics of ventricular MAP duration, refractory 383 
period (364) and AP restitution properties indistinguishable from WT. This was the case whether before or 384 
following catecholaminergic challenge (984). Ventricular AP conduction velocities, assessed by vectorial 385 
analysis of local epicardial activation times using multi-array electrode array recordings, were 386 
indistinguishable in untreated WT and RyR2S/S. However, isoproterenol and caffeine challenge that would 387 
elicit arrhythmia specifically in RyR2S/S ventricles correspondingly slowed these conduction velocities. 388 
Intracellular microelectrode recordings demonstrated correspondingly reduced values of (dV/dt)max. The 389 
latter is known directly to correlate with conduction velocity and peak INa (567, 1047). Such findings directly 390 
parallelled alterations in membrane excitability following manipulations of Ca2+ homeostasis in skeletal 391 
muscle (1161).  392 
 Further studies corroborated this existence of potential arrhythmic substrate. They revealed evidence 393 
for reduced membrane Nav1.5 expression and a correspondingly reduced INa. These could account for the 394 
slowed ventricular conduction velocities in RyR2S/S ventricles (832). Thus, Western blot analyses 395 
demonstrated that both whole tissue and membrane fractions of RyR2S/S ventricles showed similar Cx43, but 396 
reduced Nav1.5 protein expression compared to WT. Similarly, loose patch-clamp studies demonstrated a 397 
reduced INa. Extrasystolic S2 stimulation following 8-Hz S1 pacing at progressively decremented S1S2 398 
intervals correspondingly demonstrated increases in ventricular arrhythmic tendency despite unchanged 399 
VERPs in Langendorff-perfused RyR2S/S hearts. Similarly, dynamic pacing employing progressively 400 
reduced BCLs produced greater reductions in conduction velocity at equivalent BCLs and diastolic intervals 401 
in RyR2S/S compared to WT ventricles. Yet both showed comparable changes in APD90 and its alternans.  402 
 These findings were compatible with both short and long term consequences of abnormal cytosolic 403 
Ca2+ homeostasis for Nav1.5 function. Thus, ectopic activity and possible effects on Nav1.5 activation may 404 
follow transient [Ca2+]i elevations consequent upon catecholaminergic stimulation. Chronic elevations in 405 
[Ca2+]i might downregulate either Nav1.5 expression or activity. Either effect would reduce AP conduction 406 
velocity potentially generating arrhythmic substrate. Furthermore, the short-term events could potentially 407 
initiate triggering arrhythmic events then perpetuated by a longer term pre-existing arrhythmic substrate 408 
reflected in decreased conduction. Such hypotheses merit further exploration. They have broader 409 
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implications for potential therapeutic interventions involving Ca2+ homeostasis in management of potentially 410 
Nav1.5 dependent arrhythmic conditions (832). 411 
 Other situations related to disturbed Ca2+ homeostasis also caused conduction disturbance and major 412 
cardiac arrhythmia related to compromised INa. FKBP12 shares an 85% homology with FKBP12.6. 413 
However, it has mainly been associated with a modulation of skeletal rather than cardiac muscle RyR1-414 
mediated excitation–contraction coupling (1133). Nevertheless, FKBP12 has reported effects on RyR2. Its 415 
haploinsufficiency is lethal in utero, and this is accompanied by ventricular hypertrabeculation, 416 
noncompaction, and septal defect (1061). Transgenic αMyHC-FKBP12 mice overexpressing FKBP12.6 417 
showed high incidences (38%) of SCD. This accompanied ECG, electrophysiological and optical mapping 418 
evidence of slowed conduction, slowed AP upstrokes and prolonged APDs. Whole-cell patch-clamp 419 
analyses attributed these findings to an 80% reduction in peak INa, its slowed recovery from inactivation, 420 
positive shifts of its steady-state activation and inactivation curves, and enhanced INaL. Conversely, 421 
cardiomyocyte-restricted conditional FKBP12 knockout (FKBP12-f/f/αMyHC-Cre) ventricular 422 
cardiomyocytes showed faster AP upstrokes and >2-fold increased peak INa. These effects were reversed by 423 
dialysis of exogenous recombinant FKBP12 protein. This resulted in INa changes seen in the overexpression 424 
αMyHC-FKBP12 myocytes (744). 425 
(7) RyR2 phosphorylation and arrhythmic tendency 426 
 Murine hearts have also been used to model the mechanisms relating RyR2 protein abnormalities to 427 
alterations in RyR2-Ca2+ release function that would potentially trigger arrhythmia, though these remain 428 
controversial. These include the arrhythmic changes in acquired conditions including cardiac failure, which 429 
have been attributed to increased RyR2 open probabilities. However, the RyR2 is a large and complex 430 
molecule. Its monomer is associated with numerous potentially regulatory proteins including CaM, 431 
FKBP12.6, PKA, PP1 and PP2A, and CaMKII (107). Hence altered regulation of RyR2 gating by processes 432 
such as phosphorylation is likely critical to altered diastolic SR Ca2+ release. One initial line of inquiry 433 
explored suggestions that PKA could alter RyR2-Ca2+ release function through a RyR2 434 
hyperphosphorylation that dissociates a normally bound FKBP12.6 (745, 747, 856). This specifically 435 
implicated RyR2-S2808, as opposed to other possible PKA and CaMKII targets in cardiac failure. Mice with 436 
the nonphosphorylatable substitution RyR2-S2808A ablating the RyR2-S2808 phosphorylation site were 437 
correspondingly not susceptible to effects of adrenergic agonists or other pathological stressors known to 438 
induce congestive cardiac failure (747, 1242). Furthermore, selectively preventing PKA-mediated RyR2-439 
S2808 hyperphosphorylation improved postinfarction or exercise cardiac performance in the genetically 440 
modified mouse (630, 1039, 1241, 1242)  441 
 These findings led to suggestions for a physiological role for PKA-mediated RyR2-S2809 442 
phosphorylation in the increased cardiac contractility following sympathetic stimulation during exercise. 443 
Persistent pathological increases in such adrenergic activity would cause RyR2-S2809 444 
hyperphosphorylation. This would dissociate FKBP12.6 normally bound to and stabilizing the RyR2 and 445 
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thereby cause an arrhythmogenic diastolic leakage of SR Ca2+ (747). However, subsequent studies along 446 
similar or independent lines did not confirm critical predictions of this RyR-S2809 hyperphosphorylation 447 
hypothesis (449).  448 
 A first group of experiments concerned the physiological consequences of RyR2-S2809 449 
phoshorylation. Channel function in recombinant phosphorylated and dephosphorylated RyR1 and RyR2 450 
(RyR1-S2843D and RyR2-S2809D, and RyR1-S2843A and RyR2-S2809A respectively) expressed in 451 
HEK293 cells did not show alterations in their responses to applied Ca2+, Mg2+, and ATP in single channel 452 
and [3H]-ryanodine binding measurements, or to caffeine in Ca2+ imaging measurements, that differed from 453 
findings in WT. Co-immunoprecipitation and Western blot analysis demonstrated similar binding of FK506-454 
binding proteins. Metabolic labeling generated evidence for RyR2 phosphorylation sites other than S2809 455 
(1089). Excitation-contraction coupling in whole hearts and isolated cardiomyocytes from a RyR2-S2808A 456 
mouse model showed normal β-adrenergic responses with a persistent maladaptive cardiac remodeling 457 
following chronic stress. Single channel RyR2-S2808A activity showed only minor alterations and then only 458 
in their responses to applied Ca2+ (97, 356, 708). 459 
 Secondly, FKPB12.6 binding or dissociation did not modify RyR2 sensitivities to applied Ca2+ or 460 
caffeine, their tendencies to spontaneous or store overload-induced Ca2+ release, or the effect upon these of 461 
FK506, in HEK293 cells either co-expressing RyR2 and FKBP12.6 or expressing RyR2 alone. In these 462 
particular studies, FKBP12.6-null mice did not show altered tendencies for stress-induced ventricular 463 
arrhythmias. The properties of their RyR2 channels were indistinguishable from WT (1281). 464 
 Thirdly, a series of experiments in cardiomyocytes indicated that PKA phosphorylation did not 465 
dissociate FKBP12.6 from RyR2. FKBP12.6 occurred in lower abundance than RyR2 therefore binding only 466 
to ~15% of available RyR2s, in contrast to the more abundant FKBP12. However, PKA-mediated RyR-467 
S2809 phosphorylation dissociated neither FKBP12.6 nor FKBP12 from RyR2 (382). 468 
 Fourthly, Ser-2808 phosphorylation was often relatively insensitive to either PKA activation or 469 
inhibition (13, 109, 657). PKA-dependent increases in Ca2+ spark frequency in ventricular myocytes were 470 
instead attributable to enhanced SR Ca2+ load following phospholamban B phosphorylation rather than 471 
altered resting RyR2 function even under conditions of controlled [Ca2+]i (657). CaMKII- rather than PKA-472 
dependent phosphorylation of RyR2 were implicated in the enhanced SR diastolic Ca2+ leak and reduced SR 473 
Ca2+ load consequent upon adrenergic stimulation or cardiac failure (13, 227). Finally, where CaMKII, or s-474 
nitrosylation, mediated phosphorylation did enhance RyR2-mediated Ca2+ sparks and SR Ca2+ leak (232, 475 
382, 884), it did so possibly at an alternative, S2814, site (943). 476 
 Nevertheless phosphorylation events in general could still be expected to increase RyR2 Ca2+ 477 
sensitivity (747, 1241). This would then increase SR Ca2+ leak, with potential arrhythmogenic triggering 478 
effects (325). This would also ultimately deplete SR Ca2+ and thereby compromise Ca2+ transients and the 479 
resulting contraction in ventricular myocytes (411, 665, 892, 895). Thus, both RyR2-P2328S and RyR2-480 
Q4201R mutations were associated with decreased RyR2-FKBP12.6 binding, increased Ca2+ opening and 481 
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positive shifts in half-maximal inhibitory Mg2+ concentrations after PKA phosphorylation. In contrast the 482 
benzothiazepine derivative JTV519 (K201), appeared to both enhance RyR2-FKBP12.6 binding and 483 
normalise channel function (631). The RyR2-G230C mutant showed similar biophysical defects and 484 
demonstrated decreased FKBP12.6 binding and in common with RyR2-P2328S, normal luminal Ca2+ 485 
activation, but a negative shift in the cytosolic Ca2+ dependence of activation (763). Similar 486 
hyperphosphorylation hypotheses have been postulated for the triggering of arrhythmia in other systems, 487 
including a rabbit LQTS2 model (1118).  488 
 Furthermore, murine hearts with a heterozygous FKBP12.6 knockout correspondingly showed 489 
polymorphic VT with adrenergic challenge. This was rescued by JTV518 (631, 1241). RyR2-R2474S hearts 490 
also demonstrated reduced FKBP12.6-RyR2 binding on adrenergic stimulation. Rycal (S107) stabilised the 491 
binding, and therefore also stabilised the RyR2 closed state. It thus rescued the VT (629). The RyR2-492 
S2246L, RyR2-R2474S and RyR2-R4497C mutations similarly impaired RyR2-FKBP12.6 binding in 493 
parallel with their CPVT phenotype (1241). Ca2+ release by RyR2-P2328S, RyR2-Q4201R and RyR2-494 
V4653F expressed in HEK293 cells similarly showed rightward shifts in half-maximal inhibitory [Mg2+] 495 
and decreased FKBP12.6 binding (631, 1239). 496 
(8) Store overload-induced Ca2+ release 497 
 A store overload-induced Ca2+ release mechanism has been suggested as an alternative or 498 
complementary mechanism to altered FKBP12.6 binding in producing CPVT phenotypes. Murine RyR2-499 
R4496C, equivalent to human RyR2-R4497C (511) showed enhanced Ca2+ and caffeine sensitivitivity when 500 
expressed in HEK293 cells. Lipid bilayer and HL1-cardiomyocyte studies similarly suggested increased 501 
diastolic SR Ca2+ release with sympathetic activation (348, 631, 1241). Despite this, interaction between 502 
RyR2-R4496C and FKBP12.6 was normal both before and following such adrenergic challenge (348, 509). 503 
Furthermore, JTV519 did not inhibit either in vitro DADs or in vivo ventricular arrhythmias induced by 504 
adrenergic challenge (673). In lipid bilayers, JTV519 did suppress both spontaneous Ca2+ release and [3H] 505 
ryanodine-RyR2 binding. However, it did so independently of FKBP12.6 association (470), likely through a 506 
JTV519 binding site in the RyR2 2114-2149 domain (1286). The latter may further bind the central RyR2 507 
protein domain (2234–2750) and thereby stabilise the RyR2.  508 
 These findings suggested that the increased SR-Ca2+ release was alternatively attributable to an 509 
increased RyR2 channel sensitivity specifically to SR luminal Ca2+ that would thereby decrease cytosolic 510 
Ca2+ release thresholds. (509, 510). Such a store overload-induced Ca2+ release mechanism would be 511 
consistent with observed diastolic Ca2+ leaks associated with the RyR2-R176Q/T2504M and RyR2-L433P 512 
mutations that involve the channel domains of RyR2 (1131). It would also be compatible with the loss of 513 
such luminal activation with the RyR2-A4860G mutation (508).  514 
 It is nevertheless possible that these detailed differences in arrhythmogenic mechanisms could reflect 515 
genuine differences between phenotypic consequences of the various genetic RyR2 variants. Thus, in vitro 516 
assays associated mutations in the RyR2 central region not only with decreased (RyR2-R2427S, RyR2-517 
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S2246L and RyR2-P2328S) but also with increased (RyR2-N2386I and RyR2-Y2392C) FKBP12.6 binding 518 
affinities (1135, 1241). C-terminal RyR2 mutations (RyR2-Q4201R, RyR2-R4496C and RyR2-V4653F) were 519 
associated with decreased FKBP12.6 affinities (1241).  520 
(D) Genetic abnormalities in the RyR2-SR Ca2+-release channel: atrial and SAN 521 
arrhythmic phenotypes  522 
(1) Genetic RyR2 abnormalities associated with acute AF phenotypes 523 
 A number of RyR2 mutations are associated with SND and atrial arrhythmic in addition to CPVT 524 
phenotypes. Atrial arrhythmia can occur as a first clinical manifestation of CPVT (623). Both murine and 525 
clinical reports suggest that this could increase the risk of VT in this condition (302). The RyR2 exon 3 526 
deletion is associated with a broad range of atrial, ventricular and SND phenotypes. Some single RyR2 527 
mutations associated with CPVT are also associated with exercise-associated atrial arrhythmias. These 528 
include RyR2-P2328S (613, 1099, 1104), RyR2-G3946A (900), RyR2-S4153R (542) and RyR2-A7420G. 529 
Rapid AF culminating in CPVT has been associated with RyR2-M4109R and RyR2-I406T (835). VT and AT 530 
following isoproterenol infusion has been associated with RyR2-W4645R (86). 531 
 Murine hearts provided realistic models for the acute initiation of atrial arrhythmias in the presence of 532 
genetic RyR2 abnormalities classically associated with CPVT. They similarly related these to specific SR 533 
Ca2+ release abnormalities (1337). Studies in a selected group of mouse models with modified RyR2 534 
genotypes demonstrated that, in common with the ventricular arrhythmia, intracellular diastolic SR Ca2+ 535 
leak via RyR2 can trigger, and inhibiting this leak can prevent, AF (184, 824, 1040, 1098, 1334).  536 
 Increased RyR2-dependent Ca2+ leakage due to enhanced CaMKII activity may be an important 537 
downstream effect of CaMKII that generates susceptibility to AF. Thus, rapid atrial pacing in RyR2-538 
R176Q/+ mice increased atrial arrhythmic tendency compared to WT mice (184). This atrial arrhythmia in 539 
RyR2-R176Q/+ hearts accompanied increased CaMKII-mediated RyR2 phosphorylation. Both the 540 
arrhythmia and increased SR leak of Ca2+ were prevented by pharmacological inhibition of CaMKII. 541 
Similarly, preventing CaMKII-mediated RyR2 phosphorylation by a RyR2-S2814A mutation prevented AF 542 
in a vagotonic experimental model (534). Atrial biopsies from mice with atrial enlargement and spontaneous 543 
AF showed increased CaMKII-mediated RyR2 phosphorylation (184).  544 
 AF can also follow alterations in RyR2-associated proteins. These include FKBP12.6 deletion (655, 545 
1081), overexpression of the Ca2+ binding junctate 1 (438, 439), or the sarcoplasmic transmembrane protein, 546 
junctin (438), as well as deletion of the Ca2+- and GTP-dependent membrane-associated annexin Aa7 547 
(Anxa7) (423). Intra-esophageal burst pacing induced AF and diastolic SR Ca2+ leaks at the myocyte level in 548 
RyR2-R2474S+/−, RyR2-N2386I+/−, and RyR2-L433P+/− mice (1040). The RyR2-R2474S+/− RyR2s 549 
showed an increased oxidation and calstabin2 depletion compared to WT. S107 is known to stabilise RyR2-550 
calstabin2 interactions by inhibiting oxidation/phosphorylation-induced calstabin2 dissociation from RyR2. 551 
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It rescued both the increased SR-Ca2+ release and AF phenotype. It contrastingly failed to do so in 552 
calstabin2-deficient mice (1040).  553 
 The RyR2-P2328S mutation is clinically associated with atrial in addition to ventricular arrhythmia 554 
(613, 1104). RyR2S/+ and RyR2S/S mice showed normal ECG parameters whether before or following 555 
isoproterenol challenge apart from decreased cycle lengths. However, both regular and programmed 556 
stimulation resulted in a greater atrial arrhythmogenic incidence in isolated perfused RyR2S/S, though not 557 
RyR2S/+, in comparison with WT. Isoproterenol challenge increased arrhythmic incidences in all three 558 
groups. This was despite unchanged APD90 and AERPs on MAP recording. Regularly stimulated, fluo-3-559 
loaded RyR2S/S, but not RyR2S/+ or WT atrial myocytes, showed diastolic Ca2+ release phenomena. These 560 
were made more frequent by isoproterenol (1334). Floating microelectrode recordings in isolated perfused 561 
RyR2S/S but not WT atria correspondingly demonstrated DADs and ectopic APs potentially providing 562 
arrhythmic trigger (569). 563 
 (2) Altered atrial AP conduction in RyR2-P2328S hearts 564 
 In parallel with findings reporting on their ventricular arrhythmic properties (1340), murine RyR2S/S 565 
atria also demonstrated potential arrhythmic substrate potentially important for perpetuation of atrial 566 
arrhythmias. MEA recordings showed reduced epicardial AP conduction velocities despite normal MAP 567 
recovery measurements of both APD90 and AERP. Floating intracellular electrode recordings demonstrated 568 
increased interatrial conduction delays and correspondingly reduced (dV/dt)max (Figure 16F, G). In contrast, 569 
AP recovery parameters of atrial effective refractory periods (AERPs), APDs and AP amplitudes were 570 
indistinguishable from WT. Furthermore, despite persistent CV differences with extrasystolic S2 stimulation 571 
at progressively decreasing S1S2 intervals, the onset of arrhythmia coincided with similar CVs in WT and 572 
RyR2S/S (569).   573 
 These findings accompanied loose-patch clamp findings of compromised Nav1.5 activity in both 574 
RyR2S/S atria and positive Scn5a+/- controls. These took the form of reduced peak INa despite similar 575 
normalised current-voltage relationships (Figure 16H, I) and reduced Nav1.5 but normal Cx40 or Cx43 576 
protein expression. WT hearts showed similar reductions in INa under conditions of acutely increased [Ca2+]i 577 
resulting from increased extracellular [Ca2+], caffeine, or cyclopiazonic acid. These findings together 578 
suggest a slowed conduction resulting from downregulated Nav1.5 expression that could be further 579 
exacerbated by the effects of elevated [Ca2+]i upon Na+ channel function in RyR2-P2328S atria (568).  580 
 The RyR2-P2328S system thus provided an experimental platform for an examination recent clinical 581 
reports suggesting that flecainide may provide an approach to anti-arrhythmic therapies through actions 582 
mediated through the RyR2 (1233). These reported that flecainide exerted marked anti-arrhythmic effects in 583 
CPVT. This was attributed to tetracaine-like actions resulting in its acting as a potent RyR2 inhibitor (429, 584 
455, 458, 473, 1233, 1252). As indicated above, flecainide acts both as a class 1C INa (66, 675, 1064) and 585 
RyR2 inhibitor (IC50s 5-11 and 2-7 µM) (338, 417).  586 
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 MEA recording confirmed decreased CVs in isolated intact RyR2S/S atria. This directly paralleled 587 
findings of a decreased INa relative to WT and the higher incidences of atrial arrhythmia observed in these 588 
mice. Low flecainide (1 µM) concentrations both paradoxically restored CV and reduced the frequency of 589 
arrhythmia. This sharply contrasted with the effect of flecainide in decreasing CV and promoting arrhythmia 590 
in WT. Thus, low flecainide concentrations correspondingly restored INa to normal levels in intact RyR2S/S 591 
atria from a likely inhibited baseline level. These effects were replicated by the RyR2 blocker dantrolene 592 
(228, 996). These findings suggested that by inhibiting the increased SR Ca2+ leak, flecainide reduces Ca2+-593 
dependent inhibition of INa. This could restore conduction velocity in RyR2S/S hearts. Such findings target 594 
diastolic SR Ca2+ leak in potential therapeutic anti-arrhythmic strategies for heart failure (1318). 595 
 (3) Ca2+ signalling and remodelling associated with chronic AF. 596 
 Established as opposed to acute episodic clinical AF is associated with additional, anatomical or 597 
functional, atrial remodelling and congestive cardiac failure. There is often an accompanying intracellular 598 
Ca2+ overload and increased spontaneous diastolic SR Ca2+ release (309, 451, 1088, 1269). However, precise 599 
cause-and-effect relationships between these changes remain uncertain. It is also difficult to isolate 600 
contributions of disease entities associated with AF to the changes in Ca2+ signalling in AF. Thus, short-601 
term, sustained high atrial activation rates in a rabbit model appeared to produce an antiarrhythmic “Ca2+ 602 
signalling silencing”. This was accompanied by normal CaMKII expression levels but reduced CaMKII-603 
mediated RyR2 phosphorylation and [Na+]i (372). 604 
 Atrial myocytes from chronic AF patients show potentially pro-arrhythmic, increased frequencies in 605 
spontaneous Ca2+ release events (61, 451, 1194). These took place despite reduced ICaL (202, 1274). These 606 
features might reflect increased single RyR2-Ca2+ channel open probabilities as observed in canine hearts 607 
with persistent AF. There was then an increased protein kinase A-dependent RyR2-S2808 phosphorylation 608 
and decreased FKBP12.6-RyR2 binding. Such changes would be expected to compromise RyR2 channel 609 
closure (1194, 1238, 1244). However, the direct relevance of these mechanisms to AF remains uncertain 610 
(290). 611 
 Murine hearts provide experimental paradigms appropriate to the analysis of remodelling changes 612 
accompanying and potentially exacerbating atrial arrhythmia. The transgenic mouse model overexpressing 613 
the cardiac transcriptional repressor cAMP-response element M, CREM-IbΔC-X (CREM), recapitulates this 614 
clinical progression (572). Telemetric ECG recordings first showed spontaneous atrial ectopy at ~3 months. 615 
This then progressed to paroxysmal and chronic AF. These changes followed CaMKII–dependent increases 616 
in diastolic Ca2+-release (184). The latter could be attributed to increased RyR2 open probabilities and Ca2+ 617 
spark frequencies. There were accompanying atrial dilatation and atrial conduction abnormalities (654). The 618 
latter conduction changes were related to Cx40 downregulation (572). RyR2-S2814 phosphorylation 619 
accompanied, and the RyR2-S2814A mutation prevented, this remodelling. There was no accompanying 620 
fibrotic change. Increased RyR2-S2814 phosphorylation correspondingly increased AF inducility by 621 
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programmed electrical stimulation in mutant mouse models (655). These findings together paralleled clinical 622 
observations of increased CaMKII-activity and RyR2-S2814 phosphorylation in long-term AF patients.  623 
 Thus abnormal RyR2-mediated SR Ca2+ release, related to RyR2-S2814 phosphorylation in CREM-624 
mice, contributes to remodelling in AF. It results in arrhythmic substrate, in addition to triggering events. 625 
These changes directly correlated with hyperactive RyR2 channels directly stimulating the Ca2+-dependent 626 
hypertrophic nuclear factor of activated T cell (NFAT)/Rcan1-4 pathway, detected through Rcan1-4 mRNA 627 
expression, implicating it in developing substrate for longlasting AF (654). 628 
 Chronic AF is also clinically associated with reduced sarcolipin (SLN) mRNA and protein expression 629 
(1041). The transmembrane protein SLN regulates SERCA2a activity in common with PLN (54, 777). It 630 
likely does so through CaMKII rather than PKA-mediated mechanisms (120). SLN inhibits SERCA at low 631 
[Ca2+] (1151). Aged homozygous Sln-/- mice (54) developed atrial fibrosis and spontaneous AF under 632 
anaesthesia (1283), paradoxically suggesting that increased SERCA function promotes AF. 633 
 (4) RyR2 function and SAN pacemaker activity 634 
 Continuing discussions bear on possible important roles for RyR2-mediated Ca2+ release in SAN 635 
pacemaker activity (see Section III(A)) (615, 723, 1121). Enhanced SR Ca2+ release should activate inward 636 
INCX (522, 616). This would potentially facilitate AP firing in a “Ca2+ clock” mechanism (132). Ryanodine-637 
mediated RyR2 block thus reduced SAN activation frequencies (132, 522, 972). Roles of SR-Ca2+ release in 638 
regulating normal SAN pacemaker function thus merit closer study (615, 723).  639 
 However, human CPVT is associated with reduced SAN automaticity resulting in basal bradycardia, 640 
sinus pauses, and impaired chronotropic β-adrenergic responses (625, 909). In vivo telemetry revealed that 641 
RyR2-R4496C mice did not show basal bradycardia. Nevertheless they similarly showed sinus pauses 642 
followed by atrial and junctional escapes and impaired SAN automaticity with isoproterenol challenge. This 643 
did reproduce findings in CPVT patients following exercise (824). RyR2-R4496C SAN cells showed 644 
markedly reduced ICaL on whole-cell patch-clamping. Spontaneous [Ca2+]i transients studied by confocal 645 
microscopy in isolated SAN cells correspondingly showed slowed pacemaker activity, impaired 646 
chronotropic β-adrenergic responses, and sinus pauses. Isoproterenol produced 5-10 fold increases in the 647 
frequencies of Ca2+ sparks and Ca2+ waves (824). 648 
(E) Genetic abnormalities in cardiac calsequestrin 2 (CASQ2): catecholaminergic 649 
polymorphic ventricular tachycardia (CPVT) 650 
(1) Action of CASQ2 on Ca2+ homeostasis 651 
 The calsequestrin 2 (CASQ2) protein buffers SR Ca2+. This action would result in a reduction of free 652 
SR Ca2+ concentrations potentially below those expected to inhibit SERCA2a. This would then enhance SR 653 
Ca2+ re-uptake. CASQ2 thus acts both as the major SR Ca2+ reservoir and a local intra-SR Ca2+ buffer. 654 
CASQ2 also functions as a Ca2+-dependent RyR2 channel regulator in cardiac myocytes (108). Thus, 655 
CASQ2 is anchored to RyR2 via junctin and triadin. It may modulate RyR2 sensitivity to luminal Ca2+ 656 
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through functional interactions with these molecules. It has been suggested that CASQ2 binding to triadin 657 
and junctin inhibits RyR2 channel activity at low luminal [Ca2+]. Increasing luminal [Ca2+] would then 658 
relieve this inhibition. This binding would be accompanied by a CASQ2 transition from a monomeric to a 659 
polymeric form with the greater Ca2+ binding capacity. The resulting occupation of CASQ2 Ca2+ binding 660 
sites would then weaken the interactions between CASQ2 and triadin and/or junctin. This would increase 661 
RyR2 sensitivity to luminal Ca2+. The result would be an increased open probability in the RyR2-Ca2+ 662 
channel (581).   663 
 (2) CASQ2 mutations and the CPVT phenotype 664 
 Around 3% of CPVT patients show one of seven homozygous CASQ2 mutations (836). Four such 665 
mutations constitute premature stop codons. This generates truncated forms of the protein, lowering CASQ2 666 
levels. This would be expected to shorten the time required for functional SR Ca2+ store recharging thereby 667 
increasing the likelihood of diastolic RyR2-mediated Ca2+ leaks and premature RyR2 activation. This would 668 
produce phenotypic similarities to CPVT (1120).  669 
 The remaining three mutations are single nucleotide replacements involving single amino acid 670 
substitutions. CASQ2-D307H was first described in seven consanguinous Bedouin families (611). This 671 
results in a substitution of the negatively charged aspartic acid for histidine in a highly conserved putative 672 
Ca2+ binding region between the second and third thioredoxin-like domains. This likely affects the CASQ 673 
Ca2+ affinity in its monomeric form and impairs its Ca2+ binding and its interactions with junctin and triadin 674 
(448, 565). The CASQ2-R33Q mutation was first demonstrated in a CPVT patient with history of syncope 675 
and death of a male sibling at a young age (908). When overexpressed in rat cardiac myocytes it resulted in 676 
abnormal spontaneous diastolic Ca2+ release. However, it did not appear to alter SR Ca2+ store capacity. 677 
CASQ2-R33Q is associated with impaired CASQ2 dimerization (565) or polymerization which consequently 678 
only takes place at a higher [Ca2+] (1167). This reduces the CASQ2-mediated RyR2 inhibition at low 679 
luminal Ca2+ (924, 925). Finally, CASQ2-L167H was identified in a young patient with stress-induced 680 
ventricular arrhythmia and cardiac arrest. In rat cardiomyocyte expression systems, CASQ2-L167H 681 
appeared to behave like a functionally inert protein (565, 924, 925). 682 
 These features are consistent with similar mechanisms for CPVT arrhythmias whether these are 683 
associated with RYR2 or CASQ2 mutations. They suggest similar parallels for the malignant hyperthermia 684 
associated with RYR1 or CASQ1 mutations in skeletal as opposed to cardiac muscle. One could thus 685 
postulate that arrhythmia would be initiated when levels of free SR luminal [Ca2+] exceeded a threshold for 686 
a store-overflow-induced Ca2+ release (SOICR). In such a hypothesis, RyR2 mutations would reduce the 687 
threshold for such SOICR. SOICR would then take place with the increases in the SERCA-mediated Ca2+ 688 
uptake that results from β-adrenergic stimulation. In contrast, the reduced CASQ2 Ca2+ binding and 689 
buffering resulting from CASQ2 mutations would increase the free luminal Ca2+ levels beyond those of a 690 
normal RyR2 SOICR threshold (711). However, studies in murine systems suggest greater complexities in 691 
relating the genetic changes to their phenotypic consequences. 692 
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 (3) Murine hearts with modified Casq2  693 
 Features of mice with genetic Casq2 modifications, exemplified in Table 7, were consistent with 694 
reductions in Casq2 being involved in their observed catecholaminergic stress-induced polymorphic VT and 695 
bidirectional VT phenotypes. Casq2-/- mice also showed increased tendencies to AF. This was associated 696 
with increased diastolic spontaneous Ca2+ elevations and DADs. All these features were inhibited by the 697 
RyR2 inhibitor R-propafenone (303). However, whereas even heterozygous (Casq2+/-) mice showed 698 
positive phenotypes (199), heterozygous carriers of premature CASQ2 truncations were asymptomatic. 699 
Furthermore, the precise mechanisms by which the Casq2 deficiency causes the causative diastolic SR Ca2+ 700 
leak leading to premature spontaneous Ca2+ release and arrhythmogenic triggered beats remains uncertain. 701 
Casq2−/− mice appeared to show normal SR Ca2+ content (581). However, they showed compensatory 702 
increases in SR volume and post-transcriptional reductions of junctin and triadin. Casq2 thus appears not to 703 
be essential for maintaining SR Ca2+ stores (581). Yet the Casq2 deficiency appeared central to the stress-704 
induced polymorphic and bi-directional VT phenotype. In bilayer experiments, removal of CASQ2 at fixed 705 
intraluminal [Ca2+] increased RyR2 open probabilities in bilayer experiments (393). In heterozygous 706 
Casq+/− mice, even 25% decreases in Casq2 protein increased diastolic SR Ca2+ leak despite unchanged 707 
triadin and junctin levels and SR volume (199).  708 
 Two transgenic models with positive CPVT phenotypes showed evidence for increased expression of 709 
both RyR2 and the fetal SR Ca2+ binding protein calreticulin. The latter might then produce a compensatory 710 
increase in SR Ca2+ binding capacity. In common with Casq2-/- and homozygous Casq2-D307H/D307H 711 
mice, the homozygous deletion carrier Casq2-ΔE9/ΔE9 showed a 95% reduction in Casq2 protein. 712 
However, this accompanied other changes including increased RyR2 and calreticulin though normal 713 
calstabin levels (1077). Casq2-D307H/D307H mice were used to explore verapamil as a possible therapeutic 714 
anti-arrhythmic agent (540). Homozygous, Casq2-R33Q/R33Q, mice also showed stress-induced 715 
polymorphic VT and bidirectional VT. Their myocytes showed diastolic depolarisation phenomena and 716 
decreased SR Ca2+ (951). However, despite normal Casq2 mRNA, they showed a 50% reduction in Casq2 717 
protein possibly reflecting a greater degree of Casq2-R33Q protein digestion by trypsin (951). However, 718 
calreticulin and RyR2 protein levels then were normal. 719 
(F) CaMKII dysfunction, altered Ca2+ homeostasis and cardiac arrhythmogenesis 720 
 Murine systems have thrown light on CaMKII function and consequences of its modification under 721 
conditions of both genetic and pharmacological manipulation. In the latter connection, the CaMKII inhibitor 722 
KN-93 has been useful as a blocker of CaMKII activation. However, KN-93 may also act upon voltage-723 
gated K+ and L-type Ca2+ channels. Inhibition through endogenous CaMKIIN, autocamtide-3 inhibitor 724 
(AC3-I) and autocamtide-2 inhibitor proteins (AIP) may offer greater specificity and therefore future 725 
promise (882).  726 
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 Transgenic mice overexpressing either CaMKIIδ2 or CaMKIIδ3 developed DCM and cardiac failure 727 
(1331, 1332). CaMKII overexpression also altered Ca2+ homeostasis and cellular excitability. This resulted 728 
in pro-arrhythmic AP afterdepolarisations (291). In contrast, CaMKII deletion prevented the heart failure 729 
that follows transaortic constriction (55, 667). Similarly, overexpression of the CaMKII inhibitory peptide 730 
AC3-I, enhanced post-infarction cardiac function and Ca2+ handling. It reduced LV hypertrophy and 731 
dysfunction following isoproterenol challenge. It also decreased PLN phosphorylation at Thr17 and SR Ca2+ 732 
load (1329). Murine AC3-I overexpression systems also demonstrated feedback relationships between 733 
CaMKII, PLN, and sarcolemmal K+ channels. They showed upregulated inward rectifier IK1 and transient 734 
outward currents Ito,f and consequent APD shortening. This was in contrast to the decreased Ito and IK1 and 735 
APD prolongation in cardiac failure (295). These changes accompanied normal channel RNA and protein 736 
expression consistent with either altered membrane expression or post-translational modification. This 737 
remodelling was prevented with crossing of Ac3-I and Pln-/- (650). Finally, both KN-93 or AC3-I-mediated 738 
CaMKII suppression in a murine calcineurin overexpression cardiac failure model reduced spontaneous 739 
ventricular arrhythmias and improved LV function (557). 740 
 CaMKII dysfunction has also been associated with AF and SND (654, 1277, 1297), CPVT (677), 741 
LQTS3 (588), and the ankyrin-B related (LQTS4) (249) and Timothy (LQTS8) syndromes (1125). A recent 742 
study in transgenic mice with cardiomyocyte-specific expression of the SR-targeted CaMKII inhibitor aryl-743 
hydrocarbon receptor-interacting protein (AIP) implicated RyR2 phosphorylation produced by ROS-744 
activated CaMKII, in arrhythmogenic changes following impairment of glucose tolerance (857, 1076). 745 
Studies in permeabilised cardiomyocytes suggested that whereas the small proportion of CaM variants 746 
associated with a CPVT could evoke arrhythmogenic perturbations in Ca2+ homeostasis, this did not appear 747 
to be the case with variants associated with LQTS (474, 1306). Finally mice haploinsufficient in purkinje 748 
cell protein-4 (Pcp4) which may regulate CaM and CaMKII signalling specifically within His-Purkinje cells 749 
showed pro-arrhythmic ventricular phenotypes, increased ICa, positive shifts in ICa inactivation and altered 750 
evoked Ca2+ transients accompanying CaMKII activation (566).  751 
(G) Genetic modifications in dephosphorylation pathways 752 
(1) Cardiac expression of p21 activated kinase-1 (Pak1) 753 
 Increasing evidence implicates phosphatases in dampening kinase-mediated cardiac excitation and 754 
contraction mechanisms. This potentially exerts cardioprotective effects (548). The serine/threonine protein 755 
kinase p21 activated kinase-1 (Pak1) is highly expressed in different cardiac regions. It is localised to the Z-756 
disc, cell and nuclear membrane and intercalated discs in rat ventricular myocytes (547). It is directly 757 
activated by the small GTPases, cell division control protein 42 homolog (Cdc42) and Ras-related C3 758 
botulinum toxin substrate 1 (Rac1). Co-immunoprecipitation studies suggest that Pak1 is associated with the 759 
similarly localised cellular cardiac PP2A for which it might form an upstream activator in both SAN and 760 
ventricular cells (546, 1254). PP2A removes phosphate groups at PKA phosphorylation sites on the cardiac 761 
106 
 
isoform of the cTnI troponin subunit that inhibits actin-myosin ATPase activity (547, 709), MYBPC3 (547), 762 
PLN (709), inwardly rectifying K+ channels (543), as well as L-type Ca2+ channels (242) and RyR2s (730), 763 
increasing Ca2+ spark generation (1119). It also regulates transcription factors including cAMP response 764 
element-binding protein (CREB) (1208) and nuclear factor kappa-light-chain-enhancer of activated B cells 765 
(NFκB) (1291). The latter effects influence cardiac remodelling (312, 327).  766 
 Both Pak1 and its upstream activators Cdc42 and Rac1 also stimulate cytoskeletal changes. They 767 
reduce stress fibres and focal adhesion complexes, filapodia and lamelliopodia formation and membrane 768 
ruffling (544, 545, 1102, 1229). These features are compatible with a dynamic balance between phosphatase 769 
and kinase activity in regulating aspects of Ca2+ homeostasis ion channel activity influencing pacemaker and 770 
excitable activity in sino-atrial and ventricular cells respectively, and their modulation by autonomic 771 
stimulation. 772 
(2) Loss of Pak-1 function and atrial arrhythmic phenotype  773 
 Mice with either cardiac-specific conditional (Pak1-cko) or total (Pak1-/-) Pak1 deletions showed 774 
increased sinus heart rates compared to control homozygous flox (Pak1-f/f) littermates. This was despite 775 
similar electrocardiographic, P, PR, QRS and QT waveforms (1230). Conversely, infection of cultured 776 
guinea pig SAN cells with recombinant adenovirus expressing constitutively active Pak1 (CA-Pak1) 777 
depressed L-type Ca2+ and delayed rectifier K+ currents. It reduced repetitive AP frequencies in response to 778 
isoproterenol-induced β-adrenergic stimulation compared to findings in SAN cells infected with Ad-LacZ 779 
controls (545). The PP2A inhibitor okadaic acid partly reversed this suppression of L-type Ca2+ channel 780 
responses to isoproterenol in Ad-Pak1–infected cells (543). These findings led to suggestions for a dynamic 781 
balance between kinase and phosphatase activities in modulating both L-type Ca2+ channel and delayed 782 
rectifier IK activity. This could furnish a potentially important mechanism for alterations in pacemaker 783 
activity following autonomic stimulation (545). 784 
(3) Loss of Pak-1 function, SERCA function and ventricular arrhythmic phenotype  785 
 Pak1-cko and Pak1-/- hearts also showed increased incidences of polymorphic VT, despite normal 786 
refractory periods, following either acute or chronic β-adrenergic isoproterenol challenge, relative to 787 
controls (Figure 17A) (259, 1044, 1230). Pak1-cko and control, Pak1-f/f, ventricular myocytes showed 788 
comparable baseline ICaL similarly reduced by chronic β-adrenergic stress. However, Pak1-cko myocytes 789 
showed higher incidences of irregular, alternating Ca2+ transients with repetitive stimulation, and of 790 
spontaneous Ca2+ waves, both before and particularly following imposition of chronic β-adrenergic stress 791 
(Figure 17B). This appeared at least partly to reflect decreased SERCA function. The latter would reduce SR 792 
Ca2+ content and increase diastolic [Ca2+], effects induced or accentuated by either chronic or acute β-793 
adrenergic stress (Figure 17C, D). The latter target offers potential future therapeutic targets for novel agents 794 
directed at SERCA activity through PLN such as istaroxime and CDN1163 (463, 533). Such changes were 795 
suggested by assessments of SR Ca2+ levels through observed time constants and integrals of INCX, as well as 796 
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of SERCA2 activity from decay constants of systolic Ca2+ transients, following caffeine challenge. It also 797 
emerged from comparisons of the decays of systolic Ca2+ transients, and increases in diastolic and decreases 798 
in systolic [Ca2+], and reductions in systolic contraction amplitude, despite unchanged ICaL, following 799 
regularly applied stimulation (1230).   800 
 More direct assessments of effects on SERCA2 activity first interposed a caffeine challenge to deplete 801 
SR Ca2+ in regularly stimulated ventricular myocytes. They then followed the subsequent recovery of 802 
evoked Ca2+ signals to assess recovery of SR Ca2+ stores. Pak1-cko myocytes showed more prolonged 803 
recovery time courses compared to Pak1-f/f whether before or following chronic β-adrenergic stress (Figure 804 
17C, D (i)). Such chronic β-adrenergic stress increased both these differences and the recovery times. In 805 
contrast, ICaL and INCX magnitudes and time courses were indistinguishable through these conditions and the 806 
duration of recovery from caffeine challenge (Figure 17C, D (ii)-(iv)) (1230). 807 
 Pak1-cko hearts correspondingly showed reduced SERCA2a mRNA and protein expression. However, 808 
they showed normal PLN mRNA, protein and phosphorylation levels, Nav1.5 protein levels and RyR2 and 809 
Cacna1c mRNA levels whether before or following imposition of chronic β-adrenergic stress. Pak1-cko 810 
contrasted with Pak1-f/f hearts in failing to upregulate NCX protein or NCX1 mRNA following 811 
hypertrophic stress. Control Ad-shC2 virus-infected neonatal rat cardiomyocytes correspondingly showed 812 
increased SERCA2a protein and mRNA expression with phenylephrine challenge. This was abolished by 813 
Pak1-knockdown in Ad-shPak1-infected neonatal rat cardiomyocytes (NRCMs). It was accentuated by Pak1 814 
over-expression produced by Ad-CAPak1 (1230). 815 
 In parallel with these results, myocytes expressing constitutively active Pak1 (CA-Pak1) showed faster 816 
time to peak shortenings but slower [Ca2+]i decays and relengthening times compared to LacZ-expressing 817 
controls. CA-Pak1 expression also inhibited the effect of isoproterenol in increasing [Ca2+]i transient 818 
amplitude. It increased SR Ca2+ content, slowed [Ca2+]i decay rates and increased cell shortening. It also 819 
reduced Ca2+ spark amplitude and slowed propagation of spontaneous Ca2+ waves. Although it did not affect 820 
PLN phosphorylation, it reduced cardiac troponin I phosphorylation (1044). 821 
 Pak1 additionally downregulates NADPH-oxidase 2 activity in electron transfer from NADPH to O2 to 822 
generate superoxide. Simulated ischaemia thus increased [Ca2+]i, and induced spontaneous Ca2+ release and 823 
Ca2+ waves in Pak1-/- ventricular myocytes. These effects were rescued not only by the reverse mode NCX 824 
blocker KB-R7943 and the Ras-related C3 botulinum toxin substrate 1 (RAC1) inhibitor (NSC23766) but 825 
also the ROS scavenger TEMPOL. Furthermore, both Pak1-/- and WT myocytes treated with the Pak 826 
inhibitor IPA3 showed increased cellular ROS production not exhibited by either p47-phox-/-, NADPH 827 
oxidase 2 (NOX2) deficient, myocytes or WT myocytes exposed to the NADPH oxidase peptide inhibitor 828 
gp91ds-tat (258).  829 
(4) Loss of Pak-1 function and hypertrophic phenotype 830 
 Pak1-cko hearts showed an accentuated cardiac hypertrophy and heart failure following either chronic 831 
pressure overload or angiotensin II infusion. There was a reduced activation of c-Jun N-terminal kinase 832 
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(JNK). The latter is known to phosphorylate and inactivate the transcription factor NFAT, important in 833 
activating hypertrophic genes (793). The Pak1 activator FTY720 prevented these effects in WT but not 834 
Pak1-cko hearts (681). FTY720 also exerted cardioprotective effects against ischaemia/reperfusion injury in 835 
both rat and mouse models (545).  836 
 Pak1 activating peptide (PAP) is known to increase phosphorylated Pak1 levels in cultured neonatal 837 
rat ventricular myocytes. It both reduced such angiotensin II-induced hypertrophy in neonatal rat ventricular 838 
myocytes (NRVMs) and C57BL/6 ventricles and inhibited the arrhythmias that followed such ventricular 839 
hypertrophy (1225). Intriguing studies in Pak1-/- mice attributed such effects of Pak1 deficiency to 840 
decreased amplitudes and slowed kinetics in Ca2+ transients coinciding with decreased transverse tubular 841 
densities and capacitances. All these changes were rescued by overexpressing constitutively active Pak1. 842 
The resulting alterations in cytosolic Ca2+ homeostasis might then modify regulation of transcription factors 843 
involved in hypertrophic remodelling (258). 844 
 (H) Causal schemes relating altered Ca2+ homeostasis to cardiac arrhythmia 845 
The above exemplars can be organised into a hypothetic scheme (Figure 18) that could form a basis 846 
for further explorations of causal relationships between modifications in cellular Ca2+ homeostasis and 847 
cardiac arrhythmias. Such modifications might arise from acquired or genetic alterations that might increase 848 
RyR2-mediated release of SR Ca2+ or decrease SERCA2a-mediated Ca2+ re-uptake from cytosol to SR Ca2+ 849 
store. These could take place both through direct modifications of the molecules concerned, or indirectly 850 
through other signalling mechanisms (Figure 18A, B). This in turn could potentially alter NCX activity 851 
whose electrogenic effects might lead to diastolic triggering phenomena (Figure 18C). Results from some of 852 
the exemplars above also suggest that it could reduce synthesis or membrane trafficking and therefore 853 
membrane expression of Nav1.5 or acutely alter its biophysical properties (Figure 18D). These effects could 854 
either chronically or acutely slow AP conduction, resulting in arrhythmic substrate (Figure 18E) even under 855 
conditions of normal action potential recovery as reflected in normal APD/ERP ratios.  856 
VIII. CARDIAC ENERGETIC DYSFUNCTION AND ARRHYTHMIA 857 
(A) Energetic consequences of cardiac disease 858 
(1) Metabolic stress and mitochondrial dysfunction 859 
 Murine exemplars containing specific membrane ion channel modifications directly bearing upon cell 860 
excitability and Ca2+ homeostasis thus offer relatively straightforward physiological insights into the 861 
relationship between biophysical channel modification and whole-heart arrhythmogenesis. In so doing, they 862 
usefully model a range of relatively rare arrhythmic conditions. However, the clinically commoner causes of 863 
arrhythmia are often less clearly genetically characterised. Significant insights into their arrhythmia can 864 
nevertheless be obtained through a strategic physiological targeting of particular aspects of cell function. For 865 
example, both the oxidative stress associated with hypertrophic change, cardiac failure, ischaemia-866 
reperfusion (90, 201, 374, 1117), and metabolic conditions including obesity, insulin resistance and type 2 867 
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diabetes, and increasing age are accompanied by energetic, in particular, mitochondrial, dysfunction (600, 868 
1005, 1196). Mitochondria constitute the main cardiac cellular source of ATP (845). Dysfunctional 869 
mitochondria have been implicated in ventricular arrhythmia with altered ion channel function, AP 870 
heterogeneity, and cell excitability (49, 146, 483). They are also associated with the oxidative stress, 871 
possibly associated with L-type Ca2+ channel activity in atrial tachyarrhythmias (155).  872 
(2) Mitochondrial dysfunction and biophysical properties 873 
 A number of mechanisms link such alterations in metabolism to altered membrane excitability. These 874 
often take place under conditions also associated with increased frequencies of Ca2+-mediated triggers (41, 875 
42). Mitochondrial inner membranes sustain a ~200 mV potential that drives electrons down the electron 876 
transport chain. The latter ultimately drives ATP synthesis. This process is tightly regulated to match energy 877 
supply to demand. Mitochondrial oxidation destabilises this potential through a mitochondrial permeability 878 
transition. This is likely produced by activation of inner membrane anion channels (IMAC) amongst 879 
possible others (845, 881). This destabilisation initiates ROS-induced ROS release producing alternans in 880 
both mitochondrial and surface electrical activity (41). Damaged or dysfunctional mitochondria can thus 881 
increase ROS production by up to 10-fold (374). 882 
 ROS exert numerous, potentially arrhythmogenic, actions. They decrease INa (671) and IK (1217), 883 
activate sarcolemmal KATP channels (1249), modify Na+ and L-type Ca2+ channel inactivation kinetics, 884 
increase INaL and oxidise RyR2. These result in an increased leak of SR Ca2+ leak and a consequent 885 
modulation of intracellular Ca2+ cycling (135, 146, 1117). They also reduce Cx43 trafficking and function 886 
(18, 1292, 1293). These actions together also increase [K+]i, [Na+]i and [Ca2+]i. This produces a wide range 887 
of potentially pro-arrhythmic physiological effects bearing upon cell-cell coupling (1074), AP conduction 888 
(671), repolarisation (1217) and alternans (91), and Ca2+ -mediated triggers (1117).  889 
 ATP depletion or increased ADP increases open probabilities in sarcolemmal ATP-sensitive K+ 890 
channels (sarcKATP) (18). These occur at relatively high densities in myocyte surface membranes. This 891 
opening may physiologically protect myocyte viability during ischaemia (380, 532). However, even opening 892 
1% of such channels shortens APD, and therefore ERP and AP wavelength. This can potentially produce 893 
pro-arrhythmic re-entrant substrate (305, 323). In addition opening of sufficient channels generates 894 
heterogenous current sinks driving the cell membrane potential towards EK. This can compromise cell 895 
excitability and AP propagation (18).  896 
 (B) The nuclear receptor family of peroxisome proliferator-activated receptors (PPARs) 897 
(1) Role of PGC-1 species  898 
 The nuclear receptor family of peroxisome proliferator-activated receptors (PPARs) include the 899 
PPAR-α, PPAR-γ and PPAR-δ isoforms. Modifications in these offer one possible genetic access to 900 
studying actions of mitochondrial-related factors on cardiac function (944). All are subject to transcriptional 901 
co-activation by peroxisome proliferator-activated receptor gamma coactivator 1 (PGC-1) species. The latter 902 
110 
 
include PGC-1α, PGC-1β, and PGC-1-related coactivator (922). All have been increasingly implicated in 903 
regulation of energy metabolism in both health and disease (316, 661).  904 
 Both PGC-1α and PGC-1β regulate expression of genes involved in oxidative phosphorylation (555, 905 
825, 1014, 1015). High PGC-1α and PGC-1β expression levels thus occur in actively oxidative tissues often 906 
characterised by abundant mitochondria. These include brown adipose tissue, and cardiac and skeletal 907 
muscle. Nevertheless, mouse models with deletions of either PGC-1α or PGC-1β showed normal baseline 908 
cardiac contractile function. However, mutations involving both are postnatally lethal through cardiac 909 
failure. This is consistent with redundancies or overlaps between the functions of PGC-1α and PGC-1β 910 
(612). Both PGC-1α and PGC-1β deletions accentuated cardiac failure following transverse aortic 911 
constriction (44). 912 
(2) Effects of genetic modification of PGC-1α 913 
 PGC-1α appears important to cardiac adjustments that require increased ATP and work output in 914 
response to physiological stimuli. Embryonic mouse hearts showed large increases in mitochondrial 915 
biogenesis and oxidative metabolism close to birth. This followed dramatically increased PGC-1α 916 
expression (628). Ectopic PGC-1α expression drives mitochondrial biogenesis in cultured cardiac myocytes. 917 
Oxidative phosphorylation in these mitochondria was tightly coupled to ATP production (628). One of the 918 
two available PGC-1α knockout models showed normal baseline cardiac contractility, the other showed age-919 
dependent contractile dysfunction (43, 628). Both showed normal mitochondrial volume density. However, 920 
both also showed impaired expression of genes involved in oxidative phosphorylation and fatty acid 921 
oxidation. These were associated with an impaired maximal mitochondrial oxygen consumption using 922 
palmitoyl-L-carnitine substrate and mitochondrial ATP synthesis accompanied by mitochondrial uncoupling 923 
(43). In vivo and Langendorff-perfused PGC-1α-KO hearts showed impaired inotropic and chronotropic 924 
exercise, and dobutamine responses respectively.  925 
(3) Effects of genetic modification of PGC-1β  926 
 The four independently generated PGC-1β-KO models (638, 1080, 1196) showed normal inotropic 927 
responses in contrast to, but reduced chronotropic responses in common with, PGC-1α hearts following 928 
dobutamine challenge (638). PGC-1β-/- models showed impaired expression of genes involved in oxidative 929 
phosphorylation but not fatty acid oxidation (945). PGC-1β−/− mice showed irregular heartbeats and 930 
increased incidences of polymorphic VTs following isoproterenol challenge. They showed an increased 931 
SCN5A, KCNA5, RYR2, and CaMKII RNA expression. Langendorff-perfused PGC-1β−/− hearts showed AP 932 
alternans, EADs, and VT on monophasic AP recording (Figure 19A, B). Myocyte patch electrode studies 933 
(Figure 19C, E-H) demonstrated unstable oscillatory resting potentials and early and delayed after-934 
depolarisations accompanying their APs (Figure 19C). Sustained current injection elicited burst firing 935 
(Figure 19H). These changes were accompanied by diastolic Ca2+ transients exaerbated by isoprenaline 936 
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(Figure 19D), increased inwardly and outward rectifying K+ currents (Figure 19F, G), and a negatively 937 
shifted Ca2+ current inactivation (Figure 19E) (387). 938 
(C) Effects of cellular redox potential 939 
(1) Importance of NAD+/NADH 940 
 Studies in ageing skeletal muscle suggested that reduced nuclear NAD+ levels variously attributable to 941 
altered NAD+/NADH ratios (921) or altered NAD+ consumption or synthesis (205) may also compromise 942 
mitochondrial function. This may involve mechanisms independent of PGC-1α/β. Thus restoring the NAD+ 943 
levels restored the mitochondrial function (365). In addition, these pyridine nucleotides themselves have 944 
independent cellular actions. Some of these could potentially interact with those of altered mitochondrial 945 
function. Thus, NADH enhanced smooth muscle superoxide production which could result in and be further 946 
reinforced by PKC activation (221). NAD+ caused PKA activation in osteoblastic cells (960). In turn, PKA 947 
upregulated (1349), and PKC downregulated Nav1.5 function (809). Pyridines also modified voltage-948 
dependent K+ channel gating (1134), Ca2+-activated K+ channel (869) and TrypC currents (420). NAD+ 949 
enhanced and NADH inhibited RyR2-mediated Ca2+ release (1352). In addition, NAD+ is convertible, by 950 
RyR2-associated CD38 (4, 1100), to cyclic ADP-ribose, known to trigger RyR2-mediated Ca2+ release (5). 951 
 Finally, mutations in GPD1-L protein, highly expressed in cardiac tissue, are associated with reduced 952 
INa and clinically with both BrS and SIDS. GPD1-L is >80% homologous in amino-acid sequence with 953 
glycerol-3-phosphate dehydrogenase. The latter enzyme family is directly involved in NAD-dependent 954 
energy metabolism potentially altering cellular redox state as reflected in NAD+/NADH levels. This would 955 
bridge alterations in cellular energetic state with modifications in INa (689). Co-expression of Scn5a with the 956 
implicated Gpd1-l-A280V, E83K, I124V and R273C reduced INa in expression systems and neonatal 957 
myocytes (689, 840).  958 
(2) Effects of NAD+/NADH on INa 959 
 Altered NADH might modify Nav1.5 function and expression giving changes that might explain the 960 
effects of GPD1-L mutations on INa. Such studies first demonstrated that additional expression of GPD1-L-961 
A280V but not of WT-GPD-1L markedly increased [NADH]i in HEK cell lines stably expressing human 962 
Nav1.5 alone.  Secondly, [NADH]i produced marked dose-dependent (20-100 μM) rapid and stable, ≤~50%, 963 
reductions in maximum INa in HEK cells expressing human Nav1.5. It also did so to a lesser extent in rat 964 
neonatal cardiomyoctyes. In contrast, the overall voltage dependences of both activation and inactivation of 965 
Nav1.5 and Nav1.5 mRNA expression were preserved. These effects were reversed by NAD+, the PKC 966 
antagonist chelerythrine and superoxide dismutase. They were mimicked by the PKC activator, phorbol 12-967 
myristate 13-acetate (PMA). The rescue effects of NAD+ were antagonised by PKA inhibition by PKAI6–22 968 
(100 nM) (360). Conversely, the PKA activator (1 μM) forskolin blocked the NADH effect on INa whilst not 969 
by itself affecting INa. Thus, the mutually antagonistic effects of internally or externally applied NAD+ and 970 
NADH likely involved separate signalling pathways. In contrast, surface Nav1.5 expression was conserved 971 
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through these manipulations (672).  Finally, WT murine hearts exposed to increased [NADH]i through 972 
perfusion using external 10:1 lactate:pyruvate showed a reversible arrhythmogenesis on programmed 973 
electrical stimulation. Conversely, application of [NAD+]o perfusion reversibly abolished the 974 
arrhythmogenesis shown by Scn5a+/- hearts (672).  975 
 Figure 20 simplifies some of the factors outlined in Sections VIII(A-C) and their possible relationships 976 
to biophysical events leading to arrhythmogenic effects.  977 
IX. ARRHYTHMIC SUBSTRATE RESULTING FROM STRUCTURAL CHANGE 978 
(A) Fibrotic change and arrhythmic phenotype 979 
(1) Cytokine signalling and fibrotic change 980 
 In addition to ion channel and cellular homeostatic changes, structural changes, whether at the 981 
subcellular, cellular, tissue or even organ levels could alter the conditions of excitation, its conduction and 982 
recovery from such excitation. They thus would also contribute to arrhythmic phenotype. Table 8 lists 983 
examples to be considered below (465). Previous sections had alluded to the association between Nav1.5 984 
haploinsufficiency in the murine Scn5a+/- system and structural in addition to biophysical change (Section 985 
V(E)). This particularly involved a cardiac fibrotic phenotype induced by increased levels of TGF-β1 986 
(Section V(F)). This may be a manifestation of a more general regulation of fibrotic change with possible 987 
implications for arrhythmia (432, 959).  988 
 TGF-β1 is a key regulator of fibrosis in adult hearts. Increased fibrosis, to which atria are particularly 989 
susceptible (949, 1305), reduces cardiomyocyte-cardiomyocyte coupling potentially resulting in conduction 990 
defects (21). Increased TGF-β1 expression is clinically associated with chronic AF (222). In murine hearts, 991 
cardiac-specific TGF-β1 overexpression was followed by atrial fibrosis, atrial conduction disturbances, and 992 
AF (1193). The latter was attributed to triggered activity following reductions in APD and an appearance of 993 
spontaneous Ca2+ release events (198). Angiotensin II and reactive oxygen species may also increase TGF-994 
β1 promoter activity, connective tissue growth factor (Ctgf), and collagen in fibroblasts causing a profibrotic 995 
environment (408, 1146). Similarly cardiac-specific TNFα overexpression produced atrial dilation, fibrosis, 996 
thrombus development, and spontaneous AF in ambulant mice (598, 974). In some models, it resulted in 997 
Cx40 downregulation (1013). 998 
(2) G-protein signalling and fibrotic change. 999 
 Cardiac G protein–coupled receptors serve various signalling pathways involving epinephrine, 000 
angiotensin, endothelin, and adenosine as messengers. Thus, Gαq associates with α1-adrenergic, endothelin 001 
(ETA), and angiotensin II type I (AT1) receptors. They may thereby exert metabolic effects that impact on 002 
tissue fibrosis. Thus, AF patients show increased atrial angiotensin II expression (519). Rapidly paced in 003 
vitro atrial myocytes show increased angiotensin II secretion (1145, 1280). Cardiac-specific overexpression 004 
of angiotensin I converting enzyme caused atrial dilatation, fibrosis, and spontaneous AF in ambulant mice 005 
(1280). Similarly, transgenic models over-expressing adenosine A1 or A3 receptors showed atrial 006 
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bradycardia and atrioventricular block and increased susceptibility to AF dependent on the degree of 007 
bradycardia (300, 570). This could potentially lead to bradycardiomyopathy (300). Both available transgenic 008 
mouse lines overexpressing active Gαq subunit under αMhc promoter control developed cardiac hypertrophy 009 
followed by diffuse atrial and ventricular fibrosis and heart failure (233, 764) and spontaneous AF in 010 
ambulant animals (431).  011 
 The membrane-associated GTPase, Ras Homolog Gene Family Member A (RHOA), is involved in 012 
actin cytoskeleton organization. Mice overexpressing either WT RHOA or an activated form of RHOA 013 
under cardiac-specific αMhc promoter control died prematurely. They then showed cardiac, particularly 014 
atrial enlargement, cellular hypertrophy and interstitial fibrosis. This accompanied AF, atrioventricular block 015 
and heart failure (991). ECG performed under anaesthesia suggested a susceptibility to AF and 016 
atrioventricular block (991). A murine overexpression system for the rho protein GDP dissociation inhibitor 017 
RhoGDIα, showed atrial arrhythmias and mild ventricular hypertrophy and bradycardia, atrioventricular 018 
block, and atrial arrhythmias with a downregulation of Cx40. These were followed by cardiac hypertrophy 019 
and cardiac failure (1245). 020 
(3) Mitogen‐activated protein kinases, fibrotic change and atrial arrhythmic phenotype  021 
 Mitogen‐activated protein kinases (MAPKs) are serine/threonine kinases central to diverse cellular 022 
stimuli including environmental stress, pro-inflammatory cytokine action, and developmental cues. Of these, 023 
mitogen-activated protein kinase kinase 4 (MKK4) and MKK7 are critical components in the stress-024 
activated MAPK signalling pathway (1227). Both MKK4 and MKK7 are kinases for c-Jun N-terminal 025 
kinase (JNK) (255), reported to suppress TGF-β1 gene expression (1188). MKK4 additionally activates p38 026 
(139). Studies in genetically modified murine platforms suggested that attenuation of cardiac p38 activity 027 
resulted in a progressive growth response and myopathy particularly following aortic banding (141). MKK4 028 
may also regulate Cx43 remodelling by either phosphorylation- or transcription-dependent mechanisms 029 
(890). MKK4 may thus inhibit maladaptive pathological hypertrophy through its activation of the JNK 030 
pathway (680). 031 
 Genetic modifications in Mkk4 expression offered an experimental platform for investigating the 032 
consequences of alterations in Cx43 expression. The kinetics of Cx43 synthesis, trafficking, and degradation 033 
results in a rapid turnover (half-life~1–5 h) (948). This in turn potentially influences its expression in 034 
directions that could contribute arrhythmic substrate. Both knockdown of Mkk4 expression by silencer 035 
siMkk4 and inhibition of its kinase activity by infection with a dominant negative, Ad-dnMkk4, adenovirus 036 
reduced the Cx43 expression induced by phenylephrine challenge in NRCMs. This likely involved two 037 
specific activator protein-1 binding elements in the Cx43 promoter region.  038 
 Cardiomyocyte-specific knock-out mice (Mkk4-cko) showed reduced and heterogeneous Cx43 039 
expression and zonula occludens-1 (ZO-1) protein content following transverse aortic constriction. Their 040 
ECG recordings demonstrated widened QRS durations (~16 vs 10 ms), and increased yet normal QT 041 
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intervals. Programmed electrical stimulation induced VT in six of 13 Mkk4-cko but none of the studied WT 042 
mice. Finally, epicardial activation mapping indicated ventricular activation delays in Mkk4-cko 043 
hypertrophied hearts. Mathematical modelling simulated a slowed, fragmented and potentially pro-044 
arrhythmic ventricular conduction (1351). 045 
 MKK4-based systems also permitted analysis of the effects of fibrotic change on connectivity between 046 
atrial myocytes. The clinical prevalence of AF and that of atrial fibrosis increase in parallel with age. 047 
Clinical evidence implicated MKK4 in this AF pathogenesis. Thus, qPCR comparisons of MAPK 048 
components and profibrotic signalling molecules in atrial tissues demonstrated MKK4, but not MKK7, P38 049 
or JNK, downregulation, in AF relative to age-matched control patients in sinus rhythm. These findings 050 
were further confirmed as decreased MKK4 protein levels. qPCR analysis in the AF patients further 051 
suggested increased profibrotic gene expression. There were thus increased levels of Col1a1 and Col3a1 052 
collagen, and the profibrotic connective tissue growth factor (CTGF), in contrast to downregulated matrix 053 
metalloprotein 2 (MMP2) expression. MKK4 mRNA downregulation was the more marked in older (>75 y) 054 
compared to younger age AF groups. 055 
 These clinical observations could be correlated with findings in a Mkk4-acko conditional knockout 056 
mouse model with an atrial cardiomyocyte-selective deletion of Mkk4 using the natriuretic peptide precursor 057 
A (Nppa) promoter-driven Cre transgene. Young (3- to 4-month), adult (6-month), and old (1-year) Mkk4-058 
acko mice were compared with age-matched Mkk4-f/f, controls. Aging Mkk4-acko mice were more 059 
susceptible to atrial tachyarrhythmias. These were associated with slowed and dispersed atrial conduction 060 
(Figure 21Aa,b, B). There were increased incidences of arrhythmia particularly in old Mkk4-acko hearts 061 
(Figure 21C). Yet, Langendorff-perfused Mkk4-acko and Mkk4-f/f hearts showed similar APD90 and ERP 062 
values, and Cx levels and distribution through all age groups. Studies of atrial proteins that might contribute 063 
to slowed conduction and atrial arrhythmogenesis demonstrated no differences in mRNA or protein 064 
expression level expression of Nav1.5, RyR2, NCX, inositol 1,4,5‐trisphosphate receptor (IP3R), the 065 
transient receptor potential channel proteins, TRPC1, TRPC3, and TRPC6, and the gap junction proteins, 066 
Cx40 and Cx43 between young or old, Mkk4-f/f and Mkk4-acko mice. 067 
 The increased arrhythmogenecity thus more likely resulted from a development of an increased 068 
interstitial fibrosis (Figure 21D). This was accompanied by upregulated TGF-β1 signalling and dysregulation 069 
of matrix metalloproteinases (Figure 21E). Mkk4 inactivation also increased the sensitivity of TGF-β1 070 
signalling to angiotensin II-induced activation in cultured cardiomyocytes. It thus increased the expression 071 
of profibrotic molecules in cultured cardiac fibroblasts. Thus Mkk4 likely downregulates the TGF-β1 072 
signalling associated with atrial remodelling and arrhythmogenesis with age (245). Mkk4 deletion thus 073 
appeared to increase atrial arrhythmic tendency by altering conduction properties especially in old Mkk4-074 
acko mice. MEA recordings of atrial AP arrival times, following stimulus application at a point in the center 075 
of the MEA array, demonstrated similar conduction velocities in both LAs and RAs of young (3‐month) 076 
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Mkk4-f/f and Mkk4-acko hearts. However, conduction velocity was slower in old (12 month) Mkk4-acko 077 
atria than old Mkk4-f/f hearts (Figure 21F).  078 
 Modelling studies confirmed that such fibrotic processes could potentially lead to atrial 079 
arrhythmogenic phenotypes in Mkk4-acko mice through formation of electrical fibroblast – cardiomyocyte 080 
coupling (574). This decreased AP overshoots and (dV/dt)max values, prolonged APDs, and depolarised 081 
resting potentials to extents dependent upon the number of fibroblasts coupled to each myocyte. This would 082 
fulfil expectations from the coupled fibroblasts variously acting as passive electrical loads and electrical 083 
drivers through the cardiomyocyte AP time course. Two-dimensional modelling of the consequences of 084 
these loading features demonstrated that such fibroblast‐cardiomyocyte couplings slowed the conduction 085 
velocities of atrial excitation waves. Furthermore, it did so to extents increasing with fibroblast density. It 086 
thereby replicated differences in conduction velocity in young and old Mkk4-acko or Mkk4-f/f atria, 087 
particularly the greater negative dependence of conduction velocity on fibroblast density in the old than the 088 
young group. It further demonstrated wavebreaks in propagated atrial excitation resulting from such 089 
coupling. Figure 21G illustrates such effects following S1S2 stimulation protocol applied at the left edge of 090 
the 2 dimensional map representing the situation in which 1-5 fibroblasts had been coupled to any particular 091 
cardiomyocyte. Illustrations of the subsequent S2-induced excitation waves at a S1S2 coupling interval of 092 
60 ms demonstrated breakdown of the excitation wavefront and re‐entrant excitation. 093 
(B) Hypertrophic cardiomyopathy (HCM) 094 
 (1) Mutations involving sarcomeric proteins 095 
 Cardiomyopathies are characterised by structural myocardial abnormalities not accountable for by 096 
acquired, ischaemic, valvular, hypertensive or congenital conditions (732). These conditions together 097 
account for most cases of SCD. Cardiomyopathies are broadly categorised into hypertrophic (HCM), dilated 098 
(DCM), arrhythmogenic RV, restrictive and LV non-compaction cardiomyopathies (715, 732) with multiple 099 
genotypes occasionally existing through families (1220). The commonest, HCM, (prevalence 1:500) 100 
presents as asymmetric or symmetric myocyte hypertrophy, fibrosis and myofibre disarray (1260). It is 101 
associated with a wide variety of often sarcomeric mutations (732). The condition is clinically 102 
heterogeneous. The different mutant alleles involved are associated with different hypertrophic severities 103 
and clinical outcomes (1237). The anatomical abnormalities provide potential re-entrant excitation circuits 104 
leading to high arrhythmia risk (1010). Some sarcomeric mutations appear to result in high SCD risk even 105 
without cardiac hypertrophy (1173). 106 
 75% of HCM cases involve mutations in genes encoding myosin α- and β−heavy chains, MYBPC3 107 
and troponin T. The murine models available provide broad phenotypic parallels relating to their 108 
accompanying structural changes or alterations in Ca2+ homeostasis, that however merit further more 109 
detailed study. Heterozygous, particularly male, Mhc-R403Q/+ mice that contain a clinically relevant, 110 
myosin α-heavy chain mutation, developed the classical histology of disarray, hypertrophic myocytes and 111 
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interstitial fibrosis between 5-15 weeks (347). These changes accompanied prolonged ECG repolarisation 112 
intervals and right axis deviation. There were also heterogeneous ventricular electrophysiological 113 
conduction properties, prolonged sinus node recovery times and ventricular ectopic events (112). However, 114 
their arrhythmic susceptibility varied more with the extent of ventricular hypertrophy than it did with the 115 
extent or location of myocyte disarray or cardiac fibrosis (1266). 116 
 Heterozygous, MyBP-C-t/t, defects truncating myosin-binding protein C in its cardiac myosin heavy 117 
chain-binding and titin-binding domains also cause human HCM. Mice with analogous heterozygous, 118 
MyBP-C-t/+ and homozygous MyBP-C-t/t showed mild dilated and severe hypertrophic cardiomyopathic 119 
phenotypes respectively. However, they showed normal ECG intervals, and sinus node, atrial, and 120 
ventricular, conduction and refractoriness. MyBP-C-t/t but not MyBP-C-t/+ mice were more susceptible to 121 
induction of VT than WT and showed ventricular ectopic activity, to extents that however, did not correlate 122 
with their degrees of interstitial fibrosis (113). 123 
 Mutations in TNNT2 which encodes cTnT, involve the thin filament sarcomeric protein component 124 
troponin T. These are associated with ventricular arrhythmia and SCD. In the case of TNNT2-R92T, SCD 125 
occurs typically at ~17 ± 9 y. There is then minimal hypertrophy or fibrosis but significant myofilament 126 
disarray (795, 1173). Similarly, Tnnt2-I79N, clinically linked to human HCM, is associated with increased 127 
incidence of SCD despite a mild cardiac hypertrophic phenotype. However, TNNT2 mutations might cause 128 
their associated stress-induced VT through electrophysiological remodelling of Ca2+ transients and reducing 129 
IK1 rather than hypertrophy and/or fibrosis. Ambulant Tnnt2-I79N mice were more susceptible to 130 
nonsustained VT produced by behavioural stress. Intact mouse hearts and ventricular myocytes carrying 131 
Tnnt2-I79N showed Ca2+ transients with slowed decay kinetics suggesting increased Ca2+ sensitivities in 132 
their TnT. They also showed shortened APD70, and normal ICa and Ito but decreased IK1. The APD reductions 133 
were reversed by increasing intracellular Ca2+ buffering or blocking NCX function. Higher pacing rates or 134 
isoproterenol challenge resulted in diastolic Ca2+ levels higher than those found in control myocytes and 135 
increased susceptibility to ventricular ectopic events (583).  136 
 Phenotypic comparisons of HCM-linked murine TnT mutations resulting in strong (TnT-I79N), 137 
intermediate (TnT-F110I), and an absence, of Ca2+ sensitization (TnT-R278C) respectively in human cardiac 138 
fibres directly implicated myofilament Ca2+ sensitivity in this arrhythmic susceptibility which takes place in 139 
the absence of hypertrophy, fibrosis, or myofibrillar disarray (83, 422, 580). All three groups showed similar 140 
low baseline incidences of ventricular ectopic activity that were increased by isoproterenol challenge. 141 
However, fast pacing triggered sustained VT with incidences in the sequence: TnT-I79N > TnT-F110I > 142 
TnT-R278C = WT. Epifluorescence imaging demonstrated greater spatial variability in activation times in 143 
TnT-I179N than TnT-R278C hearts. Finally, the Ca2+-sensitizing agent EMD 57033 and the myofilament 144 
Ca2+ desensitizing agent blebistatin respectively reproduced and diminished these arrhythmic 145 
susceptibilities. Ca2+ sensitization altered ventricular APD, increased its beat-to beat variation and shortened 146 
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VERPs. It also increased the dispersion of ventricular conduction velocities at high heart rates. All these 147 
changes potentially create arrhythmic substrate (83). 148 
 Mutations in other sarcomeric proteins, such as the regulatory (RLC) or essential (ELC) myosin light 149 
chain, constitute rarer causes of HCM (Poetter et al., 1996). However, even genetically modified mice 150 
carrying ELC or RLC mutations known to result in human HCM with midventricular cavity obstruction 151 
frequently did not show a hypertrophic phenotype, even in the presence of myofilament and cellular level 152 
increases in Ca2+ sensitivity and relaxation rates (997). 153 
 (2) Abnormalities in nonsarcomeric cellular components  154 
 HCM can also follow abnormalities in nonsarcomeric cellular components. Syrian hamsters carrying 155 
spontaneous δ-sarcoglycan mutations show HCM, DCM (993) and stress-induced SCD (750) in common 156 
with human sarcoglycan mutation-related HCM. Gain-of-function mutations involving the Ras-Raf protein 157 
kinase pathway classically associated with development disorders including the Noonan and LEOPARD 158 
syndromes are also associated with HCM. This likely takes place through an upregulation of RAS signalling 159 
that leads to a pathological cardiomyocyte hypertrophy (865). Genetically modified mice with a targeted and 160 
chronic Ras-Raf–MAPK pathway activation developed diastolic dysfunction, SR Ca2+ defects and increased 161 
early sudden cardiac mortality (1346). Inducible gene-switch activation of the hypertrophic Ras-Raf-162 
mitogen-activated protein kinase pathway in adult murine hearts elicited ventricular hypertrophy and 163 
ventricular arrhythmias. The isolated ventricular myocytes showed an electrophysiological remodelling that 164 
paralleled changes frequently reported in hypertrophic and failing hearts. The latter took the form of AP 165 
prolongation, increased NCX activity, reduced IK, altered SR Ca2+, and deficient PKA-dependent PLN 166 
phosphorylation. The changes accompanied induction of Gα-inhibiting subunit 1 (Giα1) expression and were 167 
partly rescued by Gi/o inhibitor pertussis toxin (969).  168 
(C) Dilated cardiomyopathy (DCM) 169 
 (1) General features 170 
 DCM results in LV dilatation and consequent systolic dysfunction despite normal loading conditions 171 
and coronary function. 25-40% of cases are familial, often as autosomal dominant characteristics with 172 
variable penetrances. DCM can also be acquired following infection, toxin exposure or metabolic 173 
abnormalities. Its associated electrophysiological abnormalities include sinus node dysfunction, 174 
atrioventricular block, and atrial or ventricular arrhythmias often following tissue scarring (603, 904). DCM 175 
is associated with over 30 different cytoskeletal, sarcomeric protein/Z-band, nuclear membrane, and 176 
intercalated disc proteins (603). The murine systems replicating DCM may also demonstrate its 177 
accompanying alterations in contractile function and/or its arrhythmic phenotypes.  178 
 (2) Ion channel genes involved in DCM 179 
 Of ion channel genes associated with DCM (504, 617), SCN5A has been implicated as a candidate 180 
gene in screening studies of DCM families with cardiac conduction disorders. These include the SCN5A-181 
118 
 
D1275N (758), and SCN5A-T220I, R814W, and D1595H missense and 2550-2551insTG truncation 182 
mutations (854). SCN5A-D1275N cosegregated with age-dependent DCM phenotypes with variable 183 
penetrances associated with AF, impaired automaticity, and conduction delay. A Chinese family carrying 184 
SCN5A-A1180V showed a mild in vitro INa phenotype accompanied by DCM preceded by atrioventricular 185 
block (346). Hypertrophic change has also been associated with Na+-channel related, LQTS phenotypes 186 
(553, 1049). Murine Scn5a+/- hearts whilst similarly showing conduction defects, AF and ventricular 187 
arrhythmia, and progressive fibrotic change (see Section V(E)) did not exhibit features of DCM. This 188 
finding is in direct contrast to the remaining close phenotypic similarities between murine Scn5a+/- and 189 
human BrS phenotypes. This may prompt further investigation for differences that might be related to the 190 
effects of the intraventricular systolic pressures developed within the small murine as opposed to the 191 
relatively large human ventricular chambers. 192 
 (3) Sarcomeric protein mutations  193 
 A substantial proportion of clinical DCM cases are associated with sarcomeric protein mutations. 194 
However, the two murine myosin heavy chain (MYH6) models were not arrhythmic (1018). In contrast, 195 
murine mutations modulating myosin function showed arrhythmia thus recapitulating the corresponding 196 
clinical phenotypes. Transgenic mice containing dominant-negative mutations altering cardiac-specific 197 
expression of the intercalated disk mammalian-enabled protein (Mena) and vasodilator-stimulated 198 
phosphoprotein (VASP) showed bradycardic and sudden death phenotypes. These were associated with 199 
reduced cell-to-cell interactions (293). Similarly, mice over-expressing a dominant-negative transgenic copy 200 
of the transcriptional myosin regulator, neuron-restrictive silencer factor, showed VT and heart block 201 
associated with up-regulation of If and ICaT, normally specific to pacemaker and Purkinje cells (608). 202 
(4) Cytoskeletal protein mutations  203 
 Of mutations disrupting cytoskeletal function, those involving the lamin A/C (LMNA) gene cause a 204 
wide range of clinical conditions. Lamin A/C, LMNA+/-, mutations producing 50% reductions in normal 205 
cardiac lamin A/C resulted in a development of atrioventricular node myocyte apoptosis and conduction 206 
loss, atrial arrhythmias and VT by age 4 weeks, and DCM with age (1267). Mice carrying the missense 207 
Lmna-N195K murine variant known to cause human DCM, similarly showed DCM, a profound and 208 
progressive sinus bradycardia reflecting sinoatrial exit block, and a range of conduction abnormalities. 209 
These included progressive PR interval prolongations with a premature, arrhythmic, death on continuous 210 
ECG monitoring. They also showed mis-expression of transcription factor Hf1b/Sp4 and of Cx40 and Cx43, 211 
and disorganised sarcomeres and intercalated disks.  212 
 The cardiomyopathy thus likely arises from this disruption of internal cardiomyocyte organization and 213 
possibly an abnormal expression of transcription factors ensuring normal cardiac development (807). The 214 
LMNA-H222P missense mutation occurred in a family with the autosomal dominant Emery-Dreifuss 215 
muscular dystrophy. Homozygotic Lmna-H222P mice showed apparently normal embryonic and sexual 216 
119 
 
development. However, adult male, and at a later stage, female, mice showed abnormal voluntary locomotor 217 
activity and an echocardiographically detected DCM. They also showed ECG evidence of increased PR 218 
intervals and QRS durations, episodes of sinoatrial block and ventricular extra-systoles, and premature 219 
mortality at ~9 months. There was an accompanying cardiac and skeletal muscle degeneration and fibrosis 220 
and an activated Smad signalling (45). 221 
 (5) SR Ca2+-cycling protein mutations  222 
 Genetic abnormalities in SR Ca2+-cycling proteins, particularly those affecting the SERCA regulator 223 
PLN, also cause familial cardiomyopathies. PLN dephosphorylation reduces apparent SERCA2a Ca2+ 224 
affinity. The resulting SERCA2a inhibition can be abolished by PKA-mediated phosphorylation. Of 225 
naturally occuring PLN mutations, one carrying a homozygotic lysine 39 stop codon (PLN-L39stop) 226 
abolished PLN expression and caused a lethal DCM and heart failure at teenage. However, this clinical 227 
phenotype was not reproduced in Pln-deficient mice (398). A R9C mutation in the Pln coding region 228 
seemed to preclude PKA-mediated phosphorylation of even WT PLN producing a chronic inhibition of 229 
SERCA2a (1019). This was similarly associated with a clinical DCM recapitulated in transgenic mice 230 
overexpressing Pln-R9C.  231 
 Mutations affecting Pln transcription levels also result in inhibited SERCA2a activity. One of 87 of a 232 
series of hypertrophic patients showed an A to G mutation in this region (776). Infections of in vitro rat 233 
myocytes suggested that such a mutation markedly increased PLN promoter activity consistent with a role in 234 
producing DCM. Finally, a heterozygotic Pln-R14Del variant involving PLN coding demonstrated by 235 
genetic screening of DCM patients was clinically associated with LV dilatation, contractile dysfunction, 236 
episodic ventricular arrhythmias and heart failure by middle age. These features were reproduced in 237 
transgenic mice overexpressing Pln-R14Del. WT and Pln-R14Del co-expression in HEK-293 cells 238 
demonstrated a SERCA2a superinhibition that might provide a mechanism for the DCM (397).  239 
(6) Developmental gene mutations  240 
 Of developmental genes, the cardiac homeobox gene Nkx2-5 is central to early cardiogenesis (409). 241 
Mutations produce a wide range of malformations including septal and outflow tract defects, 242 
cardiomyopathy and LV hypoplasia, and associated arrhythmias (1022). Neonatal mice with ventricle-243 
restricted Nkx2-5 deficiency appeared structurally normal. They displayed no arrhythmias on ECG 244 
recording. They subsequently developed a trabecular muscle hypertrophy and progressive, first degree (by 245 
12 weeks) and complete heart block (at 6-12 months) recapitulating clinical findings in some Nkx2-5 246 
patients. This accompanied a cardiomyocyte dropout and fibrosis following their sarcomeric and cellular 247 
disorganization in the central conduction system. This produced a distinct form of cardiomyopathy 248 
characterised by extensive trabeculae and myocardial noncompaction. There was a progression to dilatation 249 
of both chambers, their marked trabeculation, and heart failure. There was a dysregulation of genes 250 
associated with myocardial cell proliferation and trabeculation. This included an increased expression of 251 
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bone morphogenic protein-10 (BMP-10) and a downregulated cardiac homeodomain-only protein, HOP. 252 
These findings likely represented a distinct pathway for progressive cardiomyopathy associated with 253 
conduction defects in congenital heart disease (871). 254 
(7) Cytoskeletal protein mutations  255 
 Of cytoskeletal proteins, vinculin anchors the actin cytoskeleton to the cell membrane. It is thus likely 256 
required to preserve cell-cell and cell-matrix adhesion. Murine cVcl-KO models with Cre-loxP generated 257 
cardiac-myocyte-specific vinculin (Vcl) gene inactivation showed telemetric ECG evidence of VT leading to 258 
sudden death, and optical mapping evidence of reduced myocardial conduction even at <3 months. This was 259 
followed by development of DCM often fatal at <6 months. This accompanied abnormal adherens junction 260 
and intercalated disc structure, reduced cadherin and beta1D integrin expression and mislocalization of Cx43 261 
to the lateral myocyte border (1324).  262 
(D)Arrhythmogenic right ventricular cardiomyopathy (ARVC) 263 
(1) Clinical features 264 
 Arrhythmogenic right ventricular cardiomyopathy (ARVC) is associated with ventricular arrhythmias 265 
and SCD, particularly in young athletes (79, 219), giving a phenotype unmasked by exercise testing (886). It 266 
is characterised by a fibro-fatty infiltration leading to RV dilatation. Dilatation may extend to areas of the 267 
LV but characteristically spares the septum (732). Desmosomal protein gene mutations occur in 50% of such 268 
patients (685). Desmosomes participate in end-to-end connections transmitting contractile force between 269 
cardiac myocytes (250). Abnormal junctional organization leads to myocardial damage and replacement 270 
fibrosis culminating in focal scars isolating cardiomyocytes within non-conducting fibrous tissue (80). This 271 
slows conduction, generating re-entrant substrate. 272 
(2) Plakophilin-2 (Pkp2) deletions 273 
 Murine models exist for the transmembrane desmosomal cadherins, plakoglobin (γ-catenin) and 274 
plakophilin 2, and the plakin protein desmoplakin, which links the junctional complex to the intermediate 275 
filament, desmin, thereby maintaining mechanical integrity (685, 1046). Mutation of the gene encoding 276 
plakophilin-2 may occur in up to one third of ARVC families (349). However, Pkp2+/- mice with a 277 
heterozygotic plakophilin-2 targeted deletion showed no cardiac morphological phenotype. Nevertheless, 278 
human subjects with plakophilin-2 (PKP2) mutations showed more frequent VT episodes than those without 279 
detected PKP2 mutations (68). Furthermore, the homozygous deletion was lethal at post fertilisation day 11 280 
with evidence for endothelial discontinuities in heart and vessels (376).  281 
(3) Consequences of plakoglobin (Pg) deletion and overexpression 282 
 One of the two initially available heterozygous murine plakoglobin deletion models showed RV 283 
enlargement, increased spontaneous ventricular arrhythmias and RV conduction slowing (123, 973). This 284 
took place despite an absence of replacement fibrosis, junctional remodelling or alterations in Cs43 285 
localization and distribution, at 10 months. These abnormalities were exacerbated by exercise (571) and 286 
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relieved by load reduction regimes (299). In contrast, homozygous targeted plakoglobin deletion was lethal 287 
between ED 9.5 and ED 16 with thinning of the cardiac walls, reduced trabeculation and epicardial 288 
discontinuities. Nevertheless, a cardiac-specific targeted Pg deletion controlled by αMHCcre partially 289 
recapitulated human ARVC. Pgf/f-αMHCcre mice showed ~30% of WT protein but no Pg in cardiac 290 
sections. They showed a tendency to SCD, progressive RV and LV dilatation, and fibrosis though no cardiac 291 
fat deposition from ~2 months. Desmosomal ultrastructure was disrupted (647). There was evidence of 292 
myocyte apoptosis in addition to myocyte necrosis, in contrast to the necrosis observed with desmoglein 293 
(Dsg2)-N271S over-expression. The intercalated disks also lacked other desmosomal proteins, including 294 
Dsg2 (647). However, β-catenin expression appeared increased and may have partially rescued the sudden 295 
death phenotype. The latter was suggested in crosses of double-targeted mice carrying both floxed Pg and 296 
floxed β-catenin loci (Pg-f/f; β-catenin-f/f) loci with αMHC/MerCreMer mice. Tamoxifen challenge 297 
resulting in specific targeted deletion produced a strong arrhythmogenic SCD phenotype in all animals 298 
between 3 and 5 months after tamoxifen injections (1105). Finally, mice with both WT or mutant Pg 299 
overexpression showed increased incidences of SCD (686).  300 
 Similarly, a two-base pair plakoglobin gene deletion is associated with the recessive Naxos 301 
syndrome, associated with further, keratotic, manifestations (757, 973). Yet overexpression of the resulting, 302 
truncated, Naxos-associated plakoglobin also produces an arrhythmogenic cardiomyopathic phenotype. 303 
However, it is likely that it is an insufficiency of either the normal or truncated plakoglobin that produces 304 
disease phenotypes. One of two knockin murine models expressing a Naxos-associated plakoglobin that 305 
bypassed the nonsense-mediated mRNA decay mechanism thereby producing normal levels of truncated 306 
plakoglobin showed normal cardiac function (1343).  307 
(4) Desmoplakin (Dsp) targeted deletion and overexpression  308 
 Homozygous loss-of-function desmoplakin (Dsp) mutations are clinically associated with a 309 
biventricular form of ARVC. Heterozygous Dsp+/- mice developed normally. However, adults then showed 310 
attenuated ventricular walls, increased LV diameters, reduced LV ejection fractions, spontaneous 311 
arrhythmias on ECG recordings and extrastimulus-induced ventricular arrhythmias. The structural changes 312 
were preceded by increased activation times and arrhythmic tendency measurable in Langendorff-perfused 313 
hearts (366). Homozygous, Dsp-/-, desmoplakin targeted deletions were lethal at ED 6.5 (475). Postponing 314 
this lethality to ED 11 by tetraploid aggregation permitted demonstration of severe cardiac malformation 315 
though persistent desmosomal-like ultrastructures (339). Embryos with a cardiac-specific, αMHCcre 316 
induced, targeted Dsp-/- deletion revealed poorly formed hearts (342). 317 
 Mice with cardiac overexpression of flag-tagged Dsp cDNA carrying the Dsp-R2834H-Tg C-terminal 318 
mutation demonstrated increased heart/body weight ratios compared to mice whether with human WT (WT-319 
Tg) Dsp cDNA or WT littermates (1296). Dsp-R2834H-Tg hearts also showed increased apoptosis and 320 
fibrosis, RV and LV dilatation, reduced ventricular function, widened intercalated disks and disrupted 321 
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plakoglobin-desmoplakin interaction. Overexpression of Dsp with N-terminal, Dsp-V30M and Dsp-Q90R 322 
mutations was lethal after ED 13.5, resulting in reduced ventricular wall attenuation and dilatation. 323 
 Finally, studies with crosses of desmoplakin-floxed mice (Dsp-f/f) with cardiomyocyte-specific 324 
ventricular myosin light chain-2-Cre recombinase (MLC2v-Cre) knock-in mice yielded viable animals. But 325 
these showed early ultrastructural desmosomal defects and cardiomyopathic changes including the cell 326 
death, ventricular fibro-fatty replacement, biventricular dysfunction, and failure and premature death. Hearts 327 
showed ventricular arrhythmias accentuated by exercise and catecholaminergic challenge. They also showed 328 
slowed RV conduction. These were attributable to reduced Cx40 and Cx43 expression, suggesting roles for 329 
desmoplakin in stabilizing Cx integrity (706). 330 
 (5) Desmoglein (Dsg) overexpression models 331 
 Mice with cardiac overexpression of flag-tagged Dsg2-N271S mutant, homologous with the human 332 
DSG2–N266S ARVC mutation, showed spontaneous ventricular arrhythmias, conduction slowing, 333 
ventricular dilatation and aneurysms, replacement fibrosis and SCD at age <2 weeks. This was associated 334 
with myocyte necrosis, calcification and fibrous tissue replacement. In contrast, mice with flag-tagged Dsg2-335 
WT showed normal phenotypes indistinguishable from WT littermates even at age 2 months (896). Mice 336 
with a targeted deletion in the extracellular adhesion domain of Dsg2 similarly showed RV and LV 337 
dilatation, fibrosis, calcification, and SCD (597). Hearts showed intercellular widenings at the intercalated 338 
disk and loss of desmosomal ultrastructure (536). 339 
(6) Laminin receptor mutations 340 
 341 
 A line of KK/Rvd mice with right ventricular dysplasia (RVD) contain a gene laminin receptor 1 342 
(Lamr1) mutation containing an intron-processed retroposon whose gene product binds to heterochromatin 343 
protein 1 potentially modifying transcriptional regulation. The hearts showed a marked fibrosis in the RV 344 
free wall, cardiomyocyte cell death. Electrocardiography revealed prolonged QRS durations suggesting 345 
intraventricular conduction disturbance potentially increasing susceptibility to arrhythmia (48). 346 
 (E) Left ventricular non-compaction cardiomyopathy (LVNC) 347 
 LV non-compaction cardiomyopathy (LVNC) is a rare, frequently autosomal dominant condition 348 
characterised by a histologically distinct noncompacted myocardial layer containing deep and prominent 349 
trabeculae (1248, 1320). It is associated with cardiac failure, angina pectoris and arrhythmia in the form of 350 
AF, ventricular tachyarrhythmias and SCD in some series (848). The condition has been related to mutations 351 
in the neurogenic locus notch homolog protein (NOTCH) pathway regulator E3 ubiquitin-protein ligase 352 
(MIB1) (705) as well as various genes overlapping those associated with other cardiomyopathies. These 353 
include the cypher/Z-band alternatively spliced PDZ-motif protein in the sarcomeric Z line (1178). This 354 
binds to α-actinin likely contributing cytoskeletal structural integrity during contraction, and may be 355 
involved in PKC signalling through its LIM domains (1045). Mice with disrupted Z-line proteins as a result 356 
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of mutations in the CYPHER/ZASP gene show phenotypes in common not only with LVNC but also DCM 357 
and HCM and suffer early post-natal death (1345, 1350).  358 
X. SUMMARY AND CONCLUSIONS 359 
 Cardiac arrhythmias result from a breakdown of the ordered successive patterns of excitation through 360 
the SAN, atria or ventricles essential for normal contractile function. They constitute a major public health 361 
burden (Section IA). Their analysis requires understanding of the process of normal electrical excitation, 362 
conduction, recovery and membrane stability. At the molecular level, this process depends upon normal 363 
function in a large range of individual ion channels with specific ion permeabilities and voltage dependences 364 
in their steady state and kinetic properties. Successful function at the cellular level requires a sequential and 365 
interdependent activation and inactivation of their resulting ion channel currents Ii (Section IB). At the tissue 366 
level, the resulting AP propagates through electric current flow along the intracellular resistance ra to 367 
depolarise the membrane capacitance cm. It thereby initiates excitation in hitherto quiescent connected 368 
membrane effectively along a multidimensional cable. Regularly paced APs thus acquire their characteristic 369 
duration, APD, and refractory period, ERP, separated by diastolic interval DI, through an integration of 370 
molecular mechanisms into cellular level events. The APs then propagate through myocardial tissue with 371 
velocity, θ, accordingly forming active regions with wavelength λ = θ × APD, or θ × ERP, followed by a 372 
quiescent wavelength determined by θ and the diastolic interval DI, defined by an integration of cellular 373 
events and tissue properties. These fundamental characteristics define the conditions necessary for orderly 374 
excitation patterns initiated from the pacemaker and propagating through the remaining cardiac structures 375 
(Section IC). 376 
 Arrhythmias following perturbations of these parameters may thus take place through their temporal 377 
heterogeneities resulting from transient membrane potential change, or alterations in steady state pacing 378 
rates. They may also be the consequence of spatial heterogeneities potentially resulting from varying tissue 379 
properties in different organ regions, or pathological anatomical change, particularly those impairing the 380 
processes of conduction or excitation (Section IIA). Analysis of cardiac excitation and its alterations 381 
producing arrhythmias thus requires experimental systems amenable to study at different levels of biological 382 
organization. Studies translatable to human arrhythmic conditions would require such systems to parallel 383 
human hearts in structure and function, and share a significant number of molecular species underlying their 384 
electrophysiological activation.  385 
 Mouse hearts fulfil a significant number of such criteria. In addition, they are amenable to genetic 386 
modification modifying the expression or function of particular, physiologically important, biological 387 
molecules. Murine systems further provide a range of translationally relevant exemplars for the clarification 388 
of arrhythmic processes arising from abnormalities in the initiation, propagation, and recovery of electrical 389 
activity or upon the potential for spontaneous triggering of arrhythmia (Section IIB). Each examplar was 390 
amenable to experimental and theoretical analysis at varied levels of biological organization and function 391 
through application and collation of results from a wide range of techniques. These extended from 392 
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electrocardiography in entire organisms, through extracellular and intracellular AP recording from isolated 393 
hearts subject to varied transient perturbations or steady state pacing conditions, biophysical ion channel and 394 
spectrophotometric Ca2+ homeostasis studies at the cellular level, to characterisations of protein and mRNA 395 
expression and localization at the molecular level (Section IIC). 396 
 Arrhythmic phenomena ultimately arise from biophysical events, beginning with ion channel-mediated 397 
processes in the cell surface membrane. A first group of studies examined a series of defined monogenic 398 
surface ion channel variants (Sections III-VI). These recapitulated the arrhythmic phenotype in their 399 
corresponding clinical genetic arrhythmic conditions. This gave credence to their use as disease exemplars 400 
in physiological studies including explorations for possible therapeutic manoeuvres. They fell into canonical 401 
groups that could be classified into effects relating to pacing (Section III), cellular connectivity (Section IV), 402 
AP excitation (Section V), and recovery from depolarisation as well as refractoriness (section VI). The last 403 
two recapitulated features of the Brugada Syndrome, and the long QT syndromes respectively. The analysis 404 
accordingly began with the effects of compromised or prolonged Na+ channel function whether through 405 
alterations in the conducting Nav1.5 subunit itself, or its associated β-subunits or intracellular regulatory or 406 
structural regulatory proteins (Section V and VI). These were followed by considering the physiological 407 
consequences of alterations in other ion channels carrying depolarising Ca2+ or repolarising K+ currents, and 408 
their different variants occurring variously in ventricular or atrial myocytes. The analysis of the murine 409 
systems recapitulating BrS further demonstrated longer term structural alterations recapitulating those found 410 
in human BrS and reproduced the time development of conduction change and arrhythmia in BrS and 411 
PCCD.  412 
 In each group, a systematic survey identified the observed arrhythmic properties with alterations in 413 
pacing, initiation and conduction of, as well as, recovery from excitation. They quantified critical conditions 414 
in heart rate (HR), conduction velocity θ, APDs and refractory periods ERPs. Detailed alterations in APD 415 
waveforms or recovery could modify the likelihood of re-excitation phenomena, potentially through effects 416 
upon Ca2+ current mediating EADs, and through effects on refractoriness. Arrhythmic substrate could arise 417 
from both temporal variations of these physiological parameters with extrasystolic provocation or with 418 
varying steady-state pacing rates, and spatial variations over the epicardial surface, across myocardial walls, 419 
and different cardiac regions and chambers. Genetic modifications of any particular molecular species 420 
impacted upon more than one of these physiological parameters. Conversely any one physiological 421 
parameter was affected by alterations in more than one species of channel. These complex physiological 422 
dependences have translational implications for the application of therapeutic agents directed at specific 423 
molecular species in the management of arrhythmia.  424 
 A second group of canonical variants concerned intracellular, as opposed to surface ion channel, 425 
changes. Intracellular Ca2+ is the predominant ion species involved in excitation-contraction coupling. The 426 
consequent alterations in Ca2+ homeostasis in turn impact upon surface membrane channel action (Section 427 
VII). Such alterations could take place through abnormal L-type Ca2+ channel mediated Ca2+ entry, RyR2-428 
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mediated SR Ca2+ release, SERCA mediated SR Ca2+ re-uptake and SR store levels. A range of acquired 429 
acute or chronic conditions could potentially alter the Ca2+ release process in both atria and ventricles. 430 
Similarly, murine systems with modified RyR2 or calsequestrin 2 provided genetic exemplars for an 431 
abnormal release of SR Ca2+. The resulting variations in [Ca2+]i could in turn influence the stability of 432 
surface membrane potentials through actions on electrogenic NCX mediating DAD phenomena potentially 433 
triggering extrasystolic activity. It could also potentially modify Na+ channel activity either acutely or 434 
through downregulation of its membrane expression reducing AP conduction velocity and thereby causing 435 
arrhythmic substrate. Modified intracellular Ca2+ could in turn drive metabolic alterations through its action 436 
on intracellular Ca2+ activated enzymes.  437 
 A third group of variations concerned alterations in cell metabolic state, with alterations in levels of 438 
particular intermediates affecting surface KATP and Na+ channels as well as RyR2-Ca2+ release channels 439 
(Section VIII). The latter intermediates include cellular levels of ATP, redox [NAD+]/[NADH] state, and 440 
altered mitochondrial function generating reactive oxygen species. These could be exemplified in genetic 441 
models modifying the mitochondrial upregulator PGC1, as well as models manipulating [NAD+]/[NADH].  442 
 The final group of examplars involve pathological anatomical, cardiomyopathic, changes that would 443 
be expected to modify passive membrane capacitative, cm, or intracellular resisistive, ra, cable properties 444 
determining electrophysiological conduction (Section IX). In addition to the fibrotic changes in the Na+ 445 
channels outlined previously, these could be exemplified by hearts containing variant signalling 446 
mechanisms. 447 
 Study of murine systems themselves thus provide insights concerning the function of particular ion 448 
channels at the tissue and organ levels, and the effects of their deficiencies or over-expression. They thereby 449 
contribute substantially to our understanding of the physiological basis of normal electrical activity and its 450 
propagation. This leads to developments in our fundamental understanding of the genesis and perpetuation 451 
of arrhythmia in terms of perturbations of these processes.  A substantial number of exemplars additionally 452 
show phenotypic features that parallel the corresponding human clinical conditions. In such situations, they 453 
may then be useful in fundamental explorations of both diagnostic and risk assessment criteria and possible 454 
therapeutic interventions. However, as with all physiological models, species-related differences would be 455 
expected between mouse and humans. This concern not only normal physiology, but also the pathological 456 
changes either leading to or resulting from phenotypic changes at the whole animal level. This is reflected in 457 
the small but important group of murine exemplars whose phenotypes showed marked contrasts from their 458 
corresponding human conditions. These continue to offer opportunities for specific investigations of such 459 
differences, and assessing the applicability or otherwise of specific biomarkers useful in risk stratification in 460 
mice to clinical management in man. Nevertheless, particular readouts from gene targeted mouse models 461 
provide insights into broad physiological mechanisms underlying electrophysiological stability or 462 
arrhythmogenesis. It is the latter that may be the more useful for the identification of approaches to direct 463 
translation.  464 
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 486 
Glossary of abbreviations. 4487 
 4488 
 4489 
AC3-I, autocamtide-3 inhibitor; 4490 
A-curve, APD (output) plotted against against DI (input 4491 
variable) in restitution analysis; 4492 
AERP, atrial effective refractory period; 4493 
AF, atrial fibrillation; 4494 
AIP, autocamtide-2 inhibitor protein; 4495 
AKAP9, A-kinase anchor protein 9; 4496 
AKAP-x, A-kinase anchoring protein-x; 4497 
AM, acetomethoxy-; 4498 
Ank2, ankyrin-B; 4499 
Anxa 7, annexin Aa7; 4500 
AP, action potential; 4501 
APD, action potential duration; 4502 
APDx, action potential duration to x% full repolarization; 4503 
ΔAPD90, endocardial-epicardial APD90 difference; 4504 
ARI, activation recovery interval; 4505 
ARID, difference between shortest and longest ARI; 4506 
ARVC, arrhythmogenic right ventricular cardiomyopathy; 4507 
AT, activation time; 4508 
AT1, angiotensin II type I receptor; 4509 
ATD, activation time difference; 4510 
ATP, adenosine triphosphate; 4511 
ATX-II, sea-anemone, Anemonia sulcata, toxin (INaL 4512 
agonist); 4513 
BAPTA, 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-4514 
tetraacetic acid; 4515 
BCD, basic cycle distance; 4516 
BCL, basic cycle length; 4517 
BEG, bipolar electrogram; 4518 
BMP-10, bone morphogenic protein-10; 4519 
BrS, Brugada Syndrome; 4520 
C57BL/6, mouse strain; 4521 
[Ca2+]i, cytosolic Ca2+ concentration; 4522 
CaM, calmodulin; 4523 
CaMKII, calcium/calmodulin-dependent protein kinase II; 4524 
CamKIIN, endogenous specific inhibitor of CaM-kinase II; 4525 
CaMKIIδ, δ isoform of CaMKII; 4526 
cAMP, 3,5-cyclic adenosine monophosphate; 4527 
Cdc42, cell division control protein 42 homolog; 4528 
CPA, cyclopiazonic acid; 4529 
8-CPT, protein kinase modulator:  8-(4chlorophenylthio)-2’-4530 
O-methyladenosine 3’, 5’-cyclic monophosphate; 4531 
CasQ, calsequestrin; 4532 
CASQ2, cardiac calsequestrin; 4533 
Cav-x, Caveolin-x (x = 1, 2 or 3); 4534 
CHO, Chinese hamster ovary (cell line); 4535 
CICR, Ca2+-induced Ca2+ release; 4536 
cko, conditional knockout; 4537 
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cm, membrane capacitance of unit fibre length (μF cm-1); 4538 
CPA, cyclopiazonic acid; 4539 
CPVT, catecholaminergic polymorphic ventricular 4540 
tachycardia; 4541 
Cre, cyclization recombinase; 4542 
CREB, cAMP response element-binding protein;  4543 
CREM, cAMP response element modulator; 4544 
CRISPR, clustered regularly interspaced short palindromic 4545 
repeat; 4546 
Ctgf, connective tissue growth factor; 4547 
CTGF, connective tissue growth factor;  4548 
cTnI, cardiac isoform of the cardiac troponin subunit that 4549 
inhibits actin-myosin ATPase activity; 4550 
Cx, connexin; 4551 
Cx40, connexin-40; 4552 
Cx43, connexin-43; 4553 
DAD, delayed after-depolarization; 4554 
DAG, diacylglycerol; 4555 
DCM, dilated cardiomyopathy; 4556 
DHPR, dihydropyridine receptor; 4557 
DI*,diastolic interval, DI, corresponding to sustained 4558 
duration alternans in restitution analysis; 4559 
DI, diastolic interval; 4560 
DI’, DI corresponding to sustained amplitude alternans in 4561 
restitution analysis; 4562 
di-4-ANEPPS, substituted aminonaphthylethenylpyridinium 4563 
(ANEP) voltage-sensitive dye; 4564 
DIcrit, DI corresponding to unity slope in restitution analysis; 4565 
DIERP, DI90 corresponding to effective refractory period 4566 
(ERP) in restitution analysis; 4567 
DIlimit, , DI90 corresponding to absolute refractoriness. 4568 
DLG1, disks large homolog 1; 4569 
D-line, relationship between APD and DI at a given BCL in 4570 
restitution analysis; 4571 
DNA, deoxyribonucleic acid; 4572 
DSG2, desmoglein-2; 4573 
Dsp, desmoplakin;  4574 
Dsg2, desmoglein; 4575 
(dV/dt)max, maximum rate of rise of action potential; 4576 
(dV/dt)min, maximum rates of fall of action potential trace; 4577 
EAD, early after-depolarisation; 4578 
ECa, Ca2+ Nernst potential; 4579 
ECG, electrocardiogram/electrocardiographic; 4580 
ED, embryonic day; 4581 
EGD, electrogram duration; 4582 
ELC, essential myosin light chain; 4583 
ENa, Na+ Nernst potential; 4584 
ENCX, reversal potential of the Na+/Ca2+ exchanger; 4585 
Epac, exchange proteins directly activated by cAMP; 4586 
ERK, extracellular signal-regulated kinases; 4587 
ERP, effective refractory period; 4588 
ES, embryonic stem; 4589 
ETA, endothelin receptor; 4590 
FKBP12.6, FK506 binding protein type 12.6; 4591 
G, guanine nucleotide-binding protein 4592 
G, transfer function of a feedback system; 4593 
Gi, inhibitory G protein; 4594 
glycerol-3-phosphate dehydrogenase 1-like (GPD1-L); 4595 
GPD1-L, glycerol-3-phosphate dehydrogenase 1-like; 4596 
Gq, guanine nucleotide-binding (G)-protein that activates 4597 
phospholipase C (PLC); 4598 
Gs, stimulatory G protein; 4599 
Gsα, Gs protein subunit-α; 4600 
H89, PKA inhibitor (N-[2-[[3-(4-Bromophenyl)-2-4601 
propenyl]amino]ethyl]-5-isoquinolinesulfonamide); 4602 
HCM, hypertrophic cardiomyopathy; 4603 
HEK-293, Human embryonic kidney 293 (cell line); 4604 
HOP, cardiac homeodomain-only protein; 4605 
hyperCKemia, high serum creatine kinase; 4606 
I(Ca)Cl , Ca2+-activated Cl- current; 4607 
I, input to a feedback system; 4608 
ia, axial current (A); 4609 
Ib,Na, inward background Na+ current; 4610 
ICa, Ca2+ current; 4611 
ICa,T, Cav3.2 (CACNA1H) mediated T-type Ca2+ current;  4612 
ICaL, Cav1.2 (CACNA1C) mediated L-type Ca2+ current; 4613 
ICD, implantable cardioverter defibrillator; 4614 
If, HCN-mediated hyperpolarization-activated inward 4615 
current; 4616 
ii, membrane ionic current in unit length (A cm-1); 4617 
IK1, Kir2.1, Kir2.2 and/or Kir2.3 (KCNJ2, KCNJ12 and/or 4618 
KCNJ4 respectively) mediated inwardly rectifying 4619 
K+ current; 4620 
IK2p, K2P3.1 (KCNK3)-mediated, 2-pore domain, K+ leak 4621 
current; 4622 
IKACh, Kir3.1/Kir3.4 (KCNJ3/ KCNJ5) mediated 4623 
acetylcholine-activated K+ current; 4624 
IKATP, Kir6.2 (KCNJ11) mediated ATP-sensitive K+ current; 4625 
IKCa, KCa2.x (SK1 to 3) mediated Ca2+-activated K+ current; 4626 
IKr, Kv11.1 (HERG or KCNH2) mediated rapidly activating 4627 
delayed rectifier K+ current; 4628 
IKs, Kv7.1 (KCNQ1) mediated slowly activating delayed 4629 
rectifier K+ current; 4630 
IKslow, rapidly activating but slowly inactivating K+ current; 4631 
IKslow1, Kv1.5-(KCNA5)- mediated, 4-aminopyridine 4632 
sensitive, rapidly activating, slowly inactivating K+ current; 4633 
IKslow2, Kv2.1-(KCNB1) mediated, 4-aminopyridine 4634 
insensitive, rapidly activating, slowly inactivating K+ 4635 
current; 4636 
IKur, Kv1.5 (KCNA5) mediated 4-aminopyridine-sensitive 4637 
ultrarapid delayed rectifier K+ current; (atrial, not 4638 
ventricular); 4639 
IMAC, inner membrane anion channel; 4640 
INa, Nav1.5 (SCN5A) mediated voltage-gated Na+ current; 4641 
INaK, Na+-K+-ATPase mediated electrogenic current; 4642 
INaL, late Na+ current; 4643 
INCX, Na+/Ca2+ exchange current; 4644 
IP3R, inositol 1,4,5‐trisphosphate receptor; 4645 
Iss, Kv1.5 (KCNA5) mediated sustained 4-aminopyridine 4646 
sensitive current; 4647 
Ist, sustained insward current; 4648 
Iti, transient, inward, Na+-Ca2+ exchange, current; 4649 
Ito, voltage-gated transient outward K+ current;  4650 
Ito,f, Kv4.2 (KCND2) and Kv4.3 (KCND3) mediated fast 4651 
voltage-gated transient outward K+ current; 4652 
Ito,s, Kv1.4 (KCNA4) mediated slow voltage-gated transient 4653 
outward K+ current; 4654 
JLN, Jervell and Lange Nielsen syndrome; 4655 
JNK, c-Jun N-terminal kinase; 4656 
JTV519 (K201), benzothiazepine Ca2+ channel blocker: 3-4657 
(4-benzyl-1-piperidinyl)-1-(7-methoxy-2,3-dihydro-1,4-4658 
benzothiazepin-4(5H)-yl)-1-propanone; 4659 
K201 (JTV519), benzothiazepine Ca2+ channel blocker: 3-4660 
(4-benzyl-1-piperidinyl)-1-(7-methoxy-2,3-dihydro-1,4-4661 
benzothiazepin-4(5H)-yl)-1-propanone; 4662 
KO, knockout; 4663 
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LBBB, left bundle branch block; 4664 
LMNA, lamin A/C; 4665 
LQTS, long QT syndrome; 4666 
LV, left ventricle; 4667 
LVNC, left ventricular non-compaction cardiomyopathy;  4668 
M cell, Mid-myocardial cell 4669 
MAGUK, membrane-associated guanylate kinase; 4670 
MAP, monophasic action potential; 4671 
MAPK, mitogen-activated protein kinase; 4672 
MEA, multi-electrode array; 4673 
Mena, intercalated disk mammalian-enabled protein; 4674 
MirP1, minK-related protein; 4675 
MKK4, mitogen-activated protein kinase kinase 4; 4676 
MKK7, mitogen-activated protein kinase kinase 7; 4677 
mmax, maximum slope of the restitution function; 4678 
MMP2, matrix metalloprotein 2; 4679 
mRNA, messenger ribonucleic acid; 4680 
MYBPC3, myosin binding protein C, cardiac; 4681 
MYH6, myosin heavy chain; 4682 
MyHC, β-myosin heavy chain; 4683 
n (subscript), nth beat in a series; 4684 
NAD, Nicotinamide adenine dinucleotide; 4685 
NADPH, nicotinamide adenine dinucleotide phosphate. 4686 
NCX, Na+/Ca2+ exchanger; 4687 
NFκB, nuclear factor kappa-light-chain-enhancer of 4688 
activated B cells; 4689 
NFAT, nuclear factor of activated T cell; 4690 
nNOS, neuronal nitric oxide synthase; 4691 
NOTCH, neurogenic locus notch homolog protein; 4692 
NOX2, NADPH oxidase 2; 4693 
Nppa, natriuretic peptide precursor A; 4694 
NRCM. neonatal rat cardiomyocytes; 4695 
NRVM, neonatal rat ventricular myocyte; 4696 
O, output of a feedback system; 4697 
Ora1, Ca2+ release-activated Ca2+ channel protein 1; 4698 
P2X, refers to ionotropic purinergic receptors; 4699 
P2Y, refers to G-protein-coupled purinergic receptors; 4700 
Pak1, p21 activated kinase-1; 4701 
PAP, Pak1 activating peptide; 4702 
PCCD, progressive cardiac conduction disease: Lev-Lenegre 4703 
syndrome; 4704 
PMCA, plasma membrane Ca2+ ATPase; 4705 
PCR, reverse transcriptase polymerase chain reaction; 4706 
PDZ, protein domain shared by post synaptic density protein 4707 
(PSD95), Drosophila disc large tumor suppressor (Dlg1), 4708 
and zonula occludens-1 protein (zo-1); 4709 
PEFA, programmed electrogram fractionation analysis; 4710 
PES, programmed electrical stimulation; 4711 
Pg, plakoglobin; 4712 
PGC1, peroxisome proliferator-activated receptor gamma 4713 
coactivator 1; 4714 
PKA, protein kinase A; 4715 
PKC, protein kinase C; 4716 
PKG, protein kinase G; 4717 
PKP2, plakophilin 2; 4718 
Pkp2, plakophilin-2; 4719 
PLC, phospholipase C;  4720 
PLN, phospholamban; 4721 
PMA, phorbol 12-myristate 13-acetate; 4722 
PMCA, plasma membrane Ca2+ ATPase; 4723 
PNa, membrane Na+ permeability; 4724 
Po, open probability; 4725 
PP1, protein phosphatase 1; 4726 
PP2A,  protein phosphatase 2A; 4727 
PPADS, P2 purinergic receptor antagonist: 4-[[4-Formyl-5-4728 
hydroxy-6-methyl-3-[(phosphonooxy)methyl]-2-4729 
pyridinyl]azo]-1,3-benzenedisulfonic acid; 4730 
PPAR, peroxisome proliferator-activated receptor; 4731 
qPCR, quantitative reverse transcriptase polymerase chain 4732 
reaction; 4733 
ra, intracellular axial resistance (Ώ cm); 4734 
Rac1, ras-related C3 botulinum toxin substrate 1; 4735 
RANGRF, GTP-binding nuclear protein guanine nucleotide 4736 
release factor; 4737 
RBBB, right bundle branch block; 4738 
RH237, substituted aminonaphthylethenylpyridinium 4739 
(ANEP) voltage-sensitive dye; 4740 
RHOA, Ras Homolog Gene Family Member A; 4741 
Rhod-2, cationic fluorescent 9-phenylxanthene derivative 4742 
Ca2+-sensitive dye; 4743 
RLC, regulatory myosin light chain; 4744 
rm, linear membrane resistance of unit fibre length (kΩ cm); 4745 
ROS, reactive oxygen species; 4746 
RT, recovery time; 4747 
RTD, repolarisation time difference; 4748 
RV, right ventricle/ventricular; 4749 
RVOT, right ventricular (RV) outflow tract; 4750 
RW, Romano-Ward syndrome; 4751 
RyR1, skeletal muscle ryanodine receptor; 4752 
RyR2, cardiac ryanodine receptor; 4753 
RyR2S/+, heterozygotic RyR2-P2328S/+; 4754 
RyR2S/S, homozygotic, RyR2-P2328S/P2328S; 4755 
s, seconds; 4756 
S1, regular pacing stimulus; 4757 
S1S2, time interval between the last S1 stimulus in a train 4758 
and the following extrasystolic (S2) stimulus; 4759 
S2, extrasystolic stimulus in a programmed electrical 4760 
stimulation protocol; 4761 
SAN, sino-atrial node; 4762 
SAP97, synapse-associated protein 97; 4763 
sarcKATP , sarcolemmal ATP-sensitive K+ channel; 4764 
SCD, sudden cardiac death; 4765 
SERCA2, cardiac sarcoplasmic reticular (SR) Ca2+-ATPase; 4766 
SIDS, sudden infant death syndrome; 4767 
SLMAP, sarcolemma associated protein; 4768 
SLN, sarcolipin; 4769 
SND, sinus node disorder; 4770 
SNTA1, α-1-syntrophin; 4771 
SOCE, store-operated Ca2+ entry; 4772 
SOICR, store-overflow-induced Ca2+ release; 4773 
SQTS, short QT syndrome; 4774 
SR, sarcoplasmic reticular; 4775 
ss, sustained (of alternans); 4776 
STIM, stromal interacting molecule; 4777 
SUR2A, β-subunit of Kir6.2 (ABCC9); 4778 
129/sv, mouse strain; 4779 
t, time (ms); 4780 
T, transverse, as in transverse (T-) tubules; 4781 
TALEN, transcription activator–like effector nuclease; 4782 
TdP, torsades de pointes; 4783 
TDR, transmural dispersion of repolarisation; 4784 
TGF-β1 transforming growth factor-β1; 4785 
TNF, tumour necrosis factor; 4786 
tr, transient (of alternans); 4787 
TrpC3, transient receptor potential cation channel, subfamily 4788 
C, member 3; 4789 
TrpC3, transient receptor potential cation channel, subfamily 4790 
C, member 3; 4791 
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TS, Timothy Syndrome; 4792 
TSA-201, human embryonic HEK293-derived cultured cell 4793 
line; 4794 
TTX, tetrodotoxin; 4795 
UTP, uridine-5'-triphosphate; 4796 
V, transmembrane voltage; 4797 
V, Volts; 4798 
VASP, vasodilator-stimulated phosphoprotein; 4799 
Vcl, vinculin; 4800 
VE, ventricular ectopic; 4801 
VERP, ventricular effective refractory period; 4802 
VF, ventricular fibrillation; 4803 
VT, ventricular tachycardia; 4804 
WT, wild-type; 4805 
X, independent variable in a feedback system; 4806 
x, length; 4807 
ZFN, zinc-finger nuclease; 4808 
ZO-1, zonula occludens-1; 4809 
βAR, β-adrenergic receptor 4810 
θ, velocity of AP conduction (m s-1); 4811 
λ, action potential wavelength; 4812 
λ0, resting wavelength; 4813 
λ0crit. resting wavelength corresponding to unity slope in λ0crit 4814 
restitution analysis;4815 
 816 
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 17 
Table 1. Human and murine, ventricular and atrial expression of cardiac ionic currents 18 
mediating excitable activity  19 
Current/symbol 
 
Protein Gene Human Mouse Action 
potential 
contribution. 
   ventricle atrium ventricle atrium  
Voltage-gated, inward currents 
Fast Na+ current, INa Nav1.5  SCN5A +++ +++ +++ +++ [0] 
L-type Ca2+ current, ICaL 
(dihydropyridine receptor: 
DHPR) 
Cav1.2  CACNA1C +++ ++ ++ ++ [2] 
Voltage-gated outward currents 
Fast transient outward K+ 
current,  Ito,f 
 
Kv4.2 
Kv4.3 
KCND2 
 KCND3 
++ +++ ++ +++ [1] 
Slow transient outward K+ 
current, Ito,s,  
Kv1.4 KCNA4 ++ +++ ++ +++ [1] 
Delayed rectifier K+ 
current, IKr  
Kv11.1  KCNH2 
(HERG) 
+++ + + + [3] 
Delayed rectifier K+ 
current, IKs  
Kv7.1 KCNQ1 +++ + + + [3] 
4-aminopyridine sensitive, 
rapidly activating, slowly 
inactivating K+ current, 
IKslow1 
Kv1.5 KCNA5 0 0 ++ +  
4-aminopyridine 
insensitive, rapidly 
activating, slowly 
inactivating K+ current, 
IKslow2 
Kv2.1 KCNB1 0 0 ++ +  
Sustained  4-
aminopyridine sensitive 
delayed rectifier K+ 
current, Iss 
Kv1.5  KCNA5 0 0 ++ +  
Atrial-specific 4-
aminopyridine-sensitive 
ultrarapid delayed rectifier 
K+ current, IKur, 
Kv1.5  KCNA5 0 ++ 0 ++  
131 
 
Inward rectifiers 
Inwardly rectifying 
current, IK1 
Kir2.1 
Kir2.2 
Kir2.3  
KCNJ2 
KCNJ12 
 KCNJ4 
+++ ++ +++ ++ [3], [4] 
Acetylcholine-activated, 
K+, current, IKACh,  
Kir3.1 
Kir3.4, 
KCNJ3 
 KCNJ5 
 
0 +++ 0 +++  
ATP-sensitive potassium 
channel, IKATP 
Kir6.2 KCNJ11 ++ ++ ++ ++  
Leak currents        
Two-pore domain K+ leak 
current, IK2p 
K2p3.1 KCNK3 +++ ++ ++ +++  
Ca2+-activated K+ 
currents, IKCa 
KCa2.x- KCNNx 0 +++ 0 +++  
Exchange currents 
Transient, inward, Na+-
Ca2+ exchange current, Iti 
NCX SLC8A1 ++ ++ ++ ++  
 20 
Action potential contributions (human ventricle): [0] Phase 0: rapid depolarisation; [1] Phase 1: initial rapid 21 
repolarisation [2] Phase 2: plateau; [3] Phase 3: repolarisation; [4] Phase 4: electrical diastole 22 
  23 
132 
 
 24 
Table 2. Murine models involving sino-atrial pacemaker function 25 
Gene Genotype Phenotype References 
 
 
Rapid K+ current (IKr)  
Erg1b Erg1b-/- Loss of IKr; bradycardic 
episodes 
(210, 626) 
Hyperpolarisation activated cyclic nucleotide gated (HCN) current If. 
Hcn1 Hcn1-/- (global) 
 
Bradycardic, reduced If (310, 837) 
Hcn2 Hcn2-/- (global) sinus dysrhythmia and 
reduced If 
(699) 
 Hcn2-/- (cardiac-specific) Sinus dysrhythmia (311) 
 
Hcn3 Hcn3-/- (global) Sinus rhythm, normal If (311) 
 
Hcn4  Hcn4-/- (global) Embryologically lethal (1094) 
 Hcn4-/- (cardiac-specific) Embryologically lethal; 
bradycardia; reduced If 
(1094) 
 Hcn4-R669Q/R669Q 
(global) 
Embryologically lethal; 
Bradycardia; slowed If 
(410) 
 Hcn4-/- (global; inducible) Sinus pauses; reduced If (426) 
 KiT-Hcn4-/- (inducible) Sinus pauses; reduced If (435) 
 Ci-Hcn4-/- (inducible, 
cardiac-specific) 
Bradycardia; reduced If (74) 
 Hcn4–573X KI (inducible, 
cardiac-specific) 
Bradycardia; normal If (20, 425) 
Voltage-gated Ca2+ current ICa 
Cacna1d Cacna1d-/- Bradycardia; 70% reduced 
ICa,L; residual ICa,L due to 
Cav1.2. 
(720, 751, 1344)
Cacna1c Cacna1c-DHP-/- Dihydropyridine insensitive 
Cav1.2, continued DHP 
effects implicating Cav1.3 
(1066) 
133 
 
Cacna1g Cacna1g-/- ICaT due to Cav3.1 entirely 
lacking. slowed 
atrioventricular conduction; 
moderate bradycardia 
(724) 
Cacna1h Cacna1h-/- Normal ECG characteristics  (186) 
Note: mutations involving Scn5a+/- (Scn5a) are covered in Table 4 26 
 27 
  28 
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Table 3. Selected loss-of-function murine cardiac connexin models  29 
Gene Genotype Phenotypes References 
 
 
Cx30.2 Cx30.2-/- Reduced PQ interval (590–592) 
Cx40 Cx40-/-  Prolonged ECG P-wave; 
prolonged PQ intervals; 
supraventricular arrhythmias; 
normal ventricular 
conduction 
(57, 176, 396, 573, 
1026, 1065, 1172, 
1191)  
 
Cx43 Cx43+/-  Normal P wave durations;  
reduced ventricular 
conduction velocities; 
homozygote lethal 
(296, 937, 1132) 
 Cx43- (inducible)  
 
 (286) 
 Cx43- (cardiac specific)  
 
 (389) 
Cx45 Cx45-/-  Normal AV conduction.  i.e. 
normal PQ and QRS duration 
n 
(596, 602) 
 Cx45-/- (cardiac specific)  
 
 (326) 
 30 
  31 
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Table 4. Murine variants recapitulating conduction abnormality.  32 
Gene/protein Genotype 
 
Phenotype  References  
Na+ channel Nav1.5 (α-subunits) 
Scn5a/Nav1.5; 
Na+ channel α-
subunit 
 
Scn5a+/- 
 
BrS including fibrotic conduction changes. (734, 867, 
1095) 
 Scn5a-
1798insD 
 
Overlap BrS/LQT3 syndrome  (208, 939, 
1184) 
 Serine of 
NaV1.5 SIV 
motif  replaced 
by premature 
stop codon 
causing 
truncated ΔSIV 
Loss of binding to PDZ domain of  lateral 
membrane α1-syntrophin; reduced lateral 
membrane NaV1.5 and INa. 
(1063) 
 
 
 
 
 
 
Na+ channel Navβ (β-subunits) 
Scn2b/Navβ2; 
Na+ channel, 
intercalated disk, 
β2-subunit 
 
Scnb2-/- 
 
Seizures; reduced neuronal Na+ channel 
density. cardiac phenotypes not yet 
examined. 
 
(185) 
Scn3b/Navβ3; 
Na+ channel, 
transverse 
tubular, β2-
subunit 
 
 
Scn3b-/- 
 
Reduced Na+ channel function; 
monomorphic or polymorphic VT on 
programmed stimulation 
(304, 402, 403, 
452, 713) 
Na+ channel associated proteins 
Ankyrin G 
(affecting 
intercalated disk 
Nav1.5 and and 
spectrin) 
 
 
Cardiac 
selective 
ankyrin G-/- 
 
 
Reduced INa; altered AP waveform; 
bradycardia; reduced ventricular (QRS) 
conduction; ventricular arrhythmias 
following Na+ channel antagonism. 
(716, 787, 790, 
889, 1006) 
Synapse 
associated 
protein-97 
(SAP97) 
(affecting 
αMHC-
Cre/Sap97-fl/fl: 
cardiomyocyte-
specific SAP97 
deletion 
Reduced IK1, Ito, IKur; intact INa; slightly 
increased Nav1.5 expression 
(355) 
136 
 
intercalated disk 
Nav1.5) 
, 
 
Desmosomal proteins (See also Table 8) 
Plakophilin-2  Pkp2+/- 
 
Desmosomal abnormalities; Reduced and 
modified INa; ventricular arrhythmias.  
(173, 174) 
Desmoglein-2  Dsg2-N271S 
 
Reduced INa and conduction velocities (952). 
Kv4.3 channel mediating Itos 
Semaphorin 3a 
(Sema3a). 
 
Sema3a-/- (KO 
of naturally 
occurring 
protein 
inhibitor of 
Kv4.3 
(underlies Ito) 
arrhythmic BrS-like phenotype (130, 476) 
 
 33 
  34 
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Table 5. Phenotypic similarities between arrhythmogenic properties in murine Scn5a+/- and 35 
Scn5a+/∆kpq hearts and human BrS and LQTS3 36 
Model Phenotype Mouse Human references 
Scn5a+/- 
compared with 
BrS 
Arrhythmic phenotype unmasked by 
flecainide 
+ + (150, 344, 914, 1270) 
 Arrhythmic phenotype relieved by 
quinidine 
+ + (92, 421, 792) 
 Positive ∆APD90 persistent with flecainide 
and quinidine 
+ 0 (743, 1095) 
 RVOT/Right ventricular initiation of 
arrhythmia 
+ + (734–736, 741, 754, 1336) 
 Fibrotic change with age + + (500–503) 
 Presence of male/female phenotypic 
differences 
+ + (500–503) 
Scn5a+/∆kpq 
compared with 
LQTS3 
Arrhythmic phenotype reduced by 
flecainide 
+ + (94, 914, 1096, 1263) 
 
 Arrhythmic phenotype  exacerbated by 
quinidine 
 
+ + (207) 
 Negative ∆APD90 rescued by flecainide + + (94, 1096) 
 
 Absence of male/female phenotypic 
differences 
+ + (684, 1096, 1321) 
 
  37 
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Table 6. Transgenic murine models associated with long QT syndromes 39 
Protein
/gene  
Genotype Ion 
current 
Clinical condition/phenotype References 
Channel α-subunits: Na+ channel variants 
Nav1.5
/Scn5a 
Scn5a-
∆KPQ/+ 
INaL LQTS3; prolonged APD (416, 843, 1095, 1128, 1129)  
 Scn5a-F1759A INaL Atrial and ventricular arrhythmia (1214) 
 Scn5a-
1798insD/+ 
INaL Overlap syndrome: SND, conduction 
disease, BrS and LQTS3 
(115) 
Channel α-subunits: K+ channel variants 
Kv4.2/
Kcnd2 
Kcnd2-DN  Ito,f Prolonged APD (558, 687) 
Kv1.4/
Kcna4 
Kcna4-/- Ito,s Normal APD (558, 687) 
Kv4.2/
Kcnd2 
and 
Kv1.4/
Kcna4 
Kv4.2-DN × 
Kv1.4-/- 
Ito,f 
and 
Ito,s 
Prolonged APD (558, 687) 
Kv11.1
/Kcnh2 
Merg1-/-  Embryologically lethal  (53, 688) 
 Merg1+/- ?IKr LQTS2; prolonged apical and basal 
APDs and VERPs  
 
(994) 
 Merg1b-/- ?IKr Normal APD; episodic sinus bradycardia  (627, 1307) 
 hERG-G628S 
(dominant 
negative) 
expression 
?IKr Normal QT durations (53) 
Kv7.1/
Kcnq1 
Kcnq1-/- IKs LQTS1; Jervell and Lange-Nielsen 
Syndrome; prolonged QT intervals in 
intact animal 
(167, 1138, 1222) 
 Human 
KCNQ1 
isoform 2 
overexpression  
IKs Prolonged QT interval (dominant 
negative effects on murine Kcnq1 
isoform 1) 
(254) 
Kv1.5/
Kcna5 
(ventri
cular) 
 
Cardiac Kv1.1 
N-terminal 
fragment 
overexpression 
Islow Prolonged QT intervals; spontaneous 
nonsustained VT 
(321, 688) 
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Kv1.5/ 
Kcna5 
(atrial) 
Kcna5-
E375X/+ 
IKur Atrial AP prolongation, EADs, and AF (853) 
Kir2.1/
Kcnj2 
Kcjn2-/- IK1, Anderson-Tawil syndrome (LQTS7); 
broader APs; spontaneous APs 
(1144, 1323) 
Channel α-subunits: Ca2+ channel variants 
Cav1.2
/Cacna
1c. 
Cacna1c-
G406R/+ 
ICaL  LQTS8;Timothy Syndrome (TS)) (56, 192, 277, 1086) 
 Cacna1c-
G406R/Akap-/- 
 Normal phenotype (192, 1150) 
Channel β-subunits 
Navβ1 
/Scn1b  
Scn1b-/- INa 
and 
INaL;  
Human: BrS; mouse: prolonged QT and 
RR intervals (Increased Nav1.5,  INa and 
INaL; altered Ca2+ homeostasis) 
(694) 
Navβ4/
Scn4b 
Scn4b-/- INa or 
INaL 
 
LQTS10; resurgent INa/increased INaL (373, 713) 
MinK/
Kcne1  
Kcne1-/- IKs LQTS5; Jervell and Lange-Nielsen 
syndrome 
(64, 276, 1130, 1195) 
MirP/K
cne2 
Kcne2-/- IKslow1, 
Ito,f 
LQT6: prolonged APD (956) 
Cytoskeletal proteins 
Ankyri
n-B 
Ankyrin-B+/−; 
ankyrin-B 
+/E1426G 
 LQTS4; abnormal Ca2+ homeostasis; 
triggered events, prolonged QT intervals; 
VT; atrial arrhythmias.  
 
(225, 361, 788, 790) 
 Ankyrin B-/-  Deficient Kir6.2 membrane expression 
and decreased IKATP. 
 
(182, 649) 
Caveol
in-
3/Cav3 
Cav3-/-  LQTS9 (Transverse tubular 
abnormalities) 
(337, 401, 434, 779) 
  40 
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Table 7. Transgenic murine models for catecholaminergic polymorphic ventricular 41 
tachycardia (CPVT)  42 
Gene  Genetic modification Phenotype Reference 
RyR2 (N-
terminal 
region) 
RyR2-R176Q/+ CPVT (ARVC2) (534) 
 RyR2-R420W CPVT (851) 
RyR2 (central 
region) 
RyR2-P2328S/+ and 
RyR2-
P2328S/P2328S 
CPVT (364, 1340) 
 RyR2-P2328S/ 
P2328S 
AF (569, 832, 996, 1334, 1337)  
 RyR2-R2474S/+ CPVT (585, 629, 1156) ) 
RyR2 
(C-terminal 
region) 
RyR2-R4496C/+ CPVT (172, 673) 
Casq2 Casq2-D307H 
overexpression 
CPVT (266) 
 Casq2-/- CPVT and cardiac 
hypertrophy 
(581) 
 Casq2+/- No phenotype (199) 
 Casq2-D307H/ 
D307H 
Spontaneous arrhythmias (1078) 
 Casq2-ΔE9/ΔE9 Spontaneous 
arrhythmias; cardiac 
hypertrophy with age 
(1077) 
 Casq2-R33Q/ R33Q Spontaneous arrhythmias (951) 
 43 
 44 
  45 
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Table 8.  Murine genetic models of structural disorders associated with ventricular or atrial 46 
arrhythmia 47 
Gene 
product 
Model Features References 
Fibrotic change 
TGF-β1  Cardiac-specific TGF-β1 overexpression (MHC-
TGFcys33ser) 
Atrial fibrosis and AF 
inducibility. 
(1193)  
TNFα  Cardiac-specific TNFα overexpression 
Atrial dilation, fibrosis, 
thrombosis, spontaneous AF in 
ambulant mice 
(598, 974) 
Angiotensi
n I 
converting 
enzyme 
(ACE) 
  
ACE 8/8 
Cardiac-specific 
overexpression of ACE  
atrial dilatation, fibrosis, and 
spontaneous AF in ambulant mice 
(1280) 
Adenosine 
(A1 or 
A3) 
receptors 
  
Cardiac -specific A3AR 
overexpression of at high 
(A3high) or low (A3low)  
adenosine levels 
bradycardiomyopathy  
 
 
(300) 
Ras 
Homolog 
Gene 
Family 
Member A 
(RHOA) 
 
Cardiac-specific (αMhc 
promoter) over-expression 
of WT or activated form of 
RHOA  
atrial enlargement, cellular 
hypertrophy, interstitial fibrosis; 
AF susceptibility, atrioventricular 
block, premature death 
(991) 
Mitogen-
activated 
protein 
kinase 
kinase 4 
(Mkk4), 
Atrial cardiomyocyte-
specific conditional knock-
out Mkk4-acko-Nppa-Cre4  
AF, atrial fibrosis; upregulated 
TGF-β1 signalling and 
dysregulation of matrix 
metalloproteinases. 
(245) 
Hypertrophic cardiomyopathy (HCM) 
Alpha-
myosin 
heavy 
chain 
(Myh6) 
Mhc-R403Q/+ QT dispersion, conduction 
heterogeneity, inducible VT, 
sudden death – variable degree of  
hypertrophy 
(112, 347, 
1266) 
Myosin 
binding 
protein C 
(Mybp-
C3) 
MyBP-C-t/+ and MyBP-C-
t/t; (t=  truncated Mybp-
C3) 
Hypertrophy, fibrosis, ventricular 
ectopic activity. 
(113)  
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Troponin 
T (Tnnt2) 
Severity: Tnnt2-I79N 
>TnnT-F110I>TnnT-
R278C 
Altered Ca2+ sensitivity 
Spontaneous VT, reduced IK1, 
(83, 580, 
583) 
Myosin 
light chain 
(coded by 
Mlc17) 
 
Mlc-17-M149V Hypertrophy (1185) 
Ras ( 
HRAS) 
Targeted, chronic Ras-
Raf–MAPK pathway 
activation and  αMHC-
loxp-GFP-loxp-H-RasV12 
Hypertrophy, ventricular 
arrhythmia, atrial fibrillation, 
conduction block,  
 
(969, 
1346) 
Dilated cardiomyopathy (DCM): Sarcomeric protein mutations 
Alpha-
myosin 
heavy 
chain 
(Myh6) 
 
Mhc-F764L/+, Mhc-
S532P/+, Mhc-
F764L/F764L and Mhc-
S532P/S532P)  
Dilatation (1018) 
Mammalia
n-enabled 
protein 
and 
vasodilato
r-
stimulated 
phosphopr
otein 
(Vasp)  
 
Cardiac myocyte-
restricted, α-myosin heavy 
chain promoter-directed 
expression of the 
dominant-negative VASP-
EVH1 domain. 
 
Dilatation, hypertrophy, 
bradycardia, sudden death 
(293) 
Neuron-
restrictive 
silencer 
factor 
(Nsrf) 
αMHCdnNRSF  
(Dominant-negative 
knock-in) 
 
Dilatation, heart block, sudden 
death 
(608) 
Dilated cardiomyopathy (DCM): Cytoskeletal protein mutations 
Lamin 
(coded by 
LMNA) 
LMNA+/-, AV nodal disease, atrial 
arrhythmia, VT 
(1267) 
 Lmna-N195K Dilatation, fibrosis bradycardia, 
SA node exit block 
(807) 
 Lmna-H222P/H222P Models Emery-Dreifuss syndrome; dilatation, increased 
PR interval, variable conduction 
block, QRS prolongation, 
ventricular extrasystoles 
(45) 
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Dilated cardiomyopathy (DCM): SR Ca2+-cycling protein mutation 
Phosphola
mban 
(Pln) 
 
 
Pln-R14Del Dilation, fibrosis, VT sudden 
death 
(397) 
 Pln-R9C/R9C Reduced  protein kinase A activity; delayed SERCA-Ca2+ 
re-uptake; dilated 
cardiomyopathy; congestive heart 
failure 
(1019) 
Dilated cardiomyopathy (DCM): Developmental gene mutations 
Cardiac 
homeobox 
gene 
product 
(Nkx-2.5)  
 
Ventricle-restricted 
deficiency: Nkx2-5-
f/f/cre+ 
 
Hypertrabeculation, 
noncompaction, conduction 
disturbance 
(871) 
Vinculin 
(VCL) 
Cardiac-restricted Vclfl/fl 
MLC-2vCre/+ knockout 
Dilatation, VT, sudden death (1324) 
Troponin I 
(TNNI3) 
cTnI-R192H Atrial dilatation, decreased LV 
volume, decreased EF, delayed 
relaxation 
(278, 279) 
Arrhythmogenic right ventricular dysplasia (ARVD): desmosomal protein gene 
mutations 
Plakophili
n-2 (Pkp2) 
Pkp2-/- Lethal (376) 
 Pkp2+/- Normal cardiac phenotype (376) 
Plakoglobi
n (Pg) 
 
Pg-/- Lethal (647) 
 Cardiac specific Pgf/f-
αMHCcre 
RV enlargement, fibrosis, slowed 
RV conduction, spontaneous VT 
of right ventricular origin. 
Phenotype exacerbated by training
(571, 647, 
973) 
Desmopla
kin (Dsp) 
 
Dsp-/- Embryonic lethal (339, 475) 
 Dsp+/-  Slowed conduction and inducible VT prior to adult structural 
changes 
(366) 
 Cardiac overexpression of flag-tagged Dsp cDNA 
carrying Dsp-R2834H-Tg 
C-terminal mutation  
Apoptosis, fibrosis, RV and LV 
dilatation, reduced ventricular 
function, widened intercalated 
disks  
(1296) 
 Cardiac specific Dsp-f/f- (MLC2v-Cre) 
Cardiomyopathic changes, 
Ventricular arrhythmias 
accentuated by exercise and 
catecholaminergic challenge. 
slowed RV conduction. 
(706) 
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Desmoglei
n (Dsg2) 
Cardiac overexpression of 
flag-tagged dominant 
Dsg2-N271S mutant 
(homologous with human 
DSG2–N266S ARVC 
mutation)  
 
Myocyte necrosis, calcification 
and fibrous tissue replacement; 
spontaneous ventricular 
arrhythmias, conduction slowing, 
ventricular dilatation and 
aneurysms, replacement fibrosis 
and SCD 
(896) 
Arrhythmogenic right ventricular dysplasia (ARVD): laminin receptor mutations 
Laminin 
receptor 1 
(Lamr1) 
KK/Rvd (Knock-down) 
 
Right ventricular fibrosis, QRS 
prolongation 
(48) 
Left ventricular non-compaction cardiomyopathy (LVNC) 
Cypher/Za
sp 
Mutations in Cypher/Zasp LVNC with DCM and 
HCM phenotype, early 
post-natal death  
(1345, 1350). 
 48 
  49 
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 50 
 51 
FIGURE LEGENDS 52 
Figure 1. Basic features of cardiac electrophysiological excitation.  53 
 (A) Inward and (B) outward ionic current contributions attributable to surface membrane ion channels to 54 
(C) human and (D) mouse ventricular action potential (AP) waveforms.  55 
Figure 2. Extension of cable analysis to action potential wavelength, wave-break and re-56 
entry.  57 
 (A) Typical murine monophasic right ventricular action potential (AP) waveform, indicating basic cycle 58 
length (BCL), action potential duration at 90% recovery (APD90), latency and diastolic interval (DI) of the 59 
current (nth) and preceding ((n-1)th)AP. (B) These variables yield the active and resting wavelengths λ’ and λ0’ 60 
for which the basic cycle distance, BCD’ = λ’ + λ0’. (C) Orthograde propagation of an AP with long λ’ over a 61 
heterogeneity results in the back of the propagating wave blocking retrograde propagation. (D) Propagation of 62 
an AP with a short λ’ results in the back of the wave passing the heterogeneity before retrograde excitation has 63 
crossed the unidirectional block. This results in initiation of a new propagating retrograde wave and a re-entrant 64 
circuit (reproduced by permission from Matthews et al (753). 65 
Figure 3. Conditions underlying generation of re-entrant arrhythmia.  66 
 (A) Basic features of arrhythmic substrate, consisting of slow conducting myocardial pathway, (path 1; 67 
dark gray), non-conducting myocardium, and second normally conducting pathway (path 2; white)(i). Normal 68 
action potential (blue arrow) propagates with velocity θ and effective refractory period (ERP) resulting in 69 
propagation wavelength (λ = θ × ERP) (yellow region) along path 2. It initiates a slow conducting impulse 70 
travelling along path 1 (i). In normal activity, the latter impulse cannot re-enter the circuit as it collides with 71 
refractory tissue in path 2 (ii). (B) An abnormal triggered impulse immediately following the normal action 72 
potential cannot enter path 1 as this remains refractory. (C) Self-perpetuating re-entrant excitation occurs when 73 
a retrogradely conducting AP along path 1 (i) enters the beginning of path 2 with reduced conduction velocity 74 
and effective refractory period and therefore reduced excitation wavelength smaller than the dimensions of the 75 
propagation pathways (reproduced by permission from King et al (567)). 76 
Figure 4. Temporal heterogeneity in the generation of re-entrant substrate. 77 
 (A) Classical restitution curves in which action potential duration (APDn) of the nth AP decreases with the 78 
decreasing, preceding, (n-1)th, diastolic interval (DI) observed at successively shortened basic cycle lengths 79 
(BCL). The accompanying progressively increasing slope requires successively greater number of cycles of 80 
alternans to intervene before the system reaches a new steady state APD (point 1 and 2). When unity slope is 81 
reached, alternans become sustained (point 3). Slopes exceeding unity result in waxing oscillations (point 4) in 82 
APD. This culminates in conduction block and/or tachyarrhythmia resulting from wave-break. (B) Fuller 83 
analysis of generic restitution function relating APD90 corresponding to the APD at 90% AP recovery to the 84 
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corresponding DI90. In addition to conventional measures of critical diastolic interval (DIcrit) and maximum 85 
gradient (mmax) this maps the maximum APD (APDmax) at low heart rates, DI90 at the effective refractory period 86 
(DIERP), and the horizontal axis intercept of the restitution function, (DIlimit) corresponding to absolute 87 
refractoriness. This permits definition of conditions for stability (unshaded), instability (filled), as well as 88 
relative (dotted) and complete, loss of capture (hatched areas). (C, D) Typical records reflecting arrhythmic 89 
phenotypes in monophasic action potential recordings from regularly paced (triangular markers) murine 90 
Scn5a+/- right ventricular (RV) epicardia showing nonsustained VT (BCL 134 ms) (C) and the initiation of 91 
sustained polymorphic VT (BCL 124 ms) (D) (Reproduced by permission from Martin et al (740) and 92 
Matthews et al (752)). 93 
Figure 5. Sodium (Na+) currents in Scn5a+/- hearts.  94 
 (A) Na+ currents INa, normalised to cell capacitance from myocytes from left (LV) and right ventricles 95 
(RV) of wild-type and Scn5a+/- hearts. (B, C) corresponding (B) current-voltage relationships (C) maximum 96 
INa and (D) activation and (E) inactivation curves with Boltzmann fits. (*) denotes effect of genotype and (#) 97 
denotes effect of cardiac ventricle (Reproduced by permission from Martin et al (741)).  98 
Figure 6. Re-entrant circuit initiation of ventricular arrhythmia in Scn5a+/- ventricle. 99 
 (A–F) Right ventricular (RV) isochronal propagation maps in flecainide-treated Scn5a+/- heart 00 
illustrating initiation of ventricular tachycardia (VT). Thick black lines denote propagation block. Thin arrows 01 
denote lines of propagation. (G) ECG trace with ventricular ectopic initiating polymorphic VT. (H) Part of the 02 
same ECG trace, with 8 electrogram traces, at the point of VT initiation. Electrogram numbers correspond to 03 
the channel numbers of the array marked in maps A-F. (A) Crowded isochronal lines in the last sinus beat and 04 
area of conduction slowing. (A”) Repolarisation map of the last sinus beat with increased repolarization 05 
heterogeneity in the same area. (B) Premature ventricular beat superimposed on this leads to line of block with 06 
impulse propagation flowing around it. (C) A second ventricular ectopic (VE) resulting in a reentrant circuit. 07 
(D) The circuit continuing into the next beat to initiate VT. (E, F) Changes in the line of block that create a 08 
nonstationary vortex, causing polymorphic arrhythmia. (I) Propagation map, ECG, and electrogram traces of 09 
the VT propagating as a wave front across the LV from the RV. (J) ECG trace of a VE occurring after the T 10 
wave (Reproduced by permission from Martin et al (736)). 11 
Figure 7. Conduction and arrhythmic properties in ageing male Scn5a+/- hearts. 12 
  (A) Lead II electrocardiographic traces obtained from anaesthetised aged Scn5a+/- mouse showing 13 
spontaneous non-sustained ventricular tachycardia (VTs indicated by arrow). (B) Chest lead ECG complexes 14 
from young (a) and old (b) intact anaesthetised male Scn5a+/- mice. The latter shows patterns of fragmented 15 
QRS complexes indicating bundle branch block most frequently observed with Scn5a+/-. (C, D) Activation 16 
maps from five successive cardiac cycles in young male WT (C) and old male Scn5a+/− hearts (D). (E) 17 
Picrosirius red staining demonstrating ventricular fibrosis in 85 week-old WT (a), and Scn5a+/- with mild (b) 18 
and severe fibrosis which appears red (c). (F) Corresponding INa records in ventricular myocytes from 12 week-19 
old WT (a) and mildly (b) and severely affected Scn5a+/- mice (c). (G) Frequency distributions of activation 20 
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times in young male WT (a) and old male Scn5a+/− (b) (Reproduced from Jeevaratnam et al. (Jeevaratnam et al., 21 
2010, 2011, 2012) and Leoni et al. (642)). 22 
Figure 8. Development of arrhythmia resulting from a combination of Nav1.5 23 
haploinsufficiency and structural change in progressive cardiac conduction defect (PCCD) 24 
and Brugada syndrome (BrS).  25 
 Nav1.5 haploinsufficiency produces a background electrophysiological defect in conduction. This results 26 
in arrhythmic substrate typically unmasked by ﬂecainide or ajmaline challenge. Cardiac ﬁbrotic changes occur 27 
with age, particularly in males. This further compromises action potential propagation. Superimposition of the 28 
two factors sufficiently compromises conduction thereby accentuating arrhythmic substrate to lead to 29 
arrhythmic events. There is thus a combination of biophysical and structural change with age, particularly in 30 
males, that results in arrhythmia. (Reproduced by permission from Jeevaratnam et al  (500)). 31 
Figure 9. Variations in conduction properties through the isolated sinoatrial node of 32 
Scn5a+/- hearts with age.  33 
 (A) Electrograms and activation mapping in young WT (a) and young Scn5a+/- (b), and old WT (c) and 34 
old Scn5a+/- atria (d). (B, C). Sino-atrial node (SAN) cycle lengths (B) and sino-atrial conduction times in the 35 
four experimental groups (C). (D-F) Fibrosis-regulating, TGF-β1, and vimentin, and Nav1.5 gene expression 36 
and interacting effects of ageing and genotype. (D) mRNA abundance assessed by real-time polymerase chain 37 
reaction. (E) Correlations between gene expression of TGF-β1 and Nav1.5 (a), vimentin and Nav1.5 (b), and 38 
vimentin and TGF- β1 (c). (F) TGF- β1 gene expression initiated by Nav1.5 inhibition with Nav1.5 antibody. 39 
TGF-β1 gene expression was increased by Nav1.5 antibody treatment at the transcriptional (a) and protein 40 
levels (b) in both human neonatal myocytes and fibroblasts (Reproduced by permission from Hao et al. (408)). 41 
Figure 10. The Scn3b-/- exemplar for cardiac arrhythmogenesis. 42 
 (A) INa traces from WT (a) and Scn3b-/- myocytes (b) showing peak INa that is significantly smaller in 43 
Scn3b-/- myocytes. (B) Boltzmann fits to steady-state voltage dependence of activation (squares) and 44 
inactivation (circles) in WT (filled) and Scn3b-/- (clear symbols). Differing voltage dependence of inactivation 45 
in Scn3b-/- compared to WT particularly between holding voltages of -70 and -40 mV. (C) Recovery from 46 
inactivation in WT (filled) and Scn3b-/- (clear symbols). (D) Bipolar electrogram waveforms from programmed 47 
electrical stimulation at the longest (a, c) and shortest (b,d)  S1–S2 intervals in WT (a,b) and Scn3b-/- hearts. 48 
The latter hearts showed consistently longer waveforms. (E) Representative monophasic action potential 49 
(MAP) recordings from the WT (a) and their shortening in Scn3b-/- (b) hearts. (F) ECG recordings obtained 50 
from WT (a) and Scn3b-/- mice (b). Scn3b-/- mice showed slower heart rates and prolonged PR intervals. (c) 51 
Some ECGs from Scn3b-/- mice showed ventricular QT complexes occurring independently of regularly 52 
occurring atrial, P waves i.e. third degree heart block. (G) Atrial tachycardia (AT) (a) resulting in regular 53 
deflections at a higher frequency and atrial fibrillation (AF) (b) resulting in irregular deflections at a higher 54 
frequency following atrial burst pacing (ABP) in Langendorff-perfused Scn3b-/- hearts. The ventricular spikes 55 
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result in the larger, and the atrial spikes in the smaller deflections. (c) PES-induced VT beginning as a 56 
monomorphic then deteriorating into polymorphic VT in a Scn3b-/- heart preparation (Reproduced by 57 
permission from Hakim et al (402–404)). 58 
Figure 11. Separation of contributions to arrhythmogenesis from EADs and transmural APD 59 
gradients in Scn5a+/∆KPQ hearts. 60 
 (A) Microelectrode recordings showing action potential prolongation in Scn5a+/∆KPQ myocytes. (B, C) 61 
prolonged recovery tail currents after 100 ms test pulses to +40 mV from a –120 holding potential in WT (B) 62 
and Scn5a+/∆KPQ myocytes (C). (D) Action potential (AP) waveforms with early afterdepolarisations (EAD) 63 
generating (E) inward late tetrodotoxin (TTX)-sensitive INaL in myocytes in an action potential clamp. (F, G) 64 
Epicardial monophasic AP recordings from spontaneously active Scn5a+/∆KPQ hearts showing multiple EADs 65 
and nonsustained VT (F), abolished by 1 μM nifedipine (G). (H, I) Patch clamp studies in isolated LV 66 
ventricular myocytes from Scn5a+/ΔKPQ hearts demonstrating that nifedipine (300 nM) completely suppressed 67 
the inward Ca2+ current following depolarizing steps from a –40 mV holding voltage of −40 mV to 10 mV (H). 68 
In contrast, nifedipine had no effect on inward Na+ currents in response to depolarizing steps from −100 mV to 69 
−40 mV (I). (J-L) Number of hearts showing VT arrhythmia (J), percentage of monophasic action potentials 70 
showing EADs in Scn5a+/ΔKPQ hearts (K), mean ± SEM endocardial and epicardial APD90 values and 71 
ΔAPD90 in Scn5a+/ΔKPQ (L) at different nifedipine concentrations (0 nM, 1 nM, 10 nM, 100 nM, 300 nM and 72 
1 μM). (M) Effects of nifedipine (1 μM) on VERPs of Scn5a+/∆KPQ and WT hearts (Reproduced by 73 
permission from Head et al (416) and Thomas et al (1128)). 74 
Figure 12. Electrophysiological features contributing to arrhythmogenesis in hypokalaemic 75 
murine ventricles.  76 
  (A) Outward and inward K+ currents (a,c) and representations of their respective maximum currents (b, 77 
d) from whole cell patch-clamped epicardial (a, b) and endocardial myocytes (c, d) under normokalaemic (dark 78 
lines) and hypokalaemic (3 mM) conditions (pale lines). Under normokalaemic conditions, epicardial myocytes 79 
(a) showed greater early outward IK than endocardial myocytes (c). However, whereas hypokalaemia reduced 80 
early outward IK in epicardial but not endocardial cells (b), it reduced inward IK1 in epi- and endocardial cells 81 
by similar extents (b,d). (B) Monophasic AP recordings from LV endocardial and epicardial Langendorff-82 
perfused WT murine hearts paced at 125 ms BCL, under control (5.2 mM [K+]), (a)) and hypokalaemic 83 
conditions (3 mM [K+], (b)). (C) Steady state epicardial (white columns) and endocardial APD90s (grey 84 
columns) and the resulting ΔAPD90 (black columns) at [K]o = 5.2 mM (a), 4 mM (b) and 3 mM (c) respectively. 85 
(D) Programmed electrical stimulation (PES) of isolated, WT Langendorff-perfused mouse hearts under 86 
normokalaemic (a) and hypokalaemic 4 mM (b) and 3 mM [K+]o (c) conditions did not induce VT in (a) but 87 
induced VT in two of seven hearts in 4 mM [K+]o (b) and 9 of 11 hearts in 3 mM [K+]o (c). (E) LV epicardial 88 
monophasic action potential (MAP) recordings during intrinsic pacing (a), and programmed electrical 89 
stimulation (PES) (b) in the presence of 3 mM [K+]o and 2 μM KN-93. KN-93 reduced the occurrence of early 90 
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afterdepolarizations (EADs), triggered beats and ventricular tachycardia (VT) in spontaneously beating hearts 91 
(a). It failed to protect against arrhythmia provoked by PES in six of six hearts (b) (Reproduced by permission 92 
of Killeen et al (559, 561)). 93 
Figure 13. Development of arrhythmia resulting from a combination of triggering activity 94 
and recovery abnormality exemplified by the gain of Nav1.5 function Scn5a+/ΔKPQ, or loss 95 
of K+ channel function through genetic modification or hypokalaemic challenge in murine 96 
exemplars.  97 
 Emerging from studies of murine exemplars (A), triggered activity results from the prolonged APD 98 
predisposes to L-type Ca2+ channel re-excitation, producing triggered action potentials (B). Recovery 99 
abnormality, particularly in the epicardium produces a background electrophysiological defect measurable as a 00 
LQTS, resulting in arrhythmic substrate involving alterations in recovery gradients arising from APD and 01 
VERP changes in epicardial and endocardial myocardium (C). Together (B) and (C) predispose to arrhythmic 02 
events and SCD (D). 03 
Figure 14. Signalling pathways underlying excitation-contraction coupling.  04 
 β-adrenergic receptor (βAR) activation through stimulatory guanine nucleotide-binding (Gs) proteins 05 
increases cellular cyclic 3,5-adenosine monophosphate (cAMP) levels (A). This in turn drives (A) a 06 
phosphokinase-A (PKA)-mediated phosphorylation and activation of L-type Ca2+ channels and cardiac 07 
ryanodine receptor (RyR2) SR-Ca2+ release channels, and (B) the exchange protein directly activated by cAMP 08 
(Epac) pathway producing a calmodulin kinase II (CaMKII)-mediated RyR2 activation. Either action on the 09 
Ca2+-induced Ca2+ mechanism impinges on the level of SR Ca2+ release (C), and consequent alterations in 10 
cytosolic Ca2+ (D). Experimentally used agonists (+) and antagonist (-) agents used on these pathways include 11 
isoproterenol, H-89, 8-pCPT-2-O-Me-cAMP (8-CPT) and KN-93.  12 
Figure 15. Epac-induced RyR2 activation as an exemplar for Ca2+ mediated arrhythmia.  13 
 (A) Propagation of a Ca2+ wave from one end of the cell to the other following 8-CPT challenge shown in 14 
successive confocal microscope frame scan images. (B) Ca2+ fluorescence signal from six successive 2 μm×2 15 
μm regions of interest, (a) to (f), placed along the long axis of a myocyte demonstrating progressively 16 
increasing delays in onset of the Ca2+ transient. (C) Ca2+ signals in regularly stimulated ventricular myocytes 17 
(triangles mark timing of pacing stimuli) showing irregularly occurring ectopic Ca2+ transients during 8-CPT 18 
treatment (a, b) abolished by KN-93 (c). (D) Persistent ventricular tachycardia (VT) following programmed 19 
electrogram stimulation observed during perfusion with 8-CPT prevented by CaMKII inhibition with KN-93. 20 
(E) Triggered activity (*) during intrinsic activity observed during perfusion with 8-CPT, prevented by KN-93 21 
pretreatment. (F) Epicardial (a) and endocardial APD90 (b), ΔAPD90 (c) and VERP (d) under control conditions 22 
(clear bars), during 1 μM 8-CPT treatment in the absence (black bars) and following 1 μM KN-93 pretreatment 23 
(striped bars) (Reproduced by permission from Hothi et al (446)). 24 
Figure 16. Pro-arrhythmic features in RyR2-P2328S hearts. 25 
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 (A) Sequential gallery of confocal microscope images showing Ca2+ waves in a single fluo-3 loaded 26 
ventricular homozygotic RyR2-P2328S (RyR2S/S) myocyte following isoproterenol (100 nM) challenge. 27 
Arrowed: path taken by typical Ca2+ wave. (B-D) Epicardial monophasic action potentials in intrinsically active 28 
RyR2s/s hearts. (B) Spontaneous early-after depolarizations (EADs) (*) followed by episodes of sustained 29 
monomorphic VT (sVT). (C) Coupled beats. (D) Persistent ventricular fibrillation (VF) following the cessation 30 
of regular S1 pacing after two intrinsic MAPs. (E) S2 extra-stimuli during PES typically producing limited 31 
episodes of non-sustained VT in the absence (left trace) but sustained (>30 s) VT in the presence of 100 nM 32 
isoproterenol (right trace). (F-I) Electrophysiological assessment of Na+ channel function in RyR2S/S, Scn5a+/−, 33 
and WT atria. (F) Left atrial intracellular APs showing conduction latencies from WT, Scn5a+/−, and RyR2S/S, 34 
myocytes and (G) their corresponding (dV/dt)max. (H-I) Loose-patch clamp recordings of currents during a 100 35 
mV 50 ms activation step following 50 ms pre-pulses between 20 and 100 mV for WT (H) and RyR2S/S atria (I) 36 
(Reproduced by permission from Goddard et al (364) and King et al.(568)). 37 
Figure 17. Physiological features mediating arrhythmogenesis in Pak1-deficient hearts.  38 
 (A) Monophasic action potential (AP) recordings showing AP alternans (a), torsades de pointes (TdP) (b) 39 
and polymorphic VT (c) following burst pacing (horizontal line below trace) in ex vivo Pak1-cko hearts, 40 
features not observed in Pak1-f/f hearts. (B) Ca2+ transients in field-stimulated Pak1-f/f (a) and Pak1-cko 41 
myocytes (b) at a 1 Hz stimulation frequency under baseline (left traces (i)) and chronic β-adrenergic stress 42 
conditions (right traces, (ii)). Increased pacing frequencies increase the occurrence of Ca2+ waves to greater 43 
extents in Pak1-cko than Pak1-f/f myocytes particularly with chronic β-adrenergic stress. (C, D) Recovery of 44 
SR Ca2+ stores from after previous depletion by caffeine challenge, after which regular stimulation resumed. (i) 45 
Ca2+ transients indicating recovery of SR Ca2+ in Pak1-f/f (C) and Pak1-cko myocytes (D) under baseline 46 
conditions. (a-c) Comparison of increasing Ca2+ transients (ii), constant ICaL (iii) and increasing INCX (iii) at 47 
different stages (a-c) of SR Ca2+ recovery (Reproduced with permission from Wang et al (1230)).  48 
Figure 18. Scheme exploring relationship between perturbations in Ca2+ homeostasis, 49 
triggering, arrhythmic substrate and generation of arrhythmia.  50 
 (A) Acquired or genetic perturbations resulting in increased release of sarcoplasmic reticular (SR) Ca2+ or 51 
decreased Ca2+ re-uptake from cytosol to store both perturb cytosolic Ca2+ (B). This in turn alters (C) Na+-Ca2+ 52 
exchange (NCX) electrogenic activity leading to diastolic triggering phenomena. It can also (D) reduce Nav1.5 53 
synthesis or membrane trafficking and therefore its membrane expression, or directly alter Nav1.5 biophysical 54 
properties. Both effects potentially slow conduction, resulting in arrhythmic substrate even under conditions of 55 
normal action potential recovery as reflected in action potential duration/effective refractory period (APD/ERP) 56 
ratios. Combination of (C) and (D) culminates in (E) potentially fatal ventricular arrhythmia. Possible direct 57 
actions of intermediates arising from metabolic change on INa not shown for simplicity.  58 
Figure 19. Arrhythmogenic features of PGC1β-/- hearts.   59 
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 (A) Increased heart rate following isoproterenol challenge accompanied by polymorphic ventricular 60 
tachycardia (VT) in PGC1β-/- mice during ECG recording. (B) Monophasic action potential (AP) recordings of 61 
VT following programmed electrical stimulation in Langendorff-perfused PGC1β-/- hearts. (C) APs from 62 
PGC1β-/- ventricular myocytes showing early (EADs) and delayed afterdepolarisations (DADs) and ectopic 63 
APs. Inset magnifies voltage trace 40-fold. (D) Abnormal Ca2+ homeostasis with intermittent elevations in 64 
diastolic Ca2+ and Ca2+ waves increased in amplitude and frequency in isoproterenol challenged PGC1β-/- 65 
ventricular myocytes. (E) Voltage-gated ICa and (F) transient and sustained outward IK in response to 66 
depolarizing pulses from -40 to +50 mV altered in successive 10 mV increments from a -40 mV holding 67 
potential. (G) inwardly rectifying currents obtained in response to hyperpolarizing steps from -40 to -100 mV 68 
incremented in 10 mV intervals. (E-G) shown for (a) PGC1β-/- and (b) WT ventricular myocytes, with voltage 69 
step protocols shown in (c). (H) Step current injections produced single APs with prolonged plateaus with burst 70 
AP firing in PGC1β-/- (a) but not WT myocytes (b) (Reproduced with permission from Gurung et al (387)). 71 
Figure 20. Energetic dysfunction and arrhythmic phenotype.  72 
 Possible simplified relationships beween (A) energetic dysfunction associated with ischaemic conditions, 73 
cardiac failure, ageing and diabetes, (B) mitochondrial dysfunction associated with ROS production, altered 74 
NAD+/NADH, and ATP/ADP and their possible consequences for (C) RyR2-mediated release of SR Ca2+ 75 
leading to increased [Ca2+]i, and NCX and DAD triggering activity, and (D) Na+ and K+ channel activity 76 
affecting AP excitation, propagation and recovery potentially resulting in (E) substrate that can be potentially 77 
triggered to give arrhythmic phenotypes.  78 
Figure 21. The arrhythmic mitogen-activated protein kinase kinase 4 knockout heart as an 79 
arrhythmic exemplar for fibrotic change. 80 
 In vivo and ex vivo cardiac electrophysiological characterizations of mice carrying an atrial 81 
cardiomyocyte specific mitogen-activated protein kinase kinase 4 knockout, Mkk4-acko, compared with Mkk4-82 
flox/flox, Mkk4-f/f, controls. (A) Representative in vivo ECG recordings showing (a) normal rhythm in Mkk4-83 
f/f in contrast to (b) polymorphic atrial ectopic beats and spontaneous atrial tachycardic episodes in Mkk4-acko 84 
mice. (B) Ex vivo atrial epicardial monophasic action potential (AP) recordings in Langendorff-perfused hearts 85 
during programmed electrical stimulation interposing extrasystolic S2 stimuli following trains of pacing S1 86 
stimuli. These show contrasting (a) persistent sinus rhythm in Mkk4-f/f with observations of (b) frequent AF in 87 
Mkk4-acko. (C) Occurrence of atrial arrhythmic events (AT and AF) in young (3 months) and old (12 months), 88 
Mkk4-f/f and Mkk4-acko, hearts. (D) Picrosirius red-stained atrial tissue, fibrotic areas dark red, from 3 and 12 89 
month old, Mkk4-f/f and Mkk4-acko, mice. (E) Percentage fibrotic area in 3 and 12 month old, Mkk4-f/f (white), 90 
and Mkk4-acko atria (black bar). (F) Epicardial multielectrode array (MEA) activation maps resulting from 91 
differing AP conduction velocities following pacing in the centre of the array in right (RA) and left atria (LA) 92 
of Mkk4-f/f and Mkk4-acko mice (a). (G) Computer modelling of the effects of fibroblast-cardiomyocyte 93 
coupling resulting in re-entry following a premature beat. A standard S1S2 stimulation protocol is applied at the 94 
left edge of the 2D model containing randomly distributed fibroblast populations in which between one to five 95 
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fibroblasts are coupled to any given cardiomyocyte. Subsequent snapshots demonstrate a breaking down of the 96 
wavefront of atrial excitation wave leading to formation of re-entrant excitation waves (Reproduced by 97 
permission from Davies et al (245)). 98 
 99 
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